Effective Health Care Program

Comparative Effectiveness Review
Number 78

Procalcitonin-Guided Antibiotic Therapy

Agency for Healthcare Research and Quality
Advancing Excellence in Health Care • www.ahrq.gov

Comparative Effectiveness Review

Number 78

Procalcitonin-Guided Antibiotic Therapy

Prepared for:
Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No. 290-2007-10058-I

Prepared by:
Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center
Chicago, IL

Investigators:
Nilam J. Soni, M.D.
David J. Samson, M.S.
Jodi L. Galaydick, M.D.
Vikrant Vats, Ph.D.
David L. Pitrak, M.D.
Naomi Aronson, Ph.D.

AHRQ Publication No. 12(13)-EHC124-EF
October 2012

This report is based on research conducted by the Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10058-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

This document is in the public domain and may be used and reprinted without special permission except those copyrighted materials that are clearly noted in the document. Further reproduction of those copyrighted materials is prohibited without the specific permission of copyright holders.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact EffectiveHealthCare@ahrq.hhs.gov.

None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.

Suggested citation: Soni NJ, Samson DJ, Galaydick JL, Vats V, Pitrak DL, Aronson N. Procalcitonin-Guided Antibiotic Therapy. Comparative Effectiveness Review No. 78. (Prepared by the Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-2007-10058-I.) AHRQ Publication No. 12(13)-EHC124-EF. Rockville, MD: Agency for Healthcare Research and Quality. October 2012. www.effectivehealthcare.ahrq.gov/reports/final.cfm.

Preface

The Agency for Healthcare Research and Quality (AHRQ) conducts the Effective Health Care Program as part of its mission to organize knowledge and make it available to inform decisions about health care. As part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Congress directed AHRQ to conduct and support research on the comparative outcomes, clinical effectiveness, and appropriateness of pharmaceuticals, devices, and health care services to meet the needs of Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

AHRQ has an established network of Evidence-based Practice Centers (EPCs) that produce Evidence Reports/Technology Assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care. The EPCs now lend their expertise to the Effective Health Care Program by conducting comparative effectiveness reviews (CERs) of medications, devices, and other relevant interventions, including strategies for how these items and services can best be organized, managed, and delivered.

Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews are useful because they define the strengths and limits of the evidence, clarifying whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about systematic reviews, see www.effectivehealthcare.ahrq.gov/reference/purpose.cfm.

AHRQ expects that CERs will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. In addition, AHRQ is committed to presenting information in different formats so that consumers who make decisions about their own and their family's health can benefit from the evidence.

Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an email list to learn about new program products and opportunities for input. Comparative effectiveness reviews will be updated regularly.

We welcome comments on this CER. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to epc@ahrq.hhs.gov.

Carolyn M. Clancy, M.D.
Director
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.
Director, Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Stephanie Chang, M.D., M.P.H.
Director, EPC Program
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Supriya Janakiraman, M.D., M.P.H.
Task Order Officer
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Acknowledgments

The authors gratefully acknowledge the following individuals for their contributions to this project: Claudia Bonnell, R.N., M.L.S.; Lisa Garofalo; Mark Grant, M.D., M.P.H.; Steven Gutman, M.D.; Lisa Sarsany, M.A.; Kathleen Ziegler, Pharm.D.; Elbert Huang, M.D., M.P.H; Ronald Thisted, Ph.D.; Michael Douglas, M.S.; and Jessica Hoag, B.A.

Technical Expert Panel

R. Phillip Dellinger, M.D.
Head, Critical Care Medicine
Cooper University Hospital
Camden, NJ

Jesse Hall, M.D.
Section Chief, Pulmonary and Critical Care Medicine
University of Chicago
Chicago, IL

Stephen Kahn, Ph.D.
Associate Director, Clinical Laboratories
Loyola University Chicago
Maywood, IL

Henry Masur, M.D.
Chief, Critical Care Medicine
National Institutes of Health
Bethesda, MD

Joshua Metlay, M.D., Ph.D.
Professor of Medicine, Epidemiology, and Emergency Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Emanuel Rivers, M.D., M.P.H.
Vice Chair and Director of Research for the Department of Emergency Medicine
Henry Ford Hospital
Detroit, MI

Gregory Schmidt, M.D.
Director, Critical Care Programs
University of Iowa
Iowa City, IA

Peer Reviewers

Derek Angus, M.D., M.P.H.
Professor and Chair, Critical Care Medicine
Professor, Medicine and Health Policy and Management
University of Pittsburgh School of Medicine
Pittsburgh, PA

Rongwei (Rochelle) Fu, Ph.D.
Associate Professor
Oregon Health & Science University
Portland, OR

Procalcitonin-Guided Antibiotic Therapy

Structured Abstract

Objectives. To systematically review comparative studies of the use of procalcitonin in the clinical management of adult and pediatric patients with suspected local or systemic infection.

Data sources. MEDLINE®, Embase®, the Cochrane Database of Systematic Reviews, National Institute for Clinical Excellence, the National Guideline Clearinghouse, and the Health Technology Assessment Programme were searched from January 1, 1990, to December 16, 2011; the MEDLINE, Embase, and Cochrane searches were updated in December 2011. A search of the gray literature included databases with regulatory information, clinical trial registries, abstracts and conference papers, grants and federally funded research, and information from manufacturers.

Review methods. We sought studies that compared procalcitonin-guided versus clinical-criteria-guided initiation, discontinuation, or change of antibiotic therapy. Outcomes were antibiotic use, mortality, morbidity, and adverse drug events of antibiotic therapy. Data were abstracted by a single reviewer and fact-checked by a second reviewer. Study quality was assessed using the U.S. Preventive Services Task Force framework. A meta-analysis on short-term mortality in intensive care unit (ICU) patients was performed using a random-effects model. Strength of the body of evidence was assessed according to the AHRQ Methods Guide.

Results. There were 18 randomized, controlled trials that addressed five patient populations. Procalcitonin guidance reduces antibiotic use when used to discontinue antibiotics in adult ICU patients and to initiate or discontinue antibiotics in patients with respiratory tract infections (high evidence), without increasing morbidity (moderate evidence) and mortality (low evidence). In contrast, procalcitonin-guided intensification of antibiotics in adult ICU patients increases morbidity (moderate evidence). There is moderate evidence from a single good quality study that procalcitonin guidance reduces antibiotic use for suspected early neonatal sepsis, but insufficient evidence on morbidity and mortality outcomes was found. Evidence is insufficient to draw conclusions on outcomes of procalcitonin guidance for: (1) fever of unknown source in children 1–36 months of age; and (2) preemptive antibiotics after surgery.

Immunocompromised hosts and other special populations were generally excluded from procalcitonin guidance studies. Thus, findings from this review should not be extrapolated to patients with the following conditions: pregnancy; absolute neutropenia; immunocompromised states; chronic infections, and infections for which prolonged antibiotic therapy is standard of care (e.g., infective endocarditis).

Conclusions. Procalcitonin guidance reduces antibiotic use when used to discontinue antibiotics in adult ICU patients and to initiate or discontinue antibiotics in patients with respiratory tract infections. Populations for future research include immunocompromised patients, patients with other conditions (e.g., pregnancy, cystic fibrosis), and pediatric patients. Future research should compare procalcitonin guidance with antibiotic stewardship programs and to implementation of guidelines. Outcomes of high interest for future research are the consequences of reduction in antibiotic use for antibiotic resistance and for adverse events of antibiotic therapy.

Contents

Executive Summary ES-1
Introduction 1
Background and Objectives 1
Key Questions 3
Key Question 4
Methods 6
Topic Development and Refinement 6
Analytic Framework 6
Literature Search Strategy 8
Study Selection 8
Search Strategies for Gray Literature 9
Data Extraction and Data Management 10
Data Elements 10
Evidence Tables 11
Individual Study Quality Assessment 11
Definition of Ratings Based on Criteria 11
Data Synthesis 12
Assessment of Applicability 13
Grading the Body of Evidence for Each Key Question 13
Peer Review and Public Commentary 13
Results 15
Literature Search 15
Gray Literature Search 15
Critically Ill/Ventilator-Associated Pneumonia 18
Procalcitonin-Guided Antibiotic Discontinuation 18
Procalcitonin-Guided Antibiotic Intensification 26
Respiratory Tract Infections 30
Study Characteristics 30
Study Quality 33
Antibiotic Use 35
Mortality 35
Morbidity 39
Adverse Events of Antibiotic Therapy 39
GRADE Evidence 39
Neonatal Sepsis 42
Study Characteristics 42
Study Quality 42
Antibiotic Use 44
Mortality 44
Morbidity 44
Adverse Events of Antibiotic Therapy 44
GRADE Evidence 45
Fever of Unknown Source (Children Ages 1–36 Months) 45
Study Characteristics 45
Study Quality 45

Antibiotic Use 47
Mortality 47
Morbidity 47
Adverse Events of Antibiotic Therapy 47
GRADE Evidence 47
Preemptive Postoperative Antibiotic Therapy 48
Study Quality 48
Antibiotic Use 50
Mortality 50
Morbidity 50
Adverse Effects of Antibiotic Therapy 50
GRADE Evidence 50
Summary and Discussion 52
Summary of the Main Findings 52
Intensive Care Unit Patients 52
Respiratory Tract Infection 52
Neonatal Sepsis 53
Fever of Unknown Source in Children Ages 1–36 Months 53
Postoperative Patients at Risk of Infection 53
Clinical Context and Applicability of Evidence for Decisionmaking 53
Discussion of Present Findings in Context of Other Systematic Reviews 55
Limitations of Present Review 58
Future Research 58
Summary of Weaknesses or Gaps in the Evidence 58
Summary of Methodological Weaknesses in the Evidence 61
Abbreviations 63
References 64

Tables

Table A. Summary characteristics of the included studies ES-8
Table B. Summary of outcomes measures, and strength of evidence ES-10
Table 1. FDA-cleared procalcitonin assays 2
Table 2. Summary of characteristics for five trials included in the analysis of procalcitonin-guided antibiotic discontinuation in the critically ill/ventilator-associated pneumonia patients 19
Table 3. Procalcitonin-guided antibiotic discontinuation in the critically ill/ventilator-associated pneumonia patients—study quality 21
Table 4. Procalcitonin-guided antibiotic discontinuation in the critically ill/ventilator-associated pneumonia patients—outcomes related to antibiotic use 21
Table 5. Procalcitonin-guided antibiotic discontinuation in the critically ill/ventilator-associated pneumonia patients—mortality 23
Table 6. Procalcitonin-guided antibiotic discontinuation in the critically ill/ventilator-associated pneumonia patients—morbidity 24
Table 7. Procalcitonin-guided antibiotic discontinuation in the critically ill/ventilator-associated pneumonia patients—GRADE evidence table 26

Table 8. Summary of characteristics for two trials included in the analysis of procalcitonin-guided antibiotic intensification in the critically ill/ventilator-associated pneumonia patients 27
Table 9. Procalcitonin-guided antibiotic intensification in the critically ill/ventilator-associated pneumonia patients—study quality 28
Table 10. Procalcitonin-guided antibiotic intensification in the critically ill/ventilator-associated pneumonia patients—outcomes related to antibiotic use 28
Table 11. Procalcitonin-guided antibiotic intensification in the critically ill/ventilator-associated pneumonia patients—28-day mortality 29
Table 12. Procalcitonin-guided antibiotic intensification in the critically ill/ventilator-associated pneumonia patients—morbidity 29
Table 13. Summary of characteristics for eight trials included in the analysis of procalcitonin-guided antibiotic initiation and/or discontinuation in patients with respiratory tract infections 31
Table 14. Procalcitonin-guided antibiotic initiation and/or discontinuation in patients with respiratory tract infections—study quality 34
Table 15. Procalcitonin-guided antibiotic initiation and/or discontinuation in patients with respiratory tract infections—outcomes related to antibiotic use 36
Table 16. Procalcitonin-guided antibiotic initiation and/or discontinuation in patients with respiratory tract infections—mortality 38
Table 17. Procalcitonin-guided antibiotic initiation and/or discontinuation in patients with respiratory tract infections—morbidity 40
Table 18. Procalcitonin-guided antibiotic initiation and/or discontinuation in patients with respiratory tract infections—GRADE evidence table 41
Table 19. Summary of characteristics for one trial included in the analysis of procalcitonin-guided antibiotic therapy in neonatal sepsis 43
Table 20. Procalcitonin-guided antibiotic therapy in neonatal sepsis—study quality 43
Table 21. Procalcitonin-guided antibiotic therapy in neonatal sepsis in the study by Stocker et al., 2010 (n=121)—outcomes related to antibiotic use 44
Table 22. Mortality and morbidity data for early onset neonatal sepsis in the study by Stocker et al., 2010 (n=121) 44
Table 23. Summary of characteristics for one trial included in the analysis of procalcitonin-guided antibiotic therapy in children (ages 1–36 months) with fever of unknown source 45
Table 24. Procalcitonin-guided antibiotic therapy in children (ages 1–36 months) with fever of unknown source—study quality 46
Table 25. Procalcitonin-guided antibiotic therapy in children (ages 1–36 months) with fever of unknown source—outcomes related to antibiotic use in the study by Manzano et al., 2010 (n=384) 47
Table 26. Mortality and morbidity data for fever of unknown source in children ages 1–36 months in the study by Manzano et al., 2010 (n=384) 47
Table 27. Summary of characteristics for one trial included in the analysis of procalcitonin-guided preemptive postoperative antibiotic therapy 48
Table 28. Procalcitonin-guided preemptive postoperative antibiotic therapy—study quality 49
Table 29. Procalcitonin-guided preemptive postoperative antibiotic therapy—outcomes related to antibiotic use in the study by Chromik et al., 2005 50

Table 30. Procalcitonin-guided preemptive postoperative antibiotic therapy—mortality and morbidity data in the study by Chromik et al., 2005 (n=20) 50
Table 31. Summary of systematic reviews 57

Figures

Figure A. Analytic framework for procalcitonin as a diagnostic indicator for infection and as an indicator of response to therapy ES-4
Figure B. PRISMA diagram for identified trials ES-6
Figure 1. Analytic framework for procalcitonin as a diagnostic indicator for infection and as an indicator of response to therapy 7
Figure 2. PRISMA diagram for identified trials 15
Figure 3. PRISMA diagram for identified gray literature 16
Figure 4. Meta-analysis of mean differences, antibiotic duration (days) in critically ill/ventilator-associated pneumonia patients 22
Figure 5. Meta-analysis of risk differences, short-term mortality (in-hospital or 28-day) in critically ill/ventilator-associated pneumonia patients 23
Figure 6. Meta-analysis of mean differences, ICU length of stay (days) in critically ill/ventilator-associated pneumonia patients 24
Figure 7. Meta-analysis of mean differences, antibiotic duration (days) in patients with respiratory tract infections 37
Figure 8. Meta-analysis of risk differences, antibiotic prescription rate in patients with respiratory tract infections 37
Figure 9. Meta-analysis of risk differences, short-term mortality (≤6 weeks) in patients with respiratory tract infections 38
Figure 10. Meta-analysis of risk differences in ICU admission in patients with respiratory tract infections 40

Appendixes

Appendix A. Search Strategy
Appendix B. Excluded Studies
Appendix C. Abstraction Tables
Appendix D. Ongoing Procalcitonin Studies in ClinicalTrials.gov
Appendix E. Screening Guide for Title and Abstract
Appendix F. Screening Guide for Full-Text Articles
Appendix G. Data Abstraction Form

Executive Summary

Background

Sepsis is a serious condition with high morbidity and mortality for which clinical diagnostic criteria lack sensitivity and specificity. Early initiation of appropriate antibiotics and goal-directed therapies reduces mortality. Conversely, overuse and misuse of antibiotics, including continuing antibiotics longer than necessary for cure, can result in adverse events and add to the increasing problem of antibiotic resistance. Although critically ill patients in the intensive care units (ICUs) have higher morbidity and mortality rates, the same issues are also relevant to other clinical conditions, including neonatal sepsis, febrile illness in children, pneumonia, and other respiratory tract infections with respect to the initiation, duration, or change in antibiotic therapy. Again, the duration of antibiotic therapy is often undefined, and clinical features are of limited help in guiding discontinuation of therapy.[1]

Several serum biomarkers have been identified in recent years that have the potential to help diagnose local and systemic infections, differentiate bacterial and fungal infections from viral syndromes or noninfectious conditions, prognosticate, and ultimately guide management, particularly of antibiotic therapy. Among these, procalcitonin is the most extensively studied biomarker.[2,3]

Numerous studies have investigated the potential roles of procalcitonin in diagnosing and managing local and systemic infections.[4-6] There is some evidence that procalcitonin is more specific for bacterial infections, with serum levels rising at the onset of infection and falling rapidly as the infection resolves, as compared with other markers.[7,8] However, its clinical utility in diagnosing and managing patients with suspected infections remains unclear.

In healthy people, procalcitonin levels are very low. In systemic infections, including sepsis, procalcitonin levels are generally greater than 0.5–2 ng/mL, but often reach level greater than 10 ng/mL. Higher levels correlate with the severity of illness and prognosis. In patients with suspected respiratory tract infection, the levels of procalcitonin are not necessarily as elevated, and a cutoff of greater than 0.25 ng/mL seems to be most predictive of a bacterial respiratory tract infection requiring antibiotic therapy, while a level less than 0.25 ng/mL signals resolution of the infection.[9,10]

The cutoffs for other clinical situations may be quite different. For example, neonates normally show a characteristic increase in procalcitonin after birth, with a rapid return to normal by 48 to 72 hours. In neonates, a nomogram for procalcitonin cutoffs that accounts for the time from birth in hours must be used.[11] Likewise, the stress of surgery may increase procalcitonin levels, but again, there is an incremental increase in patients with infection, including subclinical or high risk of infection. The cutoff level of procalcitonin to identify postoperative patients with infection or at risk of infection may be higher than that used for other patient groups. Although procalcitonin may have a role in diagnosis and identification of patients who need initiation of systemic antibiotics, it may have greater applicability in guiding decisions about when to discontinue antibiotic therapy as procalcitonin levels quickly return to less than 0.25 ng/mL as infection resolves.[12]

Objectives

The objective of this systematic review was to synthesize comparative studies examining the various uses of procalcitonin in the clinical management of patients with suspected local or systemic infection.

The patient populations included critically ill adults with suspected sepsis or other serious bacterial infections, neonates with suspected early neonatal sepsis, patients with upper and lower respiratory tract infections, children with fever of unknown source, and postoperative patients with infections. Initial review of the literature during topic development and topic refinement suggested that the most common use for procalcitonin-guided management was in decisionmaking related to the initiation or discontinuation of antibiotic therapy in these various populations. This led us to construct an analytical framework that focused on the following Key Question.

Key Question: In selected populations of patients with suspected local or systemic infection, what are the effects of using procalcitonin measurement plus clinical criteria for infection to guide initiation, discontinuation, or a change of antibiotic therapy when compared with clinical criteria for infection alone on:

- Intermediate outcomes, such as initiation, discontinuation, or change of antibiotic therapy; antibiotic use; and length of stay?
- Health outcomes, such as morbidity, mortality, function, quality of life, and adverse events of antibiotic therapy (persistent or recurrent infection, and antibiotic resistance)?

The PICOTS (Patient, Intervention, Comparator, Outcome, Timing, and Setting) for the Key Question follows:

Patients	Adult and pediatric patients with known or suspected local or systemic infection, including critically ill patients with sepsis syndromes or ventilator-associated pneumonia, adults with respiratory tract infections, neonates with sepsis, children with fever of unknown source, and postoperative patients at risk of infection
Intervention	Initiation, discontinuation, or intensification of antibiotic therapy guided by procalcitonin plus clinical criteria for infection
Comparator	Initiation, discontinuation, or intensification of antibiotic therapy guided by clinical criteria for infection alone
Outcome	Antibiotic use (duration of antibiotic therapy, prescription rate,[a] and total antibiotic exposure[b]), mortality, morbidity (length of stay, severity of illness score) and adverse events of antibiotic therapy (persistent or recurrent infection, and antibiotic resistance)

[a]Defined as the percentage of patients who are initiated on antibiotic therapy, either during initial presentation or subsequent followup.
[b]Calculated by multiplying the total number of antibiotics by the number of days the patient is receiving each antibiotic divided by the total duration of antibiotic therapy.

Timing	Three months
Settings	ICUs (medical and surgical), inpatient acute care hospitals, emergency departments, and outpatient clinics

As we proceeded to synthesize the evidence, it was apparent that the evidence on initiation, discontinuation, or change of antibiotic therapy was not easily separated. Many studies reported on both discontinuation and change of antibiotic therapy. For example, studies in the ICU population addressed discontinuation only, while studies of respiratory tract infection patients addressed both initiation and discontinuation. Moreover, serum procalcitonin level cutoffs differ for different patient populations, so it could be misleading to synthesize results across, rather than within, populations. Therefore, the results of our systematic review are reported by patient population, rather than in accordance with the Key Questions originally framed in our topic refinement.

Analytic Framework

Following is an analytic framework (Figure A) depicting the potential effects both on intermediate outcomes and on health outcomes from using procalcitonin. Direct evidence of the results of testing on health outcomes is shown by link A (morbidity, function, quality of life, and/or mortality) and link F (adverse events of therapy). Indirect evidence would have to be assembled in the absence of randomized controlled trials (RCTs) of the effects of testing on health outcomes. Link B addresses whether test results influence decisions about therapy, which may affect health outcomes (link C) or intermediate outcomes (link D). Intermediate outcomes—such as antibiotic exposure, duration of antibiotic therapy, length of stay, and response to therapy—may have an association with health outcomes (link E).

Methods

Input From Stakeholders

This systematic review was developed and written by the Evidence-based Practice Center (EPC) with input from stakeholders. Stakeholders were broadly defined as anyone involved with making health care decisions, including patients, clinicians, professional and consumer organizations, and purchasers of health care. Individuals from various stakeholder groups were invited as Key Informants, Technical Experts, and/or Peer Reviewers to guide this systematic review.

Key Informants are end users of research. A Key Informant panel provided input to the EPC to help refine the Key Questions and to focus on the most important aspects of procalcitonin to influence health care decisions in various clinical settings. The Key Questions were then posted on the Agency for Healthcare Research and Quality (AHRQ) Web site for public commentary. The Technical Expert Panel provided input on the research protocol in two phases: (1) initial draft protocol; (2) revised protocol that incorporated the panel's comments on the draft protocol and preliminary list of relevant studies.

All potential Key Informants, Technical Experts, and Peer Reviewers were required to disclose any potential conflicts of interest in accordance with AHRQ policy. The AHRQ Task Order Officer and the EPC worked to balance, manage, or mitigate any potential conflicts of interest identified. Individuals who had conflicts of interest that precluded participation as

Figure A. Analytic framework for procalcitonin as a diagnostic indicator for infection and as an indicator of response to therapy



AECOPD = acute exacerbations of chronic obstructive pulmonary disease
Note: A–F show links between test results and outcomes. Please see the text above Figure A for more information.

informants, experts or reviewers were able to submit comments through the public comment mechanism. Writing and editing the report was solely the responsibility of the EPC.

Data Sources and Selection

MEDLINE®, Embase® and the Cochrane Controlled Trials Register were searched from 1990 through December 16, 2011, for randomized and nonrandomized comparative studies using the following search terms: procalcitonin AND chronic obstructive pulmonary disease; COPD; critical illness; critically ill; febrile neutropenia; ICU; intensive care; intensive care unit; postoperative complication(s); postoperative infection(s); postsurgical infection(s); sepsis; septic; surgical wound infection; systemic inflammatory response syndrome OR postoperative infection. Searches were limited to English-language and human studies.

The Cochrane Controlled Trials register was also searched, with no date restriction. In addition, a search for systematic reviews was conducted in MEDLINE; the Cochrane Database of Systematic Reviews; and the Web sites of the National Institute for Clinical Excellence, the National Guideline Clearinghouse, and the Health Technology Assessment Programme**.** A search of the gray literature included databases with regulatory information, clinical trial registries, abstracts and conference papers, grants and federally funded research, and manufacturing information.

The titles and abstracts were screened for studies that looked at antibiotic use, morbidity, and mortality with procalcitonin-guided initiation and/or discontinuation of antibiotic therapy compared with use of clinical criteria in adult and pediatric patients with suspected infections. A single reviewer made decision about a full-text review. Citations marked as uncertain were reviewed by a second reviewer for full-text review. A third reviewer was consulted if necessary. We included RCTs. We also sought, but did not find, nonrandomized comparative studies. The PRISMA diagram (Figure B) depicts the flow of search screening and study selection.

Data Extraction and Quality Assessment

Data were abstracted by a single reviewer, and fact checked by another reviewer. If there were disagreements they were resolved through discussion among the review team. Categories of data elements were abstracted as follows: quality assessment (number of participants and flow of participants, treatment allocation methods, blinding, and independent outcome assessor), applicability and clinical diversity assessment (patient, diagnostic, and treatment characteristics), and outcome assessment (primary and secondary outcomes, response criteria, followup frequency and duration, and data analysis details).

Quality of included studies was assessed using the U.S. Preventive Services Task Force framework[13] based on the following criteria: assembly and maintenance of comparable groups, loss to followup, measurements (equal, reliable, and valid), clear definition of interventions, all important outcomes considered, and analysis (adjustment for potential confounders and intention-to-treat analysis). Three quality categories were used: good, fair, and poor. Quality of the abstracted studies was assessed by at least two independent reviewers, and the final quality rating was assigned by consensus adjudication.

Figure B. PRISMA diagram for identified trials



Data Synthesis and Analysis

We anticipated that the decision to incorporate formal data synthesis into this evidence review would be made after completing the formal literature search. Similarly we also anticipated that the decision to pool studies would be based on whether there were a sufficient number of studies available that were designed to ask similar questions and reported similarly defined outcomes. If a meta-analysis could be performed, subgroup and sensitivity analyses would be based on assessment of clinical diversity in available studies. The pooling method would involve inverse variance weighting and a random effects model.

Grading the Strength of the Body of Evidence

The overall strength of evidence grade was determined in compliance with AHRQ's Methods Guide for Effectiveness and Comparative Effectiveness Reviews[19] and is based on a system developed by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group.[20] This system explicitly addresses the following domains: risk of bias, consistency, directness, and precision. With respect to precision, studies could contribute to a rating of precise if confidence intervals did not overlap the null value or results were statistically significant, regardless of whether studies were powered to detect a particular effect for that outcome. The grade-of-evidence strength was classified into the following four categories: high, moderate, low, and insufficient. Specific outcomes and comparisons were rated depending on the evidence found in the literature review. The grade rating was made by independent reviewers, and disagreements were resolved by consensus adjudication.

Results

Overview

Eighteen RCTs (Table A) compared procalcitonin guidance with the use of clinical criteria to manage antibiotic therapy in patients with known or suspected infection, or at risk of infection. The evidence addressed five patient populations that were reviewed separately because of different clinical characteristics and predicted outcomes: (1) critically ill adult patients in the ICU, including patients with ventilator-associated pneumonia (VAP) and those critically ill with suspected bacterial infections, severe sepsis, and septic shock; (2) patients with symptoms and signs of various respiratory tract infections; (3) neonates with suspected sepsis; (4) children between 1 and 36 months of age with fever of unknown source; and (5) postoperative patients at risk of infection. Additionally, we separately reviewed two studies in seriously adult ill ICU patients for whom the procalcitonin-guidance was used to guide intensification of antibiotic therapy rather than use procalcitonin to guide initiation or discontinuation of therapy, a very different approach.

Conducting a meta-analysis was precluded in most instances because of heterogeneity of outcome definitions, sparseness of commonly defined outcomes, and lack of sufficient detail in outcome reporting. A meta-analysis was performed on short-term mortality (28-day or in-hospital mortality) in a group of five studies[14-18] that included critically ill patients and those with VAP. The pool of studies was too small to permit meaningful subgroup and sensitivity analyses. Additional meta-analyses were performed on antibiotic duration, ICU length of stay and hospital length of stay.

Intensive Care Unit Patients

Procalcitonin-Guided Discontinuation of Antibiotic Therapy

Five trials[14-18] (n=938) addressed procalcitonin-guided discontinuation of antibiotic therapy in critically ill patients. There is high strength of evidence (Table B) that procalcitonin guidance reduces antibiotic use. The absolute difference in duration of antibiotic use in these five studies[14-18] ranged from –1.7 to –5 days, with relative reductions ranging from 21 to 38 percent. There is moderate evidence that procalcitonin-guided antibiotic discontinuation does not increase morbidity as indicated by ICU length of stay (LOS). A major concern was uncertainty about the appropriate noninferiority margin for mortality in seriously ill patients in the ICU with sepsis and/or VAP. Although there are potential benefits of reducing antibiotic use, only one study[18] reported on multidrug-resistant organisms and superinfections. There were limited data on other adverse antibiotic effects reported in these studies.

Procalcitonin-Guided Intensification of Antibiotic Therapy

There is moderate evidence that procalcitonin-guided intensification of antibiotic therapy to broaden the spectrum of bacterial coverage does not improve outcomes in critically ill patients, and in fact, may have adverse consequences. The large (n=1,200), high-quality trial by Jensen and colleagues[21] found greater duration and increased total exposure to antibiotics with procalcitonin guidance. There was also increased morbidity, including a 1-day increase (p=0.004) in ICU LOS, a significant increase in days on mechanical ventilation, and increased days with abnormal renal function. A second study[22] (n=72) was judged too small to be informative.

Table A. Summary characteristics of the included studies

Characteristic	Critically Ill/VAP (Antibiotic Discontinuation)	Critically Ill/VAP (Antibiotic Intensification)	Respiratory Tract Infections	Neonatal Sepsis	Fever of Unknown Source (Children Ages 1–36 Months)	Preemptive Postoperative Antibiotic Therapy
Study Design	RCT=5	RCT=2	RCT=7 Cluster RCT=1	RCT=1	RCT=1	RCT=1
Number of Studies	5	2	8	1	1	1
Total N	938	1,272	3,492	121	384	250
Funding	NR=3 Mixed=2	Nonindustry=1 Mixed=1	Nonindustry=2 NR=1 Mixed=5	Industry=1	Industry=1	NR=1
Study Quality	Fair=2 Good=3	Fair=1 Good=1	Poor=4 Good=4	Good=1	Poor=1	Good=1
Conflict of Interest*	Yes=5	Yes=1 NR=1	Yes=6 No=1 NR=1	NR=1	No=1	NR=1
References	14–18	21–22	23–30	31	32	33

NR = not reported; RCT = randomized controlled trial; VAP = ventilator-associated pneumonia

*Yes implies published paper reported existence of conflict of interest; No implies published paper reported no existence of conflict of interest; and NR implies published paper did not report whether conflict of interest existed.

Respiratory Tract Infection

Eight trials[23-30] (n=3,492) addressed initiation and/or discontinuation of antibiotics in patients with acute upper and lower respiratory tract infection. Settings included primary care clinics, emergency departments (EDs), and hospital wards. There is high strength of evidence that procalcitonin guidance reduces antibiotic duration and prescription rates; and moderate evidence of reduction in total antibiotic exposure. Absolute reduction in duration of antibiotic therapy ranged from 1 to 7 days, with relative reductions ranging from -13 to -55 percent. Absolute reduction in prescription rates ranged from -2 to -7 percent with relative reductions ranging from -1.8 to -72 percent. There was moderate evidence that procalcitonin guidance did not increase mortality, hospital LOS, or ICU admission rates. However, a limitation of the evidence is the very large number of study participants that would be required to narrow the confidence interval for estimated mortality. Evidence was insufficient to judge effects on days of restricted activity or on antibiotic adverse events. Three studies[24,25,27] reported on adverse antibiotic effects, and there was a statistically significant reduction in the procalcitonin-guided arm versus the control arm that was associated with reduced antibiotic usage. No consistency was found, however, on how adverse effects were defined and details on the types of adverse reactions were lacking.

Neonatal Sepsis

One good-quality[31] study (n=121) provided moderate evidence that procalcitonin guidance reduces the use of antibiotic therapy for suspected early neonatal sepsis. The duration of antibiotic use was overall reduced by 22.4 hours (22.0%). Further, the proportion of neonates on antibiotics for longer than 72 hours was reduced by 27 percent. Greatest reductions were seen among neonates who were judged according to clinical criteria to have possible infection or unlikely to have infection as compared with those with proven or probable infection. Strength of evidence was judged insufficient to make conclusions on mortality and morbidity because of the small study size.

Fever of Unknown Source in Children Ages 1–36 Months

The strength of evidence was judged insufficient to draw conclusions on outcomes of procalcitonin-guided antibiotic therapy for fever of unknown source in children 1 to 36 months of age. One good-quality RCT[32] (n=384) reported no significant results.

Postoperative Patients at Risk of Infection

The strength of evidence was judged insufficient to draw conclusions on outcomes of procalcitonin guidance to determine preemptive antibiotic therapy for patients after colorectal surgery. The evidence consisted of one small (n=20) trial.[33]

Table B. Summary of outcomes measures, and strength of evidence

Patient Group	Outcome	Unit	No. of Studies	References	No. of Subjects	B	C	D	P	Overall Grade	Effect*
Critically ill/VAP patients (antibiotic discontinuation)	Antibiotic use	Duration of use, days	5	14–18	938	L	Y	Y	Y	High	Improve (Range: –1.7 to –5)
	Mortality	In-hospital, overall or 28- day	5	14–18	938	L	Y	Y	Y	Low**	No worse
	Morbidity	ICU length of stay, days	5	14–18	837	L	Y	Y	Y	Moderate	No worse
Critically ill/VAP patients (antibiotic intensification)	Morbidity	Percent days in ICU with GFR<60	1	21	1,200	L	U	Y	Y	Moderate	Worse (5.0%, 95% CI: 3.0, 6.9)
		Percent days on ventilator	1	21	1,200	L	U	Y	Y	Moderate	Worse (4.9%, 95% CI: 3.0, 6.7)
Respiratory tract infection	Antibiotic use	Duration of use, days	7	23-27, 29, 30	3,284	L	Y	Y	Y	High	Improve (Range: –1 to –7)
		Prescription rate	7	23–30	3,492	L	Y	Y	Y	High	Improve (Range: –2 to –7%)
	Mortality	≤ 6 wks or 6 months	8 (7/1)	23–30	3,492	L	Y	Y	Y	Moderate	No worse
	Morbidity	Hospital length of stay	5	25, 26, 28–30	2,303	M	Y	Y	Y	Moderate	No worse
		ICU admission rates	5	25, 26, 28–30	2,303	M	Y	Y	Y	Moderate	No worse
		Antibiotic adverse events	3	24, 25, 27	2,367	L	N	Y	N	Insufficient	Unknown
Neonatal sepsis	Duration of antibiotic use	Hours	1	31	121	L	U	Y	Y	Moderate	Improve (–22.4, p=0.012)
	Morbidity	Recurrence of infection	1	31	121	L	U	Y	N	Insufficient	Unknown
	Mortality	In-hospital	1	31	121	L	U	Y	N	Insufficient	Unknown
Fever of unknown source in children	Antibiotic use	Prescription rate	1	32	384	H	U	Y	N	Insufficient	Unknown
	Morbidity	Hospitalization rate	1	32	384	H	U	Y	N	Insufficient	Unknown
	Mortality	In-hospital	1	32	384	H	U	Y	N	Insufficient	Unknown
Preemptive postoperative antibiotic therapy	Morbidity	Sepsis/SIRS	1	33	20	L	U	Y	N	Insufficient	Unknown
	Mortality	In-hospital	1	33	20	L	U	Y	N	Insufficient	Unknown

B = risk of bias; C = consistency; CI = confidence interval; D = directness; GFR = glomerular filtration rate; ICU = intensive care unit; N = no; P = precision; SIRS = systemic inflammatory response syndrome; U = unknown; VAP = ventilator-associated pneumonia; Y = yes

*Comparison between procalcitonin measurement plus clinical criteria versus clinical criteria alone to guide initiation, discontinuation, or a change of antibiotic therapy.

**The overall grade was low based on uncertainty about the appropriate minimum important difference for assessing noninferiority with respect to mortality.

Discussion

Clinical Context and Applicability

The diagnosis of sepsis is challenging because the clinical criteria for the diagnosis overlap with noninfectious causes of systemic inflammation such as the systemic inflammatory response syndrome. Initiation of antibiotic therapy for sepsis is necessary even while the diagnostic evaluation is ongoing because delayed antibiotic therapy is associated with increased mortality.[34-36] A biomarker, such as procalcitonin, that improves decisions about initiating, discontinuing, or changing antibiotic therapy, could have substantial clinical benefits. Our systematic review found that procalcitonin guidance reduces antibiotic use for adult patients in both medical and surgical ICUs. Studies included patients who had comorbidities that are common in ICU patients (e.g., cardiac disease, diabetes, chronic lung disease, cirrhosis, chronic renal failure, cancer), and thus, the evidence from these studies is applicable to clinical practice in the ICU setting.

Respiratory tract infections contribute significantly to the problem of antibiotic misuse. Approximately 75 percent of all antibiotics prescribed in the ambulatory setting are for acute respiratory tract infections, but the vast majority of these infections are viral and do not benefit from antibiotic treatment.[37] Clinical and microbiological evaluations are neither sensitive nor specific to differentiate bacterial from viral respiratory tract infections. Our systematic review found that procalcitonin guidance for initiation and discontinuation of antibiotic therapy significantly reduced antibiotic prescription rates and duration in patients with acute respiratory tract infections, including acute exacerbations of COPD, community acquired pneumonia (CAP), and acute bronchitis.

Certain populations, however, were excluded from one or more studies of procalcitonin guidance reviewed in this report. Thus, findings from this review should not be extrapolated to these high-risk groups, which include pregnant patients, patients with absolute neutropenia, and other immunocompromised populations (solid organ and stem-cell transplant recipients, patients with advanced HIV infection/AIDS). Patients with chronic infections and infections for which a longer duration of antibiotic therapy is the standard of care, such as infective endocarditis, were also appropriately excluded from these studies. Patients with these conditions account for a significant proportion of the ICU population.

Although such patients were excluded in these studies, future studies may help to determine whether procalcitonin-guided antibiotic therapy is beneficial in these groups as well. For example, febrile neutropenic patients are usually continued on antibiotics until the neutropenia resolves; the most recent guidelines suggest patients can be switched to an oral fluoroquinolone when an infection has been adequately treated, and procalcitonin guidance could potentially be used in this context.[38]

Applicability to pediatric settings is a significant gap in the present evidence. Only two RCTs[31,32] reported on procalcitonin guidance in pediatric populations. One study[31] included neonates with suspected early sepsis. While antibiotic use was reduced, the trial was underpowered for morbidity and mortality outcomes. The second study[32] evaluated procalcitonin-guided antibiotic therapy in children ages 1–36 months presenting to the ED with fever of unknown source. No significant differences were observed for measures of antibiotic use, morbidity, or mortality with procalcitonin guidance. The evidence from this single study

was judged insufficient to reach conclusions about the use of procalcitonin guidance in this setting. There were no studies of procalcitonin guidance in children ages 3 to 18 years.

Ultimately, the value of procalcitonin-guided antibiotic therapy depends on the clinical benefits of reduced antibiotic use, which is difficult to quantify. Immediate consequences may include decrease in allergic reactions, drug toxicities, and frequency of *Clostridium difficile* infection. A major downstream effect of reducing antibiotic use may be a lower probability of emergence of antibiotic-resistant strains. Antimicrobial resistance contributes to morbidity, mortality, and health care costs. Several studies and indirect lines of evidence suggest that control of antibiotic use can reduce emergence of resistance, but the data are limited.[39]

Reductions in antibiotic course duration have been associated with significant reductions in antibiotic adverse effects, *C. difficile* colitis, and superinfection with multidrug-resistant (MDR) Gram-negative rods.[34,39 40] In our systematic review, few studies reported on allergic and adverse events of antibiotic use,[24,25,27] and only one reported on antibiotic resistance.[14]

The durability in reduction of antibiotic use is not addressed in these trials, which limits their applicability to clinical practice. The setting of a clinical trial, or highly visible introduction of a new practice, can have a halo effect on physician behavior, so the present evidence does not address the long-term outcome of using procalcitonin guidance in a real-world clinical setting. Antibiotic stewardship programs are now recommended for all institutions, and guidelines are available for how they should function.[41] Antibiotic stewardship programs are associated with reduced antibiotic use and also the decreased adverse effects of antibiotic therapy. The evidence in this review does not compare outcomes of using procalcitonin guidance versus antibiotic stewardship programs, nor does it address whether the addition of procalcitonin to an antibiotic stewardship program improves outcomes.

Antibiotic stewardship activities are usually limited to the acute-care hospital setting. Although it would be difficult or impractical for antibiotic stewardship programs to have active interventions in the outpatient setting, the use of procalcitonin might complement other types of outpatient programs, such as educational programs for physicians and patients aimed at reducing the use of antibiotics for viral respiratory tract infections.[37]

Key Findings and Strength of Evidence

Our systematic review concludes that procalcitonin-guided antibiotic therapy can lead to significant reductions in antibiotic use (high strength of evidence [SOE]) without adversely affecting patient outcomes in critically ill patients in the ICU setting (moderate SOE for morbidity, low SOE for mortality). Evidence on mortality was initially rated as stronger but was downgraded to low based on uncertainty about the appropriate noninferiority margin for this outcome. In patients with a variety of respiratory tract infections, procalcitonin-guided antibiotic therapy reduced antibiotic prescription rates and the duration of antibiotic therapy (high SOE) in different clinical settings, again without any increase in morbidity or mortality (moderate SOE). There is insufficient evidence to recommend procalcitonin-guided antibiotic therapy in cases of neonatal sepsis, febrile children, and postoperative patients when procalcitonin has been used to identify patients who may need preemptive antibiotic therapy to prevent local or systemic infections. Use of procalcitonin as an indicator of inappropriate initial antibiotic therapy and the need for intensified antibiotic therapy in the ICU should be discouraged because this approach may lead to increased organ dysfunction (moderate SOE).

Discussion of Present Findings in Context of Other Systematic Reviews

We are aware of four systematic reviews[4,42-44] that were published before our review; the findings of our review are discussed in the context of these prior reviews. All the previous reviews (including the present review) came to similar conclusions: procalcitonin-guided antibiotic decisionmaking, compared with clinical criteria-guided antibiotic decisionmaking reduces antibiotic use and is not associated with increased mortality or morbidity.

We reviewed all published RCTs of the use of procalcitonin-guided initiation or discontinuation of antibiotic therapy, as well as studies that used procalcitonin for other interventions in patients with infection and/or sepsis. Eighteen RCTs[14-18,21-33] were included in our systematic review. Our systematic review differs from previous systematic reviews in terms of the number of studies included, the scope of indications addressed, and how populations were grouped for clinical relevance. The number of trials included in previous systematic reviews ranged from seven trials[4,42,44] to 14 trials.[43] Our review addresses pediatric populations separately from adult patients, and it also recognizes that there are distinct patient groups within the pediatric population as stratified by age.

As the most recent systematic review, ours is the only one that includes the Jensen trial.[21] This trial was unique in showing that procalcitonin-guided intensification of antibiotic therapy to broaden the spectrum of bacterial coverage does not improve outcomes in critically ill patients, and in fact, may have adverse consequences.

Summary of Gaps in the Evidence

We identified five gaps in the evidence related to specific populations or comparators.

Research Gap 1: What Are the Outcomes of Procalcitonin Guidance in Subgroups of Patients Who Are Immunocompromised?

Patients with certain conditions, including neutropenia, and those in immunocompromised states (solid organ and stem-cell transplant recipients, and patients with advanced HIV infection) were excluded from this study. Immunocompromised patients often comprise a significant portion of the ICU population. In the large PRORATA[18] study, immunocompromised patients made up 16.6 percent of the study population and were included in the trial. In the PROVAP[16] study of ventilator-associated pneumonia, 27.9 percent of the eligible patients were excluded because of immunosuppression.

Even in community respiratory tract infections, such as CAP (7.6% excluded), and even in other respiratory tract infections (2.5% excluded), there is a significant subpopulation of patients who are immunocompromised or have condition such as cystic fibrosis for whom the efficacy and safety of procalcitonin-guided antibiotic therapy is unknown.[29,30]

While severely immunocompromised patients presenting with clinical signs of infection are most likely treated empirically with antibiotics, patients with mild to moderate immunosuppression, such as patients on low-dose corticosteroids for chronic inflammatory conditions, may not benefit from antibiotic therapy, even though they are often treated empirically. Procalcitonin guidance may have a potential role in reducing antibiotic use in the ambulatory patients with mild to moderate immunosuppression as compared with standard therapy.

Research Gap 2: What Are the Outcomes of Procalcitonin Guidance in Pediatric Patients?

Only two studies[31,32] reported on procalcitonin guidance in pediatric populations, and both were underpowered to assess morbidity and mortality outcomes. Both studies were limited to the acute-care hospital setting. The overuse of antibiotics in pediatrics, in both the inpatient and outpatient setting, is as important among children as it is in adults.

Research Gap 3: What Are the Outcomes of Procalcitonin Guidance in Identifying Patients at Risk of Infection Who Might Benefit From Preemptive Antibiotic Therapy?

The study by Chromik and colleagues[33] reported that procalcitonin levels could accurately identify a subpopulation, 8 percent of patients who underwent elective colorectal surgery, who were at risk of a local or systemic infection. Although this was a small study, it suggests that this approach might identify a group who would benefit from preemptive antibiotic therapy given before any infection is clinically evident. Larger studies are needed to confirm that preemptive antibiotic therapy can reduce infection-related complications. Other patient populations who are at risk for infection-related complications include burn patients, ICU patients, and postoperative patients who have undergone procedures other than colorectal surgery.

Research Gap 4: Does the Use of Procalcitonin Guidance Reduce Antibiotic Resistance and Antibiotic Adverse Events?

Although the importance of reducing antibiotic use is recognized, there was insufficient evidence from the RCTs we reviewed that the observed reduction in antibiotic use had benefits with respect to antibiotic adverse reactions, superinfections, or the development of resistance. When designing future studies, there should be consideration for standardized reporting of adverse events from antibiotics, the incidence of *C. difficile*, and active surveillance for colonization of patients with drug-resistant pathogens.

Research Gap 5: How Does Procalcitonin-Guided Antibiotic Therapy Compare With Other Approaches for Reducing Unnecessary Antibiotic Use, Such as Antibiotic Stewardship Programs and Implementation of Practice Guidelines?

In view of the present emphasis on the overuse of antibiotics, other interventions to reduce antibiotic use, such as the institution of antibiotic stewardship programs and the structured implementation of practice guidelines, may be more robust comparators by which to assess the outcomes of procalcitonin-guided decisions on the initiation and discontinuation of antibiotic therapy.

Summary of Methodological Weaknesses in the Evidence

In addition to the research gaps listed above, we also identified four important methodological weaknesses that were common across the studies and bodies of evidence reviewed in this report.

Weakness 1: Measurement of Total Antibiotic Exposure

Total antibiotic exposure is used to capture a patient's total exposure to all antibiotics and is conventionally reported as mean days per 1,000 days of followup. However, some of the studies in this review only reported relative or absolute differences. Consistent use of the conventional measure would improve accumulation of evidence on the outcomes of procalcitonin guidance.

Weakness 2: Measurement of Morbidity

There were various measures of morbidity across these studies. Although admission rates, LOS, and ICU LOS were easy to compare, other measures were not. In the ICU populations, for example, the need for mechanical ventilation was often reported differently, and studies used a variety of severity of illness scores (SOFA, SAP II, SAP III, and APACHE II). This makes it difficult to compare or pool data across studies.

Weakness 3: Rationale for Noninferiority Margins for Studies of Mortality

Mortality rates in trials of procalcitonin-guided antibiotic therapy implicitly or explicitly pose a question of noninferiority. That is: Can reduction in antibiotic use be achieved without a deleterious effect on survival? The choice of a noninferiority margin incorporates clinical and statistical judgments.[45] Studies should provide an explicit rationale for the choice of a noninferiority margin in specific patient populations.

Weakness 4: Reporting and Interpreting Nonsignificant Differences

A common statistical error in the medical literature is the conclusion that nonsignificant differences ($p>0.05$) are "similar."[46] Clearly stating in the abstract that the study was not powered to detect a difference in mortality would provide a more accurate reporting of the results.

Limitations of the Review Process

A challenging aspect of this review was appraising the strength of evidence that procalcitonin-guided antibiotic therapy did not result in any increased morbidity or mortality in critically ill patients and those with respiratory tract infections. In the studies of critically ill patients for whom procalcitonin was used to reduce antibiotic exposure, only the Bouadma study[18] did a power analysis and used a predefined a margin for noninferiority for 28- and 60-day mortality. Meta-analysis was performed looking at early mortality across all five ICU studies. Results show a pooled point estimate of 0.4 percentage point reduction in mortality, and the 95% confidence interval (CI) for the difference in mortality between procalcitonin-guided antibiotic therapy and standard care was between -6 percent and 5 percent, favoring the procalcitonin-guided antibiotic therapy group. There is disagreement, however, over whether this range falls within the appropriate noninferiority margin. The choice of a noninferiority margin only requires sufficient precision to exclude a minimal important difference.[47] Although a 10 percent noninferiority margin for mortality has been recommended by the Infectious Diseases Society of America and American College of Chest Physicians in relevant populations, there is concern, expressed by some of our peer reviewers and in literature, that a 10 percent margin may be too high. Initially, a higher strength of evidence was considered, but because of the uncertainty of the noninferiority margin, the strength of evidence that procalcitonin-guided antibiotic therapy in the ICU does not increase mortality was downgraded to low. Although overall strength of evidence

was low, the results were judged to be precise because the pooled point estimate was centered on the null and the 95% CI was narrow (11 percentage points). While only one study was powered for mortality, one purpose for meta-analysis is to overcome insufficient power, and the group of studies was highly consistent: statistical heterogeneity, as expressed by the I^2 statistic, was found to be 0 percent. Sixty-day mortality was reported by one study[18] and was not included in our analysis because late mortality is more likely related to underlying comorbidities. Moreover, there are presently two large trials in progress, which may yield more precise estimates of mortality.

Another limitation of our review is that we did not systematically seek evidence comparing procalcitonin guidance to antibiotic stewardship programs or other programs aimed at reducing antibiotic use. Nor did we seek studies that changed procalcitonin-guided antibiotic therapy into an antibiotic stewardship program.

Implications for Future Research

We identified gaps and opportunities in the available evidence for improving the methods of studies comparing procalcitonin guidance with the use of clinical criteria to guide antibiotic therapy.

Populations of interest for future research on procalcitonin guidance are:

- Immunocompromised patient subgroups
- Patients with other conditions who were excluded from the study (e.g., pregnant women)
- Pediatric populations, stratified by age (neonates; younger than 3 years of age; older than 3 years of age)
- Patients at high risk of infection who may benefit from preemptive antibiotic therapy

Comparators of interest for future research are:

- Procalcitonin guidance compared with antibiotic stewardship programs
- Antibiotic stewardship programs compared with and without procalcitonin guidance
- Procalcitonin guidance compared with implementation of guidelines

Outcomes of interest for future research are:

- Consequences of reduction in antibiotic use on antibiotic resistance
- Consequences of reduction in antibiotic use on antibiotic adverse events
- Establishing the appropriate noninferiority margins for mortality and morbidity outcome

Opportunities for Improving Study Methods

1. Studies should use a consistent measurement of total antibiotic exposure: mean days of total exposure to all antibiotics per 1,000 days of followup.
2. Studies should use consistent measurements of morbidity; for example, the need for mechanical ventilation; severity of illness scores.
3. Studies should provide an explicit rationale for noninferiority margins for mortality in specific patient populations.
4. Studies should provide transparent reporting and interpretation of nonsignificant differences: Clearly stating in the abstract whether the study was not powered to detect a difference in mortality or morbidity.

Glossary

Infection: An infection is an invasion and multiplication of microorganisms or parasites in body tissues.

Procalcitonin: Procalcitonin is a precursor of the hormone calcitonin, which is produced by parafollicular cells (C cells) of the thyroid and other tissues, such as the neuroendocrine cells of the lung and the intestine. Its levels are low in healthy individuals but they rise in a response to a proinflammatory stimulus, especially of bacterial origin.

Sepsis: Sepsis is a clinical syndrome caused by the presence of a microbe or microbial products in the blood or other tissue resulting in a systemic inflammatory state.

References

1. Polin RA. The "ins and outs" of neonatal sepsis. J Pediatr 2003 Jul;143(1):3-4. PMID: 12915813
2. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14(1):R15. PMID: 20144219.
3. Marshall JC, Reinhart K. Biomarkers of sepsis. Crit Care Med. 2009 Jul;37(7):2290-8. PMID: 19487943.
4. Tang H, Huang T, Jing J, et al. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection. 2009 Dec;37(6):497-507. PMID: 19826761.
5. Jones AE, Fiechtl JF, Brown MD, et al. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann Emerg Med. 2007 Jul;50(1):34-41. PMID: 17161501.
6. Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol. 2010 Jan 1;159(2):253-64. PMID: 20002097.
7. Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med. 1998 Aug;24(8):888-9. PMID: 9757936.
8. Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994 Dec;79(6):1605-8. PMID: 7989463.
9. Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004 Jul 15;39(2):206-17. PMID: 15307030.
10. Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J. 2007 Sep;30(3):556-73. PMID: 17766633.
11. Chiesa C, Panero A, Rossi N, et al. Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. Clin Infect Dis. 1998 Mar;26(3):664-72. PMID: 9524841.
12. Luyt CE, Guerin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med. 2005 Jan 1;171(1):48-53. PMID: 15447947.
13. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001 Apr;20(3 Suppl):21-35. PMID: 11306229.
14. Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008 Mar 1;177(5):498-505. PMID: 18096708.

15. Schroeder S, Hochreiter M, Koehler T, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg. 2009 Mar;394(2):221-6. PMID: 19034493.

16. Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J. 2009 Dec;34(6):1364-75. PMID: 19797133.

17. Hochreiter M, Kohler T, Schweiger AM, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care. 2009;13(3):R83. PMID: 19493352.

18. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010 Feb 6;375(9713):463-74. PMID: 20097417.

19. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(11)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality.; March 2011. www.effectivehealthcare.ahrq.gov.

20. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol. 2010 May;63(5):513-23. PMID: 19595577.

21. Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial. Crit Care Med. 2011 May 12. PMID: 21572328.

22. Svoboda P, Kantorova I, Scheer P, et al. Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery? Hepatogastroenterology. 2007 Mar;54(74):359-63. PMID: 17523274.

23. Long W, Deng X, Zhang Y, et al. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology. 2011 Jul;16(5):819-24. PMID: 21507143.

24. Burkhardt O, Ewig S, Haagen U, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J. 2010 Sep;36(3):601-7. PMID: 20185423.

25. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009 Sep 9;302(10):1059-66. PMID: 19738090.

26. Kristoffersen KB, Sogaard OS, Wejse C, et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission--a randomized trial. Clin Microbiol Infect. 2009 May;15(5):481-7. PMID: 19416298.

27. Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med. 2008 Oct 13;168(18):2000-7; discussion 7-8. PMID: 18852401.

28. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007 Jan;131(1):9-19. PMID: 17218551.

29. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006 Jul 1;174(1):84-93. PMID: 16603606.

30. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004 Feb 21;363(9409):600-7. PMID: 14987884.

31. Stocker M, Fontana M, El Helou S, et al. Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology. 2010;97(2):165-74. PMID: 19776651.

32. Manzano S, Bailey B, Girodias JB, et al. Impact of procalcitonin on the management of children aged 1 to 36 months presenting with fever without source: a randomized controlled trial. Am J Emerg Med. 2010 Jul;28(6):647-53. PMID: 20637377.

33. Chromik AM, Endter F, Uhl W, et al. Pre-emptive antibiotic treatment vs 'standard' treatment in patients with elevated serum procalcitonin levels after elective colorectal surgery: a prospective randomised pilot study. Langenbecks Arch Surg. 2006 Jun;391(3):187-94. PMID: 16369855.

34. Ibrahim EH, Ward S, Sherman G, et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med. 2001 Jun;29(6):1109-15. PMID: 11395584.

35. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001 Aug 1;164(3):396-402. PMID: 11500339.

36. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999 Feb;115(2):462-74. PMID: 10027448.

37. Gonzales R, Steiner JF, Lum A, et al. Decreasing antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults. JAMA. 1999 Apr 28;281(16):1512-9. PMID: 10227321.

38. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011 Feb 15;52(4):e56-93. PMID: 21258094.

39. Carling P, Fung T, Killion A, et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003 Sep;24(9):699-706. PMID: 14510254.

40. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003 Nov 19;290(19):2588-98. PMID: 14625336.

41. Dellit TH, Owens RC, McGowan JE, Jr., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007 Jan 15;44(2):159-77. PMID: 17173212.

42. Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis. 2011 Aug;53(4):379-87. PMID: 21810753.

43. Schuetz P, Chiappa V, Briel M, et al. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med. 2011 Aug 8;171(15):1322-31. PMID: 21824946.

44. Kopterides P, Siempos, II, Tsangaris I, et al. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med. 2010 Nov;38(11):2229-41. PMID: 20729729.

45. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med. 2006 Jul 4;145(1):62-9. PMID: 16818930.

46. Zinsmeister AR, Connor JT. Ten common statistical errors and how to avoid them. Am J Gastroenterol. 2008 Feb;103(2):262-6. PMID: 18289193.

47. Assessing Equivalence and Non-Inferiority (Draft). Rockville, MD: Agency for Healthcare Research and Quality; September 2011.

Introduction

Background and Objectives

Sepsis is a condition with high morbidity and mortality for which clinical diagnostic criteria lack sensitivity and specificity. Rapid diagnosis of sepsis and early initiation of antibiotic and goal-directed therapies have demonstrated a reduction in mortality. Conversely, overuse and misuse of antibiotics can result in adverse events and add to the increasing problem of antibiotic resistance. Several serum biomarkers have been identified in recent years with potential uses to help diagnose local and systemic infections, differentiate bacterial and fungal infections from viral syndromes or noninfectious conditions, prognosticate, and ultimately guide management, particularly antibiotic therapy. Among these potential uses of serum biomarkers, there is particular interest in finding a biomarker for diagnosis of sepsis. Currently, there are at least 178 serum biomarkers that have potential roles in the management of patients with infections, and 34 have been studied specifically as a diagnostic tool for sepsis. Among these, procalcitonin is the most extensively studied biomarker.[1,2]

Serum levels of procalcitonin were recognized to be elevated in patients with infections during the early 1990s, and since that time, numerous studies have investigated the potential roles of procalcitonin in diagnosing and managing of local and systemic infections.[3-5] Procalcitonin is the prohormone precursor of calcitonin that is expressed primarily in C-cells of the thyroid gland and to a smaller extent in neuroendocrine tissue of other organs, such as the lungs and intestines. The final step in conversion of procalcitonin to calcitonin is inhibited by various cytokines and bacterial endotoxins and, therefore, high levels of cytokines and/or bacterial endotoxins cause procalcitonin levels to rise. Cytokines are released nonspecifically in response to inflammation and infection, but endotoxins are released specifically during bacterial infections because they are derived primarily from the Gram-negative bacterial cell wall. There is some evidence that procalcitonin is more specific for bacterial infections, with serum levels rising and falling more rapidly in bacterial infection.[6,7]

Although viruses, parasites, and fungi can increase procalcitonin levels due to systemic inflammation, procalcitonin's primary diagnostic utility is thought to be in establishing the presence of local or systemic bacterial infections particularly in bacterial sepsis. In case of fungal infection, the diagnostic utility of procalcitonin is limited because the levels do not rise until 1 to 2 days after the onset of infection. A greater increase in procalcitonin levels would be anticipated in Gram-negative versus Gram-positive bacterial infections due to the release of endotoxin from the Gram-negative bacterial cell wall; however, only few studies have demonstrated higher levels of procalcitonin with Gram-negative bacterial infections when compared to Gram-positive bacterial infections.[5] Procalcitonin appears to be a promising serum biomarker for infection, but its exact utility in diagnosing and managing patients with suspected infections remains unclear.

The U.S. Food and Drug Administration (FDA) has cleared for marketing at least three procalcitonin quantitative assays that are commercially available (see Table 1), but the optimal approach to laboratory testing of procalcitonin has yet to be clarified. The labeled indication is the same for all three assays. According to the approved labels, these assays are intended for use in conjunction with other laboratory findings and clinical assessments to aid in the risk assessment of critically ill patients on their first day of intensive care unit (ICU) admission, for progression to severe sepsis and septic shock.[8-10] Quantitative and qualitative (semi-quantitative) assays for measuring procalcitonin are currently available. The qualitative tests use test strips,

are rapid (results available in less than 30 minutes), and are designed for point-of-care testing. The quantitative tests use a luminescence immunoassay platform, are slower (results available in a few hours), and are designed for once or twice daily batch testing. Most studies supporting the use of procalcitonin have used the quantitative test, which is neither rapid nor available at the bedside. Whether or not the semiquantitative test will yield similar results to the quantitative test is unknown.[4,11]

Table 1. FDA-cleared procalcitonin assays

Test Name	Device Type	Manufacturer	FDA Marketing Clearance Approval Date
BRAHMS PCT LIA[8]	Immunoluminometric assay (ILMA)	BRAHMS Aktiengelsellschaft	January 7, 2005
VIDAS BRAHMS PCT LIA Assay[9]	Enzyme-linked fluorescent immunoassay (ELFA)	bioMerieux, Inc.	October 11, 2007
BRAHMS PCT sensitive KRYPTOR®[10]	Immunofluorescent test based on Time-Resolved Amplified Cryptate Emission (TRACE®)	BRAHMS Aktiengelsellschaft	March 31, 2008

LIA = luminescence immunoassay; PCT = procalcitonin

The purpose of this systematic review is to synthesize comparative studies examining the use of procalcitonin in the management of patients with presumed local or systemic infection. Although important, the analytic validity of quantitative and qualitative procalcitonin testing is beyond the scope of this comparative effectiveness review. However, diagnostic accuracy studies that look at the use of procalcitonin in determining the cause of fever or other symptoms and signs of systemic or localized infections will be discussed briefly, since these studies are the basis for the cutoff procalcitonin levels used in the randomized controlled trials (RCTs). The comparator in the diagnostic accuracy studies is usually clinical criteria for the diagnosis of the particular infection, such as the criteria for the diagnosis of systemic inflammatory response syndrome (SIRS) and sepsis, which were developed at a 1992 consensus conference.[12] Unfortunately, clinical criteria for sepsis require identifying a source of infection, which may be difficult. Microbiological evaluation may be helpful, but insensitivity of cultures is problematic. These same issues are also true for clinical criteria for the diagnosis of neonatal sepsis, pneumonia, and other respiratory tract infections.[13]

In healthy people, procalcitonin levels are very low. In systemic infections, including sepsis, procalcitonin levels are generally greater than 0.5–2 ng/mL, but often reach levels of greater than 10 ng/mL, and higher levels correlate with the severity of illness and prognosis. Studies indicate procalcitonin is superior to C-reactive protein, interleukin-6, and interleukin-8 for diagnosis of sepsis.[14] Lower respiratory tract infections (LRTIs) are often less serious, although patients with severe community acquired pneumonia (CAP) may have life-threatening disease. Procalcitonin levels in patients with suspected respiratory tract infection (RTI) may be useful in determining if patients require antibiotic therapy. In RTIs, the levels of procalcitonin are not necessarily as elevated, and a cutoff of greater than 0.25 ng/mL seems to be most predictive of a bacterial respiratory tract infection requiring antibiotic therapy, while a level less than 0.25 ng/mL signals resolution of the infection.[15,16]

The cutoffs for other clinical situations may be quite different. For example, neonates normally show a characteristic increase in procalcitonin after birth, with a rapid return to normal by 48 to 72 hours. In this circumstance, the elevated procalcitonin levels are an acute phase reactant in response to the stress of the birth process, yet an incremental increase is still

detectable in infants with neonatal sepsis. Unlike adults with systemic bacterial or fungal infection, sepsis, or RTIs that require antibiotic therapy, a nomogram for procalcitonin cutoffs that accounts for the time from birth in hours must be used.[17] Likewise, the stress of surgery may increase procalcitonin levels, but again, there is an incremental increase in patients with infection, including subclinical or high risk of infection. Postoperatively, the procalcitonin cutoff level to identify patients with infection or at risk of infection may be higher than that used for other patient groups. Although procalcitonin may have a role in diagnosis and identification of patients who need initiation of systemic antibiotics, it may have greater applicability in guiding decisions about when to discontinue antibiotic therapy as procalcitonin levels quickly return to less than 0.25 ng/mL as infection resolves.[18]

Most of the RCTs of procalcitonin-guided diagnosis or management use one of the BRAHMS assays cleared for use in the United States and currently being marketed by bioMerieux. The recommendations for clinical cutoffs being marketed are in consensus with the cutoff used and evaluated in the RCTs looking at the use of procalcitonin in patient management. Most of these RCTs of procalcitonin-guided diagnosis or management involve two clinical entities: sepsis/systemic bacterial infections and LRTIs. As a result, two different cutoffs for interpretation of results are being marketed for these two clinical entities. A nomogram for neonates is also recommended.

Although the utility of procalcitonin in clinical management has been reviewed in other meta-analyses and systematic reviews, this report will afford valuable new information. Some of the previous reviews have been limited to selected populations, or have evaluated studies of distinct populations or different procalcitonin-guided therapies together. When this systematic review was initiated, the most recent meta-analysis of the effects of procalcitonin-guided therapy in patients with infections included seven RCTs published through November 2008.[3] Since that time, the number of trials, including RCTs, studying procalcitonin-guided therapy has more than doubled. Further, there have also been several comprehensive literature reviews and two very recent systematic reviews of the use of procalcitonin to guide duration of antibiotic therapy in the ICU.[19-21] Even though our understanding of the potential clinical benefits of procalcitonin assays is still evolving, clinicians have already begun to request that laboratories perform procalcitonin measurements and, therefore, another systematic review of the use of procalcitonin is needed at the present time. Furthermore, a comprehensive review evaluating different patient populations and all the potential uses of procalcitonin will identify the areas that require further prospective investigation and will serve as a roadmap for future research. The following Key Question and Analytic Framework outline the approach and key issues to be addressed in this review.

Key Questions

During the period the Key Questions were posted for public comment on the Effective Health Care Program Web site (www.effectivehealthcare.ahrq.gov), four general comments were received. The comments varied greatly from being supportive to being skeptical of procalcitonin's utility in diagnosing and managing infections. The contrasting opinions about procalcitonin's utility underscore the importance of performing a formal comparative effectiveness review. One comment questioned whether or not pediatric populations will be included in this review; in response, we note that pediatric populations have not been excluded from this review. Some studies have explored the use of procalcitonin in children with suspected infections, such as neonatal sepsis, urinary tract infections, and meningitis. The utility of procalcitonin as a screening tool for bacterial skin colonization or as a diagnostic tool for heat

stroke is beyond the scope of this review and will not be included. No changes were made to the key clinical questions based on the public comments; however, the two Key Questions were combined into a single Key Question in the final report after further refinement.

Key Question: In selected populations of patients with suspected local or systemic infection, what are the effects of using procalcitonin measurement plus clinical criteria for infection to guide initiation, discontinuation, or a change of antibiotic therapy when compared with clinical criteria for infection alone on:

- Intermediate outcomes, such as initiation, discontinuation, or change of antibiotic therapy; antibiotic use; and length of stay?
- Health outcomes, such as morbidity, mortality, function, quality of life, and adverse events of antibiotic therapy (persistent or recurrent infection, and antibiotic resistance)?

The PICOTS (Patient, Intervention, Comparator, Outcome, Timing, and Setting) for the Key Question follows:

Patients

- Adult patients with suspected infection, including, but not limited to, the following:
  - Local infections
    - Acute exacerbation of chronic obstructive pulmonary disease
    - Pneumonia
    - Surgical site infection
    - Osteomyelitis
  - Systemic infections
    - Neutropenic fever
    - Bacteremia
    - Sepsis
    - Septic shock
- Pediatric patients with suspected infection, including, but not limited to, the following:
  - Local infections
    - Pneumonia
    - Urinary tract infection
    - Meningitis
  - Systemic infections
    - Neutropenic fever
    - Bacteremia
    - Sepsis
    - Septic shock

Interventions

- Initiation, discontinuation, or intensification of antibiotics therapy guided by procalcitonin plus clinical criteria for infection

Comparators

- Initiation, discontinuation, or intensification of antibiotic therapy guided by clinical criteria for infection alone

Outcomes

- Intermediate outcomes
    - Antibiotic exposure
    - Duration of antibiotic therapy
    - Length of stay
- Health outcomes
    - Morbidity
    - Mortality
    - Function
    - Quality of life as measured by validated scales
- Adverse events
    - Persistent or recurrent infection
    - Antibiotic resistance

Timing

- Three months

Settings

- Outpatient: ambulatory clinics, urgent care centers
- Inpatient: hospital wards, intensive care units, emergency departments

Methods

Methodological practices followed in this review were derived from the Agency for Healthcare Research and Quality (AHRQ) Methods Guide for Effectiveness and Comparative Effectiveness Reviews[22] (hereafter referred to as the "Methods Guide") and its subsequent updates.

Topic Development and Refinement

Key Questions were reviewed and refined as needed by the Evidence-based Practice Center (EPC) with input from Key Informants and the Technical Expert Panel (TEP) to ensure that the questions were specific and explicit about what information was being reviewed. In addition, for Comparative Effectiveness reviews, the Key Questions were posted for public comment and finalized by the EPC after review of the comments.

Key Informants are the end users of research, including patients and caregivers, practicing clinicians, relevant professional and consumer organizations, purchasers of health care, and others with experience in making health care decisions. Within the EPC program, the Key Informant role is to provide input into identifying the Key Questions for research that will guide health care decisions. The EPC solicits input from Key Informants when developing questions for systematic review or when identifying high priority research gaps and needed new research. Key Informants are not involved in analyzing the evidence or writing the report and have not reviewed the report, except as given the opportunity to do so through the peer or public review mechanism.

Key Informants had to disclose any financial conflicts of interest greater than $10,000 and any other relevant business or professional conflicts of interest. Because of their role as end-users, individuals were invited to serve as Key Informants and those who presented without potential conflicts were retained. The AHRQ Task Order Officer and the EPC worked to balance, manage, or mitigate any potential conflicts of interest identified.

Analytic Framework

Following is an analytic framework (see Figure 1) depicting the potential impact of using procalcitonin on both intermediate outcomes and health outcomes. Direct evidence of the impact of testing on health outcomes is shown by link A (morbidity, function, quality of life, and/or mortality) and link F (adverse events of therapy). Indirect evidence would have to be assembled in the absence of RCTs of the effects of testing on health outcomes. Link B addresses whether test results influence decisions about therapy, which may have an impact on health outcomes (link C) or intermediate outcomes (link D). Intermediate outcomes—such as antibiotic exposure, duration of antibiotic therapy, length of stay, and response to therapy—may have an association with health outcomes (link E).

Figure 1. Analytic framework for procalcitonin as a diagnostic indicator for infection and as an indicator of response to therapy



AECOPD = acute exacerbations of chronic obstructive pulmonary disease
Note: A–F show links between test results and outcomes. Please see the text above Figure 1 for more information.

Literature Search Strategy

The databases listed below were searched for citations. The full search strings and strategies can be found in Appendix A. The search was limited to English-language references because our EPC's experience in past projects that included non-English references did not yield high-quality information that justified the resources required for translation. Furthermore, the search was limited to literature published after 1990, which is approximately 10 years before reports of the use of modern serum biomarkers began to appear in the medical literature in the late 1990s.

- MEDLINE® (January 1, 1990, to December 16, 2011)
- Embase® (January 1, 1990, to December 16, 2011)
- Cochrane Controlled Trials Register (through December 16, 2011)

To identify systematic reviews, we searched MEDLINE®, the Cochrane Database of Systematic Reviews, and the websites of the National Institute for Clinical Excellence (www.nice.org.uk), the National Guideline Clearinghouse (www.guidelines.gov), and the Health Technology Assessment Programme (www.hta.ac.uk) from January 1, 1990, to August 6, 2010. The MEDLINE® search was updated in December 2011. We used results from previously conducted meta-analyses and systematic reviews when appropriate.

The TEP and individuals and organizations providing peer review were asked to inform the project team of any studies relevant to the Key Questions that were not included in the draft list of selected studies.

Search results were stored in EndNote9® and ProCite® databases. Using the study selection criteria for screening titles and abstracts, a single reviewer marked each citation as: (1) eligible for review as full-text articles; (2) ineligible for full-text review; or (3) uncertain. Citations marked as uncertain were reviewed by a second reviewer and inclusion and exclusion were decided by consensus opinion; a third reviewer was consulted if necessary. Using the final study selection criteria, full-text articles were reviewed in the same fashion to determine their inclusion in the systematic review. Records of the reason for exclusion for each paper retrieved in full-text, but excluded from the review, were kept in the EndNote9 and ProCite databases. A listing of excluded studies with reasons for exclusion can be found in Appendix B.

Study Selection

Inclusion criteria: Studies were included if they fulfilled all of the following criteria:

- Study was a randomized controlled trial or a nonrandomized comparative study (observational, case-control, and cohort studies).
- Study included adult and/or pediatric patients with known or suspected local or systemic infection, including critically ill patients with sepsis syndromes or ventilator-associated pneumonia, adults with respiratory tract infections, neonates with sepsis, children with fever of unknown source, and postoperative patients at risk of infection.
- Study intervention included initiation, discontinuation, and/or intensification of antibiotic therapy guided by procalcitonin plus clinical criteria for infection.
- Study outcomes included antibiotic use, mortality, morbidity, and adverse events of antibiotic therapy.

Exclusion criteria: Studies were excluded if they fulfilled at least one of the following criteria:

- Published in non-English language
- Did not report primary data (i.e., did not report data from original research)
- Did not use a relevant design
- Did not study relevant disease
- Did not report relevant outcomes

A screening guide for titles and abstracts can be found in Appendix E; a guide for full text articles can be found in Appendix F.

Search Strategies for Gray Literature

The EPC staff conducted a systematic search of the following gray literature sources to identify unpublished studies or studies published in journals that are not indexed in major bibliographic citation database in accordance with guidance from Effective Health Care Scientific Resource Center. The search strategies can be found in Appendix A.

1. Regulatory information
    a. Food and Drug Administration (FDA)
2. Clinical trial registries
    a. ClinicalTrials.gov
    b. Current controlled trials
    c. Clinical study results
    d. World Health Organization (WHO) clinical trials
3. Abstracts and conference papers
    a. Conference Papers Index
    b. Scopus
    c. Annual meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy
    d. Annual meeting of Infectious Diseases Society of America (IDSA)
    e. Annual meeting of American College of Chest Physicians
    f. Annual meeting of Pediatric Academic Societies
4. Grants and federally funded research
    a. NIH RePORTER (a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other research institutions)
    b. HSRPROJ (a database providing access to ongoing grants and contracts in health services research)
    c. AHRQ GOLD (an online searchable database of AHRQ grants, working papers, and HHS recovery act projects)
5. Manufacturer database: Industry stakeholders were invited to submit the following types of information for possible inclusion as evidence:
    - A current product label;
    - Published RCTs and observational studies relevant to the clinical outcomes; and
    - Unpublished RCTs and observational studies relevant to the clinical outcomes

These sources were searched using sensitive searches similar to the searches in bibliographic databases, except for the following:

- Regulatory information: The FDA Web site was searched for only 510(k) decision summary documents related to procalcitonin assays.
- For clinical registries, NIH RePORTER, HSRPROJ, and AHRQ GOLD searches were limited to completed studies only.
- For abstracts and conferences, studies published prior to 2006 were excluded.

Data Extraction and Data Management

Data Elements

The following data elements from the intervention studies were abstracted, or recorded as not reported. The data elements to be abstracted were defined in consultation with the TEP and included the following: The data abstraction form can be found in Appendix G.

- Quality assessment
    - Number of participants and flow of participants through steps of study
    - Treatment-allocation methods (including concealment)
    - Use of blinding
    - Prospective versus retrospective
    - Use of an independent outcome assessor
    - Additional elements are described below under Assessment of Methodological Quality of Individual Studies
- Study funding sponsorship source acknowledgement
- Assessment of Applicability and Clinical Diversity
    - Patient characteristics, including:
        - Age
        - Sex
        - Race/ethnicity
        - Disease and type
        - Disease duration
        - Other prognostic characteristics (e.g., co-morbidities and other potential confounders and/or effect modifiers)
        - Setting
            - Outpatient
            - Inpatient
    - Diagnostic and treatment characteristics, including:
        - Procalcitonin assay type
        - Other measured indicators of sepsis or of response to treatment (e.g., fever, white blood cell count)
        - Decisionmaking for diagnosis and/or treatment (e.g., when to administer antibiotic therapy)
        - Antibiotic use during study period
        - Duration of observation
        - Other treatment modalities

- Outcome Assessment
    - Identified primary outcome
    - Identified secondary outcomes
    - Response criteria
    - Followup frequency and duration
    - Data analysis details, including:
        - Statistical analyses (statistical test/estimation results)
            - Test used
            - Summary measures
            - Sample variability measures
            - Precision of estimate
            - p values

Evidence Tables

Templates for evidence tables were created in Microsoft Word®. One reviewer performed primary data abstraction of all data elements into the evidence tables, and a second reviewer reviewed the articles and evidence tables for accuracy. Disagreements were resolved by discussion, and if necessary, by consultation with a third reviewer. When small differences occurred in quantitative estimates of data from published figures, the values were calculated by averaging the estimates of the first two reviewers. Data abstraction tables can be found in Appendix C.

Individual Study Quality Assessment

Definition of Ratings Based on Criteria

In adherence with the Methods Guide,[22] the general approach to grading individual comparative studies was performed by using a method used by the U.S. Preventive Services Task Force.[23] The quality of the abstracted studies and the body of evidence were assessed by two independent reviewers. Discordant quality assessments were resolved with input from a third reviewer, if necessary.

- The quality of studies was assessed on the basis of the following criteria:
    - Initial assembly of comparable groups: adequate randomization, including concealment and whether potential confounders (e.g., other concomitant care) were distributed equally among groups.
    - Maintenance of comparable groups (includes attrition, crossovers, adherence, and contamination).
    - Important differential loss to followup or overall high loss to followup.
    - Measurements: equal, reliable, and valid (includes masking of outcome assessment).
    - Clear definition of interventions.
    - All important outcomes considered.
    - Analysis: adjustment for potential confounders and intention-to-treat analysis.
        - Intention-to-treat analysis was defined as no more than 5 percent loss in the analysis or use of a missing data handling procedure and all patients analyzed within the groups to which they were randomized.

The rating of intervention studies encompasses these three quality categories:

- **Good.** Meets all criteria; comparable groups were assembled initially and maintained throughout the study (followup at least 80 percent); reliable and valid measurement instruments were used and applied equally to the groups; interventions were spelled out clearly; all important outcomes were considered; and appropriate attention was given to confounders in analysis. In addition, intention-to-treat analysis was used for RCTs.
- **Fair.** Studies were graded "fair" if any or all of the following problems occurred, without the fatal flaws noted in the "poor" category below: In general, comparable groups were assembled initially, but some questions remained about whether some (although not major) differences occurred with followup; measurement instruments were acceptable (although not the best) and were generally applied equally; some but not all important outcomes were considered; and some but not all potential confounders were accounted for. Intention-to-treat analysis was done for RCTs.
- **Poor.** Studies were graded "poor" if any of the following fatal flaws existed: Groups assembled initially were not close to being comparable or maintained throughout the study; unreliable or invalid measurement instruments were used or not applied at all equally among groups; and key confounders were given little or no attention. Generally, lack of masked outcome assessment is considered a fatal flaw, but due to the nature of the interventions and comparators in this systematic review, it was not considered a fatal flaw. For RCTs, intention-to-treat analysis was lacking

Data Synthesis

We anticipated that the decision to incorporate formal data synthesis into this evidence review would be made after completing the formal literature search. Similarly we also anticipated that the decision to pool studies would be based if there were sufficient number of studies available that were designed to ask similar questions and reported similarly defined outcomes. Specifically, meta-analysis was performed if a minimum of three studies selected a similar population and reported an outcome that was measured similarly and with sufficient detail. An example of similarly measured outcomes included combining in-hospital mortality, 28-day mortality or 6-week mortality. Several antibiotic outcomes were found not to be similar enough to be pooled, including duration of antibiotic therapy in days, rate of antibiotic prescription as a proportion, and total antibiotic exposure in number of days on antibiotics per total patient-days for an entire group as a rate. Sufficient detail for an outcome measured as a mean, such as length of stay, requires reporting of standard deviations. When meta-analysis could be performed, subgroup and sensitivity analyses would be based on assessment of study-level clinical diversity in a sufficient number of available studies. Degree of statistical heterogeneity is reported by the I^2 statistic. The pooling method involves inverse variance weighting and a random effects model. Studies reporting zero events in one or both arm are excluded from pooling.

Assessment of Applicability

Applicability of findings in this review was assessed within the EPICOT framework (Evidence, Population, Intervention, Comparison, Outcome, Timestamp).[24] Selected studies were assessed for relevance against target populations, interventions of interest, and outcomes of interest.

Grading the Body of Evidence for Each Key Question

The system used for rating the strength of the overall body of evidence is outlined in the Methods Guide[22] and is based on a system developed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group.[25] This system explicitly addressed the following domains: risk of bias, consistency, directness, and precision. With respect to precision, studies could contribute to a rating of precise if confidence intervals did not overlap the null value or results were statistically significant, regardless of whether studies were powered to detect a particular effect for that outcome. The grade of evidence strength was classified into the following four categories:

- **High.** High confidence that the evidence reflected the true effect. Further research was very unlikely to change our confidence in the estimate of effect.
- **Moderate.** Moderate confidence that the evidence reflected the true effect. Further research may have changed our confidence in the estimate of effect and may have changed the estimate.
- **Low.** Low confidence that the evidence reflected the true effect. Further research was likely to change our confidence in the estimate of effect and was likely to change the estimate.
- **Insufficient.** Evidence was either unavailable or did not permit estimation of an effect.
- Additional domains including strength of association, publication bias, coherence, dose-response relationship, and residual confounding were addressed if appropriate.

Specific outcomes and comparisons were rated depending on the evidence found in the literature review. The grade rating was made by independent reviewers, and disagreements were resolved by consensus adjudication. In combining information from separate domains into an overall strength of evidence rating, we took into account the following considerations: whether the standard for comparison is superiority or noninferiority, the narrowness of a meta-analysis 95% confidence interval (CI), the consistency of narrow 95% CIs among individual studies, the consistency of statistically significant results, whether the direction of effect or both direction of effect and magnitude were consistent and whether similar outcomes measured differently had consistent findings.

Peer Review and Public Commentary

Peer Reviewers were invited to provide written comments on the draft report based on their clinical, content, or methodological expertise. Peer review comments on the preliminary draft of the report were considered by the EPC in preparation of the final draft of the report. Peer Reviewers did not participate in writing or editing the final report or other products. The synthesis of the scientific literature presented in the final report does not necessarily represent the views of individual reviewers. The dispositions of the peer review comments will be documented and published three months after the publication of the evidence report.

Potential reviewers had to disclose any financial conflicts of interest greater than $10,000 and any other relevant business or professional conflicts of interest. Invited Peer Reviewers could not have any financial conflict of interest greater than $10,000. Peer Reviewers who disclosed potential business or professional conflicts of interest were allowed to submit comments on the draft report through the public comment mechanism.

Results

Literature Search

Of the 2,000 records identified through the literature search, 1,986 were excluded at various stages of screening and 14 records were included. The PRISMA diagram (Figure 2) depicts the flow of search screening and study selection. We sought, but did not find, nonrandomized comparative studies (observational, case-control, and cohort studies) of populations, comparisons, interventions, and outcomes that were not adequately studied in the randomized controlled trials (RCTs).

Figure 2. PRISMA diagram for identified trials



Gray Literature Search

We evaluated the results of the gray literature search with results summarized in Figure 3.

- **Regulatory information:** The search yielded three 510(k) summaries for procalcitonin assay; BRAHMS PCT LIA,[8] VIDAS® BRAHMS PCT,[9] and BRAHMS PCT sensitive KRYPTOR® Test System.[10] Citations in the summary documents were screened against the main bibliographic databases. No new studies were identified from this source.
- **Clinical trial registries:** Citations for published articles linked to trials registered at ClinicalTrials.gov were included. The search yielded 91 clinical trials of which 89 were excluded during the title and abstract screen: 47 were duplicate (literature

Figure 3. PRISMA diagram for identified gray literature



ACCP = American College of Chest Physicians; AHRQ GOLD = Agency for Healthcare Research and Quality Grants On-Line Database; CSA = database at www.csa.com; FDA = Food and Drug Administration; HSRPROJ = Health Services Research Projects in Progress; ICAAC = Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; IDSA = Infectious Diseases Society of America; PAS = Annual meeting of Pediatric Academic Societies; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RePORTER = Research Portfolio Online Reporting Tools; WHO = World Health Organization

citations already included in our reference database), 16 were ongoing studies and 26 met the exclusion criterion (study did not compare procalcitonin-guided antibiotic therapy to an alternative). Two references (Manzano et al., 2010[26] and Burkhardt et al., 2010[27]) were reviewed in full-text and were included according to the study protocol.

- **Abstracts and conference papers:** The search yielded 450 citations of which 447 were excluded during the title and abstract screen: 183 references were duplicates and 264 met the exclusion criterion. The three remaining references (Jensen et al., 2011[28]; Rho 2010[29]; Sanches et al., 2010[30]) were randomized studies comparing procalcitonin-guided antibiotic therapy to an alternative. Two of these studies (Rho 2010[29] and Sanches et al., 2010[30]) were published only as abstracts at international meetings and were, therefore, excluded. The remaining study (Jensen et al., 2011[28]) was included in the report.
- **Grants and federally funded research:** The search yielded three citations and all three were excluded as they met the exclusion criterion.
- **Manufacturer database (SIPs):** In response, scientific information packets (SIPs) were received from Thermo Fisher Scientific. The submissions consisted of 67 published references or listings of clinical trials with abstracts; no unpublished data were provided by the company. Of the 67 references, 65 were excluded during abstract and title screen: 52 were duplicate and 12 met the exclusion criterion and one study could not be retrieved. The remaining two references were reviewed in full-text and one was excluded as it met the exclusion criterion. The remaining study (Long et al., 2011[31]) was included in the report.

Overall, search of gray literature yielded four published studies[26-28,31] that were included in the present evidence review. No unpublished studies meeting eligibility criteria were found.

We reviewed all published RCTs of the use of procalcitonin-guided initiation or discontinuation of antibiotic therapy, as well as studies that used procalcitonin for other interventions in patients with infection and/or sepsis. A total of 18 RCTs were identified for the review. Data abstraction tables can be found in Appendix C. The studies identified looked at very distinct clinical conditions in different patient populations and therefore, we grouped these 18 studies into 5 patient populations. These were: (1) critically ill adult patients in intensive care unit (ICU), including patients with ventilator-associated pneumonia (VAP) and those critically ill with suspected bacterial infections, severe sepsis, and septic shock; (2) patients with symptoms and signs of various respiratory tract infections; (3) neonates with suspected sepsis; (4) children between 1 to 36 months of age with fever of unknown source; and (5) postoperative patients at risk of infection (pre-emptive antibiotic therapy). In addition to being different patient populations with respect to age, underlying diseases, and morbidity and mortality, some studies also differed with respect to the specific algorithms for procalcitonin-guided management. Among these different strategies, one strategy used procalcitonin measurements to discontinue antibiotic therapy, while other strategies used procalcitonin levels to intensify or initiate antibiotic therapy. Sixteen studies[27,28,31-44] used a BRAHMS® quantitative procalcitonin assay and remaining two studies[26,45] used the BRAHMS semi-quantitative assay. The cutoffs for initiation and discontinuation of therapy were for the most part similar in each group, and many of the studies used similar measures for the outcomes of interest.

We also reviewed ongoing clinical trials that use procalcitonin-guided antibiotic therapy listed atClinicalTrials.gov. The details of these ongoing trials including sample size, presenting condition, primary and secondary outcomes and expected date of completion are summarized in Appendix D.

Critically Ill/Ventilator-Associated Pneumonia

There were a total of seven RCTs[28,32-35,39,45] comparing procalcitonin-guided therapy with standard antibiotic therapy in this population. Five studies[32-35,39] addressed procalcitonin-guided discontinuation of antibiotics. Two studies[28,45] addressed procalcitonin-guided intensification of antibiotic therapy.

Procalcitonin-Guided Antibiotic Discontinuation

Study Characteristics

There were five RCTs[32-35,39] comparing procalcitonin-guided therapy with standard antibiotic therapy (Table 2). Analyses of outcomes tested superiority of procalcitonin-guided therapy in all but one case: one study[39] conducted a noninferiority analysis for mortality. Sample sizes ranged from 27 to 621, with three studies[34,35,39] greater than 100. Overall, 938 patients were enrolled into these trials.

Procalcitonin criteria for discontinuation of antibiotic varied somewhat. Absolute values that prompted antibiotic discontinuation included 0.25, 0.5, and 1 ng/mL. Relative values included 25 to 35 percent of baseline or 80 and 90 percent reductions from baseline. Physicians in the control groups administered antibiotics according to their standard practice. In the largest study by Bouadma et al.,[39] local and international guidelines on duration of antibiotic therapy were available on a website. While the lack of specificity about what constituted antibiotic could be viewed as a limitation in study designs, it could also be viewed as a strength regarding applicability to actual practice. Study duration varied, but was for the duration of hospitalization, at least 28 days in three studies,[32,35,39] and at 60 days in one study.[39]

Three studies[32,35,39] identified antibiotic use as a primary outcome and two studies[33,34] did not mention a primary endpoint. One study[39] looked at mortality as a primary outcome, and mortality was a predefined secondary outcome in one other study.[32] Mortality data were available from all five studies.

Table 2. Summary of characteristics for five trials included in the analysis of procalcitonin-guided antibiotic discontinuation in the critically ill/ventilator-associated pneumonia patients

Author, Year, Country	Disease State	N	PCT for ABT Discontinuation	Control Interventions	Study Duration	Predefined Endpoints
Bouadma, 2010, France[39]	Critically ill, suspected bacterial infection	PCT 307 Ctrl 314	PCT <0.5 ng/mL or >/= 80% decrease from peak	Broad-spectrum ABTs started ASAP; de-escalation based on cultures if possible; ABT duration by local and international guidelines	60 days	Primary outcome mortality, number of days without ABT Secondary ABT exposure, morbidity
Schroeder, 2009, Germany[33]	Severe sepsis	PCT 14 Ctrl 13	PCT ≤1 ng/mL or 25-35% of baseline	Dx of severe sepsis by ACCP guidelines; standard ABT therapy	Not defined	Not defined
Stolz, 2009, Switzerland & USA[35]	ICU, VAP	PCT 51 Ctrl 50	PCT <0.5 ng/mL or decrease of > /= 80% from baseline	VAP Dx by ATS guidelines; standard ABT therapy	28 days	Primary outcome ABT-free days at day 28
Nobre, 2008, Switzerland[32]	Severe sepsis	PCT 39 Ctrl 40	PCT <0.25 ng/mL or decreased by 90% from baseline	Sepsis, septic shock Dx by ACCP criteria; standard broad-spectrum ABT therapy	28 days	Primary outcome ABT exposure Secondary outcomes 28 day mortality, ICU LOS, other
Hochreiter, 2009, Germany[34]	ICU, sepsis	PCT 57 Ctrl 53	PCT <1 ng/mL or 25-35% of baseline over 3 days	SIRS Dx by ACCP criteria; standard ABT therapy for 8 days	Not defined	Not defined

ABT = antibiotic; ACCP = American College of Chest Physicians; ASAP = as soon as possible; ATS = American Thoracic Society; Ctrl = control; Dx = diagnosis; ICU = intensive care unit; LOS = length of stay; PCT = procalcitonin; SIRS = systemic inflammatory response syndrome; VAP = ventilator-associated pneumonia

Study Quality

The overall rating for three studies[32,35,39] was good and fair for the remaining two studies[33,34] (Table 3). All studies assembled groups appearing to have similarly distributed potential confounders with no obvious imbalances. Two studies[33,34] did not describe their procedure for allocation concealment.

Judgments of whether outcome measurements were equal, valid and reliable usually depend in part on the requirement for blinded outcome assessor. However, in these studies, it was not feasible to blind the treating physicians to the patient's assigned treatment. Decisions on antibiotic use were made by unblinded physicians who could take other clinical information into account and override the algorithm based on their clinical judgment. Procalcitonin guidance is intended as an adjunct to, not a replacement for, clinical criteria for assessing and managing infection. In this setting, we did not require use of a blinded outcome assessor as a dimension of study quality.

Intention-to-treat analyses were consistently performed. One study[32] reported both intention-to-treat and per-protocol analyses. The study designed to test noninferiority of mortality in the procalcitonin-guided group was powered to exclude a 10 percent between-group mortality

difference. No other studies were powered to detect differences in mortality or morbidity outcomes.

Antibiotic Use

Outcomes related to antibiotic use are summarized in Table 4. The duration of antibiotic therapy was reduced in the procalcitonin-guided arm of all five studies.[32-35,39] The absolute difference ranged from -1.7 to -5 days, with a percent reduction of 21 to 38 percent. Figure 4 shows the results of a meta-analysis of antibiotic duration. It included three studies[33,34,39] that reported sufficient information for pooling and yielded a statistically significant pooled mean difference of 2.05 days (95% CI: -2.59, -1.52) favoring procalcitonin guidance and an I^2 value of 41 percent, indicating moderate statistical heterogeneity. The two excluded studies[32,35] that did not report sufficient information for pooling reported larger effects than the pooled estimate, so including them would have produced a stronger pooled effect favoring procalcitonin guidance. Three studies reported the reduction in antibiotic use in terms of days without antibiotic therapy. Again, this favored procalcitonin-guided therapy, with an additional 2.3 to 3.8 days without antibiotics, an 18 to 37 percent reduction. Three studies[32,35,39] reported total antibiotic exposure, which also accounted for the use of multiple agents (intensity), as well as duration of therapy. Total exposure per 1,000 patient-days ranged from 644 to 1,341 for the control groups, with a longer duration seen for VAP, but in all 3 studies total exposure in the procalcitonin-guided arm was reduced by 16 to 20 percent. The study[32] that reported both intention-to-treat and per-protocol analyses found statistically significant reductions only with the latter for antibiotic duration, days without antibiotic and total antibiotic exposure. In summary, procalcitonin-guided therapy resulted in consistent reductions in antibiotic use by all measures. The range of reduction in antibiotic use was also similar across studies.

Table 3. Procalcitonin-guided antibiotic discontinuation in the critically ill/ventilator-associated pneumonia patients—study quality

Author, Year	Assembled Comparable Groups	Maintained Comparable Groups	Minimal Followup Loss	Measurements Equal, Valid, and Reliable	Interventions Clearly Defined	Important Outcomes Considered	Appropriate Analysis of Results	Overall USPSTF Rating
Bouadma, 2010[39]	Y	Y	Y	Y	Y	Y	Y	Good
Schroeder, 2009[33]	Y*	Y	Y	Y	Y	Y	Y	Fair
Stolz, 2009[35]	Y	Y	Y	Y	Y	Y	Y	Good
Nobre, 2008[32]	Y	Y	Y	Y	Y	Y	Y	Good
Hochreiter, 2009[34]	Y*	Y	Y	Y	Y	Y	Y	Fair

USPSTF = United States Preventive Services Task Force; Y = yes

*No details on allocation concealment, but groups were comparable

Table 4. Procalcitonin-guided antibiotic discontinuation in the critically ill/ventilator-associated pneumonia patients––outcomes related to antibiotic use

Outcome	Author, Year	N	PCT-Guided Therapy[Ψ]	Control[Ψ]	Difference PCT-CTRL (95% CI)	p-Value
ABT Duration (days)	Hochreiter, 2009[34]	110	5.9	7.9	-2.0 (-2.5, -1.5)	< 0.001
	Nobre, 2008[32]	79	6 6	9.5 (ITT) 10 (PP)	-2.6 (5.5, -0.3), -3.2 (-1.1,- 5.4)	0.15 0.003
	Schroeder, 2009[33]	27	6.6	8.3	-1.7 (-2.4, -1.0)	<0.001
	Stolz, 2009[35]	101	10 (6-16)[‡]	15 (10-23)[‡]	-5	0.049
	Bouadma, 2010[39]	621	10.3	13.3	-3.0 (-4.20,-1.80)	<0.0001
Days without ABTs (day 28)	Nobre, 2008[32]	79	15.3 17.4	13 13.6	2.3 (-5.9, 1.8) 3.8 (0.1, 7.5)[§]	0.28 0.04
	Stolz, 2009[35]	101	13 (2-21)[‡]	9.5 (1.5-17)[‡]	3.5	0.049
	Bouadma, 2010[39]	621	14.3	11.6	2.7 (1.4, 4.1)	<0.001
Total ABT exposure*	Nobre, 2008[32]	79	541 504	644 655	1.1[**] (0.9, 1.3) 1.3[**] (1.1, 1,5)[§]	0.07 0.0002
	Stolz, 2009[35]	101	1077	1341		
	Bouadma*, 2010[39]	621	653	812	-159 (-185, -131)	<0.001

ABT = antibiotic; CI = confidence interval; CTRL = control; ITT = intention to treat; PCT = procalcitonin; PP = per protocol

*Per 1,000 inpatient days

**Rate ratios

§Per protocol analysis

ΨValues are mean unless specified

‡ Median (interquartile range)

Figure 4. Meta-analysis of mean differences, antibiotic duration (days) in critically ill/ventilator-associated pneumonia patients



CI = confidence interval; IV = inverse variance weighted; SD = standard deviation

Mortality

Three studies[32,35,39] reported 28-day mortality, one study[39] reported both 28- and 60-day mortality, two studies[32,35] reported in-hospital mortality, and two studies[33,34] reported overall mortality (Table 5). Mortality rates at 28 days in control arms ranged from 20 to 24 percent.

In one study,[33] the reduction in 28-day mortality with procalcitonin-guided therapy was 8.3 percent, and in two studies, mortality increased by 0.5 percent[32] and 0.8 percent.[39] None of these differences was statistically significant.

Only one study[39] reported 60-day mortality. There was a 3.9 percent increase in mortality in the procalcitonin-guided group that was not statistically significant, but procalcitonin-guided therapy met the predefined criteria for noninferiority with respect to 60-day mortality. Additionally, deaths between 28 and 60 days were analyzed, and none was related to relapse of infection. In-hospital mortality was higher in the procalcitonin-guided group by 0.6 percent in one study[32] and reduced by 8.4 percent in one study,[35] but neither difference reached statistical significance. Overall mortality was slightly reduced in the two studies from 0.1[34] to 1.7[33] percent reduction, but the differences were not significant.

Most studies were powered to determine if there was a difference in antibiotic use, and not powered to detect differences in morbidity and mortality. Only the study by Bouadma et al.,[39] the largest RCT looking at procalcitonin-guided therapy to date, was powered to determine noninferiority of procalcitonin-guided therapy versus standard care. The study was powered to have an 80 percent power to exclude a 10 percent difference in mortality between groups. Noninferiority was met for 28-day and 60-day mortality in this study, but there is concern whether the 10 percent margin chosen is the appropriate noninferiority margin to assure there is no excess mortality associated with procalcitonin-guided antibiotic therapy in this patient population.

Table 5. Procalcitonin-guided antibiotic discontinuation in the critically ill/ventilator-associated pneumonia patients––mortality

Outcome	Author, Year	N	Mortality PCT-Guided Therapy	Mortality Control	Difference PCT-CTRL (95% CI)	p-Value
28-day mortality	Nobre, 2008[32]	79	8/39 (20.5%) 5/31 (16.1%)	8/40 (20.0%) 6/37 (16.2%)	0.5 (-17.2, 18.2), -0.1 (-17.7, 17.5) [§]	0.95 0.99
	Stolz, 2009[35]	101	8/51 (15.7%)	12/50 (24.0%)	-8.3 (-23.8, 7.2)	0.29
	Bouadma, 2010[39]	621	65/307 (21.2%)	64/314 (20.4%)	0.8 (-5.6, 7.2)	0.81
60-day mortality	Bouadma, 2010[39]	621	92/307 (30.0%)	82/314 (26.1%)	3.9 (-3.2, 10.9)	0.29
In-hospital mortality	Nobre, 2008[32]	79	9/39 (23.1%) 6/31 (19.4%)	9/40 (22.5%) 7/37 (18.9%)	0.6 (-17.9, 19.1) 0.4+ (-18.3, 19.2)	0.95 0.96
	Stolz, 2009[35]	101	10/51 (19.6%)	14/50 (28.0%)	-8.4, (-24.9, 8.1)	0.32
	Hochreiter, 2009[34]	110	15/57 (26.3%)	14/53 (26.4%)	-0.1, (-16.6, 16.4)	0.99
	Schroeder, 2009[33]	27	3/14 (21.4%)	3/13 (23.1%)	-1.7, (-33.1, 29.8)	0.92

CI = confidence interval; CTRL = control; PCT = procalcitonin
[§]Per protocol analysis

A meta-analysis was performed to pool mortality data from all five studies[32-35,39] in order to increase the probability of detecting a significant difference in between-group mortality. Pooling was performed for studies reporting short-term (28-day or in-hospital) mortality. Results show a pooled point estimate of 0.4 percentage point reduction in mortality (95% CI: -6 percent, 5 percent) favoring the procalcitonin-guided therapy group (Figure 5). Statistical heterogeneity, as expressed by the I^2 statistic, was found to be 0 percent.

Figure 5. Meta-analysis of risk differences, short-term mortality (in-hospital or 28-day) in critically ill/ventilator-associated pneumonia patients



CI = confidence interval; IV = inverse variance weighted; SD = standard deviation

Morbidity

Three studies[32,35,39] evaluated hospital length of stay (LOS), four studies[32-34,39] evaluated ICU LOS, one study[35] evaluated ICU-free days alive, three studies[33,34,39] evaluated some type of severity of illness score, and three studies[35,39] reported on days without mechanical ventilation (Table 6). Hospital LOS was reduced by 0 to 2.5 days in the procalcitonin-guided arms. This represents a 0 to 11 percent reduction in LOS, but the difference was not statistically significant in any of the studies. ICU LOS similarly was reduced by 0.3 to 4.6 days in three studies, and increased by 1.5 days in another study. The only study reporting a significant decrease in ICU LOS was the Nobre study[32] of severe sepsis and septic shock, where ICU LOS was reduced by 43 percent. The study by Stolz[35] found that the difference in ICU-free days alive within 28 days

was higher by 1.5 days in the procalcitonin-guided therapy group, but it was not statistically significant. Among studies reporting severity of illness scales, there was a small difference in severity that favored procalcitonin-guided therapy in two[33,34] out of three[33,34,39] studies, but the differences were not significant. Only one study[39] showed a significant increase in the severity of illness at 28 days, but the difference was minimal and the absolute severity scores were extremely low for both groups. One study[39] reported a reduction in mechanical ventilation and one study[35] reported an increase in mechanical ventilation, but none of the differences was significant.

Because ICU LOS was reported by four studies,[32-34,39] we considered conducting meta-analysis on this outcome. One study[32] did not report data necessary for calculation, so only three studies were represented in the meta-analysis (Figure 6). The pooled mean difference is 0.33 days, but the 95% CI is between -1.88 days and 2.53 days, suggesting that neither procalcitonin nor control are favored. Statistical heterogeneity was negligible (I^2=14 percent).

Table 6. Procalcitonin-guided antibiotic discontinuation in the critically ill/ventilator-associated pneumonia patients—morbidity

Outcome	Author, Year	N	PCT[Ψ]	Control[Ψ]	Difference, PCT-CTRL (95% CI)	p-Value
LOS (days)	Nobre, 2008[32]	79	17	23.5	-2.5 (-6.5, 1.5)	0.85
	Stolz, 2009[35]	101	26 (7-21)[‡]	26 (16.8-22.3)[‡]	0	0.15
	Bouadma, 2010[39]	621	26.1	26.4	-0.3 (-3.2, 2.7)	0.87
ICU LOS (days)	Hochreiter, 2009[34]	110	15.5	17.7	-2.2	0.046
	Nobre, 2008[32]	79	4	7	-4.6 (-8.2, -1.0)	0.02
	Schroeder, 2009[33]	27	16.4	16.7	-0.3,(-5.6, 5.0)	NSS
	Bouadma, 2010[39]	621	15.9	14.4	1.5 (-0.9, 3.1)	0.23
ICU-free days alive, 1-28	Stolz, 2009[35]	101	10 (0-18)[‡]	8.5 (0-18)[‡]	1.5	0.53
SOFA day 28	Bouadma, 2010[39]	621	1.5	0.9	0.6 (0.0, 1.1)	0.037
SOFA score max	Schroeder, 2009[33]	27	7.3	8.3	-8.1 (-4.1, 1.7)	NSS
SAPS II score	Hochreiter, 2009[34]	110	40.1	40.5	-0.4 (-6.4, 5.6)	> 0.05
Days without MV	Stolz, 2009[35]	101	21 (2-24)[‡]	19 (8.5-22.5)[‡]	2.0	0.46
	Bouadma, 2010[39]	621	16.2	16.9	-0.7 (-2.4, 1.1)	0.47

CI = confidence interval; CTRL = control; ICU = intensive care unit; LOS = length of stay; MV = mechanical ventilation; NSS = not statistically significant; PCT = procalcitonin; SAPS = Simplified Acute Physiology Score; SOFA = Sepsis-Related Organ Failure Assessment

[Ψ]All values are mean unless specified.

[‡] Median (interquartile range).

Figure 6. Meta-analysis of mean differences, ICU length of stay (days) in critically ill/ventilator-associated pneumonia patients



CI = confidence interval; IV = inverse variance weighted; SD = standard deviation

Adverse Events of Antibiotic Therapy

Only one study[39] reported on adverse effects of antibiotic therapy. Bouadma et al. reported on emergence of multidrug resistant (MDR) organisms (17.9% vs. 16.6% in the procalcitonin vs. the control group respectively, difference 1.3%, 95% CI: -4.6, 7.2, p=0.67) and superinfection (34.5% vs. 30.9% in the procalcitonin vs. the control group respectively, difference 3.6%, 95% CI: -3.8, 11, p=0.29).

GRADE Evidence

Methods for grading strength of evidence[25] developed for the AHRQ Effective Health Care Program were applied to this body of literature (Table 7). The quality of studies reviewed was an important consideration. Three of the five studies[32,35,39] received a good quality rating and two studies[33,34] received a fair rating.

For the body of evidence reviewed here, the strength of evidence was graded high for a reduction in antibiotic use. There were three different measures of antibiotic use: antibiotic duration in days, antibiotic prescription rate as a proportion and total antibiotic exposure as a rate: The consistency of findings across these three measures strengthened our confidence that there was a high strength of evidence. The three studies[32,35,39] judged as good quality included 85 percent of the total patient population (801 of 938) and also reported on all three antibiotic use measures. The results consistently favored procalcitonin-guided therapy, and differences were generally highly statistically significant and were of a magnitude that has been associated with clinical benefits using other approaches to reduction of antibiotic use, such as active interventions of antibiotic stewardship programs and implementation of practice guidelines.[46-48] The absolute difference in antibiotic use duration, the measure that was reported by all five studies, ranged from -1.7 to -5 days, with a percent reduction of 21 to 38 percent.

The strength of evidence that there was no difference in mortality with procalcitonin-guided discontinuation of antibiotic therapy in the critically ill/VAP patients was graded as low. The results of all five studies[32-35,39] were consistent in finding no significant difference in short-term (28-day or in-hospital) mortality between procalcitonin-guided therapy and control groups. Four of the studies[32-35] were not sufficiently powered to assess mortality. The largest study by Bouadma et al.[39] was a noninferiority study that had 80 percent power to exclude a 10 percent difference in mortality between groups. Meta-analysis was performed to increase the power of detecting a significant difference in between-group mortality. Results show a pooled point estimate of 0.4 percentage point reduction in mortality favoring the procalcitonin-guided therapy group (95% CI: -6%, 5%).

The strength of evidence grading system described by Owens[25] was designed with the assumption of a superiority conclusion. A conclusion of noninferiority only requires sufficient precision to exclude a minimal important difference (MID), i.e., the noninferiority margin.[49] In grading the strength of evidence as low that procalcitonin-guided antibiotic therapy does not increase mortality, a major concern was disagreement about the appropriate noninferiority margin for mortality. Although a 10 percent noninferiority margin has been recommended by the IDSA and American College of Chest Physicians (ACCP) in relevant populations, there is also strong sentiment that this is too high a noninferiority margin for mortality, which was expressed among our peer reviewers and also in the published literature. Moreover, there are presently two large trials in progress, which may in the future yield more precise estimates of mortality.

All five studies[32-34,39] reported on ICU LOS as a measure of morbidity. Risk of bias was rated low due to the preponderance of patients in good quality studies. Evidence was judged consistent

as four of five studies[32-34] reported shorter ICU LOS for procalcitonin arm. Evidence was considered direct and sufficiently precise to support the judgment that procalcitonin guidance does not increase morbidity as indicated by ICU LOS. The strength of evidence that procalcitonin does not increase ICU LOS was graded moderate primarily because only three studies reported sufficient details for pooling into a meta-analysis for this outcome.

Table 7. Procalcitonin-guided antibiotic discontinuation in the critically ill/ventilator-associated pneumonia patients––GRADE evidence table

Outcome Category	Outcome	No. of Studies (Subjects)	Risk of Bias	Consistency	Direct-ness	Precision	Overall Grade
Antibiotic use	Duration	5 RCTs (n=938)[32-35,39]	Low	Consistent	Direct	Precise	High
	Days without ABTs (day 28)	3 RCTs (n=801)[32,35,39]	Low	Consistent	Direct	Precise	High
	Total exposure	3 RCTs (n=801)[32,35,39]	Low	Consistent	Direct	Precise	High
Mortality	In-hospital, overall or 28 day	5 RCTs (n=938)[32-35,39]	Low	Consistent	Direct	Precise	Low*
Morbidity	ICU length of stay	5 RCTs (n=837)[32-35,39]	Low	Consistent	Direct	Precise	Moderate**

ABT = antibiotic; GRADE = grading of recommendations assessment, development, and evaluation; ICU = intensive care unit; RCT = randomized controlled trial

*The overall grade was low based on uncertainty about the appropriate minimum important difference for assessing noninferiority with respect to mortality.

**Only three studies reported sufficient details for pooling into a meta-analysis for this outcome.

Procalcitonin-Guided Antibiotic Intensification

Study Characteristics

There were two RCTs[28,45] of procalcitonin-guided antibiotic intensification (Table 8). Both studies evaluated critically ill patients in the ICU. The Svoboda study[45] was limited to patients in the surgical ICU, while surgical patients were only a portion, but well represented, subgroup in the Jensen study.[28] One study[45] followed the patients for the duration of hospitalization, while the other study[28] looked at outcomes at 28 days. Both studies reported intention-to-treat to treat analysis. Svoboda et al.[45] enrolled 72 patients and Jensen[28] enrolled 1,200 patients. In the Svoboda study[45] an elevated procalcitonin level prompted IV catheter changes and changes in the antibiotic regimen. In the Jensen study,[28] an algorithm for expanded radiographic evaluation and broadening the spectrum of antimicrobial therapy was used for patients with elevated procalcitonin. In the Svoboda study,[45] the only description of antibiotic therapy in the control group was that it was standard of care. Jensen,[28] in contrast, had a very detailed approach to antibiotic therapy and physicians were educated as to the approach to be taken for empiric therapy and intensification of antibiotic therapy. Mortality was the primary outcome for the large study by Jensen.[28] The other study[45] did not predetermine outcomes to be assessed.

Table 8. Summary of characteristics for two trials included in the analysis of procalcitonin-guided antibiotic intensification in the critically ill/ventilator-associated pneumonia patients

Author, Year, Country	Disease State	N	PCT for ABT Discontinuation	Other PCT-Guided Interventions	Control Interventions	Study Duration	Predefined Endpoints
Svoboda, 2007, Czechoslovakia[45]	Severe sepsis, septic shock	PCT 38 Ctrl 34	NA	PCT >2, change catheters and ABTs, PCT <2, US or CT and repeat surgery	Standard supportive care; broad-spectrum ABTs; catheter changes as indicated by guidelines	Not defined	Not defined
Jensen, 2011, Denmark[28]	Critically ill in the ICU	PCT 604 Ctrl 596	NA	PCT $\geq$1.0 or less than 10% lower than previous day, enhanced radiographic evaluation and broadened spectrum of ABT therapy	Standard microbiological and radiographic evaluation, ABT therapy	28 days	Primary 28-day mortality Secondary Duration of organ failure; duration of stay in the ICU

ABT = antibiotic; CT = computed tomography; Ctrl = control; ICU = intensive care unit; NA = not applicable; PCT = procalcitonin; US = ultrasound

Study Quality

The quality ratings for the two studies[28,45] are described in Table 9. Both studies[28,45] assembled comparable groups and described randomization concealment. The study by Jensen[28] clearly outlined the specific interventions for intensification, while the other study[45] only vaguely described a push to change intravenous (IV) catheter and change antibiotics. One study[45] broadly described an initiative to change antibiotics and IV catheters, pursue radiographic imaging, and reoperation if a local infection was confirmed, but did not give any details regarding these interventions. The outcomes were strictly defined, and in the higher quality study by Jensen,[28] there was assurance that physicians, investigators, and coordinators were unaware of outcomes during the study or procalcitonin levels in the control group.

Antibiotic Use

In the study by Jensen,[28] procalcitonin-guided intensification resulted in a 2-day (50%) increase in the duration of antibiotic therapy (Table 10). It also resulted in greater antibiotic exposure with a 7.9 percent increase in number of days on three or more antibiotics in the ICU.

Table 9. Procalcitonin-guided antibiotic intensification in the critically ill/ventilator-associated pneumonia patients—study quality

Author, Year	Assembled Comparable Groups	Maintained Comparable Groups	Minimal Followup Loss	Measurements Equal, Valid, and Reliable	Interventions Clearly Defined	Important Outcomes Considered	Appropriate Analysis of Results	Overall USPSTF Rating
Svoboda, 2007[45]	Y	Y	Y	Y	N	Y	Y	Fair
Jensen, 2011[28]	Y	Y	Y	Y	Y	Y	Y	Good

N = no; USPSTF = United States Preventive Services Task Force; Y = yes

Table 10. Procalcitonin-guided antibiotic intensification in the critically ill/ventilator-associated pneumonia patients—outcomes related to antibiotic use

Author, Year	Outcome	N	PCT	Control	Difference PCT-CTRL (95% CI)	p-Value
Jensen, 2011[28]	ABT Duration (days)	1200	6 (3-11)‡	4 (3-10)‡	NR	NR
Jensen, 2011[28]	Days spent in ICU on ≥ 3 ABTs	1200	3,570/5,447 (65.5%)	2,721/4,717 (57.7%)	7.9% (6.0 to 9.7)	0.002

ABT = antibiotic; CI = confidence interval; CTRL = control; ICU = intensive care unit; NR = not reported; PCT = procalcitonin
‡Median (interquartile range)

Mortality

The impact of procalcitonin-guided antibiotic intensification on mortality is described in Table 11. There was a statistically insignificant reduction in mortality in the Svoboda[45] study, which was not powered to show differences in mortality. Jensen[28] was a superiority trial powered to test a 7.5 percent decrease in 28-day mortality, but no significant difference in mortality was observed with procalcitonin-guided intensification. Jensen[28] showed no beneficial or adverse effect on mortality with procalcitonin-guided intensification.

Table 11. Procalcitonin-guided antibiotic intensification in the critically ill/ventilator-associated pneumonia patients––28-day mortality

Author, Year	N	PCT	Control	Difference PCT-CTRL (95% CI)	p-Value
Svoboda, 2007[45]	72	10/38 (26.3%)	13/34 (38.2%)	-11.9 (-33.4, 9.6)	0.28
Jensen, 2011[28]	1200	190/604 (31.5%)	191/596 (32.0%)	-0.6 (-4.7 to 5.9)	0.83

CI = confidence interval; CTRL = control; PCT = procalcitonin

Morbidity

The Svoboda[45] showed a 3.3-day reduction in ICU stay, which was not statistically significant. Jensen[28] study showed a significant 1-day increase in ICU LOS (Table 12). Furthermore, this larger, good quality study demonstrated a significant increase in organ dysfunction, specifically an extra 5 days of mechanical ventilation and an additional 5 days of abnormal renal function, both of which were statistically significant.

Table 12. Procalcitonin-guided antibiotic intensification in the critically ill/ventilator-associated pneumonia patients––morbidity

Outcome	Author, Year	N	PCT	Control	Difference PCT-CTRL (95% CI)	p-Value
ICU LOS (days)[Ψ]	Svoboda, 2007[45]	72	16.1	19.4	-3.3 (-7.0, 0.4)	0.09
	Jensen, 2011 [28]	1200	6 (3-12)[‡]	5 (3-11)[‡]	1	0.004
SOFA score[Ψ]	Svoboda, 2007[45]	72	7.9	9.3	-1.4. (-2.8, 0.0)	0.06
Days on MV[Ψ]	Svoboda, 2007[45]	72	10.3	13.9	-3.6 (-7.6, 0.4)	0.08
	Jensen, 2011[28]	1200	3569 (65.5%)	2861 (60.7%)	4.9% (3 to 6.7)	< 0.0001
Percent days in ICU with GFR <60	Jensen, 2011[28]	1200	2796 (51.3%)	2187 (46.4%)	5.0 % (3.0 to 6.9)	<0.0001

CI = confidence interval; CTRL = control; GFR = glomerular filtration rate; ICU = intensive care unit; LOS = length of stay; MV = mechanical ventilation; PCT = procalcitonin

[Ψ] Values are mean unless specified.

[‡] Median (inter quartile range).

Adverse Events of Antibiotic Therapy

None of the studies in this patient group reported the adverse events of antibiotic therapy.

GRADE Evidence

The strength of evidence is moderate that procalcitonin-guided intensification of antibiotic therapy increases morbidity. The large (n=1,200) good quality study by Jensen[28] was judged to have low risk of bias. This study was notable for its specificity in describing study interventions,

especially treatment algorithms. Consistency was rated as unknown (single study). The evidence is direct and sufficiently precise to judge that procalcitonin-guided intensification does not improve outcomes in critically ill patients. A second study (n=72)[45] was too small to be informative.

Respiratory Tract Infections

There were eight studies[27,31,36-38,40-42] in total, seven randomized controlled trials[27,31,36,38,40-42] and one cluster-randomized controlled trial.[37] All studies compared procalcitonin-guided initiation and/or discontinuation of antibiotics in patients with respiratory tract infections to standard therapy. The sample size in these studies ranged from 162 to 1,359, with all studies having populations larger than 100. Overall, 3,492 patients were enrolled in these trials.

Study Characteristics

The populations in this study consisted of patients with acute upper and lower respiratory tract infections in the community, including CAP, acute exacerbation of chronic obstructive pulmonary disease (COPD), and acute bronchitis (Table 13). The study populations and settings varied between studies. Three studies[31,36,41] looked only at CAP, but the settings varied in these studies. One study[31] included patients from the outpatient setting, one study[36] included patients from the emergency department, and one study[41] included patients admitted to the hospital. Two studies[27,42] included patient populations that had upper or lower respiratory tract infections. Both of these studies looked at patients in the outpatient setting (primary care clinics). Two studies[37,40] included patients with lower respiratory tract infections only, and both of these studies enrolled patients that presented to emergency departments. One study[38] looked only at patients with acute exacerbation of COPD in the emergency department.

All studies[27,31,36-38,40-42] evaluated the use of procalcitonin for the initiation of antibiotics. All studies encouraged initiation of antibiotics with procalcitonin levels greater than 0.25 ng/mL, and four studies[36,37,40,41] strongly encouraged antibiotics with procalcitonin levels greater than 0.5 ng/mL. Seven studies[27,31,36,37,40-42] used procalcitonin measurement to recommend discontinuation of antibiotics. Five studies [27,31,37,41,42] recommended discontinuing antibiotics if procalcitonin level was less than 0.25 ng/mL, and one of these studies[31] strongly recommended discontinuation if level was less than 0.1 ng/mL. One study[40] recommended discontinuation if the procalcitonin level was less than 20 percent of the baseline level, and strongly recommended discontinuation if the level was less than 10 percent. One study[36] recommended discontinuation of antibiotics if the procalcitonin level was 10 percent of baseline, if the baseline level was greater than 10 ng/mL.

Physicians in the control groups administered antibiotics according to their own standard practices and/or evidence-based guidelines. Two studies[31,36] used international guidelines on standard therapy that were cited in the references. One study[40] used evidence-based, international guidelines which were stated in the methods section but not cited in the references.

The study durations ranged from 14 days to 30 days in five studies,[27,31,40,37,42] 6 weeks in one study,[36] and 6 months in one study.[38] Study duration was not defined in one study.[41]

Table 13. Summary of characteristics for eight trials included in the analysis of procalcitonin-guided antibiotic initiation and/or discontinuation in patients with respiratory tract infections

Author, Year, Country	Disease State	N	PCT for ABT Initiation	PCT for ABT Discontinuation	Study Duration	Predefined Endpoints
Long, 2011, China[31]	Suspected CAP outpatient	PCT 81 Ctrl 81	PCT >0.25 ng/mL	PCT< 0.1ng/mL strongly discouraged PCT 0.1-0.25 ng/mL antibiotics discouraged	28 days	Primary : Total ABT use and duration of ABT treatment, ABT prescription rate Secondary outcomes: Treatment failure, treatment success, death, recurrence, relapse, patients lost to followup
Burkhardt, 2010, Germany[27]	Acute respiratory tract infection	PCT 275 Ctrl 275	PCT ≥0.25 ng/ml	PCT <0.25 ng/mL	28 days	Primary: Number of days with significant health impairment due to RTI at day 14 Secondary: Prescription rate, duration of ABTs, days with ABT-associated SEs, symptoms on day 14 and 28, revisit within 28 days, change of ABTs within 28 days, hospitalization within 28 days, 28 day mortality
Schuetz, 2009, Switzerland[40]	LRTI; (CAP, AECOPD, acute bronchitis)	PCT 671 Ctrl 688	PCT <0.1 ng/mL, strongly discouraged; PCT ≤0.25 ng/mL, discouraged; PCT > 0.25 ng/mL, encouraged; PCT >0.5 ng/mL, strongly encouraged	PCT <10% of baseline, stopping strongly encouraged; PCT <20% of baseline, stopping discouraged	30 days	Primary: (Noninferiority) Total adverse event rate at 30 days (composite outcome of death, ICU admission, disease-specific complications, and recurrent LRTI in need of ABTs with or without hospital readmission) Secondary: ABT exposure, duration, adverse effects, LOS
Kristoffersen, 2009, Denmark[41]	LRTI (CAP)	PCT 103 Ctrl 107	PCT <0.25 ng/mL, discouraged PCT 0.25-5.0 ng/mL, encouraged PCT >0.5 ng/mL, strongly encouraged	PCT <0.25 ng/mL, discontinued	Not defined	Primary: ABT duration, LOS Secondary: Proportion of patients for whom physicians disregarded treatment guidelines
Briel, 2008, Switzerland[42]	URTI (cold, sinusitis, pharyngitis, tonsillitis), LRTI (CAP, AECOPD, tracheobronchitis)	PCT 232 Ctrl 226	PCT >0.25 ng/mL, recommended PCT 0.1-0.25 ng/mL, not recommended, PCT increase 50% with worse symptoms, ABTs, recommended	PCT ≤0.25	28 days	Primary: (Noninferiority) Number of days of restricted activity due to respiratory infection Secondary: ABT prescription rate and duration, discomfort scale, days work missed, days with adverse effects of medication, relapse of infection, serious adverse events

Table 13. Summary of characteristics for eight trials included in the analysis of procalcitonin-guided antibiotic initiation and/or discontinuation in patients with respiratory tract infections (continued)

Author, Year, Country	Disease State	N	PCT for ABT Initiation	PCT for ABT Discontinuation	Study Duration	Predefined Endpoints
Stolz, 2007, Switzerland[38]	Acute exacerbation of COPD	PCT 102 Ctrl 106	PCT <0.1 ng/mL strongly discouraged; PCT ≥1.0 ≤0.25 ng/mL, ABTs based on clinical condition; PCT >0.25 ng/mL, encouraged	NA	6 months	Primary: ABT use at index AECOPD ABT use up to 6 months Secondary: Success, LOS, ICU need, CRP, PCT, PFTs on admission, short- and long-term F/U, exacerbation rate, time to next exacerbation
Christ-Crain, 2006, Switzerland[36]	CAP admitted to ED, single center	PCT 151 Ctrl 151	PCT <0.1 strongly discouraged PCT ≥0.1, <0.25, discouraged PCT ≥0.25, ≤0.5 ng/mL, encouraged PCT >0.5 ng/mL, strongly encouraged	If baseline >10 ng/mL, ABTs discontinued if less than 10% of initial value	6 weeks	Primary: Total ABT use (prescription) and duration Secondary: Laboratory, clinical outcomes
Christ-Crain, 2004, Switzerland[37]	LRTI (CAP, AECOPD, acute bronchitis, asthma)	PCT 124 Ctrl 119	PCT ≤0.1 ng/mL, strongly discouraged PCT 0.1-0.25 ng/mL, discouraged PCT 0.25-0.5 ng/mL, encouraged PCT ≥0.5 ng/mL, strongly encouraged	PCT <0.25 ng/mL	14 days	Primary: ABT prescription rate, ABT exposure, costs Secondary: QOL, Temp, WBC count, CRP, PCT, Admission rates, LOS, ICU, death for LRTIs, Re-exacerbation, readmission for AECOPD

ABT = antibiotic; AECOPD = acute exacerbation of chronic obstructive pulmonary disease; CAP = community acquired pneumonia; COPD = chronic obstructive pulmonary disease; CRP = C-reactive protein; Ctrl = control; ED = emergency department; F/U = followup; ICU = intensive care unit; LOS = length of stay; LRTI = lower respiratory tract infection; NA = not applicable; PCT = procalcitonin; PFT = pulmonary function test; QOL = quality of life; RTI = respiratory tract infection; SEs = side effects; URTI = upper respiratory tract infection; WBC = white blood cells

The primary endpoints varied by the study. Prescription rate[a], antibiotic duration and total antibiotic exposure[b] were primary endpoints in four studies.[31,36-38] Number of days of restricted activity was the primary endpoint in two studies.[27,42] LOS was a primary endpoint in one study,[41] and cost was a primary endpoint in another study.[37] The 2009 study by Schuetz et al.[40] was a noninferiority trial that calculated a composite outcome of total adverse events as the primary endpoint.

Study Quality

The overall study rating was good for four studies[27,36,40,42] and poor for the other four studies[31,37,38,41] (Table 14). Four of the studies were given a poor rating because of lack of intention-to-treat analysis. The studies rated poor because of percentages of excluded patients are: Christ-Crain et al. (2004)[37] (8.6%), Kristoffersen et al., (2009)[41] (5.8%), Long et al., (2011)[31] (5.8%), and Stolz et al., (2007)[38] (8.0%). All studies assembled groups appearing to have similarly distributed potential confounders with no obvious imbalances. Allocation concealment was not explicitly stated in two studies,[31,38] and concealment was not applicable in the one cluster-randomized controlled trial.[37] All studies had clearly defined interventions.

Judgments of whether outcome measurements were equal, valid and reliable usually depend in part on the requirement for blinded outcome assessor. For studies comparing procalcitonin-guided therapy and standard therapy, this requirement was not applied. In these studies, it was not feasible to blind treating physicians to which group participants were allocated. Decisions on antibiotic use were made by unblinded physicians who could take other clinical information into account and override the algorithm based on their clinical judgment. Procalcitonin guidance is intended as an adjunct to, not a replacement for, clinical criteria for assessing and managing infection. In this setting, we did not require use of a blinded outcome assessor as a dimension of study quality.

Five of the trials[27,31,36,38,41] were superiority trials with intention-to-treat analyses, and two trials[40,42] were noninferiority trials with both intention-to-treat and per-protocol analyses. One study[40] tested for noninferiority of the composite adverse event rate, including death, ICU admission, disease-specific complications, or recurrent infection requiring antibiotic treatment within 30 days. A predefined noninferiority boundary of 7.5 percent was used, and based on this noninferiority boundary, a sample size of 1,002 patients was determined to allow for an adverse outcome rate in the control group of 20 percent or less with a power of 90 percent. A second study[42] used noninferiority design to compare the number of days of restricted activity due to respiratory infection. Noninferiority was defined as a difference between the procalcitonin-guided therapy and control groups of no more than one day.

[a]Defined as the percentage of patients that are initiated on antibiotic therapy, either during initial presentation or subsequent followup.
[b]Calculated by multiplying the total number of antibiotics by the number of days the patient is receiving each of antibiotic divided by total duration of antibiotic therapy.

Table 14. Procalcitonin-guided antibiotic initiation and/or discontinuation in patients with respiratory tract infections––study quality

Author, Year	Assembled Comparable Groups	Maintained Comparable Groups	Minimal Followup Loss	Measurements Equal, Valid, and Reliable	Interventions Clearly Defined	Important Outcomes Considered	Appropriate Analysis of Results	Overall USPSTF Rating
Schuetz, 2009[40]	Y-balanced Y-concealment	Y	Y	Y	Y	Y	Y	Good
Christ-Crain, 2004[37] (cluster-randomized controlled trial)	Y-balanced N/A-concealment	Y	Y	Y	Y	Y	N	Poor*
Kristoffersen, 2009[41]	Y- balanced Y-concealment	Y	Y	Y	Y	Y	N	Poor*
Briel, 2008[42]	Y- balanced Y-concealment	Y	Y	Y	Y	Y	Y	Good
Long, 2011[31]	Y- balanced U-concealment	Y	Y	Y	Y	Y	N	Poor*
Burkhardt, 2010[27]	Y balanced Y-concealment	Y	Y	Y	Y	Y	Y	Good
Stolz, 2007[38]	Y- balanced U-concealment	Y	Y	Y	Y	Y	N	Poor*
Christ-Crain, 2006[36]	Y- balanced Y-concealment	Y	Y	Y	Y	Y	Y	Good

N = no; U = unknown; USPSTF = United States Preventive Services Task Force; Y = yes

*Overall study rating was poor due to >5% of patients excluded from analyses.

Antibiotic Use

The results consistently demonstrated reduction in antibiotic use, with regard to duration, prescription rates, and total exposure (Table 15).

Antibiotic duration was reported in all studies except for one.[38] The duration of antibiotic therapy was reduced with procalcitonin-guided therapy in six of the seven studies, and the absolute reduction ranged from -1.0 to -7.1 days, with a relative reduction of -12.7 to -55 percent. Only one study[27] reported an absolute increase in antibiotic duration of 0.1 days with a relative increase of 1.3 percent. The absolute reduction was statistically significant in four of the five studies in which p values were either reported or calculated. Meta-analysis of 4 studies (Figure 7) found a statistically significant pooled mean difference of -2.35 days favoring procalcitonin (95% CI: -4.38, -0.33). A high degree of statistical heterogeneity was observed (I^2=97%). Three studies[31,40,41] did not report sufficient detail to be included in the pooling but the largest study[40] which accounted for more than three quarters of the total patients, had a greater mean difference (-3.0) than the pooled mean difference. Thus, if these studies could have also been pooled, the difference likely would still favor procalcitonin.

Antibiotic prescription rate was reported in all eight studies.[27,31,36-38,40-42] An absolute reduction in antibiotic prescription rate was demonstrated with procalcitonin-guided therapy in seven of the eight studies. The absolute reduction in prescription rates ranged from -1.8 to -72 percent, and the reductions were statistically significant in all seven studies, with five being highly statistically significant. Only one study[41] reported an absolute increase in prescription rate by 6.0 percent, which was not statistically significant. Meta-analysis of eight studies (Figure 8) yielded a statistically significant pooled risk difference of -22 percent (95% CI: -41%, -4%). The degree of statistical heterogeneity was quite high (I^2=98%).

Four studies[31,36-38] reported on total antibiotic exposure, which accounted for the use of multiple agents, as well as duration of therapy. Two studies[36,37] reported total exposure per 1,000 patient-days with relative reductions of 0.52 and 0.49, which were both highly statistically significant. One study[38] reported an absolute reduction of -31.5 percent, which was highly statistically significant. One study[31] reported a statistically significant relative risk of 0.55, but no additional details were given.

Mortality

Overall, mortality results were consistent and did not suggest higher mortality rates with procalcitonin-guided therapy as compared to the control arm (Table 16). Mortality rates in patients in the control arm ranged from 0 to 13.2 percent. The absolute differences between the procalcitonin and control arms ranged from -3.6 to 1.0 percent. One study[36] reported higher mortality rates in both the procalcitonin-guided therapy and control groups which appear to be due to disease-related mortality.

Six studies[27,31,37,40-42] reported 28-day mortality, and only one study[37] reported a reduction in mortality with procalcitonin-guided therapy by -0.1 percent. The other five studies[27,31,40-42] reported absolute differences ranging from 0 to 1.0 percent. None of the differences in 28-day mortality were statistically significant.

One study[36] reported 6-week mortality with an absolute reduction in mortality of 1.3 percent. Studies reporting mortality at 6 weeks or less were pooled in a meta-analysis (Figure 9), but

Table 15. Procalcitonin-guided antibiotic initiation and/or discontinuation in patients with respiratory tract infections––outcomes related to antibiotic use

Outcome	Author, Year	N	PCT	Control	Absolute Difference PCT-CTRL (95% CI)	p-Value	Relative Difference PCT-CTRL (95% CI)	p-Value
ABT Duration (days[Ψ])	Schuetz, 2009[40]	1359	5.7	8.7	-3.0	--	-34.8% (-40.3 to -28.7)	--
	Christ-Crain, 2004[37]	243	10.9	12.8	-1.9 (-3.1 to -0.7)	0.002	-14.8%	--
	Kristoffersen, 2009[41]	210	5.1	6.8	-1.7	--	-25%	0.007
	Briel, 2008[42]	458	6.2	7.1	-1.0 (-1.7 to -0.4)	<0.05	-12.7%	--
	Long, 2011[31]	162	5 (3-6)[‡]	7 (5-9)[‡]	-2.0	<0.001	-28.6%	--
	Burkhardt, 2010[27]	550	7.8	7.7	0.1 (-0.7 to 0.9)	0.8	1.3%	--
	Christ-Crain, 2006[36]	302	5.8	12.9	-7.1(-8.4 to -5.8)	<0.0001	-55.0%	--
ABT Prescription Rate (%)	Schuetz, 2009[40]	1,359	506/671 (75.4%)	603/688 (87.6%)	-12.2% (-16.3 to -8.1)	<0.05	--	--
	Christ-Crain, 2004[37]	243	55/124 (44.4%)	99/119 (83.2%)	-38.8% (-49.9 to -27.8)	<0.0001	--	--
	Kristoffersen, 2009[41]	210	88/103 (85.4%)	85/107 (79.4%)	6.0% (-4.3 to 16.2)	0.25	--	--
	Briel, 2008[42]	458	58/232 (25.0%)	219/226 (96.9%)	-72% (-78 to -66)	<0.05	--	--
	Long, 2011[31]	162	NR (84.4%)	NR (97.5%)	-13.1%	0.004	--	--
	Stolz, 2007[38]	208	41/102 (40.2%)	76/106 (71.7%)	-31.5% (-44.3 to -18.7)	<0.0001	--	--
	Christ-Crain, 2006[36]	302	128/151 (84.8%)	149/151 (98.79%)	-13.9% (-19.9 to -7.9)	<0.0001	--	--
	Burkhardt, 2010[27]	550	84/275 (30.5%)	89/275 (32.4%)	-1.8% (-9.6 to 5.9)	0.701	--	--
Total ABT Exposure	Stolz, 2007[38]	208	NR	NR	-31.5% (18.7 to 44.3)	<0.0001	44% (0.27 to 0.57)	<0.0001
	Long, 2011[31]	162	NR	NR	NR	--	0.55[*] (0.51 to 0.60)	0.003
	Christ-Crain, 2006[36]	302	136**	323**	--	--	0.52 (0.48 to 0.55)[∞]	<0.001
	Christ-Crain, 2004[37]	243	332**	661**	--	--	0.49 (0.44 to 0.55)[‡∞]	<0.0001

ABT = antibiotic; CI = confidence interval; CTRL = control; NR = not reported; PCT = procalcitonin

[Ψ]Values are mean unless specified.

[*]Relative risk.

[**]Mean per 1,000 days of followup.

[‡]Adjusted for potential confounding and possible cluster effects.

[∞]Rate ratios.

[‡] Median (interquartile range).

Figure 7. Meta-analysis of mean differences, antibiotic duration (days) in patients with respiratory tract infections

Study or Subgroup	Procalcitonin Mean	SD	Total	Control Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI
Briel 2008	6.2	2.5	231	7.1	2.2	224	26.1%	-0.90 [-1.33, -0.47]
Burkhardt 2010	7.8	2.8	275	7.7	3.3	275	26.0%	0.10 [-0.41, 0.61]
Christ-Crain 2004	10.9	3.6	124	12.8	5.5	119	24.3%	-1.90 [-3.07, -0.73]
Christ-Crain 2006	5.8	5.3	151	12.9	6.5	151	23.7%	-7.10 [-8.44, -5.76]
Total (95% CI)			**781**			**769**	**100.0%**	**-2.35 [-4.38, -0.33]**

Heterogeneity: Tau² = 4.04; Chi² = 99.94, df = 3 (P < 0.00001); I² = 97%

Test for overall effect: Z = 2.28 (P = 0.02)



CI = confidence interval; IV = inverse variance weighted; SD = standard deviation

Figure 8. Meta-analysis of risk differences, antibiotic prescription rate in patients with respiratory tract infections

Study or Subgroup	Procalcitonin Events	Total	Control Events	Total	Weight	Risk Difference IV, Random, 95% CI
Briel 2008	58	232	219	226	12.7%	-0.72 [-0.78, -0.66]
Burkhardt 2010	84	275	89	275	12.6%	-0.02 [-0.10, 0.06]
Christ-Crain 2004	55	124	99	119	12.3%	-0.39 [-0.50, -0.28]
Christ-Crain 2006	128	151	149	151	12.7%	-0.14 [-0.20, -0.08]
Kristoffersen 2009	88	103	85	107	12.4%	0.06 [-0.04, 0.16]
Long 2011	65	77	77	79	12.5%	-0.13 [-0.22, -0.04]
Schuetz 2009	506	671	603	688	12.8%	-0.12 [-0.16, -0.08]
Stolz 2007	41	102	76	106	12.1%	-0.32 [-0.44, -0.19]
Total (95% CI)		**1735**		**1751**	**100.0%**	**-0.22 [-0.41, -0.04]**
Total events	1025		1397			

Heterogeneity: Tau² = 0.07; Chi² = 363.21, df = 7 (P < 0.00001); I² = 98%

Test for overall effect: Z = 2.35 (P = 0.02)



CI = confidence interval; IV = inverse variance weighted; SD = standard deviation

Table 16. Procalcitonin-guided antibiotic initiation and/or discontinuation in patients with respiratory tract infections—mortality

Outcome	Author, Year	N	PCT	Control	Absolute Difference PCT-CTRL (95% CI)	p-Value
6-month mortality	Stolz, 2007[38]	208	5/102 (4.9%)	9/106 (8.5%)	-3.6% (-10.3 to 3.2)	0.30
6-week mortality	Christ-Crain, 2006[36]	302	18/151 (11.9%)	20/151 (13.2%)	-1.3% (-8.8 to 6.2)	0.73
≤28-day mortality	Christ-Crain, 2004[37]	243	4/124(3.2%)	4/119 (3.4%)	-0.1% (-4.6 to 4.4)	0.95
	Schuetz, 2009 (30-day)[40]	1359	34/671(5.1%)	33/688(4.8%)	0.3% (-2.1 to 2.5)	0.82
	Briel, 2008[42]	458	0/231(0%)	1/224 (0.4%)	-0.4% (-1.3 to 0.4)	0.31
	Burkhardt, 2010[27]	550	0/275(0%)	0/275 (0%)	0	--
	Kristoffersen, 2009[41]	210	2/103(1.9%)	1/107 (0.9%)	1.0% (-2.2 to 4.2)	0.54
	Long, 2011[31]	162	0/81 (0%)	0/81 (0%)	0	--

CI = confidence interval; CTRL = control; PCT = procalcitonin
Note: All studies performed intention-to-treat analyses.

Figure 9. Meta-analysis of risk differences, short-term mortality (≤6 weeks) in patients with respiratory tract infections



CI = confidence interval; IV = inverse variance weighted; SD = standard deviation

those reporting zero events in either arm were excluded. Combining four studies[36,37,40,41] produces a risk difference of 0.3 percent with a very narrow 95% CI (-1 percent, 2 percent). Statistical heterogeneity was nil (I^2=0 percent).

One study [38]reported 6-month mortality with an absolute reduction in mortality of 3.6 percent. None of the 6-week or 6-month absolute reductions in mortality rate were statistically significant.

Morbidity

Overall, studies did not suggest an increase in-hospital LOS, ICU admission rates, antibiotic adverse events, or days of restricted activity with procalcitonin-guided therapy (Table 17).

Five studies[36,38,40-42] reported hospital LOS. Hospital LOS was reduced with procalcitonin-guided therapy in four of five studies with an absolute reduction in days ranging from -0.5 to -1. The differences were not statistically significant in any of the studies. One study[40] reported an absolute increase in LOS by 0.2 days.

Five studies[36,38,40-42] reported need for ICU admission. ICU admission rates were reduced with procalcitonin-guided therapy with absolute reductions ranging from -0.7 to -2.5 percent. None of the reductions in ICU admissions was statistically significant. Meta-analysis of these five studies (Figure 10) produced a risk difference of -1 percent with a very narrow 95% CI (-4%, 1%). No statistical heterogeneity was detected (I^2=0 percent).

Two studies[27,42] evaluated days of restricted activity. It was defined as number of self-assessed impaired days of daily work and/or leisure activities within the first 14 days of illness. The absolute differences were -0.25 and 0.2 days and none were statistically significant.

Adverse Events of Antibiotic Therapy

For the respiratory tract infection studies, three studies[27,40,42] reported on adverse antibiotic effects, but the definition of antibiotic adverse events differed with each study. Schuetz et al.[40] reported a reduction in the proportion of patients with an antibiotic adverse events (19.8% vs. 28.1%, difference – 8.2%, 95% CI: -12.7, -3.7) that favored procalcitonin-guided therapy. Briel et al.[42] reported that there was a statistically significant decrease in the days with adverse antibiotic effects in the procalcitonin-guided arm (2.3±4.6 vs. 3.6±6.1, difference -1.1, 95% CI: -2.1, -0.1) that was mainly due to a lower incidence of antibiotic-associated diarrhea. Burkhardt et al.[27] reported a lower incidence of antibiotic adverse effects (11/275 vs. 16/275, p=0.331) and fewer days with antibiotic adverse effects (5.6±2.2 vs. 6.1±3.7, p=0.94), but neither difference was statistically significant.

GRADE Evidence

Methods for grading strength of evidence developed for the AHRQ Effective Health Care Program[25] were applied to this body of literature. An important consideration in grading the literature was the quality ratings of the studies. Four[27,36,40,42] of the eight studies[27,31,36-38,40-42] received a good quality rating, but the other four studies[31,37,38,41] received a poor quality rating due to lack of intention-to-treat analysis (Table 18). However, the studies receiving a poor rating represent 23.6 percent of the total patients in these studies (823 of 3,492 patients).

Table 17. Procalcitonin-guided antibiotic initiation and/or discontinuation in patients with respiratory tract infections—morbidity

Outcome	Author, Year	N	PCT	Control	Absolute Difference PCT-CTRL (95% CI)	p-Value
LOS (days[Ψ])	Schuetz, 2009[40]	1,359	9.4	9.2	0.2 days	--
	Christ-Crain, 2004[37]	224	10.7 ± 8.9	11.2 ± 10.6	-0.5 days (-3.0 to 2.0)	0.69
	Kristoffersen, 2009[41]	210	5.9	6.7	-0.8 days	0.22
	Stolz, 2007[38]	208	9 (1-15)[‡]	10 (1-15)[‡]	-1 days	0.96
	Christ-Crain, 2006[36]	302	12.0±9.1	13.0±9.0	-1 days (-3.0 to 1.0)	0.34
ICU Admission (%)	Schuetz, 2009[40]	1,359	43/671 (6.4%)	60/688 (8.7%)	-2.3% (-5.2 to 0.4)	0.12
	Christ-Crain, 2004[37]	224	5/124 (4.0%)	6/119 (5.0%)	-1.0% (-6.2 to 4.2)	0.71
	Kristoffersen, 2009[41]	210	7/103 (6.8%)	5/107 (4.7%)	-2.1% (-4.2 to 8.4)	0.51
	Stolz, 2007[38]	208	8/102 (7.8%)	11/106 (10.4%)	-2.5% (-10.3 to 5.3)	0.53
	Christ-Crain, 2006[36]	302	20/151 (13.2%)	21/151 (13.94%)	-0.7% (-8.4 to 7.1)	0.87
Antibiotic Adverse Events	Schuetz, 2009[40†]	1,359	133/671 (19.8%)	193/688 (28.1%)	-8.2% (-12.7 to -3.7)	--
	Briel, 2008[42‡]	458	2.3±4.6 days	3.6±6.1 days	-1.1 days(-2.1 to -0.1)	<0.05
	Burkhardt, 2010[27∞]	550	11 /59 (18.6%)	16/101 (15.8%)	2.8% (-9.4 to 15.0)	0.65
Restricted Activity (days)*	Briel, 2008[42]	458	8.7±3.9	8.6±3.9	0.2 days (-0.4 to 0.9)	>0.05
	Burkhardt, 2010[27]	550	9.1	8.8	0.25 days (-0.52 to 1.03)	>0.05

CI = confidence interval; CTRL = control; ICU = intensive care unit; LOS = length of stay; PCT = procalcitonin
[Ψ]Values are mean unless specified.
[†]Nausea, diarrhea, and rash.
[‡]Abdominal pain, diarrhea, nausea, vomiting, and rash.
[∞]Antibiotic adverse events not defined.
*Days during the first 14 days of illness that work and leisure activities were restricted.
[‡]Median (interquartile range).

Figure 10. Meta-analysis of risk differences in ICU admission in patients with respiratory tract infections



CI = confidence interval; IV = inverse variance weighted; SD = standard deviation

Table 18. Procalcitonin-guided antibiotic initiation and/or discontinuation in patients with respiratory tract infections—GRADE evidence table

Outcome	No. of Studies (Subjects)	Risk of Bias	Consistency	Directness	Precision	Overall GRADE
Antibiotic duration	7 RCTs (n=3,284)[27,31,36,37,40-42]	Low	Consistent	Direct	Precise	High
Antibiotic prescription rate	8 RCTs (n=3,492)[27,31,36-38,40-42]	Low	Consistent	Direct	Precise	High
Total antibiotic exposure	4 RCTs (n=915)[31,36-38]	Medium	Consistent	Direct	Precise	Moderate
Mortality	8 RCTs (n=3,492)[27,31,36-38,40-42]	Low	Consistent	Direct	Precise	Moderate
Hospital length of stay	5 RCTs (n=2,303)[36-38,40,41]	Medium	Consistent	Direct	Precise	Moderate
ICU admission rates	5 RCTs (n=2,303)[36-38,40,41]	Medium	Consistent	Direct	Precise	Moderate
Antibiotic adverse events	3 RCTs (n=2,367)[27,40,42]	Low	Inconsistent	Direct	Imprecise	Insufficient

GRADE = grading of recommendations assessment, development, and evaluation; ICU = intensive care unit; RCT = randomized controlled trial

Overall, the grade of the strength of evidence was high, and the data demonstrate a reduction in antibiotic duration and prescription rates which were reported in the majority of studies. The risk of bias was low and the evidence was consistent, direct, and precise for these antibiotic outcomes. The reduction in antibiotic duration ranged from -1.0 to -7.1 days and from -1.8 to -72 percent for antibiotic prescription rates.

The overall grade of the evidence for total antibiotic exposure was moderate. Total antibiotic exposure was only reported by four studies,[31,36-38] but three of these studies[31,37,38] were given a poor quality rating. In general, total antibiotic exposure is difficult to calculate, and the data for this outcome were reported differently in these studies. Two studies[31,35] reported relative risk ratios without providing additional details, and two studies[36,37] reported means per 1,000 days of followup. Because the majority of these studies were poor quality and the reporting differed, the data were graded to have a moderate risk of bias. The evidence was graded to be consistent, direct, and precise. All of the absolute or relative reductions reported in total antibiotic exposure were statistically significant, and overall, the data suggest a reduction in total antibiotic exposure.

The mortality data were given a moderate overall grade. All eight studies[27,31,36-38,40-42] reported mortality rates. The absolute difference in 28-day mortality rates ranged from -0.3 to 0.4 percent, but none of these differences was statistically significant. The data were graded to have a low risk of bias and be consistent, direct, and precise. Overall grade was moderate, largely due to the low baseline mortality rates in patients with respiratory tract infections. While the confidence interval around the pooled estimate was narrow, uncertainty about the minimum important difference for mortality leads us to rule out high strength of evidence.

The overall grade of the evidence for hospital LOS and ICU admission rates was moderate. Five studies[36,38,40-42] reported these outcomes. The data were graded to have a M risk of bias because three[37,38,41] of the five studies[36,38,40-42] were given a poor quality rating. The absolute differences in LOS and ICU admission rates ranged from -1 to 0.2 days and -2.5 to -0.7 percent, respectively, but none of these differences was statistically significant. Thus, the present evidence does not suggest an increase in hospital LOS or ICU admission rates.

The current data do not permit a conclusion regarding the effects of procalcitonin-guided therapy on antibiotic adverse events, and the overall grade was insufficient. Three studies[27,40,42] with a low risk of bias reported this outcome; however, the data were inconsistent and imprecise.

Two studies reported percentages with absolute differences of -8.2 percent[40] and 2.8 percent,[27] and one study[42] reported an absolute difference of -1.1 days that was statistically significant. The data for this outcome are limited, and therefore, no conclusions can be drawn on the impact of procalcitonin-guided therapy on antibiotic adverse events.

Neonatal Sepsis

Study Characteristics

There was only one RCT[43] of procalcitonin-guided antibiotic therapy for suspected early onset neonatal sepsis that included 101 neonates, both arms stratified by the likelihood of infection (Table 19). Neonatal sepsis was suspected on the basis of risk factors, as well as clinical signs and symptoms including apnea, tachycardia or bradycardia, hypotension, seizures, "floppiness," irritability, or ileus, and standard laboratory tests, including C-reactive protein and immature leukocyte ratio. Procalcitonin values used to decide on antibiotic initiation and discontinuation were based on a nomogram based on the time since birth, since procalcitonin is elevated in the first three days of life due to birth stress. Antibiotic therapy in the standard group was based on the attending physician's assessment. The trial was designed to have 90 percent power to detect a 30 percent difference in antibiotic duration. The primary outcomes for this study were the duration of antibiotics and the proportion of neonates on antibiotics longer than 72 hours. Secondary outcomes were recurrence of infection and mortality, but the study was not powered to detect differences in these outcomes. Followup duration was 21 days.

Study Quality

The quality rating for the one study is described in Table 20. In this study[43] of neonatal sepsis, neonates in the two arms were comparable at baseline. Details of allocation concealment were described. Analysis was appropriate, but again, this study was not powered to detect differences in morbidity or mortality.

Table 19. Summary of characteristics for one trial included in the analysis of procalcitonin-guided antibiotic therapy in neonatal sepsis

Author, Year, Country	Disease State	N	PCT for ABT Initiation	PCT for ABT Discontinuation	Other PCT-Guided Interventions	Study Duration	Predefined Endpoints
Stocker, 2010, Switzerland[43]	Suspected early onset neonatal sepsis	PCT 60 Ctrl 61	PCT according to nomogram based on age since birth, hours	PCT according to nomogram based on age since birth, hours	NA	30 days	Primary outcome ABTs ≥72 hours, duration of ABTs Secondary outcomes, Survival, recurrence of infection

ABT = antibiotic; Crtl = control; PCT = procalcitonin; NA = not applicable

Table 20. Procalcitonin-guided antibiotic therapy in neonatal sepsis—study quality

Author, Year	Assembled Comparable Groups	Maintained Comparable Groups	Minimal Followup Loss	Measurements Equal, Valid, and Reliable	Interventions Clearly Defined	Important Outcomes Considered	Appropriate Analysis of Results	Overall USPSTF Rating
Stocker, 2010[43]	Y	Y	Y	Y	Y	Y	Y	Good

USPSTF = United States Preventive Services Task Force; Y = yes

Antibiotic Use

Outcomes related to antibiotic use are summarized in Table 21. The duration of antibiotic use was significantly decreased overall by 22.4 hours (24 percent reduction), with the greatest differences seen for the 80 to 85 percent of neonates who had possible infection or were unlikely to have infection and little difference for the small proportion of neonates with proven of probable infection. The proportion of neonates on antibiotics for 72 or more hours was significantly reduced overall by 27 percent, again with the difference seen only for neonates with possible sepsis (38 percent reduction) or neonates unlikely to have infection (27 percent reduction).

Table 21. Procalcitonin-guided antibiotic therapy in neonatal sepsis in the study by Stocker et al., 2010[43] (n=121)—outcomes related to antibiotic use

Outcome	Patient Subgroup	PCT	Control	Difference PCT-CTRL (95% CI)	p-Value
ABTs ≥72 hours (%)	All neonates	33/60 (55%)	50/61 (82%)	-27.0 (-42.8 to -11.1)	0.002
	Infection proven/probably	9/9 (100%)	12/12 (100%)	0% (0 to 0)	NA
	Infection possible	13/21 (61.9%)	19/19 (100%)	-38.1 (-58.9 to -17.3)	0.003
	Infection unlikely	11/30 (36.7%)	19/30 (63.3%)	-26.6 (-51.1 to -2.3)	0.038
ABT duration, hours	All neonates	79.1	101.5	-22.4	0.012
	Infection proven/probably	177.8	170.8	-7	NSS
	Infection possible	83.4	111.5	-28.1	< 0.001
	Infection unlikely	46.5	67.4	-20.9	0.001

ABT = antibiotic; CI = confidence interval; CTRL = control; NA = not applicable; NSS = not statistically significant; PCT = procalcitonin

Mortality

Only in-hospital mortality was reported by Stocker et al.[43] No deaths occurred in either study arm (Table 22).

Morbidity

There was a small but statistically insignificant reduction in the rate of recurrence of infection in the study by Stocker et al.,[43] i.e., the neonates treated with antibiotics for 120 or more hours (Table 22).

Table 22. Mortality and morbidity data for early onset neonatal sepsis in the study by Stocker et al., 2010[43] (n=121)

Outcome	PCT	Control	Difference PCT-CTRL (95% CI)	p-Value
Mortality (in-hospital)	0%	0%	0 (0 to 0)	NA
Morbidity (recurrence of infection)	32%	39%	-7	0.45

CI = confidence interval; CTRL = control; NA = not applicable; PCT = procalcitonin

Adverse Events of Antibiotic Therapy

The study by Stocker et al.[43] did not report adverse events of antibiotic therapy.

GRADE Evidence

The strength of evidence was judged to be moderate that use of procalcitonin guidance reduces the use of antibiotic therapy for suspected neonatal sepsis. This good quality study was judged to have low risk of bias. The finding that significant reduction in duration of antibiotic therapy was observed in the subgroups with possible or unlikely infection, rather than those with probable infection, lends face validity to the results. Consistency was rated as unknown (single study). The evidence was direct and sufficiently precise to conclude that procalcitonin guidance reduces antibiotic use. This small study[43] (n=121) was not powered to detect mortality or morbidity outcomes, and strength of evidence was judged insufficient to make conclusions on mortality and morbidity.

Fever of Unknown Source (Children Ages 1–36 Months)

Study Characteristics

There was only one RCT[26] of procalcitonin-guided antibiotic therapy for fever of unknown source in children 1–36 months of age (Table 23). This study used BRAHMS PCT-Q® semi-quantitative assay method for procalcitonin measurement. Three-hundred and eighty-four children were enrolled. Sixty-two (16 percent) were subsequently diagnosed with a serious bacterial infection and 10 (2.6 percent) were found to be neutropenic. Procalcitonin values used to decide on antibiotic initiation and discontinuation were based on a nomogram based on the time since birth, since procalcitonin is elevated in the first three days of life due to birth stress. Antibiotic therapy in the standard group was based on the attending physician's assessment. The primary outcome for this study[26] was the antibiotic prescription rate. The secondary outcome was difference in hospitalization rate. Sample size needed was calculated based on rates of antibiotic prescription. Followup duration for this study was 30 days.

Table 23. Summary of characteristics for one trial included in the analysis of procalcitonin-guided antibiotic therapy in children (ages 1-36 months) with fever of unknown source

Author, Year, Country	Disease State	N	PCT for ABT Initiation	PCT for ABT Discontinuation	Other PCT-Guided Interventions	Study Duration	Predefined Endpoints
Manzano, 2010, Canada[26]	Fever without a source, children 1-36 months of age	PCT 192 Ctrl 192	PCT < 0.5, infection unlikely; PCT ≥ 0.5, moderate risk; PCT ≥ 2.0, high risk	----	----	30 days	Primary outcome ABT prescription rate Secondary outcomes Hospitalization, additional studies

ABT = antibiotic; Ctrl = control; PCT = procalcitonin

Study Quality

The quality rating for the one study is described in Table 24. The two study arms were comparable, but more than 10 percent of patients in each arm were excluded from the analysis

Table 24. Procalcitonin-guided antibiotic therapy in children (ages 1-36 months) with fever of unknown source—study quality

Author, Year	Assembled Comparable Groups	Maintained Comparable Groups	Minimal Followup Loss	Measurements Equal, Valid, and Reliable	Interventions Clearly Defined	Important Outcomes Considered	Appropriate Analysis of Results	Overall USPSTF Rating
Manzano, 2010[26]	Y	Y	Y	Y	Y	Y	N	Poor

N = no; USPSTF = United States Preventive Services Task Force; Y = yes

(insufficient blood for assay) and no strategy to adjust for missing data was performed. Details of allocation concealment were described. This study was not powered to detect differences for the morbidity and mortality outcomes.

Antibiotic Use

There were no differences in the antibiotic prescription rates or hospitalization rate, although rates were low for both arms with only one-quarter of children being hospitalized and receiving antibiotics[26] (Table 25).

Table 25. Procalcitonin-guided antibiotic therapy in children (ages 1–36 months) with fever of unknown source–outcomes related to antibiotic use in the study by Manzano et al., 2010[26] (n=384)

Outcome	Subgroup	PCT	Control	Difference PCT-CTRL (95% CI)	p-Value
Antibiotic prescription rate (%)	All children	48/192 (25%)	54/192 (28.0%)	-3.1 (-12.0 to 5.7)	0.49
	No SBI or neutropenia	14/158 (9%)	16/154 (10%)	-1.5 (-8.1 to -5.0)	0.65

CI = confidence interval; CTRL = control; PCT = procalcitonin; SBI = serious blood infection

Mortality

Only in-hospital mortality was reported, and mortality was 0 percent in both arms (Table 26).

Morbidity

In this single RCT,[26] overall rates of hospitalization were relatively low, with only one quarter of the children being admitted (Table 26). This rate was even lower for those children who did not have a serious bacterial infection or neutropenia. There were no significant differences in the proportion of infants who were started on empiric antibiotic therapy, all children, and the subgroup of children without a serious blood infection or neutropenia. Overall, procalcitonin measurement did not have a statistically significant effect on antibiotic use or hospitalization in this population.

Table 26. Mortality and morbidity data for fever of unknown source in children ages 1-36 months in the study by Manzano et al., 2010[26] (n=384)

Outcome	Subgroup	PCT	Control	Difference PCT-CTRL (95% CI)	p-Value
Mortality	All children	0%	0%	0 (0 to 0)	NA
Morbidity (hospitalization rate)	All children	50/192 (26%)	48/192 (25%)	1 (-8 to 10)	0.81
	No SBI or neutropenia	16/158 (10%)	11/154 (7%)	3 (-3 to 10)	0.34

CI = confidence interval; CTRL = control; NA = not applicable; PCT = procalcitonin; SBI = serious blood infection

Adverse Events of Antibiotic Therapy

The study by Manzano et al.[26] did not report adverse events of antibiotic therapy.

GRADE Evidence

The strength of evidence was judged insufficient to draw conclusions on outcome of procalcitonin-guided antibiotic therapy for fever of unknown source in children 1–36 months of age. This RCT[26] (n=384) reported no significant results.

Preemptive Postoperative Antibiotic Therapy

There was only one study[44] that evaluated the value of monitoring procalcitonin postoperatively in 250 consecutive patients undergoing colorectal surgery (Table 27). Procalcitonin levels were used to identify patients at risk for local and systemic infectious complications who might benefit from antibiotic therapy (ceftriaxone) given as a prophylaxis or preemptive therapy in patients without other clinical evidence of infection. Of 230 patients with low postoperative procalcitonin, only 16 local wound infections (7.0 percent) not requiring surgery or antibiotics occurred and systemic infection occurred in only 4 patients (1.7 percent). The negative predictive value of procalcitonin for systemic infections requiring antibiotics was 98.3 percent and 93.0 percent for local wound infections that resolved without antibiotics or re-operation.

The other 20 patients had two or more procalcitonin measurements greater than 1.5 ng/mL in the first three postoperative days, and these patients were randomized to receive IV ceftriaxone or standard management. The 10 patients in the control arm of the randomized portion of this study were treated when signs of infection became evident. Patients were followed for the duration of their hospitalization.

Table 27. Summary of characteristics for one trial[44] included in the analysis of procalcitonin-guided preemptive postoperative antibiotic therapy

Author, Year, Country	Disease State	N	PCT for ABT Initiation	PCT for ABT Discontinuation	Other PCT-Guided Interventions	Study Duration	Predefined Endpoints
Chromik, 2005, Germany[44]	Colorectal surgery patients	250 patients overall 230 patients with low PCT, 20 with elevated PCT post-op	PCT > 1.5 post-op randomized to receive preemptive ABTs or standard care			Not defined	Primary outcome Local and systemic infectious complications Secondary outcomes Mortality, decreased LOS, duration of ABTs

ABT = antibiotic; LOS = length of stay; PCT = procalcitonin; Post-op = postoperative

Study Quality

The quality rating for the one study is described in Table 28. The patients in the two arms of the interventional part of this trial[44] were comparable at baseline. Details of allocation concealment were described. Analysis was appropriate, but again, this study was not powered to detect differences in morbidity or mortality.

Table 28. Procalcitonin-guided preemptive postoperative antibiotic therapy—study quality

Author, Year	Assembled Comparable Groups	Maintained Comparable Groups	Minimal Followup Loss	Measurements Equal, Valid, and Reliable	Interventions Clearly Defined	Important Outcomes Considered	Appropriate Analysis of Results	Overall USPSTF Rating
Chromik, 2005[44]	Y	Y	Y	Y	Y	Y	Y	Good

USPSTF = United States Preventive Services Task Force; Y = yes

Antibiotic Use

Although all patients in the preemptive ceftriaxone arm received this antibiotic for a period of time (range: 4–11 days), the duration of antibiotic therapy was lower by 3.5 days in the procalcitonin-guided therapy group compared with the control group[44] (Table 29). This difference, however, did not reach statistical significance.

Table 29. Procalcitonin-guided preemptive postoperative antibiotic therapy–outcomes related to antibiotic use in the study by Chromik et al., 2005[44]

N	Outcome	PCT	Control	Difference PCT-CTRL (95% CI)	p-Value
20	ABT duration (days)	5.5	9	-3.5	0.27

ABT = antibiotic; CI = confidence interval; CTRL = control; PCT = procalcitonin

Mortality

Mortality was 20 percent higher in the control arm (Table 30). This was not statistically significant.

Morbidity

Patients in the control arm of the study had a more prolonged LOS (12 days longer), and the difference approached statistical significance (Table 30). The control arm also had a higher incidence of local and systemic infection. Patients in the control arm were significantly more likely to have systemic inflammatory response syndrome (SIRS) or sepsis and require vasopressors for shock.

Table 30. Procalcitonin-guided preemptive postoperative antibiotic therapy—mortality and morbidity data in the study by Chromik et al., 2005[44] (n=20)

	Outcome	PCT	Control	Difference PCT-CTRL (95% CI)	p-Value
Mortality		1/10 (10%)	3/10 (30%)	-20 (-54.0 to 14.0)	0.07
Morbidity	Hospital LOS (days)	18	30	-12	0.057
	Local wound infection (%)	1/10	2/10	-10 (-41.0 TO 21.0)	0.53
	Systemic infection (%)	3/10	7/10	-40.0 (-80.2 to 0.2)	0.07
	Sepsis/SIRS (%)	2/10	8/10	-60.0 (-95.1 to -24.9)	0.007

CI = confidence interval; CTRL = control; LOS = length of stay; PCT = procalcitonin; SIRS = systemic inflammatory response syndrome

Adverse Events of Antibiotic Therapy

The study by Chromik et al.[44] did not report adverse events of antibiotic therapy.

GRADE Evidence

This single RCT[44] suggests procalcitonin levels can identify postoperative patients who are at risk for wound and systemic infection who will benefit from prophylaxis or preemptive antibiotic therapy. Not only did procalcitonin identify a group of patient for whom antibiotics can prevent significant morbidity and mortality, but low procalcitonin levels accurately identified a low-risk group for whom antibiotics were unnecessary. The use of procalcitonin helped limit the use of antibiotic prophylaxis to 8 percent of the entire postsurgical population. Further studies of this strategy are needed to confirm this result. The evidence on procalcitonin-guided preemptive

postoperative antibiotic therapy was deemed insufficient to be graded as only one small study (n=20) was available for peer review.

Summary and Discussion

Summary of the Main Findings

There were 18 randomized controlled trials (RCTs) that compared procalcitonin guidance with the use of clinical criteria to manage antibiotic therapy in patients with known or suspected infection, or at risk of infection. The evidence addressed five patient populations: (1) seriously ill adult patients in the intensive care unit (ICU), including patients with ventilator-associated pneumonia (VAP) and those critically ill with suspected bacterial infections, severe sepsis, and septic shock; (2) patients with symptoms and signs of various respiratory tract infections; (3) neonates with suspected sepsis; (4) children between 1 to 36 months of age with fever of unknown etiology; and (5) postoperative patients without clinical evidence of infection.

Intensive Care Unit Patients

Five trials[32-35,39] (n=938) addressed procalcitonin-guided discontinuation of antibiotic therapy. Strength of evidence was judged to be high that procalcitonin guidance reduces antibiotic use. The absolute difference in duration of antibiotic use, the measure that was reported by all five studies,[32-35,39] ranged from -1.7 to -5 days, with relative reductions that ranged from 21 to 38 percent. There is moderate evidence that procalcitonin-guided antibiotic discontinuation does not increase morbidity as indicated by ICU and hospital length of stay. The strength of evidence was judged low that procalcitonin guided antibiotic therapy in the ICU does not increase mortality. Evidence on mortality was initially rated as stronger but was downgraded to low based on uncertainty about the appropriate noninferiority margin for this outcome. Although a 10 percent noninferiority margin has been recommended by the Infectious Diseases Society of America (IDSA) and American College of Chest Physicians (ACCP) in relevant populations, there is also strong sentiment that this is too high a noninferiority margin for mortality, which was expressed among our peer reviewers and also in the published literature. Moreover, there are presently two large trials in progress, which may in the future yield more precise estimates of mortality.

There is moderate evidence that procalcitonin-guided intensification of antibiotic therapy that broadens the spectrum of bacterial coverage does not improve outcomes in critically ill patients, and in fact, may have adverse consequences. The large (n=1,200), high-quality trial by Jensen et al.[28] found greater duration and increased total exposure to antibiotics with procalcitonin guidance. There was also increased morbidity, including a 1 day increase (p=0.004) in ICU length of stay (LOS), a significant increase in days on mechanical ventilation, and increased days with abnormal renal function. A second fair quality study[45] (n=72) was judged to be too small to be informative.

Reduced antibiotic use should decrease the number of allergic reactions, antibiotic-related side effects and toxicities, and superinfections, including the emergence of multi-drug resistant (MDR) organism and *Clostridium difficile*. Only one study[39] reported on the emergence of MDR organisms and superinfections.

Respiratory Tract Infection

Eight trials[27,31,36-38,40-42] (n=3,492) addressed initiation and/or discontinuation of antibiotics in patients with acute upper and lower respiratory tract infection. Settings included primary care clinics, emergency department (ED), and hospital wards. There is high strength of evidence that

procalcitonin guidance reduces antibiotic duration and prescription rates; and moderate evidence of reduction in total antibiotic exposure. Absolute reduction in duration of antibiotic therapy ranged from 1 to 7 days with relative reductions ranging from -13 to -55 percent. Absolute reduction in prescription rates ranged from -2 to -7 percent with relative reductions ranging from -1.8 to -72 percent. There was moderate evidence that procalcitonin guidance did not increase mortality, hospital length of stay, or ICU admission rates. However, a limitation of the evidence is the very large number of study participants that would be required to narrow the confidence interval for estimated mortality. There was insufficient evidence to judge effects on days of restricted activity or on antibiotic adverse events. Three studies[27,40,42] reported on adverse antibiotic effects, and there was a statistically significant reduction in the procalcitonin-guided arm versus the control arm that was associated with reduced antibiotic use. There was no consistency, however, on how adverse effects were defined and details on the types of adverse reactions were lacking. Only one study[42] reported that the reduction in adverse antibiotic adverse effects was mainly due to a reduction in diarrhea. A more uniform approach to evaluating and reporting adverse effects related to antibiotic use would be useful in future studies.

Neonatal Sepsis

One good quality[43] study (n=121) provided moderate evidence that procalcitonin guidance reduces the use of antibiotic therapy for suspected early neonatal sepsis. The duration of antibiotic use was overall reduced by 22.4 hours (22.0%). Further, the proportion of neonates on antibiotics for longer than 72 hours was reduced by 27 percent. Greatest reductions were seen among neonates who were judged according to clinical criteria to have possible infection or unlikely to have infection as compared with those with proven or probable infection. Strength of evidence was judged insufficient to make conclusions on mortality and morbidity due to small study size.

Fever of Unknown Source in Children Ages 1–36 Months

The strength of evidence was judged insufficient to draw conclusions on outcomes of procalcitonin-guided antibiotic therapy for fever of unknown source in children 1–36 months of age. One good quality RCT[26] (n=384) reported no significant results.

Postoperative Patients at Risk of Infection

The strength of evidence was judged insufficient to draw conclusions on outcomes of procalcitonin-guidance to determine preemptive antibiotic therapy for patients after colorectal surgery. The evidence consisted of one small (n=20) trial.[44]

Clinical Context and Applicability of Evidence for Decisionmaking

The diagnosis of sepsis is challenging because the clinical criteria for the diagnosis overlap with noninfectious causes of systemic inflammation, such as the systemic inflammatory response syndrome. Initiation of antibiotic therapy for sepsis is necessary even while the diagnostic evaluation is ongoing since delayed antibiotic therapy is associated with increased mortality.[14,48,50] A biomarker, such as procalcitonin, that improves decisions about initiating, discontinuing, or changing antibiotic therapy, could have substantial clinical benefits. This

systematic review found that procalcitonin guidance reduces antibiotic use for adult patients in both medical and surgical ICUs. Generalizing results from the studies reviewed here, conducted primarily in Europe, would depend on similar use of and adherence with trial-based algorithms guiding antibiotic decision-making. Studies included patients who had co-morbidities that are common in the ICU patients (e.g., cardiac disease, diabetes, chronic lung disease, cirrhosis, chronic renal failure, cancer), and thus, the evidence from these studies are applicable to clinical practice in the ICU setting.

Respiratory tract infections contribute significantly to the problem of antibiotic misuse. Approximately 75 percent of all antibiotics prescribed in the ambulatory setting are for acute respiratory tract infections, but the vast majority of these infections are viral and do not benefit from antibiotic treatment.[51] Clinical and microbiological evaluations are neither sensitive nor specific to differentiate bacterial from viral respiratory tract infections. Because procalcitonin levels rise soon after the onset of a bacterial infection, procalcitonin can help to differentiate bacterial from viral infections. Our systematic review found that procalcitonin guidance for initiation and discontinuation of antibiotic therapy significantly reduced antibiotic prescription rates and duration in patients with acute respiratory tract infections, including acute exacerbations of chronic obstructive pulmonary disease, community acquired pneumonia (CAP) and acute bronchitis. In most of these studies, antibiotic therapy was encouraged if the procalcitonin level was greater than 0.25 ng/mL, because a bacterial infection was likely. Similarly antibiotic therapy was discouraged if the procalcitonin level was less than 0.25 ng/mL because a bacterial infection was unlikely.

Certain populations, however, were excluded from one or more studies of procalcitonin guidance reviewed in this report. These groups might be considered high risk for increased morbidity and/or mortality with delayed initiation or shorter courses of antibiotic therapy, or may not have the same procalcitonin rise in response to infection due to their co-morbidities. Thus, findings from this review should not be extrapolated to these high-risk groups, which include pregnant patients; patients with absolute neutropenia; and other immunocompromised populations (solid organ and stem-cell transplant recipients, patients with advanced HIV infection/AIDS). Although such patients were excluded in these studies, future studies may help to determine if procalcitonin-guided antibiotic therapy is beneficial in these groups, as well. Although febrile neutropenic patients are usually continued on antibiotics until the neutropenia resolves, the most recent guidelines suggest that patients can be switched to an oral fluoroquinolone when an infection has been adequately treated, and procalcitonin guidance could potentially be used in this context.[52] Of note, patients with chronic infections and infections where a longer duration of antibiotic therapy is standard of care, such as infective endocarditis, were also appropriately excluded from these studies.

Applicability to pediatric settings is a significant gap in the present evidence. Only two RCTs[26,43] reported on procalcitonin guidance in pediatric populations. One study[43] included neonates with suspected early sepsis. While antibiotic use was reduced, the trial was underpowered for morbidity and mortality outcomes. In fact, there were no mortality events in either arm of the study and only 21 of 121 neonates in the study had a probable or proven infection.[43] The second study[26] evaluated procalcitonin-guided antibiotic therapy in children ages 1–36 months presenting to the ED with fever of unknown etiology. No significant differences were observed for measures of antibiotic use, morbidity, or mortality with procalcitonin guidance. The evidence from this single study was judged insufficient to reach conclusions about the use of procalcitonin guidance in this setting. It is important to note that bacterial infections

were uncommon in the study population. Only 25 percent of children were admitted to the hospital and about 27 percent received antibiotics overall. This rate was even lower, 10 and 9 percent respectively, if the children with neutropenia or a serious bacterial infection were excluded. There were no studies in children ages 3 to 18 years.

Ultimately, the value of procalcitonin-guided antibiotic therapy depends on the clinical benefits of reduced antibiotic use, which is difficult to quantify. Immediate consequences may include decrease in allergic reactions, drug toxicities, and frequency of *C. difficile* infection. A major downstream effect of reducing antibiotic use may be a lower probability of emergence of antibiotic-resistant strains. Antimicrobial resistance contributes to morbidity, mortality, and health care costs. Though infection control programs reduce transmission of resistant bacteria between patients, they do not affect development of resistance which occurs, in part, due to antibiotic overuse. There is some evidence that the development of resistance is more related to antibiotic treatment than transmission from patient to patient.[53,54] There are several studies and indirect lines of evidence that suggest that control of antibiotic use can reduce emergence of resistance, but the data are limited.[46] Reductions in antibiotic course duration have been associated with significant reductions in antibiotic adverse effects, *C. difficile* colitis, and superinfection with multidrug-resistant Gram-negative rods.[46-48]

In our systematic review, few studies reported on allergic and adverse events of antibiotic use [27,40,42] and only one[32] reported on antibiotic resistance. The durability in reduction of antibiotic use is not addressed in these trials which limits their applicability to clinical practice. The setting of a clinical trial, or highly visible introduction of a new practice, can have a halo effect on physician behavior so the present evidence does not address long-term impact of using procalcitonin guidance a in real-world clinical setting. Antibiotic stewardship programs are now recommended for all institutions and there are guidelines for how they should function.[55] Antibiotic stewardship programs are associated with reduced antibiotic use and also decreased adverse effects of antibiotic therapy. The evidence in this review does not compare outcomes of using procalcitonin guidance versus antibiotic stewardship programs nor does it address whether addition of procalcitonin to an antibiotic stewardship programs improves outcomes. There is at least one report[56] that indicates the use of procalcitonin measurements may be used as part of an antibiotic stewardship program to decrease the duration of antibiotic therapy. Antibiotic stewardship activities are usually limited to the acute care hospital setting. Although it would be difficult or impractical for antibiotic stewardship programs to have active intervention in the outpatient setting, the use of procalcitonin might complement other types of outpatient programs, such as educational programs for physicians and patients aimed at reducing the use of antibiotics for respiratory tract infections.[51]

Discussion of Present Findings in Context of Other Systematic Reviews

We are aware of four systematic reviews[3,19-21] that were published prior to our present review; the findings of our review are discussed in the context of these prior reviews. All of the previous reviews (including the present review) came to similar conclusions: procalcitonin-guided antibiotic decisionmaking compared with clinical criteria-guided antibiotic decision making reduces antibiotic use and is not associated with increased mortality or morbidity. We reviewed all published RCTs of the use of procalcitonin-guided initiation or discontinuation of antibiotic therapy, as well as studies that used procalcitonin for other interventions in patients with infection and/or sepsis. A total of 18 RCTs were included in our systematic review. As the

most recent systematic review, ours is the only one that includes the large (n=1,200) high quality trial by Jensen et al.[28] The Jensen trial[28] is unique in showing that procalcitonin-guided intensification of antibiotic therapy to broaden the spectrum of bacterial coverage does not improve outcomes in critically ill patients, and in fact, may have adverse consequences. Among all the systematic reviews, only ours distinguished between procalcitonin-guided antibiotic intensification therapy, in contrast to procalcitonin-guided antibiotic initiation or discontinuation therapy.

As Table 31 shows, our systematic review differs from previous systematic reviews in terms of number of studies included, scope of indications addressed, and how populations were grouped for clinical relevance. The number of trials included in previous systematic reviews ranged from seven trials[3,20,21] to 14 trials.[19] While the three systematic reviews[3,20,21] that each included seven studies overlapped to a large degree, none included the same studies. Agarwal and Schwartz included one published abstract[57] not included in any other systematic review. We did not include the published abstract by Layios[57] in our review, since it was not possible to assess study quality from an abstract. Tang[3] included patients in ICUs and patients with respiratory tract infections, but did not analyze the data from each population separately. Kopterides[21] focused on studies in the ICU population but their meta-analysis of antibiotic use outcomes pooled data from neonatal population with the adult population. A strength of the Scheutz review[19] was separate meta-analyses of mortality based on acuity of illness (primary care, ED, and ICU patients), as well as a meta-analysis for the total population. The authors concluded that procalcitonin guidance reduces antibiotic duration in primary care, ED, and ICU patients, and reduces prescription rates only in lower acuity primary care and ED patients. The Scheutz review included the 2009 study by Long,[58] whereas we had access to an overlapping, but more recent report of this study.[31]

A strength of the present review is that it addresses pediatric populations separately from adult patients. In addition, it also recognizes that there are distinct patient groups within the pediatric population stratified by age. In our review, we separately grouped neonates and children ages 1–36 months, each represented by a single study. There were no studies in children ages 3 years to 18 years.

Table 31. Summary of systematic reviews

Author, Year	Studies	N	Pediatric Patients?	Pooled Patient Groups (Number of Studies)	Boudama, 2010	Schroeder, 2009	Stolz, 2009	Nobre, 2008	Hochreiter, 2009	Svoboda, 2007	Jensen, 2011	Long, 2011	Burkhardt, 2010	Schuetz, 2009	Kristoffersen, 2009	Briel, 2008	Stolz, 2007	Christ-Crain, 2004	Christ-Crain, 2006	Stocker, 2010	Manzano, 2010	Chromik, 2005	Laiyos, 2009†	Long, 2009
Tang, 2008[3]	7	1,458	No	Adult ICU (3) and RTI (4)				X	X	X						X	X	X	X					
Kopterides, 2010[21]	7	1,131	Yes	ICU [adult (6) and neonates(1)]	X	X	X	X	X	X										X				
Agarwal, 2011[20]	6	1,476	No	Adult ICU (6)	X	X	X	X	X														X	
Scheutz, 2011[19]	14	4,467	No	Primary care (2)									X			X								
				ED (6)										X	X		X	X	X					X
				ICU (6)	X	X	X	X	X	X														
Current Review	18	4,955	Yes	Adult ICU discontinuation	X	X	X	X	X															
				Adult ICU intensification						X	X													
				Adult RTI								X	X	X	X	X	X	X	X					
				Neonates																X				
				Children, 1-36 months																	X			
				Post-op patients																		X		

ED = emergency department; ICU = intensive care unit; post-op = postoperative; RTI = respiratory tract infection
†Published only as an abstract.

Limitations of Present Review

A challenging aspect of this review was appraising the strength of evidence that procalcitonin-guided therapy did not result in any increased morbidity or mortality in the critically ill and respiratory tract infection populations. In the studies of critically ill patients where procalcitonin was used to reduce antibiotic exposure, only the Bouadma study[39] did a power analysis and used a predefined a margin for noninferiority for 28- and 60-day mortality. Meta-analysis was performed looking at early mortality across all five ICU studies. Results show a pooled point estimate of 0.4 percentage-point reduction in mortality, and the 95% confidence interval (CI) for the difference in mortality between procalcitonin-guided therapy and standard care was between -6 percent and 5 percent favoring the procalcitonin-guided therapy group. There is disagreement, however, whether or not this falls within the appropriate noninferiority margin. The choice of a noninferiority margin only requires sufficient precision to exclude a minimal important difference (MID).[49] Although a 10 percent noninferiority margin for mortality has been recommended by the IDSA and ACCP in relevant populations, there is concern, expressed by some peer reviewers and in literature, that a 10 percent margin may be too high. Initially, a higher strength of evidence was considered but due to this uncertainty of the noninferiority margin, the strength of evidence was downgraded to low that procalcitonin-guided antibiotic therapy in the ICU does not increase mortality. Even though overall strength of evidence was low, the results were judged to be precise because the pooled point estimate was centered on the null and the 95% CI was narrow (11 percentage points). While only one study was powered for mortality, one purpose for meta-analysis is to overcome insufficient power and the group of studies was highly consistent: statistical heterogeneity, as expressed by the I^2 statistic, was found to be 0 percent. Sixty-day mortality was reported by one study[39] and was not included in our analysis because late mortality is more likely related to underlying comorbidities. Moreover, there are presently two large trials in progress, which may in the future yield more precise estimates of mortality.

Our systematic review compared procalcitonin guidance with antibiotic therapy based on usual clinical criteria, algorithms, or guidelines. In view of the present emphasis on the overuse of antibiotics, other interventions to reduce antibiotic use, such as institution of antibiotic stewardship programs and implementation of practice guidelines in institutional settings, may have been more robust comparators by which to assess the outcomes of procalcitonin guidance. A limitation of our review is that we did not systematically seek evidence comparing procalcitonin guidance with antibiotic stewardship programs or other programs aimed at reducing antibiotic use. We also did not assess studies that have implemented procalcitonin-guided antibiotic therapy into an antibiotic stewardship program.

Future Research

Summary of Weaknesses or Gaps in the Evidence

This systematic review compared outcomes of procalcitonin guidance compared with clinical criteria alone to initiate, discontinue or intensify antibiotic therapy. We identified five gaps in the evidence related to specific populations or comparators. We also identified methodologic weaknesses that were common across the studies and bodies of evidence reviewed in this report.

Research Gap 1: What Are the Outcomes of Procalcitonin Guidance in Subgroups of Patients Who Are Immunocompromised?

Patients with certain conditions were excluded from these studies, including neutropenia and immunocompromised states (solid organ and stem-cell transplant recipients, and patients with advanced HIV infection). The reasons for excluding such patients were not specifically stated. Because procalcitonin levels are affected by the host cytokine response to infection, the procalcitonin cutoff levels are most likely to differ in these populations. These populations are often excluded from clinical trials because these groups may be at higher risk of adverse outcomes. Finally, for some groups, such as neutropenic patients, antibiotics are continued until the neutropenia resolves, rather than until there is a clinical resolution.

Immunocompromised patients often comprise a significant portion of the ICU population, and in the large PRORATA[39] study, where immunocompromised patients were included, they accounted for 16.6 percent of the population. In the PROVAP[35] study of ventilator-associated pneumonia, 27.9 percent of the eligible patients were excluded because of immunosuppression. Even in community respiratory tract infections, such as CAP (7.6% excluded) and even in other respiratory tract infections (2.5% excluded), there is a significant subpopulation of patients who are immunocompromised or have condition such as cystic fibrosis where the efficacy and safety of procalcitonin-guided therapy is unknown.[36,37]

Six[31,36-38,40,42] of the eight[27,31,36-38,40-42] studies evaluating procalcitonin guidance in patients with acute respiratory tract infections specifically excluded immunocompromised patients. While severely immunocompromised patients presenting with clinical signs of infection are most likely treated empirically with antibiotics, patients with mild to moderate immunosuppression, such as patients on low-dose corticosteroids for chronic inflammatory conditions, may not benefit from antibiotic therapy, even though they are often treated empirically. Procalcitonin guidance may have a potential role in reducing antibiotic use in the ambulatory patients with mild to moderate immunosuppression compared with standard therapy.

Exclusion of immunocompromised patients was common across all five patient populations in this review. Immunocompromised patients are considered high risk for increased morbidity and/or mortality with delayed initiation or shorter courses of antibiotic therapy, or may not have the same procalcitonin rise in response to infection due to their co-morbidities. However, immunocompromised patients may also gain significant clinical benefits if their antibiotic use can be safely reduced, because they are vulnerable to mortality and morbidity from antibiotic resistance and adverse effects of antibiotics.

In addition to immunocompromised patients, future research in needed in patients with certain local or systemic infections, such as skin and soft tissue infections and osteomyelitis. These are relatively common infections in which initiation and/or duration of antibiotic therapy is often unclear, and procalcitonin guidance may have a potential role in reducing antibiotic use.

Research Gap 2: What Are the Outcomes of Procalcitonin Guidance in Pediatric Patients?

Only two studies[26,43]reported on procalcitonin guidance in pediatric populations, and both were underpowered to assess morbidity and mortality outcomes. Both studies were limited to the acute care hospital setting. In our review, we grouped separately neonates[43] and children[26] ages 1-36 months, each represented by a single study. There were no studies in children ages 3 years to 18 years. Future studies of procalcitonin-guided initiation and discontinuation of antibiotics in

the pediatric population will be extremely important. The overuse of antibiotics in pediatrics, in both the inpatient and outpatient setting, is as important among children, as it is in adults.

Research Gap 3: What Are the Outcomes of Procalcitonin Guidance in Identifying Patients at Risk of Infection Who Might Benefit From Preemptive Antibiotic Therapy?

The study by Chromik et al.[44] reported that procalcitonin levels could accurately identify a subpopulation, 8 percent of patients who underwent elective colorectal surgery, who were at risk of a local or systemic infection. Although this was a small study, the evidence suggests that this approach might identify a group who would benefit from preemptive antibiotic therapy given before any infection is clinically evident. Larger studies are needed to confirm that preemptive antibiotic therapy can reduce infectious complications. Other patient populations who are at risk for infectious complications include burn patients, ICU patients, and postoperative patients who have undergone procedures other than colorectal surgery.

Research Gap 4: Does the Use of Procalcitonin Guidance Reduce Antibiotic Resistance and Antibiotic Adverse Events?

Although the importance of reducing antibiotic use is recognized and accepted, there was insufficient evidence from the RCTs we reviewed that the observed reduction in antibiotic use had any benefits with respect to antibiotic adverse reactions, superinfections, or the development of resistance. Adverse antibiotic effects were reported in only three studies[27,40,42] and the findings were reported in different ways. Only one study[39] reported on the emergence of multidrug resistant bacteria, with no differences found between procalcitonin-guided and standard antibiotic therapy, and none reported on the incidence of *C. difficile*. When designing future studies, there should be consideration for standardized reporting of adverse events from antibiotics, the incidence of *C. difficile,* and active surveillance for colonization with drug-resistant pathogens. Quality of life was not addressed in any of the randomized controlled studies included in this review, and if future research demonstrates a significant reduction in antibiotic adverse events, addressing quality of life would be an important consideration to include in future trials.

Research Gap 5: How Does Procalcitonin-Guided Antibiotic Therapy Compare With Other Approaches for Reducing Unnecessary Antibiotic Use, Such as Antibiotic Stewardship Programs and Implementation of Practice Guidelines?

In view of the present emphasis on the overuse of antibiotics, other interventions to reduce antibiotic use, such as institution of antibiotic stewardship programs and structured implementation of practice guidelines, may have been more robust comparators by which to assess the outcomes of procalcitonin-guided decisions on initiation and discontinuation of antibiotic therapy. Our review did not systematically seek evidence comparing procalcitonin guidance with other interventions to reduce antibiotic use, or evidence assessing whether addition of procalcitonin guidance to other interventions improves outcomes. So a systematic review that addresses a broader range of comparators is likely an initial step to determine whether there is an evidence gap and the nature of any gap or gaps. Given the urgency of

reducing unnecessary use of antibiotics, there may be promising opportunities for future research that can inform clinical practice.

In addition to the research gaps above, we also identified four important methodologic weaknesses that were common across the studies and bodies of evidence reviewed in this report.

Summary of Methodological Weaknesses in the Evidence

Weakness 1: Measurement of Total Antibiotic Exposure

Total antibiotic exposure is used to capture the patient's total exposure to all antibiotics, and it is calculated by multiplying the total number of antibiotics by the number of days the patient is receiving each of the antibiotics. Total antibiotic exposure is conventionally reported as mean days per 1,000 days of followup, but some of the studies in this review only reported relative or absolute differences. The differences in reporting limited our ability to pool the total antibiotic exposure data in this review. Consistent use of the conventional measure of mean days per 1,000 days of followup would improve accumulation of a robust body of evidence on the outcomes of procalcitonin guidance.

Weakness 2: Measurement of Morbidity

There were various measures of morbidity across these studies, and that was true even between studies that were grouped together because of their similarities. Although admission rates, LOS, and ICU LOS were easy to compare, other measures were not. In the ICU populations, for example, the need for mechanical ventilation was often reported differently and studies used a variety of severity of illness scores (SOFA, SAP II, SAP III, and APACHE II). This makes it difficult to compare or pool data across studies.

Weakness 3: Rationale for Noninferiority Margins for Studies of Mortality

Mortality rates in trials of procalcitonin-guided therapy implicitly or explicitly pose a question of noninferiority, that is, can reduction in antibiotic use be achieved without a deleterious impact on survival? Is mortality no worse than with usual care? The choice of a noninferiority margin incorporates clinical and statistical judgments.[59] The PRORATA[39] trial, which was the largest trial (n=621) of procalcitonin used to discontinue antibiotic in the ICU populations, was designed to have an 80 percent power to exclude a 10 percent difference in mortality between groups. However, there is concern that the 10 percent noninferiority margin chosen was not sufficiently narrow to exclude excess mortality.[60-62] Studies where mortality is an outcome of interest should provide an explicit rationale for the choice of noninferiority margin in specific patient populations. Moreover, "the choice of margin should be independent of considerations of power as the size of the clinically important difference is not altered by the size of the study."[63]

Weakness 4: Reporting and Interpreting Nonsignificant Differences

A common statistical error in the medical literature is the conclusion that nonsignificant differences ($p>0.05$) are "similar."[64] Most studies included in our systematic review were insufficiently powered to address mortality outcomes. Of the five studies[32-35,39] of antibiotic discontinuation in ICU patients, only the Bouadma et al. study[39] was powered to show noninferiority in mortality between procalcitonin-guided and control group antibiotic therapy.

However, three[32,33,35] of the four[32-35] remaining studies have erroneously concluded that mortality was similar between procalcitonin and control group guided antibiotic therapy based on observed nonsignificant differences in mortality. These three studies reported results as follows: "…without any adverse effects on outcome…,"[33] "…a similar mortality were observed in procalcitonin and control groups…,"[32] and "…absence of differences in overall mortality suggest that procalcitonin guided antibiotic reduction is not associated with a worse outcome in VAP…"[35] Clearly stating in the abstract that the study was not powered to detect a difference in mortality would provide a more accurate reporting of the results.

Abbreviations

ABT	antibiotic
ACCP	American College of Chest Physicians
AECOPD	acute exacerbations of chronic obstructive pulmonary disease
AIDS	acquired immunodeficiency syndrome
APACHE	acute physiology and chronic health evaluation
ATS	American Thoracic Society
CAP	community acquired pneumonia
CI	confidence interval
COPD	chronic obstructive pulmonary disease
CRP	C-reactive protein
ED	emergency department
EPC	evidence practice center
EPICOT	evidence, population, intervention, comparison, outcome, timestamp
FDA	food and drug administration
GOLD	global initiative for chronic obstructive pulmonary diseases
GRADE	grading of recommendations assessment, development, and evaluation
HIV	human immunodeficiency virus
ICU	intensive care unit
IDSA	Annual Meeting of Infectious Diseases Society of America
IL	interleukin
LOS	length of stay
LRTI	Lower respiratory tract infection
NR	not reported
NSS	not statistically significant
PCT	procalcitonin
PFT	pulmonary function test
PICOTS	patient, intervention, comparator, outcome, timing, and setting
PRORATA	Procalcitonin to Reduce Antibiotic Treatments In Acutely Ill Patients
QOL	quality of life
RCT	randomized controlled trial
RTI	respiratory tract infection
SAPS	simplified acute physiology score
SBI	serious blood infections
SD	standard deviation
SIPs	scientific information packets
SIRS	systemic inflammatory response syndrome
SOE	strength of evidence
SOFA	Sepsis-Related Organ Failure Assessment
TEP	technical expert panel
TOO	Task Order Officer
URTI	upper respiratory tract infection
VAP	ventilator-associated pneumonia
WBC	white blood cells

References

1. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14(1):R15. PMID: 20144219.
2. Marshall JC, Reinhart K. Biomarkers of sepsis. Crit Care Med. 2009 Jul;37(7):2290-8. PMID: 19487943.
3. Tang H, Huang T, Jing J, et al. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection. 2009 Dec;37(6):497-507. PMID: 19826761.
4. Jones AE, Fiechtl JF, Brown MD, et al. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann Emerg Med. 2007 Jul;50(1):34-41. PMID: 17161501.
5. Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol. 2010 Jan 1;159(2):253-64. PMID: 20002097.
6. Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatrogenic sepsis. Intensive Care Med. 1998 Aug;24(8):888-9. PMID: 9757936.
7. Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994 Dec;79(6):1605-8. PMID: 7989463.
8. 510(k) Summary of Safety and Effectiveness: B.R.A.H.M.S PCT LIA. January 7, 2005. www.accessdata.fda.gov/cdrh_docs/pdf4/K040887.pdf. Accessed on August 18 2011.
9. 510(k) Summary VIDAS B.R.A.H.M.S PCT Assay. October 11, 2007. www.accessdata.fda.gov/cdrh_docs/pdf7/K071146.pdf. Accessed on August 18 2011.
10. 510(k) Summary B.R.A.H.M.S PCT sensitive KRYPTOR® Test System. March 31, 2008. www.accessdata.fda.gov/cdrh_docs/pdf7/K070310.pdf. Accessed on August 18 2011.
11. Schneider HG, Lam QT. Procalcitonin for the clinical laboratory: a review. Pathology. 2007 Aug;39(4):383-90. PMID: 17676478.
12. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992 Jun;101(6):1644-55. PMID: 1303622.
13. Polin RA. The "ins and outs" of neonatal sepsis. J Pediatr. 2003 Jul;143(1):3-4. PMID: 12915813.
14. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001 Aug 1;164(3):396-402. PMID: 11500339.
15. Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004 Jul 15;39(2):206-17. PMID: 15307030.
16. Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J. 2007 Sep;30(3):556-73. PMID: 17766633.
17. Chiesa C, Panero A, Rossi N, et al. Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. Clin Infect Dis. 1998 Mar;26(3):664-72. PMID: 9524841.
18. Luyt CE, Guerin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med. 2005 Jan 1;171(1):48-53. PMID: 15447947.
19. Schuetz P, Chiappa V, Briel M, et al. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med. 2011 Aug 8;171(15):1322-31. PMID: 21824946.

20. Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis. 2011 Aug;53(4):379-87. PMID: 21810753.

21. Kopterides P, Siempos, II, Tsangaris I, et al. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med. 2010 Nov;38(11):2229-41. PMID: 20729729.

22. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(11)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality.; March 2011.

23. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001 Apr;20(3 Suppl):21-35. PMID: 11306229.

24. Brown P, Brunnhuber K, Chalkidou K, et al. How to formulate research recommendations. BMJ. 2006 Oct 14;333(7572):804-6. PMID: 17038740.

25. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. J Clin Epidemiol. 2010 May;63(5):513-23. PMID: 19595577.

26. Manzano S, Bailey B, Girodias JB, et al. Impact of procalcitonin on the management of children aged 1 to 36 months presenting with fever without source: a randomized controlled trial. Am J Emerg Med. 2010 Jul;28(6):647-53. PMID: 20637377.

27. Burkhardt O, Ewig S, Haagen U, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J. 2010 Sep;36(3):601-7. PMID: 20185423.

28. Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial. Crit Care Med. 2011 May 12. PMID: 21572328.

29. Roh Y-H. Antibiotic Therapy With the Guidance of Procalcitonin in Patients With Community-Acquired Pneumonia. Chest; 2010 October 1, 2010. 138. p. 592A.

30. Sanches PR, Deliberato RO, Paes AT, et al. Procalcitonin as a marker to shorten antimicrobial treatment in septic patient in intensive care setting. Fifth Decennial International Conference on Healthcare-Associated Infections; 2010 Atlanta, USA.

31. Long W, Deng X, Zhang Y, et al. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology. 2011 Jul;16(5):819-24. PMID: 21507143.

32. Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008 Mar 1;177(5):498-505. PMID: 18096708.

33. Schroeder S, Hochreiter M, Koehler T, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg. 2009 Mar;394(2):221-6. PMID: 19034493.

34. Hochreiter M, Kohler T, Schweiger AM, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care. 2009;13(3):R83. PMID: 19493352.

35. Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J. 2009 Dec;34(6):1364-75. PMID: 19797133.

36. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006 Jul 1;174(1):84-93. PMID: 16603606.

37. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004 Feb 21;363(9409):600-7. PMID: 14987884.

38. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007 Jan;131(1):9-19. PMID: 17218551.

39. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010 Feb 6;375(9713):463-74. PMID: 20097417.

40. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009 Sep 9;302(10):1059-66. PMID: 19738090.

41. Kristoffersen KB, Sogaard OS, Wejse C, et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission--a randomized trial. Clin Microbiol Infect. 2009 May;15(5):481-7. PMID: 19416298.

42. Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med. 2008 Oct 13;168(18):2000-7; discussion 7-8. PMID: 18852401.

43. Stocker M, Fontana M, El Helou S, et al. Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology. 2010;97(2):165-74. PMID: 19776651.

44. Chromik AM, Endter F, Uhl W, et al. Pre-emptive antibiotic treatment vs 'standard' treatment in patients with elevated serum procalcitonin levels after elective colorectal surgery: a prospective randomised pilot study. Langenbecks Arch Surg. 2006 Jun;391(3):187-94. PMID: 16369855.

45. Svoboda P, Kantorova I, Scheer P, et al. Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery? Hepatogastroenterology. 2007 Mar;54(74):359-63. PMID: 17523274.

46. Carling P, Fung T, Killion A, et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003 Sep;24(9):699-706. PMID: 14510254.

47. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003 Nov 19;290(19):2588-98. PMID: 14625336.

48. Ibrahim EH, Ward S, Sherman G, et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med. 2001 Jun;29(6):1109-15. PMID: 11395584.

49. Assessing Equivalence and Non-Inferiority (Draft). Rockville, MD: Agency for Healthcare Rsearch and Quality; September 2011.

50. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999 Feb;115(2):462-74. PMID: 10027448.

51. Gonzales R, Steiner JF, Lum A, et al. Decreasing antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults. JAMA. 1999 Apr 28;281(16):1512-9. PMID: 10227321.

52. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011 Feb 15;52(4):e56-93. PMID: 21258094.

53. McGowan JE, Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis. 1983 Nov-Dec;5(6):1033-48. PMID: 6318289.

54. Levy SB. Balancing the drug-resistance equation. Trends Microbiol. 1994 Oct;2(10):341-2. PMID: 7850197.

55. Dellit TH, Owens RC, McGowan JE, Jr., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007 Jan 15;44(2):159-77. PMID: 17173212.

56. Liew YX, Chlebicki MP, Lee W, et al. Use of procalcitonin (PCT) to guide discontinuation of antibiotic use in an unspecified sepsis is an antimicrobial stewardship program (ASP). Eur J Clin Microbiol Infect Dis. 2011 Jul;30(7):853-5. PMID: 21279532.

57. Layios N LB, Ledoux D, Morimont P, Massion P, Garweg C, Frippiat F, Nys M, Chapelle J-P, Damas P. Usefulness of procalcitonin for the decision of antibiotic treatment in ICU patients. Vienna; 2009. http://poster-consultation.esicm.org/ModuleConsultationPoster/posterDetail.aspx?intIdPoster=486. Accessed on September 6 2011.

58. Long W, Deng XQ, Tang JG, et al. [The value of serum procalcitonin in treatment of community acquired pneumonia in outpatient]. Zhonghua Nei Ke Za Zhi. 2009 Mar;48(3):216-9. PMID: 19576090.

59. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med. 2006 Jul 4;145(1):62-9. PMID: 16818930.

60. Tarnow-Mordi W, Gebski V. Procalcitonin in intensive care units: the PRORATA trial. Lancet. 2010 May 8;375(9726):1605; author reply 6-7. PMID: 20452513.

61. Landman GW, Kleefstra N. Procalcitonin in intensive care units: the PRORATA trial. Lancet. 2010 May 8;375(9726):1606; author reply -7. PMID: 20452516.

62. Gibot S. Procalcitonin in intensive care units: the PRORATA trial. Lancet. 2010 May 8;375(9726):1605-6; author reply 6-7. PMID: 20452514.

63. European Medicines Agency Guideline on the Choice of the Non-Inferiorirty Margin. 2005. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003636.pdf. Accessed September 6 2011.

64. Zinsmeister AR, Connor JT. Ten common statistical errors and how to avoid them. Am J Gastroenterol. 2008 Feb;103(2):262-6. PMID: 18289193.

Appendix A. Search Strategy

The following electronic databases were searched for citations.

- MEDLINE® (inception [1948] through December 16, 2011)
- EMBASE® (inception [1974] through December 16, 2011)
- Cochrane Controlled Trials Register (no date restriction)

MEDLINE search 12/16/11

1. procalcitonin
2. "Systemic Inflammatory Response Syndrome"[MeSH] OR "Pulmonary Disease, Chronic Obstructive"[MeSH] OR "Surgical Wound Infection"[MeSH] OR "Critical Illness"[MeSH] OR "Intensive Care"[MeSH]
3. ("Neutropenia"[MeSH] OR neutropenia) AND febrile
4. sepsis OR septic OR "systematic inflammatory response syndrome" OR ICU OR "critically ill" OR "intensive care unit" OR "postoperative infection*"
5. "Postoperative Complications"[MeSH] OR "Intensive Care Units"[MeSH] Limits: Humans, English
6. (2 OR 3 OR 4 OR 5) AND Limits: Humans, English
7. 1 AND 6 Limits: Humans, English
8. A second result set was created in the database with set number 1 NOT set 7

EMBASE search 12/16/11

1. procalcitonin AND Limit: Humans NOT MEDLINE
2. 'sepsis'/exp OR septic OR 'systemic inflammatory response syndrome'/exp OR 'copd'/exp OR 'chronic obstructive pulmonary disease'/exp OR 'febrile neutropenia'/exp OR 'postoperative infection'/exp OR 'postoperative infections'/exp OR 'postoperative complications'/exp OR 'post-surgical infection' OR 'post-surgical infections' OR 'critically ill'/exp OR icu OR 'intensive care'/exp OR 'intensive care units'/exp AND Limit: Humans
3. 1 AND 2
4. 1 NOT 3

Search Strategy For Gray Literature

Regulatory Information

FDA
Source: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm
Date searched: 6/3/2011
Search strategy: key word “procalcitonin assay”
Records: 3

Clinical trial registries

NIH database
Source: http://clinicaltrials.gov/
Date searched: 7/06/2011
Search strategy: Procalcitonin [ALL-FIELDS] AND "Completed" [OVERALL-STATUS]
Records: 29

BioMed central
Source: http://www.controlled-trials.com/mrct/
Date searched: 6/16/2011
Search strategy: “Procalcitonin” for completed trials
Records:7

PhRMA
Source: http://www.clinicalstudyresults.org/home/
Date searched: 6/16/2011
Search strategy: Search String = “Procalcitonin”
Records: 0

WHO International Clinical Trials Registry Platform Search Portal
Source: http://apps.who.int/trialsearch/
Date searched: 6/16/2011
Search strategy: Search String = “Procalcitonin” for ALL recruitment status trials
Records: 55

Conference papers and abstracts

Cambridge scientific abstracts
Source: http://www.csa.com/factsheets/cpi-set-c.php
Date searched: 6/28/2011
Search strategy: search string “procalcitonin”
Records:41

Scopus
Source: http://www.scopus.com/home.url
Date searched:6/29/2011
Search strategy:
1 TITLE-ABS-KEY(sepsis) RESULT 93,988
2 TITLE-ABS-KEY(biomarker* OR procalcitonin) RESULT 73,083
3 TITLE-ABS-KEY(screen* OR test*) RESULT 3,391,802
4 (TITLE-ABS-KEY(sepsis) AND (TITLE-ABS-KEY(biomarker* OR procalcitonin)) AND (TITLE-ABS-KEY(screen* OR test*) RESULT 538
LIMIT: SUBJAREA(mult OR agri OR bioc OR immu OR neur OR phar OR mult OR medi OR nurs OR vete OR dent OR heal)
Records:376

Specific conferences and association meetings
Source:
Annual meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Annual meeting of Infectious Diseases Society of America (IDSA)
Annual meeting of American College of Chest Physicians (ACCP)
Annual meeting of Pediatric Academic Societies (PAS)
Date searched: 6/21/2011
Search strategy: KW: “procalcitonin” or “sepsis” in the title
Records:33

Government documents

RePORTER
Source: http://projectreporter.nih.gov/reporter.cfm
Date searched: 6/16/2011
Search strategy: key word “procalcitonin” AND “sepsis”
Records:2

HSRPROJ
Source: http://wwwcf.nlm.nih.gov/hsr_project/home_proj.cfm
Date searched: 6/16/2011
Search strategy: key word “procalcitonin” AND “sepsis”
Records:0

AHRQ GOLD
Source: http://gold.ahrq.gov/projectsearch/
Date searched: 6/16/2011
Search strategy: key word “procalcitonin” AND “sepsis”
Records:1

Manufacturer database

Source: Thermo Fisher Scientific
Date posted: 6/13/2011
Date searched:6/15/2011
Search strategy: Not applicable
Records:67

Gray Literature searching

Scopus (performed June 2011) = 376 records
Conference Papers Index (performed June 2011) = 42 records
Clinicaltrials.gov = 2 records
Meeting abstracts from 2006-2010 for:
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Infectious Disease Society of America (IDSA)
American College of Chest Physicians
Pediatric Academic Societies (PAS)

Appendix B. Excluded Studies

EXC exclude
NRD not relevant disease (not relevant population)
NDE not relevant design
NRO not relevant outcome
SMN small n

Aalto, H., A. Takala, H. Kautiainen, and H. Repo. Laboratory markers of systemic inflammation as predictors of bloodstream infection in acutely ill patients admitted to hospital in medical emergency. Eur J Clin Microbiol Infect Dis 2004 23(9):699-704.
Rec#: 4180
Exclusion Codes: SMN, EXC

Adamik, B., J. Kubler-Kielb, B. Golebiowska, A. Gamian, and A. Kubler. Effect of sepsis and cardiac surgery with cardiopulmonary bypass on plasma level of nitric oxide metabolites, neopterin, and procalcitonin: correlation with mortality and postoperative complications. Intensive Care Med 2000 26(9):1259-67.
Rec#: 5940
Exclusion Codes: NDE, EXC

Ahmadinejad, Z., B. Dadsetan, M. Jalili, A. Soudbakhsh, and M. Rasolinejad. Evaluation of serum procalcitonin in patients with systemic inflammatory response syndrome with and without infection. Acta Med. Iran. 2009 47(5):383-388.
Rec#: 11910
Exclusion Codes: NDE, EXC

Ahmadinejad, Z., A.R. Soudbakhsh, and A. Tayebi. Serum procalcitonin level in infectious and non- infectious systemic inflammatory response syndrome: A three- year study. Tehran Uni. Med. J. 2010 67(10):724-730.
Rec#: 11880
Exclusion Codes: NRD, EXC

Ahn, S., W.Y. Kim, J.Y. Yoon, C.H. Sohn, D.W. Seo, S.H. Kim, S.B. Hong, C.M. Lim, Y.S. Koh, and W. Kim. Procalcitonin in 2009 H1N1 influenza pneumonia: Role in differentiating from bacterial pneumonia. Tuberc. Respir. Dis. 2010 68(4):205-211.
Rec#: 15470
Exclusion Codes: NRD, EXC

Aikawa, N., S. Fujishima, S. Endo, I. Sekine, K. Kogawa, Y. Yamamoto, S. Kushimoto, H. Yukioka, N. Kato, K. Totsuka, K. Kikuchi, T. Ikeda, K. Ikeda, K. Harada, and S. Satomura. Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother 2005 11(3):152-9.
Rec#: 3770
Exclusion Codes: NDE, EXC

Ali, A. M., M. A. Moaz, E. Ghoniem, T. Abd El Motaleb, and N. Sheri. Reliability of serum procalcitonin concentrations for the diagnosis of sepsis in neonates. Egypt J Immunol 2008 15(1):75-84.
Rec#: 2210
Exclusion Codes: NDE, EXC

Al-Nawas, B., I. Krammer, and P. M. Shah. Procalcitonin in diagnosis of severe infections. Eur J Med Res 1996 1(7):331-3.
Rec#: 6910
Exclusion Codes: NDE, EXC

Al-Nawas, B., and P. Shah. Procalcitonin in acute malaria. Eur J Med Res 1997 2(5):206-8.
Rec#: 6840
Exclusion Codes: SMN, EXC

al-Nawas, B., and P. M. Shah. Procalcitonin in patients with and without immunosuppression and sepsis. Infection 1996 24(6):434-6.
Rec#: 6890
Exclusion Codes: NDE, EXC

Ames, P. R., E. Walker, D. Aw, D. Marshall, F. de Villiers, and M. Staber. Multi-organ failure in adult onset Still's disease: a septic disguise. Clin Rheumatol 2009 28 Suppl 1:S3-6.
Rec#: 1360
Exclusion Codes: NDE, EXC

Amour, J., A. Birenbaum, O. Langeron, Y. Le Manach, M. Bertrand, P. Coriat, B. Riou, M. Bernard, and P. Hausfater. Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery. Crit Care Med 2008 36(4):1147-54.
Rec#: 1950
Exclusion Codes: NDE, EXC

Andermahr, J., A. Greb, T. Hensler, H. J. Helling, B. Bouillon, S. Sauerland, K. E. Rehm, and E. Neugebauer. Pneumonia in multiple injured patients: a prospective controlled trial on early prediction using clinical and immunological parameters. Inflamm Res 2002 51(5):265-72.
Rec#: 5300
Exclusion Codes: NDE, EXC

Anderson, R., and R. Schmidt. Clinical biomarkers in sepsis. Front Biosci (Elite Ed) 2010 2:504-20.
Rec#: 270
Exclusion Codes: NRD, EXC

Andreola, B., S. Bressan, S. Callegaro, A. Liverani, M. Plebani, and L. Da Dalt. Procalcitonin and C-reactive protein as diagnostic markers of severe bacterial infections in febrile infants and children in the emergency department. Pediatr Infect Dis J 2007 26(8):672-7.
Rec#: 8250
Exclusion Codes: NDE, EXC

Aouifi, A., V. Piriou, O. Bastien, P. Blanc, H. Bouvier, R. Evans, M. Celard, F. Vandenesch, R. Rousson, and J. J. Lehot. Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients. Crit Care Med 2000 28(9):3171-6.
Rec#: 6010
Exclusion Codes: NDE, EXC

Aouifi, A., V. Piriou, P. Blanc, H. Bouvier, O. Bastien, P. Chiari, R. Rousson, R. Evans, and J. J. Lehot. Effect of cardiopulmonary bypass on serum procalcitonin and C-reactive protein concentrations. Br J Anaesth 1999 83(4):602-7.
Rec#: 6260
Exclusion Codes: NRO, EXC

Apostolakis, E. E., C. Prokakis, and D. Dougenis. Are procalcitonin levels sufficient for the follow up of patients undergoing lung decortication for pleural empyema? Eur J Cardiothorac Surg 2009 35(1):193; author reply 194.
Rec#: 1220
Exclusion Codes: NDE, EXC

Arkader, R., E. J. Troster, M. R. Lopes, R. R. Junior, J. A. Carcillo, C. Leone, and T. S. Okay. Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome. Arch Dis Child 2006 91(2):117-20.

Rec#: 3560
Exclusion Codes: SMN, EXC

Assicot, M., D. Gendrel, H. Carsin, J. Raymond, J. Guilbaud, and C. Bohuon. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993 341(8844):515-8.
Rec#: 6930
Exclusion Codes: NRO, EXC

Atanasova, V., R. Rosmanova, and H. Andreeva. Procalcitonin: An innovative marker for bacterial infections. Biochemical, immunological and clinical aspects (chapter 2). Clin. Appl. Immunol. 2002 1(1):23-27.
Rec#: 14680
Exclusion Codes: NDE, EXC

Athhan, F., B. Akagunduz, F. Genel, M. Bak, and D. Can. Procalcitonin: a marker of neonatal sepsis. J Trop Pediatr 2002 48(1):10-4.
Rec#: 5490
Exclusion Codes: NDE, EXC

Ayazi, P., A. Mahyar, H.J. Hashemi, M.-M. Daneshi, T. Karimzadeh, and F. Salimi. Comparison of procalcitonin and C-reactive protein tests in children with urinary tract infection. Iran. J. Pediatr. 2009 19(4):381-386.
Rec#: 15670
Exclusion Codes: NDE, EXC

Aygun, C., O. Oran, and O. Portakal. Procalcitonin: Levels in newborns and as an indicator in the diagnosis of neonatal sepsis: Yenidoganlarda prokalsitonin duzeyleri ve sepsis tanisindaki yeri. Cocuk Sagligi Hast. Derg. 2003 46(2):83-89.
Rec#: 14410
Exclusion Codes: NRD, EXC

Azarpira, N., M. Ramzi, M. Aghdaie, and M. Daraie. Procalcitonin and C-reactive protein serum levels after hematopoietic stem-cell transplant. Exp Clin Transplant 2009 7(2):115-8.
Rec#: 580
Exclusion Codes: NDE, EXC

Aznar-Oroval, E., M. Sanchez-Yepes, P. Lorente-Alegre, M.C. San Juan-Gadea, B. Ortiz-Munoz, P. Prez-Ballestero, I. Picn-Roig, and J. Maquez-Richart. Diagnostic value of procalcitonin, interleukin 8, interleukin 6, and c-reactive protein for detecting bacteremia and fungemia in cancer patients: Valor diagnostico de la procalcitonina, la interleucina 8, la interleucina 6 y la proteina C reactiva en la deteccin de bacteriemia y fungemia en pacientes con cancer. Enferm. Infecc. Microbiol. Clin. 2010 28(5):273-277.
Rec#: 11510
Exclusion Codes: NDE, EXC

Balci, C., R. Sivaci, G. Akbulut, and H. S. Karabekir. Procalcitonin levels as an early marker in patients with multiple trauma under intensive care. J Int Med Res 2009 37(6):1709-17.
Rec#: 170
Exclusion Codes: NDE, EXC

BalcI, C., H. Sungurtekin, E. Gurses, U. Sungurtekin, and B. Kaptanoglu. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care 2003 7(1):85-90.
Rec#: 4970
Exclusion Codes: SMN, EXC

Ballot, D. E., O. Perovic, J. Galpin, and P. A. Cooper. Serum procalcitonin as an early marker of neonatal sepsis. S Afr Med J 2004 94(10):851-4.
Rec#: 4070
Exclusion Codes: NDE, EXC

Barati, M., F. Alinejad, M. A. Bahar, M. S. Tabrisi, A. R. Shamshiri, N. O. Bodouhi, and H. Karimi. Comparison of WBC, ESR, CRP and PCT serum levels in septic and non-septic burn cases. Burns 2008 34(6):770-4.
Rec#: 1600
Exclusion Codes: SMN, EXC

Bargues, L., Y. Chancerelle, J. Catineau, P. Jault, and H. Carsin. Evaluation of serum procalcitonin concentration in the ICU following severe burn. Burns 2007 33(7):860-4.
Rec#: 2710
Exclusion Codes: SMN, EXC

Barnes, C., V. Ignjatovic, F. Newall, J. Carlin, F. Ng, S. Hamilton, D. Ashley, K. Waters, and P. Monagle. Change in serum procalcitonin (deltaPCT) predicts the clinical outcome of children admitted with febrile neutropenia. Br J Haematol 2002 118(4):1197-8.
Rec#: 5190
Exclusion Codes: SMN, EXC

Baruti Gafurri, Z., H. Pacarizi, B. Zhubi, L. Begolli, and V. Topciu. The importance of determining procalcitonin and C reactive protein in different stages of sepsis. Bosn J Basic Med Sci 2010 10(1):60-4.
Rec#: 150
Exclusion Codes: NRO, EXC

Basler, T., A. Meier-Hellmann, D. Bredle, and K. Reinhart. Amino acid imbalance early in septic encephalopathy. Intensive Care Med 2002 28(3):293-8.
Rec#: 5460
Exclusion Codes: SMN, EXC

Batard, E., N. Asseray, A. Kenzi, I. Gueffet, J.-L. Orsonneau, and G. Potel. Role of C-reactive protein and procalcitonin in the management of sepsis: Meningitis: Interet de la proteine C-reactive et de la procalcitonine dans la prise en charge des sepsis: L'exemple de la meningite. Med. Ther. 2003 9(1-2):26-31.
Rec#: 14500
Exclusion Codes: NRD, EXC

Baumgarten, R., N.C.V. Pequeriaux, M.J.E. Van Puyenbroek, and B. Speelberg. Diagnosis of sepsis by procalcitonin: Is procalcitonine van additionele waarde bij de diagnostiek van sepsis? Ned. Tijdschr. Klin. Chem. 2002 27(1):32-35.
Rec#: 14670
Exclusion Codes: NRD, EXC

Baykut, D., J. Schulte-Herbruggen, and A. Krian. The value of procalcitonin as an infection marker in cardiac surgery. Eur J Med Res 2000 5(12):530-6.
Rec#: 5910
Exclusion Codes: NRO, EXC

Baylan, O., A. Balkan, A. Inal, O. Kisa, A. Albay, L. Doganci, and C. H. Acikel. The predictive value of serum procalcitonin levels in adult patients with active pulmonary tuberculosis. Jpn J Infect Dis 2006 59(3):164-7.
Rec#: 8770
Exclusion Codes: NDE, EXC

Becker, K. L., R. Snider, and E. S. Nylen. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008 36(3):941-52.
Rec#: 1870
Exclusion Codes: NRD, EXC

Becker, K. L., R. Snider, and E. S. Nylen. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol 2010 159(2):253-64.

Rec#: 300
Exclusion Codes: NDE, EXC

Beghetti, M., P. C. Rimensberger, A. Kalangos, W. Habre, and A. Gervaix. Kinetics of procalcitonin, interleukin 6 and C-reactive protein after cardiopulmonary-bypass in children. Cardiol Young 2003 13(2):161-7.
Rec#: 9870
Exclusion Codes: NRO, EXC

Bell, K., M. Wattie, K. Byth, R. Silvestrini, P. Clark, E. Stachowski, and E. M. Benson. Procalcitonin: a marker of bacteraemia in SIRS. Anaesth Intensive Care 2003 31(6):629-36.
Rec#: 4500
Exclusion Codes: NDE, EXC

Bellmann-Weiler, R., M. Ausserwinkler, K. Kurz, I. Theurl, and G. Weiss. Clinical potential of C-reactive protein and procalcitonin serum concentrations to guide differential diagnosis and clinical management of pneumococcal and Legionella pneumonia. J. Clin. Microbiol. 2010 48(5):1915-1917.
Rec#: 15440
Exclusion Codes: NDE, EXC

Benador, N., C. A. Siegrist, D. Gendrel, C. Greder, D. Benador, M. Assicot, C. Bohuon, and E. Girardin. Procalcitonin is a marker of severity of renal lesions in pyelonephritis. Pediatrics 1998 102(6):1422-5.
Rec#: 10720
Exclusion Codes: SMN, EXC

Bender, L., J. Thaarup, K. Varming, H. Krarup, S. Ellermann-Eriksen, and F. Ebbesen. Early and late markers for the detection of early-onset neonatal sepsis. Dan Med Bull 2008 55(4):219-23.
Rec#: 1040
Exclusion Codes: NDE, EXC

Benhamou, D. Optimal duration of antibiotic therapy in community acquired pneumonia: Durees optimales de l'antibiotherapie dans les pneumonies communautaires. Rev. Mal. Respir. 2009 26(4):458-460.
Rec#: 12380
Exclusion Codes: NDE, EXC

Benitz, W.E. Adjunct laboratory tests in the diagnosis of early-onset neonatal sepsis. Clin. Perinatol. 2010 37(2):421-438.
Rec#: 11410
Exclusion Codes: NDE, EXC

Benoist, J. F., O. Mimoz, M. Assicot, and A. Edouard. Serum procalcitonin, but not C-reactive protein, identifies sepsis in trauma patients. Clin Chem 1998 44(8 Pt 1):1778-9.
Rec#: 6720
Exclusion Codes: NDE, EXC

Beovic, B., S. Kreft, J. Osredkar, D. Kese, and B. Bonac-Tuma. Serum procalcitonin levels in patients with mild community-acquired pneumonia. Clin Microbiol Infect 2005 11(12):1050-1.
Rec#: 8990
Exclusion Codes: NRO, EXC

Berger, C., S. Schwarz, W. R. Schaebitz, A. Aschoff, and S. Schwab. Serum procalcitonin in cerebral ventriculitis. Crit Care Med 2002 30(8):1778-81.
Rec#: 5220
Exclusion Codes: SMN, EXC

Bergmann, A., and C. Bohuon. Decrease of serum dipeptidylpeptidase activity in severe sepsis patients: relationship to procalcitonin. Clin Chim Acta 2002 321(1-2):123-6.

Rec#: 5320
Exclusion Codes: NRO, EXC

Bernard, L., F. Ferriere, P. Casassus, F. Malas, S. Leveque, L. Guillevin, and O. Lortholary. Procalcitonin as an early marker of bacterial infection in severely neutropenic febrile adults. Clin Infect Dis 1998 27(4):914-5.
Rec#: 6640
Exclusion Codes: NDE, EXC

Bernstein, L.H., A. Devakonda, E. Engelman, G. Pancer, J. Ferraraf, J. Rucinski, S. Raoof, L. George, and L. Melniker. The role of procalcitonin in the diagnosis of sepsis and patient assignment to medical intensive care. J. Clin. Ligand Assay 2007 30(3-4):98-104.
Rec#: 13240
Exclusion Codes: NDE, EXC

Bewick, T., and W.S. Lim. Diagnosis of community-acquired pneumonia in adults. Expert Rev. Respir. Med. 2009 3(2):153-164.
Rec#: 15790
Exclusion Codes: NDE, EXC

Bhatia, B. D., and S. Basu. Newer diagnostic tests for bacterial diseases. Indian J Pediatr 2007 74(7):673-7.
Rec#: 8310
Exclusion Codes: NDE, EXC

Bignardi, G. E., R. Dhar, R. Heycock, S. Bansal, and N. Majmudar. Can procalcitonin testing reduce antibiotic prescribing for respiratory infections? Age Ageing 2006 35(6):625-6.
Rec#: 8730
Exclusion Codes: NDE, EXC

Billeter, A., M. Turina, B. Seifert, L. Mica, R. Stocker, and M. Keel. Early serum procalcitonin, interleukin-6, and 24-hour lactate clearance: useful indicators of septic infections in severely traumatized patients. World J Surg 2009 33(3):558-66.
Rec#: 1080
Exclusion Codes: NDE, EXC

Bistrian, B. R. Acute phase proteins and the systemic inflammatory response. Crit Care Med 1999 27(3):452-3.
Rec#: 6550
Exclusion Codes: NDE, EXC

Bitkover, C. Y., L. O. Hansson, G. Valen, and J. Vaage. Effects of cardiac surgery on some clinically used inflammation markers and procalcitonin. Scand Cardiovasc J 2000 34(3):307-14.
Rec#: 6070
Exclusion Codes: NRO, EXC

Blijlevens, N. M., J. P. Donnelly, J. F. Meis, M. H. De Keizer, and B. E. De Pauw. Procalcitonin does not discriminate infection from inflammation after allogeneic bone marrow transplantation. Clin Diagn Lab Immunol 2000 7(6):889-92.
Rec#: 10480
Exclusion Codes: NDE, EXC

Blommendahl, J., M. Janas, S. Laine, A. Miettinen, and P. Ashorn. Comparison of procalcitonin with CRP and differential white blood cell count for diagnosis of culture-proven neonatal sepsis. Scand J Infect Dis 2002 34(8):620-2.
Rec#: 5120
Exclusion Codes: NDE, EXC

Boeken, U., P. Feindt, M. Micek, T. Petzold, H. D. Schulte, and E. Gams. Procalcitonin (PCT) in cardiac surgery: diagnostic value in systemic inflammatory response syndrome (SIRS), sepsis and after heart transplantation (HTX). Cardiovasc Surg 2000 8(7):550-4.
Rec#: 5980
Exclusion Codes: NDE, EXC

Boeken, U., P. Feindt, E. Mohan, Th. Petzold, M. Micek, and E. Gams. The influence of extracorporeal circulation and inflammatory responses such as SIRS and sepsis on secretion of procalcitonin (PCT). J. Clin. Basic Cardiol. 1999 2(2):225-227.
Rec#: 15020
Exclusion Codes: SMN, EXC

Boeken, U., P. Feindt, T. Petzold, M. Klein, M. Micek, U. T. Seyfert, E. Mohan, H. D. Schulte, and E. Gams. Diagnostic value of procalcitonin: the influence of cardiopulmonary bypass, aprotinin, SIRS, and sepsis. Thorac Cardiovasc Surg 1998 46(6):348-51.
Rec#: 6590
Exclusion Codes: NRO, EXC

Bogar, L., Z. Molnar, P. Kenyeres, and P. Tarsoly. Sedimentation characteristics of leucocytes can predict bacteraemia in critical care patients. J Clin Pathol 2006 59(5):523-5.
Rec#: 3410
Exclusion Codes: SMN, EXC

Bogar, L., Z. Molnar, P. Tarsoly, P. Kenyeres, and S. Marton. Serum procalcitonin level and leukocyte antisedimentation rate as early predictors of respiratory dysfunction after oesophageal tumour resection. Crit Care 2006 10(4):R110.
Rec#: 3240
Exclusion Codes: SMN, EXC

Bollu, M., A. C. Marte-Grau, and R. K. Bobba. Procalcitonin-guided antibiotic use in acute respiratory tract infections. Arch Intern Med 2009 169(7):716.
Rec#: 7450
Exclusion Codes: NDE, EXC

Bonac, B., M. Derganc, B. Wraber, and S. Hojker. Interleukin-8 and procalcitonin in early diagnosis of early severe bacterial infection in critically ill neonates. Pflugers Arch 2000 440(5 Suppl):R72-4.
Rec#: 6020
Exclusion Codes: NDE, EXC

Boo, N. Y., A. A. Nor Azlina, and J. Rohana. Usefulness of a semi-quantitative procalcitonin test kit for early diagnosis of neonatal sepsis. Singapore Med J 2008 49(3):204-8.
Rec#: 1990
Exclusion Codes: NDE, EXC

Bossink, A. W., A. B. Groeneveld, and L. G. Thijs. Prediction of microbial infection and mortality in medical patients with fever: plasma procalcitonin, neutrophilic elastase-alpha1-antitrypsin, and lactoferrin compared with clinical variables. Clin Infect Dis 1999 29(2):398-407.
Rec#: 6420
Exclusion Codes: NDE, EXC

Bota, D. P., M. Van Nuffelen, A. N. Zakariah, and J. L. Vincent. Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver. J Lab Clin Med 2005 146(6):347-51.
Rec#: 3570
Exclusion Codes: NDE, EXC

Bottner, F., A. Wegner, W. Winkelmann, K. Becker, M. Erren, and C. Gotze. Interleukin-6, procalcitonin and TNF-alpha: markers of peri-prosthetic infection following total joint replacement. J Bone Joint Surg Br 2007 89(1):94-9.
Rec#: 2970
Exclusion Codes: SMN, EXC

Bouadma, L., C.-E. Luyt, F. Tubach, J. Chastre, and M. Wolff. Procalcitonin in intensive care units: the PRORATA trial - Authors' reply. Lancet 2010 375(9726):1606-1607.
Rec#: 11430
Exclusion Codes: NDE, EXC

Bouros, D., and S. Anevlavis. Scoring systems in community acquired pneumonia. Pneumon 2009 22(4).
Rec#: 12070
Exclusion Codes: NRD, EXC

Boussekey, N., O. Leroy, S. Alfandari, P. Devos, H. Georges, and B. Guery. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006 32(3):469-72.
Rec#: 3450
Exclusion Codes: NDE, EXC

Boussekey, N., O. Leroy, H. Georges, P. Devos, T. d'Escrivan, and B. Guery. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 2005 33(4):257-63.
Rec#: 3690
Exclusion Codes: NDE, EXC

Bressan, S., B. Andreola, P. Zucchetta, G. Montini, M. Burei, G. Perilongo, and L. Da Dalt. Procalcitonin as a predictor of renal scarring in infants and young children. Pediatr Nephrol 2009 24(6):1199-204.
Rec#: 7560
Exclusion Codes: SMN, EXC

Briel, M., M. Christ-Crain, J. Young, P. Schuetz, P. Huber, P. Periat, H. C. Bucher, and B. Muller. Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners. BMC Fam Pract 2005 6:34.
Rec#: 9090
Exclusion Codes: NDE, EXC

Brines, R., and M. Thorne. Clinical consensus on COPD. Respir. Med. COPD Update 2007 3(2):42-48.
Rec#: 13340
Exclusion Codes: NDE, EXC

Brodska, H., T. Drabek, K. Malickova, A. Kazda, A. Vitek, T. Zima, and M. Markova. Marked increase of procalcitonin after the administration of anti-thymocyte globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis: a prospective study. Crit Care 2009 13(2):R37.
Rec#: 1010
Exclusion Codes: NDE, EXC

Brown, J. S. Biomarkers and community-acquired pneumonia. Thorax 2009 64(7):556-8.
Rec#: 7320
Exclusion Codes: NDE, EXC

Brown, R. O., E. Jr Alexander, S. D. Hanes, G. C. Wood, K. A. Kudsk, and R. N. Dickerson. Procalcitonin and enteral nutrition tolerance in critically ill patients. JPEN J Parenter Enteral Nutr 2003 27(1):84-8.
Rec#: 5010
Exclusion Codes: NRO, EXC

Brunkhorst, F. M. Endotoxins in chronic heart failure. Lancet 1999 354(9178):599-600.
Rec#: 10670
Exclusion Codes: NRD, EXC

Brunkhorst, F. M., B. Al-Nawas, F. Krummenauer, Z. F. Forycki, and P. M. Shah. Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Clin Microbiol Infect 2002 8(2):93-100.
Rec#: 5390
Exclusion Codes: NRO, EXC

Brunkhorst, F. M., A. L. Clark, Z. F. Forycki, and S. D. Anker. Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation. Int J Cardiol 1999 72(1):3-10.
Rec#: 6320
Exclusion Codes: NRO, EXC

Brunkhorst, F. M., O. K. Eberhard, and R. Brunkhorst. Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med 1999 27(10):2172-6.
Rec#: 6360
Exclusion Codes: NRO, EXC

Brunkhorst, F.M., and Z.F. Forycki. Procalcitonin - An early and highly specific marker of bacterial or fungal induced sepsis. Clin. Chem. Lab. Med. 1998 36(4):A13.
Rec#: 15170
Exclusion Codes: NRO, EXC

Brunkhorst, F.M., Z.F. Forycki, and J. Wagner. Early identification of biliary acute pancreatitis with procalcitonin immunoreactivity-preliminary results: FRUHE IDENTIFIZIERUNG DER BILIAREN AKUTEN PANKREATITIS DURCH PROCALCITONIN-IMMUNREAKTIVITAT-VORLAUFIGE ERGEBNISSE. CHIR. GASTROENTEROL. INTERDISZIP. GESPR. 1995 11(SUPPL. 2):42-46.
Rec#: 17170
Exclusion Codes: NRD, EXC

Brunkhorst, F. M., K. Wegscheider, Z. F. Forycki, and R. Brunkhorst. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 2000 26 Suppl 2:S148-52.
Rec#: 1770
Exclusion Codes: NDE, EXC

Brunkhorst, R., O. K. Eberhardt, M. Haubitz, and F. M. Brunkhorst. Procalcitonin for discrimination between activity of systemic autoimmune disease and systemic bacterial infection. Intensive Care Med 2000 26 Suppl 2:S199-201.
Rec#: 7910
Exclusion Codes: NDE, EXC

Brusius, A. C., A. P. Zavascki, and S. Costa. How efficient is procalcitonin-guided antibiotic use in acute respiratory tract infections in primary care? Arch Intern Med 2009 169(13):1244.
Rec#: 7300
Exclusion Codes: NDE, EXC

Bugden, S. A., C. Coles, and G. D. Mills. The potential role of procalcitonin in the emergency department management of febrile young adults during a sustained meningococcal epidemic. Emerg Med Australas 2004 16(2):114-9.
Rec#: 9580
Exclusion Codes: NDE, EXC

Bulbuller, N., O. Dogru, R. Ayten, H. Akbulut, Y. S. Ilhan, and Z. Cetinkaya. Procalcitonin is a predictive marker for severe acute pancreatitis. Ulus Travma Acil Cerrahi Derg 2006 12(2):115-20.

Rec#: 8800
Exclusion Codes: SMN, EXC

Bulut, G., D. Yasmin, D. Ak, and M. Yyldyz. Value of procalcitonin in differentiating post-surgical systemic and infectious complications from inflammatory reaction caused by surgical trauma in fracture surgery: Preliminary report. Eur. J. Orthop. Surg. Traumatol. 2010 20(1):1-10.
Rec#: 11900
Exclusion Codes: SMN, EXC

Burgel, P.-R. Applications and limitations of biological markers in lower respiratory tract infections: Apports et limites des marqueurs biologiques dans les infections respiratoires basses. Rev. Mal. Respir. 2009 26(4):456-457.
Rec#: 15950
Exclusion Codes: NDE, EXC

Butbul-Aviel, Y., A. Koren, R. Halevy, and W. Sakran. Procalcitonin as a diagnostic aid in osteomyelitis and septic arthritis. Pediatr Emerg Care 2005 21(12):828-32.
Rec#: 3550
Exclusion Codes: NDE, EXC

Cabioglu, N., S. Bilgic, G. Deniz, E. Aktas, Y. Seyhun, A. Turna, K. Gunay, and F. Esen. Decreased cytokine expression in peripheral blood leukocytes of patients with severe sepsis. Arch Surg 2002 137(9):1037-43; discussion 1043.
Rec#: 5160
Exclusion Codes: NRO, EXC

Cabre, M. Pneumonia in the elderly. Curr. Opin. Pulm. Med. 2009 15(3):223-229.
Rec#: 15890
Exclusion Codes: NDE, EXC

Cakir, E., O. Deniz, O. Ozcan, E. Tozkoparan, H. Yaman, E. O. Akgul, C. Bilgi, H. Bilgic, K. Ekiz, and M. K. Erbil. Pleural fluid and serum procalcitonin as diagnostic tools in tuberculous pleurisy. Clin Biochem 2005 38(3):234-8.
Rec#: 9350
Exclusion Codes: SMN, EXC

Cals, J. W., and J. P. Metlay. Procalcitonin-based guidelines and lower respiratory tract infections. JAMA 2010 303(5):418; author reply 419-20.
Rec#: 7000
Exclusion Codes: NDE, EXC

Cardelli, P., M. Ferraironi, R. Amodeo, F. Tabacco, R. A. De Blasi, M. Nicoletti, R. Sessa, A. Petrucca, A. Costante, and P. Cipriani. Evaluation of neutrophil CD64 expression and procalcitonin as useful markers in early diagnosis of sepsis. Int J Immunopathol Pharmacol 2008 21(1):43-9.
Rec#: 2020
Exclusion Codes: NDE, EXC

Carlet, J. Rapid diagnostic methods in the detection of sepsis. Infect Dis Clin North Am 1999 13(2):483-94, xi.
Rec#: 6510
Exclusion Codes: NDE, EXC

Carpenter, C. R., S. M. Keim, S. Upadhye, and H. B. Nguyen. Risk stratification of the potentially septic patient in the emergency department: the Mortality in the Emergency Department Sepsis (MEDS) score. J Emerg Med 2009 37(3):319-27.
Rec#: 890
Exclusion Codes: NDE, EXC

Carrol, E. D., L. A. Mankhambo, G. Jeffers, D. Parker, M. Guiver, P. Newland, D. L. Banda, E. M. Molyneux, R. S. Heyderman, M. E. Molyneux, and C. A. Hart. The diagnostic and prognostic accuracy of five markers of serious bacterial infection in Malawian children with signs of severe infection. PLoS One 2009 4(8):e6621.
Rec#: 7260
Exclusion Codes: NDE, EXC

Carrol, E. D., P. Newland, F. A. Riordan, A. P. Thomson, N. Curtis, and C. A. Hart. Procalcitonin as a diagnostic marker of meningococcal disease in children presenting with fever and a rash. Arch Dis Child 2002 86(4):282-5.
Rec#: 5440
Exclusion Codes: NDE, EXC

Carrol, E. D., P. Newland, A. P. Thomson, and C. A. Hart. Prognostic value of procalcitonin in children with meningococcal sepsis. Crit Care Med 2005 33(1):224-5.
Rec#: 4020
Exclusion Codes: SMN, EXC

Carrol, E. D., A. P. Thomson, and C. A. Hart. Procalcitonin as a marker of sepsis. Int J Antimicrob Agents 2002 20(1):1-9.
Rec#: 5240
Exclusion Codes: NDE, EXC

Casado-Flores, J., A. Blanco-Quiros, J. Asensio, E. Arranz, J. A. Garrote, and M. Nieto. Serum procalcitonin in children with suspected sepsis: a comparison with C-reactive protein and neutrophil count. Pediatr Crit Care Med 2003 4(2):190-5.
Rec#: 4820
Exclusion Codes: SMN, EXC

Casado-Flores, J., A. Blanco-Quiros, M. Nieto, J. Asensio, and C. Fernandez. Prognostic utility of the semi-quantitative procalcitonin test, neutrophil count and C-reactive protein in meningococcal infection in children. Eur J Pediatr 2006 165(1):26-9.
Rec#: 3620
Exclusion Codes: SMN, EXC

Castelli, G. P., C. Pognani, M. Cita, and R. Paladini. Procalcitonin as a prognostic and diagnostic tool for septic complications after major trauma. Crit Care Med 2009 37(6):1845-9.
Rec#: 920
Exclusion Codes: SMN, EXC

Castelli, G. P., C. Pognani, M. Cita, A. Stuani, L. Sgarbi, and R. Paladini. Procalcitonin, C-reactive protein, white blood cells and SOFA score in ICU: diagnosis and monitoring of sepsis. Minerva Anestesiol 2006 72(1-2):69-80.
Rec#: 3490
Exclusion Codes: NDE, EXC

Castelli, G. P., C. Pognani, M. Meisner, A. Stuani, D. Bellomi, and L. Sgarbi. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care 2004 8(4):R234-42.
Rec#: 4170
Exclusion Codes: NDE, EXC

Caterino, J. M., M. D. Scheatzle, M. L. Forbes, and J. A. D'Antonio. Bacteremic elder emergency department patients: procalcitonin and white count. Acad Emerg Med 2004 11(4):393-6.
Rec#: 4400
Exclusion Codes: NDE, EXC

Celebi, S., O. Koner, F. Menda, H. Balci, A. Hatemi, K. Korkut, and F. Esen. Procalcitonin kinetics in pediatric patients with systemic inflammatory response after open heart surgery. Intensive Care Med 2006 32(6):881-7.
Rec#: 3310

Exclusion Codes: SMN, EXC

Cetinkaya, M., H. Ozkan, N. Koksal, S. Celebi, and M. Hacimustafaoglu. Comparison of serum amyloid A concentrations with those of C-reactive protein and procalcitonin in diagnosis and follow-up of neonatal sepsis in premature infants. J Perinatol 2009 29(3):225-31.
Rec#: 1160
Exclusion Codes: NDE, EXC

Chaker, S., D. Gnat, N. Ben-Ali, V. Hansen, P. Barlow, D. Haumont, and F. Vertongen. Measure of maternal procalcitonin in the pregnancy by an ultrasensitive immunoluminometric assay: Diagnostic and pronostic interests: Dosage de la procalcitonine maternelle au cours de la grossesse par une methode immunoluminometrique ultrasensible: Interets diagnostique et pronostique. Immuno-Anal. Biol. Spec. 2003 18(5):256-259.
Rec#: 16800
Exclusion Codes: NDE, EXC

Chakhunashvili, L., A. Inasaridze, S. Svanidze, J. Samkharadze, and I. Chkhaidze. Procalcitonin as the biomarker of inflammation in diagnostics of pediatric appendicular peritonitis and for the prognosis of early postoperative complications. Georgian Med News 2005 (129):78-81.
Rec#: 3470
Exclusion Codes: NRO, EXC

Chan, Y. L., C. P. Tseng, P. K. Tsay, S. S. Chang, T. F. Chiu, and J. C. Chen. Procalcitonin as a marker of bacterial infection in the emergency department: an observational study. Crit Care 2004 8(1):R12-20.
Rec#: 4470
Exclusion Codes: NDE, EXC

Charles, P. E., C. Castro, S. Ruiz-Santana, C. Leon, P. Saavedra, and E. Martin. Serum procalcitonin levels in critically ill patients colonized with Candida spp: new clues for the early recognition of invasive candidiasis? Intensive Care Med 2009 35(12):2146-50.
Rec#: 480
Exclusion Codes: NDE, EXC

Charles, P. E., F. Dalle, S. Aho, J. P. Quenot, J. M. Doise, H. Aube, N. O. Olsson, and B. Blettery. Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients. Intensive Care Med 2006 32(10):1577-83.
Rec#: 3180
Exclusion Codes: NRO, EXC

Charles, P. E., E. Kus, S. Aho, S. Prin, J. M. Doise, N. O. Olsson, B. Blettery, and J. P. Quenot. Serum procalcitonin for the early recognition of nosocomial infection in the critically ill patients: a preliminary report. BMC Infect Dis 2009 9:49.
Rec#: 910
Exclusion Codes: SMN, EXC

Charles, P. E., S. Ladoire, S. Aho, J. P. Quenot, J. M. Doise, S. Prin, N. O. Olsson, and B. Blettery. Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram negative or Gram positive bacteria. BMC Infect Dis 2008 8:38.
Rec#: 1980
Exclusion Codes: SMN, EXC

Charles, P. E., S. Ladoire, A. Snauwaert, S. Prin, S. Aho, A. Pechinot, N. O. Olsson, B. Blettery, J. M. Doise, and J. P. Quenot. Impact of previous sepsis on the accuracy of procalcitonin for the early diagnosis of blood stream infection in critically ill patients. BMC Infect Dis 2008 8:163.
Rec#: 1200
Exclusion Codes: NDE, EXC

Charles, P. E., C. Tinel, S. Barbar, S. Aho, S. Prin, J. M. Doise, N. O. Olsson, B. Blettery, and J. P. Quenot. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care 2009 13(2):R38.
Rec#: 1000
Exclusion Codes: NDE, EXC

Chastre, J., C. E. Luyt, J. L. Trouillet, and A. Combes. New diagnostic and prognostic markers of ventilator-associated pneumonia. Curr Opin Crit Care 2006 12(5):446-51.
Rec#: 3150
Exclusion Codes: NDE, EXC

Chen, D. Y., Y. M. Chen, W. L. Ho, H. H. Chen, G. H. Shen, and J. L. Lan. Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still's disease. Ann Rheum Dis 2009 68(6):1074-5.
Rec#: 7380
Exclusion Codes: SMN, EXC

Chen, N., H. Li, L.-Y. Zhao, J.-B. Liu, Q. Huang, T.-H. Wang, and X.-M. Hao. Therapy for clearing heat and resolving phlegm in treatment of systemic inflammatory response syndrome in acute deterioration stage of chronic obstructive pulmonary disease: A randomized controlled trial. J. Chin. Integr. Med. 2009 7(2):105-109.
Rec#: 12430
Exclusion Codes: NRD, EXC

Cheval, C., J. F. Timsit, M. Garrouste-Orgeas, M. Assicot, B. De Jonghe, B. Misset, C. Bohuon, and J. Carlet. Procalcitonin (PCT) is useful in predicting the bacterial origin of an acute circulatory failure in critically ill patients. Intensive Care Med 2000 26 Suppl 2:S153-8.
Rec#: 1760
Exclusion Codes: SMN, EXC

Chiesa, C., L. Pacifico, G. Mancuso, and A. Panero. Procalcitonin in pediatrics: overview and challenge. Infection 1998 26(4):236-41.
Rec#: 6700
Exclusion Codes: NDE, EXC

Chiesa, C., L. Pacifico, N. Rossi, A. Panero, M. Matrunola, and G. Mancuso. Procalcitonin as a marker of nosocomial infections in the neonatal intensive care unit. Intensive Care Med 2000 26 Suppl 2:S175-7.
Rec#: 1720
Exclusion Codes: NDE, EXC

Chiesa, C., A. Panero, N. Rossi, M. Stegagno, M. De Giusti, J. F. Osborn, and L. Pacifico. Reliability of procalcitonin concentrations for the diagnosis of sepsis in critically ill neonates. Clin Infect Dis 1998 26(3):664-72.
Rec#: 6790
Exclusion Codes: NDE, EXC

Chiesa, C., G. Pellegrini, A. Panero, J. F. Osborn, F. Signore, M. Assumma, and L. Pacifico. C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness severity, risk status, antenatal and perinatal complications, and infection. Clin Chem 2003 49(1):60-8.
Rec#: 5020
Exclusion Codes: NDE, EXC

Chirouze, C., H. Schuhmacher, C. Rabaud, H. Gil, N. Khayat, J. M. Estavoyer, T. May, and B. Hoen. Low serum procalcitonin level accurately predicts the absence of bacteremia in adult patients with acute fever. Clin Infect Dis 2002 35(2):156-61.
Rec#: 5260
Exclusion Codes: NDE, EXC

Chiwakata, C. B., C. Manegold, L. Bonicke, I. Waase, C. Julch, and M. Dietrich. Procalcitonin as a parameter of disease severity and risk of mortality in patients with Plasmodium falciparum malaria. J Infect Dis 2001 183(7):1161-4.
Rec#: 10410
Exclusion Codes: SMN, EXC

Chopin, N., B. Floccard, F. Sobas, J. Illinger, E. Boselli, F. Benatir, A. Levrat, C. Guillaume, J. Crozon, C. Negrier, and B. Allaouchiche. Activated partial thromboplastin time waveform analysis: a new tool to detect infection? Crit Care Med 2006 34(6):1654-60.
Rec#: 3380
Exclusion Codes: NDE, EXC

Christ-Crain, M., N. G. Morgenthaler, D. Stolz, C. Muller, R. Bingisser, S. Harbarth, M. Tamm, J. Struck, A. Bergmann, and B. Muller. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Crit Care 2006 10(3):R96.
Rec#: 3270
Exclusion Codes: NDE, EXC

Christ-Crain, M., and B. Muller. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007 30(3):556-73.
Rec#: 2430
Exclusion Codes: NRD, EXC

Christ-Crain, M., and B. Muller. Procalcitonin and Pneumonia: Is it a useful marker? Curr. Infect. Dis. Rep. 2007 9(3):233-240.
Rec#: 16360
Exclusion Codes: NRD, EXC

Christ-Crain, M., P. Schuetz, A.R. Huber, and B. Muller. Procalcitonin: Importance for the diagnosis of bacterial infections: Procalcitonin und seine bedeutung fur die diagnose bakterieller infektionen. LaboratoriumsMedizin 2008 32(6):425-433.
Rec#: 12630
Exclusion Codes: NDE, EXC

Christ-Crain, M., D. Stolz, S. Jutla, O. Couppis, C. Muller, R. Bingisser, P. Schuetz, M. Tamm, R. Edwards, B. Muller, and A. B. Grossman. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med 2007 176(9):913-20.
Rec#: 2490
Exclusion Codes: NDE, EXC

Christofilopoulou, S., E. Charvalos, and G. Petrikkos. Could procalcitonin be a predictive biological marker in systemic fungal infections? Study of 14 cases. Eur. J. Intern. Med. 2002 13(8):493-495.
Rec#: 16860
Exclusion Codes: SMN, EXC

Chua, A. P., and K. H. Lee. Procalcitonin in severe acute respiratory syndrome (SARS). J Infect 2004 48(4):303-6.
Rec#: 4390
Exclusion Codes: NRO, EXC

Ciaccio, M., G. Fugardi, L. Titone, A. Romano, S. Giordano, G. Bivona, F. Scarlata, L. Vocca, and M. Di Gangi. Procalcitonin levels in plasma in oncohaematologic patients with and without bacterial infections. Clin Chim Acta 2004 340(1-2):149-52.
Rec#: 9710
Exclusion Codes: NRO, EXC

Claessens, Y. E., T. Mathevon, G. Kierzek, S. Grabar, D. Jegou, E. Batard, C. Loyer, A. Davido, P. Hausfater, H. Robert, L. Lavagna-Perez, B. Bernot, P. Plaisance, C. Leroy, and B. Renaud. Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia. Intensive Care Med 2010 36(5):799-809.
Rec#: 6960
Exclusion Codes: NDE, EXC

Claessens, Y.-E., J. Schmidt, E. Batard, S. Grabar, D. Jegou, P. Hausfater, G. Kierzek, S. Guerin, J.-L. Pourriat, J.-F. Dhainaut, and C. Ginsburg. Can C-reactive protein, procalcitonin and mid-regional pro-atrial natriuretic peptide measurements guide choice of in-patient or out-patient care in acute pyelonephritis? Biomarkers In Sepsis (BIS) multicentre study. Clin. Microbiol. Infect. 2010 16(6):753-760.
Rec#: 15320
Exclusion Codes: NDE, EXC

Claeys, R., S. Vinken, H. Spapen, K. ver Elst, K. Decochez, L. Huyghens, and F. K. Gorus. Plasma procalcitonin and C-reactive protein in acute septic shock: clinical and biological correlates. Crit Care Med 2002 30(4):757-62.
Rec#: 5420
Exclusion Codes: SMN, EXC

Clec'h, C., F. Ferriere, P. Karoubi, J. P. Fosse, M. Cupa, P. Hoang, and Y. Cohen. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med 2004 32(5):1166-9.
Rec#: 4300
Exclusion Codes: SMN, EXC

Clec'h, C., J. P. Fosse, P. Karoubi, F. Vincent, I. Chouahi, L. Hamza, M. Cupa, and Y. Cohen. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med 2006 34(1):102-7.
Rec#: 3500
Exclusion Codes: NDE, EXC

Cojocaru, I. M., C. Musuroi, S. Iacob, and M. Cojocaru. Investigation of TNF-alpha, IL-6, IL-8 and of procalcitonin in patients with neurologic complications in sepsis. Rom J Intern Med 2003 41(1):83-93.
Rec#: 4080
Exclusion Codes: NDE, EXC

Connert, S., W. Stremmel, and C. Elsing. Procalcitonin is a valid marker of infection in decompensated cirrhosis. Z Gastroenterol 2003 41(2):165-70.
Rec#: 10000
Exclusion Codes: NDE, EXC

Cooper, D., L. Sharples, J. Cornelissen, J. Wallwork, G. Alexander, and A. Trull. Comparison between procalcitonin, serum amyloid A, and C-reactive protein as markers of serious bacterial and fungal infections after solid organ transplantation. Transplant Proc 2001 33(1-2):1808-10.
Rec#: 10370
Exclusion Codes: NDE, EXC

Corona, G., A. Artemisia, C. Liotta, A. Musolino, G. Vita, G. Quartarone, G. Zirilli, and I. Barberi. Comparison of procalcitonin with C reactive protein and absolute neutrophil count for the early diagnosis of neonatal infection. Ital. J. Pediat. 2004 30(4):240-244.
Rec#: 16720
Exclusion Codes: NRO, EXC

Cuculi, F., S. Toggweiler, M. Auer, C. h. A. der Maur, M. Zuber, and P. Erne. Serum procalcitonin has the potential to identify Staphylococcus aureus endocarditis. Eur J Clin Microbiol Infect Dis 2008 27(11):1145-9.
Rec#: 1580
Exclusion Codes: SMN, EXC

Cunha, B. A. Empiric antimicrobial therapy of community-acquired pneumonia: clinical diagnosis versus procalcitonin levels. Scand J Infect Dis 2009 41(10):782-4.
Rec#: 7250
Exclusion Codes: NDE, EXC

Dahaba, A. A., B. Hagara, A. Fall, P. H. Rehak, W. F. List, and H. Metzler. Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis. Br J Anaesth 2006 97(4):503-8.
Rec#: 3260
Exclusion Codes: NDE, EXC

Dahaba, A. A., and H. Metzler. Procalcitonin's role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator? Minerva Anestesiol 2009 75(7-8):447-52.
Rec#: 1290
Exclusion Codes: NDE, EXC

Dalton, H. Procalcitonin: a predictor of lung injury attributable to sepsis? Crit Care Med 1999 27(10):2304-5.
Rec#: 6350
Exclusion Codes: NDE, EXC

Dambrauskas, Z., J. Pundzius, and G. Barauskas. Predicting development of infected necrosis in acute necrotizing pancreatitis. Medicina (Kaunas) 2006 42(6):441-9.
Rec#: 8740
Exclusion Codes: NDE, EXC

Damoiseaux, R. A. Procalcitonin-guided antibiotic use in primary care: the ultimate proof still ahead. Arch Intern Med 2009 169(7):717-8.
Rec#: 7440
Exclusion Codes: NDE, EXC

Dandona, P., D. Nix, M. F. Wilson, A. Aljada, J. Love, M. Assicot, and C. Bohuon. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994 79(6):1605-8.
Rec#: 11030
Exclusion Codes: NRO, EXC

Dauber, A., S. Weiss, V. Maniaci, E. Nylen, K. L. Becker, and R. Bachur. Procalcitonin levels in febrile infants after recent immunization. Pediatrics 2008 122(5):e1119-22.
Rec#: 7700
Exclusion Codes: NDE, EXC

Daubin, C., J. J. Parienti, S. Fradin, A. Vabret, M. Ramakers, N. Terzi, F. Freymuth, P. Charbonneau, and D. du Cheyron. Procalcitonin levels and bacterial aetiology among COPD patients admitted to the ICU with severe pneumonia: a prospective cohort study. BMC Infect Dis 2009 9:157.
Rec#: 460
Exclusion Codes: SMN, EXC

Daubin, C., J. J. Parienti, A. Vabret, M. Ramakers, S. Fradin, N. Terzi, F. Freymuth, P. Charbonneau, and D. du Cheyron. Procalcitonin levels in acute exacerbation of COPD admitted in ICU: a prospective cohort study. BMC Infect Dis 2008 8:145.
Rec#: 1320
Exclusion Codes: SMN, EXC

Davis, B. H. Improved diagnostic approaches to infection/sepsis detection. Expert Rev Mol Diagn 2005 5(2):193-207.
Rec#: 3840
Exclusion Codes: NDE, EXC

Davis, T. M., M. Assicot, C. Bohuon, A. St John, G. Q. Li, and T. K. Anh. Serum procalcitonin concentrations in acute malaria. Trans R Soc Trop Med Hyg 1994 88(6):670-1.
Rec#: 11040
Exclusion Codes: NRO, EXC

de Jager, C. P., N. C. de Wit, G. Weers-Pothoff, T. van der Poll, and P. C. Wever. Procalcitonin kinetics in Legionella pneumophila pneumonia. Clin Microbiol Infect 2009 15(11):1020-5.
Rec#: 870
Exclusion Codes: NRO, EXC

de Kruif, M. D., M. Limper, H. Gerritsen, C. A. Spek, D. P. Brandjes, H. ten Cate, P. M. Bossuyt, P. H. Reitsma, and E. C. van Gorp. Additional value of procalcitonin for diagnosis of infection in patients with fever at the emergency department. Crit Care Med 2010 38(2):457-63.
Rec#: 7030
Exclusion Codes: NDE, EXC

De La Flor I Bru, J. Procalcitonin and C-reactive protein as diagnostic markers of severe bacterial infections in febrile infants and children in the emergency department. Pediatr. Integr. 2007 11(8):729-730.
Rec#: 16260
Exclusion Codes: FLA, EXC

De La Rosa, G. D., M. L. Valencia, C. M. Arango, C. I. Gomez, A. Garcia, S. Ospina, S. Osorno, A. Henao, and F. A. Jaimes. Toward an operative diagnosis in sepsis: a latent class approach. BMC Infect Dis 2008 8:18.
Rec#: 2100
Exclusion Codes: NDE, EXC

de Mendonca-Filho, H. T., G. S. Gomes, P. M. Nogueira, M. A. Fernandes, B. R. Tura, M. Santos, and H. C. Castro-Faria-Neto. Macrophage migration inhibitory factor is associated with positive cultures in patients with sepsis after cardiac surgery. Shock 2005 24(4):313-7.
Rec#: 3640
Exclusion Codes: SMN, EXC

De Talance, N., C. Claudel, and C. Burlet. Procalcitonin as a specific indication of septic shock?: La procalcitonine (PCT) est-elle le marqueur specifique du choc septique? Immuno-Anal. Biol. Spec. 2003 18(2):120-122.
Rec#: 14470
Exclusion Codes: NDE, EXC

De Talance, N., H. Schumacher, P.M. Mertes, and C. Burlet. Interest of procalcitonin assay in case of infections diseases: Interets du dosage de procalcitonine en infectiologie. Immuno-Anal. Biol. Spec. 2001 16(1):18-21.
Rec#: 16960
Exclusion Codes: NDE, EXC

de Werra, I., C. Jaccard, S. B. Corradin, R. Chiolero, B. Yersin, H. Gallati, M. Assicot, C. Bohuon, J. D. Baumgartner, M. P. Glauser, and D. Heumann. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 1997 25(4):607-13.
Rec#: 6860
Exclusion Codes: SMN, EXC

de Wit, N. C., C. P. de Jager, J. C. Meekelenkamp, M. Schoorl, A. B. van Gageldonk-Lafeber, A. C. Leenders, R. Kusters, and P. C. Wever. Markers of infection in inpatients and outpatients with acute Q-fever. Clin Chem Lab Med 2009 47(11):1407-9.
Rec#: 7170
Exclusion Codes: NRO, EXC

de Wolf, H. K., J. K. Gunnewiek, Y. Berk, J. van den Ouweland, and M. de Metz. Comparison of a new procalcitonin assay from roche with the established method on the brahms kryptor. Clin Chem 2009 55(5):1043-4.
Rec#: 7510
Exclusion Codes: NDE, EXC

De Wolf, H.K., J. Klein Gunnewiek, Y. Berk, J. Van Den Ouweland, and M. De Metz. Comparison of a new Roche Modular procalcitonin test with Brahms Kryptor method: Vergelijking van een nieuwe Roche Modular procalcitoninetest met de Brahms Kryptor methode. Ned. Tijdschr. Klin. Chem. Lab. Geneeskd. 2009 34(4):261-262.
Rec#: 15820
Exclusion Codes: NDE, EXC

Debard, A. L., C. Vautrin, C. Pariset, J. Bienvenu, and G. Monneret. High serum procalcitonin levels do not predict bacteremia in adult patients with acute fever. Clin Infect Dis 2003 36(6):825-6; author reply 826-7.
Rec#: 4930
Exclusion Codes: NDE, EXC

Decaluwe, H., L. M. Harrison, M. M. Mariscalco, D. Gendrel, C. Bohuon, V. L. Tesh, and F. Proulx. Procalcitonin in children with Escherichia coli O157:H7 associated hemolytic uremic syndrome. Pediatr Res 2006 59(4 Pt 1):579-83.
Rec#: 8890
Exclusion Codes: NDE, EXC

Deis, J. N., C. B. Creech, C. M. Estrada, and T. J. Abramo. Procalcitonin as a marker of severe bacterial infection in children in the emergency department. Pediatr Emerg Care 2010 26(1):51-60; quiz 61-3.
Rec#: 250
Exclusion Codes: NDE, EXC

Dejmkova, H., K. Pavelka, and J. Uhrova. Procalcitonin in the diagnosis of bacterial infection in patients with autoimmune rheumatic diseases: Prokalcitonin v diagnoze bakterialni infekce u nemocnych s autoimunitnimi revmatickymi chorobami. Ceska Revmatol. 2007 15(4):186-189.
Rec#: 13140
Exclusion Codes: NRD, EXC

Dejmkova, H., O. Sleglova, R. Becvar, K. Pavelka, and J. Uhrova. Limited significance of procalcitonin in differentiation between sepsis and flare of a rheumatic disease: Omezeny vyznam prokalcitoninu v odliseni septickeho stavu od vzplanuti autoimunitniho onemocneni. Ceska Revmatol. 2009 17(2):79-82.
Rec#: 12160
Exclusion Codes: NDE, EXC

Del Castillo Martin, F., M. Duque Alcorta, R. Madero Jarabo, M.J. Garcia Miguel, M.I. De Jose Gomez, F. Baquero Artigao, J. Aracil, and A. Buno Soto. C-reactive protein and procalcitonin in community-adquired pneumococcal pneumonia: Proteina C reactiva y procalcitonina en la neumonia por neumococo adquirida en la comunidad. Pediatr. Integr. 2008 12(9):909-912.
Rec#: 16020
Exclusion Codes: NDE, EXC

Delevaux, I., M. Andre, O. Aumaitre, R. J. Begue, M. Colombier, and J. C. Piette. Procalcitonin measurement for differential diagnosis between pulmonary embolism and pneumonia. Crit Care Med 2003 31(2):661.
Rec#: 10020
Exclusion Codes: NDE, EXC

Delevaux, I., M. Andre, M. Colombier, E. Albuisson, F. Meylheuc, R. J. Begue, J. C. Piette, and O. Aumaitre. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 2003 62(4):337-40.
Rec#: 9970

Exclusion Codes: NDE, EXC

Denes, E., J.P. Rogez, and P. Weinbreck. Procalcitonin level for the diagnosis of fever in non-neutropenic adults: Dosage de la procalcitonine pour le diagnostic d'une fievre chez l'adulte non neutropenique. Med. Mal. Infect. 2003 33(4):206-209.
Rec#: 16810
Exclusion Codes: NDE, EXC

Di Filippo, A., A. Lombardi, A. Ognibene, G. Messeri, and F. Tonelli. Procalcitonin as an early marker of postoperative infectious complications. Minerva Chir 2002 57(1):59-62.
Rec#: 5520
Exclusion Codes: NDE, EXC

Distefano, G., R. Curreri, P. Betta, M. G. Romeo, and M. Amato. Procalcitonin serum levels in perinatal bacterial and fungal infection of preterm infants. Acta Paediatr 2004 93(2):216-9.
Rec#: 4420
Exclusion Codes: NDE, EXC

Don, M., F. Valent, M. Korppi, and M. Canciani. Differentiation of bacterial and viral community-acquired pneumonia in children. Pediatr Int 2009 51(1):91-6.
Rec#: 7430
Exclusion Codes: NDE, EXC

Don, M., F. Valent, M. Korppi, E. Falleti, A. De Candia, L. Fasoli, A. Tenore, and M. Canciani. Efficacy of serum procalcitonin in evaluating severity of community-acquired pneumonia in childhood. Scand J Infect Dis 2007 39(2):129-37.
Rec#: 8510
Exclusion Codes: NDE, EXC

Dorge, H., F. A. Schondube, P. Dorge, R. Seipelt, M. Voss, and B. J. Messmer. Procalcitonin is a valuable prognostic marker in cardiac surgery but not specific for infection. Thorac Cardiovasc Surg 2003 51(6):322-6.
Rec#: 4520
Exclusion Codes: NDE, EXC

Dorizzi, R. M., E. Polati, P. Sette, A. Ferrari, P. Rizzotti, and A. Luzzani. Procalcitonin in the diagnosis of inflammation in intensive care units. Clin Biochem 2006 39(12):1138-43.
Rec#: 3090
Exclusion Codes: NDE, EXC

Dornbusch, H. J., V. Strenger, R. Kerbl, H. Lackner, W. Schwinger, P. Sovinz, and C. Urban. Procalcitonin and C-reactive protein do not discriminate between febrile reaction to anti-T-lymphocyte antibodies and Gram-negative sepsis. Bone Marrow Transplant 2003 32(9):941-5.
Rec#: 4600
Exclusion Codes: SMN, EXC

Dornbusch, H. J., V. Strenger, P. Sovinz, H. Lackner, W. Schwinger, R. Kerbl, and C. Urban. Non-infectious causes of elevated procalcitonin and C-reactive protein serum levels in pediatric patients with hematologic and oncologic disorders. Support Care Cancer 2008 16(9):1035-40.
Rec#: 2160
Exclusion Codes: NRO, EXC

Drage, S.M., V.S. Barber, and J.D. Young. Statins and sepsis: panacea or Pandora's box? Lancet Infect. Dis. 2007 7(2):80.
Rec#: 13530
Exclusion Codes: NRD, EXC

Du, B., D. Chen, J. Pan, and Y. Li. Procalcitonin may be a better predictor of interleukin-6 than conventional inflammatory markers. Crit. Care Shock 2002 5(3):177-182.
Rec#: 14590
Exclusion Codes: SMN, EXC

Du, B., J. Pan, D. Chen, and Y. Li. Serum procalcitonin and interleukin-6 levels may help to differentiate systemic inflammatory response of infectious and non-infectious origin. Chin Med J (Engl) 2003 116(4):538-42.
Rec#: 4720
Exclusion Codes: SMN, EXC

Dubos, F., B. Korczowski, D. A. Aygun, A. Martinot, C. Prat, A. Galetto-Lacour, J. Casado-Flores, E. Taskin, F. Leclerc, C. Rodrigo, A. Gervaix, S. Leroy, D. Gendrel, G. Breart, and M. Chalumeau. Serum procalcitonin level and other biological markers to distinguish between bacterial and aseptic meningitis in children: a European multicenter case cohort study. Arch Pediatr Adolesc Med 2008 162(12):1157-63.
Rec#: 7660
Exclusion Codes: NDE, EXC

Dubos, F., A. Martinot, D. Gendrel, G. Breart, and M. Chalumeau. Clinical decision rules for evaluating meningitis in children. Curr Opin Neurol 2009 22(3):288-93.
Rec#: 7420
Exclusion Codes: NDE, EXC

Dubos, F., F. Moulin, V. Gajdos, N. De Suremain, S. Biscardi, P. Lebon, J. Raymond, G. Breart, D. Gendrel, and M. Chalumeau. Serum procalcitonin and other biologic markers to distinguish between bacterial and aseptic meningitis. J Pediatr 2006 149(1):72-6.
Rec#: 8710
Exclusion Codes: NDE, EXC

Dubska, L., L. Bacikova, M. Vyskocilova, P. Jelinek, and D. Valik. Monitoring of infection and sepsis in patients with solid tumors: Monitorovani infekcnich a septickych stavu u nemocnych se solidni malignitou. Alergie 2009 11(4):264-268.
Rec#: 11960
Exclusion Codes: NDE, EXC

Duflo, F., R. Debon, G. Monneret, J. Bienvenu, D. Chassard, and B. Allaouchiche. Alveolar and serum procalcitonin: diagnostic and prognostic value in ventilator-associated pneumonia. Anesthesiology 2002 96(1):74-9.
Rec#: 10210
Exclusion Codes: SMN, EXC

Eberhard, O. K., M. Haubitz, F. M. Brunkhorst, V. Kliem, K. M. Koch, and R. Brunkhorst. Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 1997 40(7):1250-6.
Rec#: 10900
Exclusion Codes: NDE, EXC

Eberhard, O. K., I. Langefeld, E. R. Kuse, F. M. Brunkhorst, V. Kliem, H. J. Schlitt, R. Pichlmayr, K. M. Koch, and R. Brunkhorst. Procalcitonin in the early phase after renal transplantation--will it add to diagnostic accuracy? Clin Transplant 1998 12(3):206-11.
Rec#: 10800
Exclusion Codes: NDE, EXC

Ecker-Schlipf, B. Infections in the intensive care unit: Orientation to the procalcitonin level minimizes the use of antibiotics: Infektionen auf der intensivstation: Orientierung am procalcitonin-spiegel verringert den antibiotikaeinsatz. Arzneimitteltherapie 2010 28(5):176-177.
Rec#: 15430

Exclusion Codes: NRD, EXC

Economou, M.S., B. Bau, G. Steinbach, F. Gansauge, J.M. Mayer, A. Gnucrt, and H.G. Beger. The potential role of procalcitonin and interleukin-8 in the prediction of infected necrosis in acute pancreatitis. Hell. J. Gastroenterol. 1997 10(3):248-249.
Rec#: 15210
Exclusion Codes: NDE, EXC

Egger, G., R. Aigner, A. Glasner, H. P. Hofer, H. Mitterhammer, and S. Zelzer. Blood polymorphonuclear leukocyte migration as a predictive marker for infections in severe trauma: comparison with various inflammation parameters. Intensive Care Med 2004 30(2):331-4.
Rec#: 4480
Exclusion Codes: SMN, EXC

Eisenhut, M. Procalcitonin measurement to reduce antibiotic use in influenza. Biosecur Bioterror 2009 7(4):453-4.
Rec#: 7060
Exclusion Codes: NDE, EXC

Elefsiniotis, I. S., A. Petrocheilou, N. Scarmeas, I. Ketikoglou, K. D. Pantazis, M. Toutouza, and E. V. Tsianos. Serum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatment. J Clin Virol 2006 37(4):329-31.
Rec#: 8640
Exclusion Codes: NRO, EXC

Elefsiniotis, I. S., M. Skounakis, E. Vezali, K. D. Pantazis, A. Petrocheilou, M. Pirounaki, G. Papatsibas, C. Kontou-Kastellanou, and A. Moulakakis. Clinical significance of serum procalcitonin levels in patients with acute or chronic liver disease. Eur J Gastroenterol Hepatol 2006 18(5):525-30.
Rec#: 8820
Exclusion Codes: NDE, EXC

Elsammak, M., H. Hanna, A. Ghazal, F. B. Edeen, and M. Kandil. Diagnostic value of serum procalcitonin and C-reactive protein in Egyptian children with streptococcal tonsillopharyngitis. Pediatr Infect Dis J 2006 25(2):174-6.
Rec#: 8940
Exclusion Codes: SMN, EXC

Endo, S., N. Aikawa, S. Fujishima, I. Sekine, K. Kogawa, Y. Yamamoto, S. Kushimoto, H. Yukioka, N. Kato, K. Totsuka, K. Kikuchi, T. Ikeda, K. Ikeda, H. Yamada, K. Harada, and S. Satomura. Usefulness of procalcitonin serum level for the discrimination of severe sepsis from sepsis: a multicenter prospective study. J Infect Chemother 2008 14(3):244-9.
Rec#: 1530
Exclusion Codes: SMN, EXC

Endter, F., H.B. Reith, and A. Thiede. Strategies for the prevention and early detection of peri- and postoperative secondary infection and impaired wound healing. Chir. Prax. 2001 59(1):13-28.
Rec#: 14710
Exclusion Codes: NDE, EXC

Engel, A., G. Steinbach, P. Kern, and W. V. Kern. Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis 1999 31(2):185-9.
Rec#: 6430
Exclusion Codes: NDE, EXC

Engel, C., F.M. Brunkhorst, M. Loffler, and K. Reinhart. Diagnosis and epidemiology of sepsis: Diagnose und epidemiologie der sepsis. Med. Welt 2007 58(7-8):307-310.
Rec#: 13320
Exclusion Codes: NRD, EXC

Engelmann, L., S. Petros, K. Gundelach, and K. Wegscheider. The importance of 'second hit' for the course of sepsis: Die bedeutung des "second hit" fur den sepsisverlauf. Intensivmed. Notf.med. 2006 43(3):189-201.
Rec#: 13890
Exclusion Codes: NDE, EXC

Engle, W. D., G. L. Jackson, D. M. Sendelbach, E. K. Stehel, D. M. Ford, K. M. McHugh, M. R. Norris, D. A. Vedro, S. Velaphi, I. C. Michelow, and K. D. Olsen. Pneumonia in term neonates: laboratory studies and duration of antibiotic therapy. J Perinatol 2003 23(5):372-7.
Rec#: 4730
Exclusion Codes: NDE, EXC

Enguix, A., C. Rey, A. Concha, A. Medina, D. Coto, and M. A. Dieguez. Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children. Intensive Care Med 2001 27(1):211-5.
Rec#: 5820
Exclusion Codes: NDE, EXC

Erickson, Y. O., N. I. Samia, B. Bedell, K. D. Friedman, B. S. Atkinson, and T. J. Raife. Elevated procalcitonin and C-reactive protein as potential biomarkers of sepsis in a subpopulation of thrombotic microangiopathy patients. J Clin Apher 2009 24(4):150-4.
Rec#: 710
Exclusion Codes: NRO, EXC

Ernst, A., N. G. Morgenthaler, K. Buerger, R. Dodel, C. Noelker, N. Sommer, M. Schwarz, J. Koehrle, A. Bergmann, and H. Hampel. Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation. J Neuroimmunol 2007 189(1-2):169-74.
Rec#: 2500
Exclusion Codes: SMN, EXC

Erten, N., S. Genc, S. K. Besisik, B. Saka, M. A. Karan, and C. Tascioglu. The predictive and diagnostic values of procalcitonin and C-reactive protein for clinical outcome in febrile neutropenic patients. J Chin Med Assoc 2004 67(5):217-21.
Rec#: 4130
Exclusion Codes: NDE, EXC

Ertugrul, B. M., A. Yilmabasar, O. Ertugrul, H. B. Ayabakan, S. Kizilirmak, and S. Turkmen. Do C-reactive protein and procalcitonin predict hospital-acquired infection in patients with trauma? Saudi Med J 2006 27(4):560-2.
Rec#: 8850
Exclusion Codes: NDE, EXC

Escobar, G. J. Effect of the systemic inflammatory response on biochemical markers of neonatal bacterial infection: a fresh look at old confounders. Clin Chem 2003 49(1):21-2.
Rec#: 5030
Exclusion Codes: NDE, EXC

Espinosa-Morales, R., and A. Escalante. Use of procalcitonin as a diagnostic test: comment on the article by Eberhard et al. Arthritis Rheum 1998 41(3):567-8.
Rec#: 10840
Exclusion Codes: NRD, EXC

Ewig, S. Pneumonia alerts: Highlights pneumonie. Pneumologie 2007 61(9):610-612.
Rec#: 13250
Exclusion Codes: NDE, EXC

Faesch, S., B. Cojocaru, C. Hennequin, S. Pannier, C. Glorion, B. Lacour, and G. Cheron. Can procalcitonin measurement help the diagnosis of osteomyelitis and septic arthritis? A prospective trial. Ital. J. Pediat. 2009 35(33).
Rec#: 12000
Exclusion Codes: NDE, EXC

Falcoz, P. E., F. Laluc, M. M. Toubin, M. Puyraveau, F. Clement, M. Mercier, S. Chocron, and J. P. Etievent. Usefulness of procalcitonin in the early detection of infection after thoracic surgery. Eur J Cardiothorac Surg 2005 27(6):1074-8.
Rec#: 3820
Exclusion Codes: NDE, EXC

Fallaha, D., and B. Cuthbertson. The application of biomarkers in critical illness. Care Crit. Ill 2007 23(6):167-172.
Rec#: 13130
Exclusion Codes: NRD, EXC

Feezor, R. J., C. Oberholzer, H. V. Baker, D. Novick, M. Rubinstein, L. L. Moldawer, J. Pribble, S. Souza, C. A. Dinarello, W. Ertel, and A. Oberholzer. Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria. Infect Immun 2003 71(10):5803-13.
Rec#: 4640
Exclusion Codes: NDE, EXC

Feld, R. Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents 2008 32 Suppl 1:S30-3.
Rec#: 1410
Exclusion Codes: NDE, EXC

Fendler, W. M., and A. J. Piotrowski. Procalcitonin in the early diagnosis of nosocomial sepsis in preterm neonates. J Paediatr Child Health 2008 44(3):114-8.
Rec#: 2350
Exclusion Codes: NDE, EXC

Fernandez Lopez, A., C. Luaces Cubells, J. J. Garcia Garcia, and J. Fernandez Pou. Procalcitonin in pediatric emergency departments for the early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and utility of a rapid qualitative test for this marker. Pediatr Infect Dis J 2003 22(10):895-903.
Rec#: 4620
Exclusion Codes: NDE, EXC

Fioretto, J. R., F. C. Borin, R. C. Bonatto, S. M. Ricchetti, C. S. Kurokawa, M. de Moraes, M. F. Carpi, C. R. Padovani, and J. G. Martin. Procalcitonin in children with sepsis and septic shock. J Pediatr (Rio J) 2007 83(4):323-8.
Rec#: 2620
Exclusion Codes: SMN, EXC

Fioretto, J. R., J. G. Martin, C. S. Kurokawa, M. F. Carpi, R. C. Bonatto, S. M. Ricchetti, M. A. de Moraes, and C. R. Padovani. Interleukin-6 and procalcitonin in children with sepsis and septic shock. Cytokine 2008 43(2):160-4.
Rec#: 1540
Exclusion Codes: NDE, EXC

Fiumefreddo, R., R. Zaborsky, J. Haeuptle, M. Christ-Crain, A. Trampuz, I. Steffen, R. Frei, B. Muller, and P. Schuetz. Clinical predictors for Legionella in patients presenting with community-acquired pneumonia to the emergency department. BMC Pulm. Med. 2009 9.
Rec#: 16000
Exclusion Codes: NDE, EXC

Flatley, M. Procalcitonin-guided antibiotic use for respiratory tract infections. Thorax 2009 64(4):367.
Rec#: 12360

Exclusion Codes: NRD, EXC

Fleischhack, G., D. Cipic, J. Juettner, C. Hasan, and U. Bode. Procalcitonin-a sensitive inflammation marker of febrile episodes in neutropenic children with cancer. Intensive Care Med 2000 26 Suppl 2:S202-11.
Rec#: 1680
Exclusion Codes: NDE, EXC

Fleischhack, G., I. Kambeck, D. Cipic, C. Hasan, and U. Bode. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol 2000 111(4):1093-102.
Rec#: 5900
Exclusion Codes: NDE, EXC

Florianczyk, B. Structure and diagnostic value of procalcitonin. Ann Univ Mariae Curie Sklodowska Med 2003 58(1):338-42.
Rec#: 4150
Exclusion Codes: NRO, EXC

Fottner, A., C. Birkenmaier, C. von Schulze Pellengahr, B. Wegener, and V. Jansson. Can serum procalcitonin help to differentiate between septic and nonseptic arthritis? Arthroscopy 2008 24(2):229-33.
Rec#: 2130
Exclusion Codes: SMN, EXC

Franz, A. R., M. Kron, F. Pohlandt, and G. Steinbach. Comparison of procalcitonin with interleukin 8, C-reactive protein and differential white blood cell count for the early diagnosis of bacterial infections in newborn infants. Pediatr Infect Dis J 1999 18(8):666-71.
Rec#: 10680
Exclusion Codes: NDE, EXC

Frasquet, J., J. Saez, C. Trigo, J. Martinez, J. Such, and M. Perez-Mateo. Early measurement of procalcitonin does not predict severity in patients with acute pancreatitis. Br J Surg 2003 90(9):1129-30.
Rec#: 9850
Exclusion Codes: SMN, EXC

Fraunberger, P., E. Holler, K.G. Parhofer, A.K. Walli, and D. Seidel. Interleukin 6, procalcitonin and CRP levels during first increase of fever in intensive care patients: Haben die konzentrationen von interleukin 6, procalcitonin und CRP bei intensivpatienten wahrend des ersten fieberanstieges eine prognostische bedeutung? LaboratoriumsMedizin 2008 32(6):434-437.
Rec#: 12620
Exclusion Codes: NDE, EXC

Fraunberger, P., and A.K. Walli. Biomarkers in sepsis and inflammation: Biomarker bei sepsis und entzundung. LaboratoriumsMedizin 2007 31(6):294-309.
Rec#: 13110
Exclusion Codes: NDE, EXC

Fraunberger, P., Y. Wang, E. Holler, K. G. Parhofer, D. Nagel, A. K. Walli, and D. Seidel. Prognostic value of interleukin 6, procalcitonin, and C-reactive protein levels in intensive care unit patients during first increase of fever. Shock 2006 26(1):10-2.
Rec#: 3280
Exclusion Codes: SMN, EXC

Gaini, S., O. G. Koldkjaer, H. J. Moller, C. Pedersen, and S. S. Pedersen. A comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: a prospective study. Crit Care 2007 11(4):R76.
Rec#: 2640

Exclusion Codes: NDE, EXC

Gaini, S., O. G. Koldkjaer, C. Pedersen, and S. S. Pedersen. Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care 2006 10(2):R53.
Rec#: 3390
Exclusion Codes: NDE, EXC

Gaini, S., S. S. Pedersen, O. G. Koldkaer, C. Pedersen, S. K. Moestrup, and H. J. Moller. New immunological serum markers in bacteraemia: anti-inflammatory soluble CD163, but not proinflammatory high mobility group-box 1 protein, is related to prognosis. Clin Exp Immunol 2008 151(3):423-31.
Rec#: 2170
Exclusion Codes: NDE, EXC

Gaini, S., S. S. Pedersen, O. G. Koldkjaer, C. Pedersen, and H. J. Moller. High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study. Crit Care 2007 11(2):R32.
Rec#: 2900
Exclusion Codes: NDE, EXC

Galetto-Lacour, A., S. A. Zamora, and A. Gervaix. Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center. Pediatrics 2003 112(5):1054-60.
Rec#: 9800
Exclusion Codes: SMN, EXC

Gattas, D. J., and D. J. Cook. Procalcitonin as a diagnostic test for sepsis: health technology assessment in the ICU. J Crit Care 2003 18(1):52-8.
Rec#: 4910
Exclusion Codes: NDE, EXC

Gavazzi, G. Procalcitonin in elderly patients: State of the Art: Procalcitonine chez le sujet age : etat des lieux. Antibiotiques 2010 12(2):82-89.
Rec#: 11370
Exclusion Codes: NDE, EXC

Gendrel, D., M. Assicot, J. Raymond, F. Moulin, C. Francoual, J. Badoual, and C. Bohuon. Procalcitonin as a marker for the early diagnosis of neonatal infection. J Pediatr 1996 128(4):570-3.
Rec#: 6920
Exclusion Codes: NRO, EXC

Gendrel, D., and C. Bohuon. Procalcitonin, a marker of bacterial infection. Infection 1997 25(3):133-4.
Rec#: 6850
Exclusion Codes: NDE, EXC

Gendrel, D., and C. Bohuon. Procalcitonin as a marker of bacterial infection. Pediatr Infect Dis J 2000 19(8):679-87; quiz 688.
Rec#: 10520
Exclusion Codes: NDE, EXC

Gendrel, D., F. Moulin, M. Lorrot, E. Marc, S. Guerin, N. Soulier, P. Lebon, J. Coste, J.L. Iniguez, G. Kalifa, F. Brunet, and J. Raymond. Procalcitonin and markers of infection in community-acquired pneumonia of children: Procalcitonine et marqueurs de l'infection dans les pneumonies communautaires de l'enfant. Med. Mal. Infect. 2002 32(2):88-97.
Rec#: 16950
Exclusion Codes: NDE, EXC

Gendrel, D., F. Moulin, J. Raymond, and C. Bohuon. Serum markers in lower respiratory tract infections in children: Marqueurs seriques dans les infections respiratoires basses de l'enfant. Med. Ther. Pediatr. 1999 2(SPEC. ISS. MAR.):46-50.
Rec#: 17080
Exclusion Codes: FLA, EXC

Gendrel, D., J. Raymond, M. Assicot, S. Avenel, H. Lefevre, S. Ravilly, F. Moulin, C. Lacombe, P. Palmer, P. Lebon, and C. Bohuon. ProCalcitonin, C-reactive protein and interleukin-6 in children with bacterial and viral meningitis: Procalcitonine, proteine C-reactive et interleukine 6 dans les meningites bacteriennes et virales de l'enfant. Presse Med. 1998 27(23):1135-1139.
Rec#: 17130
Exclusion Codes: NDE, EXC

Gendrel, D., J. Raymond, M. Assicot, F. Moulin, J. L. Iniguez, P. Lebon, and C. Bohuon. Measurement of procalcitonin levels in children with bacterial or viral meningitis. Clin Infect Dis 1997 24(6):1240-2.
Rec#: 10910
Exclusion Codes: SMN, EXC

Gendrel, D., J. Raymond, J. Coste, F. Moulin, M. Lorrot, S. Guerin, S. Ravilly, H. Lefevre, C. Royer, C. Lacombe, P. Palmer, and C. Bohuon. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J 1999 18(10):875-81.
Rec#: 10640
Exclusion Codes: NDE, EXC

Gendrel, D., C. Vallet, C. Gelmetti, F. Moulin, J.F. Brasme, M. Chalumeau, R. Cohen, and J. Raymond. Pneumococcal pneumonia highly probable in immunized children cared for in-group settings: Pneumonies a pneumocoque hautement probables chez les enfants vaccines gardes en collectivite. Arch. Pediatr. 2010 17(4):373-377.
Rec#: 15480
Exclusion Codes: NRD, EXC

George, A., C. Coulson, and R. De. Procalcitonin: a bacterial specific marker of infection. Clin Otolaryngol 2007 32(4):310.
Rec#: 2570
Exclusion Codes: NRD, EXC

Geppert, A., A. Steiner, G. Delle-Karth, G. Heinz, and K. Huber. Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock. Intensive Care Med 2003 29(8):1384-9.
Rec#: 4740
Exclusion Codes: SMN, EXC

Gerard, Y., D. Hober, M. Assicot, S. Alfandari, F. Ajana, J. M. Bourez, C. Chidiac, Y. Mouton, C. Bohuon, and P. Wattre. Procalcitonin as a marker of bacterial sepsis in patients infected with HIV-1. J Infect 1997 35(1):41-6.
Rec#: 6830
Exclusion Codes: NRO, EXC

Gerard, Y., D. Hober, S. Petitjean, M. Assicot, C. Bohuon, Y. Mouton, and P. Wattre. High serum procalcitonin level in a 4-year-old liver transplant recipient with a disseminated candidiasis. Infection 1995 23(5):310-1.
Rec#: 10950
Exclusion Codes: NRO, EXC

Gervaix, A., A. Galetto-Lacour, T. Gueron, L. Vadas, S. Zamora, S. Suter, and E. Girardin. Usefulness of procalcitonin and C-reactive protein rapid tests for the management of children with urinary tract infection. Pediatr Infect Dis J 2001 20(5):507-11.
Rec#: 10330
Exclusion Codes: SMN, EXC

Ghorbani, G. Procalcitonin role in differential diagnosis of infection stages and non infection inflammation. Pak J Biol Sci 2009 12(4):393-6.
Rec#: 730
Exclusion Codes: NRO, EXC

Giamarellos-Bourboulis, E. J., P. Giannopoulou, P. Grecka, D. Voros, K. Mandragos, and H. Giamarellou. Should procalcitonin be introduced in the diagnostic criteria for the systemic inflammatory response syndrome and sepsis? J Crit Care 2004 19(3):152-7.
Rec#: 4090
Exclusion Codes: NDE, EXC

Giamarellos-Bourboulis, E. J., P. Grecka, G. Poulakou, K. Anargyrou, N. Katsilambros, and H. Giamarellou. Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 2001 32(12):1718-25.
Rec#: 5770
Exclusion Codes: NDE, EXC

Giamarellos-Bourboulis, E. J., A. Mega, P. Grecka, N. Scarpa, G. Koratzanis, G. Thomopoulos, and H. Giamarellou. Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient? Intensive Care Med 2002 28(9):1351-6.
Rec#: 5170
Exclusion Codes: NDE, EXC

Giamarellou, H., E. J. Giamarellos-Bourboulis, P. Repoussis, L. Galani, N. Anagnostopoulos, P. Grecka, D. Lubos, M. Aoun, K. Athanassiou, E. Bouza, E. Devigili, V. Krcmery, F. Menichetti, E. Panaretou, E. Papageorgiou, and D. Plachouras. Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study. Clin Microbiol Infect 2004 10(7):628-33.
Rec#: 4290
Exclusion Codes: NDE, EXC

Gibot, S. Procalcitonin in intensive care units: the PRORATA trial. Lancet 2010 375(9726):1605-6; author reply 1606-7.
Rec#: 60
Exclusion Codes: NDE, EXC

Gibot, S., and A. Cravoisy. Soluble form of the triggering receptor expressed on myeloid cells-1 as a marker of microbial infection. Clin Med Res 2004 2(3):181-7.
Rec#: 3800
Exclusion Codes: SMN, EXC

Gibot, S., A. Cravoisy, R. Dupays, D. Barraud, L. Nace, B. Levy, and P. E. Bollaert. Combined measurement of procalcitonin and soluble TREM-1 in the diagnosis of nosocomial sepsis. Scand J Infect Dis 2007 39(6-7):604-8.
Rec#: 2650
Exclusion Codes: SMN, EXC

Gibot, S., A. Cravoisy, M. N. Kolopp-Sarda, M. C. Bene, G. Faure, P. E. Bollaert, and B. Levy. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med 2005 33(4):792-6.
Rec#: 3860
Exclusion Codes: SMN, EXC

Gilbert, D.N. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J. Clin. Microbiol. 2010 48(7):2325-2329.
Rec#: 11320
Exclusion Codes: NDE, EXC

Girault, C. Management of pneumonia acquired from mechanical ventilation: Prise en charge des pneumopathies acquises sous ventilation mecanique. Rev. Mal. Respir. 2003 20(5 II):6S151-6S154.
Rec#: 14330
Exclusion Codes: NDE, EXC

Girault, C. Updates in intensive care unit: Actualites en reanimation. Rev. Mal. Respir. Actual. 2009 1(5):613-616.
Rec#: 12040
Exclusion Codes: NDE, EXC

Gomez Gerique, J.A., M. Ortiz Espejo, M.I. Torrealba Rodriguez, J. Gordillo Alvarez, A. Castellanos-Ortega, B. Suberviola, and J.L. Teja. Evaluation of the diagnostic and prognostic capacity of procalcitonin, C reactive protein, interleukin-6 and lipopolysaccharide binding protein in patients suspected of having sepsis: Evaluacion de la capacidad diagnostica y pronostica de procalcitonina, proteina C reactiva, interleucina-6 y proteina ligadora del lipopolisacarido en pacientes con sospecha de sepsis. Rev. Lab. Clin. 2010 3(1):12-19.
Rec#: 11860
Exclusion Codes: NDE, EXC

Gorisek, B., N. G. Miksic, P. Krajnc, M. Pakiz, and Z. Turk. The role of procalcitonin in gynaecological surgery. J Int Med Res 2009 37(3):918-26.
Rec#: 720
Exclusion Codes: NRO, EXC

Gramm, H.-J., P. Dollinger, and W. Beier. Procalcin - A new marker for inflammatory host response. Serial studies in patients with sepsis and peritonitis: PROCALCITONIN - EIN NEUER MARKER DER INFLAMMATORISCHEN WIRTSANTWORT. LONGITUDINALSTUDIEN BEI PATIENTEN MIT SEPSIS UND PERITONITIS. CHIR. GASTROENTEROL. INTERDISZIP. GESPR. 1995 11(SUPPL. 2):51-54.
Rec#: 15240
Exclusion Codes: NRD, EXC

Gregor, H., H. Helmer, A. Witt, K. Reisenberger, and H. Kiss. Amniotic fluid levels of procalcitonin, interleukin-6, tumor necrosis factor (alpha), glucose and leukocytes for detecting intraamniotic infection: Die wertigkeit von procalcitonin, interleukin-6, tumor-nekrose-faktor- alpha, glukose und leukozytenzahl im fruchtwasser als diagnostische parameter fur intrauterine infektionen - Erste ergebnisse. Geburtshilfe Frauenheilkd. 2000 60(7):362-365.
Rec#: 17020
Exclusion Codes: NRD, EXC

Greksova, K., V. Parrak, D. Chovancova, P. Stencl, J. Oravec, L. Marsik, R. Sysak, D. Fuchs, Z. Peskova, and M. Borovsky. Procalcitonin, neopterin and C-reactive protein in diagnostics of intrauterine infection and preterm delivery. Bratisl Lek Listy 2009 110(10):623-6.
Rec#: 7070
Exclusion Codes: NDE, EXC

Grieb, G., D. Simons, A. Piatkowski, J. Bernhagen, G. Steffens, and N. Pallua. Macrophage migration inhibitory factor-A potential diagnostic tool in severe burn injuries? Burns 2010 36(3):335-342.
Rec#: 11500
Exclusion Codes: SMN, EXC

Groeneveld, A. B., and C. E. Hack. The role of the innate immune response in hospital- versus community-acquired infection in febrile medical patients. Int J Infect Dis 2008 12(6):660-70.
Rec#: 1590
Exclusion Codes: NDE, EXC

Groselj-Grenc, M., A. Ihan, M. Pavcnik-Arnol, A. N. Kopitar, T. Gmeiner-Stopar, and M. Derganc. Neutrophil and monocyte CD64 indexes, lipopolysaccharide-binding protein, procalcitonin and C-reactive protein in sepsis of critically ill neonates and children. Intensive Care Med 2009 35(11):1950-8.
Rec#: 500
Exclusion Codes: NDE, EXC

Guen, C. G., C. Delmas, E. Launay, J. Caillon, V. Loubersac, G. Picherot, and J. C. Roze. Contribution of procalcitonin to occult bacteraemia detection in children. Scand J Infect Dis 2007 39(2):157-9.
Rec#: 2870
Exclusion Codes: NDE, EXC

Guibourdenche, J., A. Bedu, L. Petzold, M. Marchand, P. Mariani-Kurdjian, M. F. Hurtaud-Roux, Y. Aujard, and D. Porquet. Biochemical markers of neonatal sepsis: value of procalcitonin in the emergency setting. Ann Clin Biochem 2002 39(Pt 2):130-5.
Rec#: 5430
Exclusion Codes: NDE, EXC

Gurda-Duda, A., B. Kusnierz-Cabala, W. Nowak, J. W. Naskalski, and J. Kulig. Assessment of the prognostic value of certain acute-phase proteins and procalcitonin in the prognosis of acute pancreatitis. Pancreas 2008 37(4):449-53.
Rec#: 7720
Exclusion Codes: NDE, EXC

Gurgoze, M. K., S. Akarsu, E. Yilmaz, A. Godekmerdan, Z. Akca, I. Ciftci, and A. D. Aygun. Proinflammatory cytokines and procalcitonin in children with acute pyelonephritis. Pediatr Nephrol 2005 20(10):1445-8.
Rec#: 9110
Exclusion Codes: NDE, EXC

Guven, A. G., H. Z. Kazdal, M. Koyun, F. Aydn, F. Gungor, S. Akman, and Y. E. Baysal. Accurate diagnosis of acute pyelonephritis: How helpful is procalcitonin? Nucl Med Commun 2006 27(9):715-21.
Rec#: 8670
Exclusion Codes: SMN, EXC

Guven, H., L. Altintop, A. Baydin, S. Esen, D. Aygun, M. Hokelek, Z. Doganay, and Y. Bek. Diagnostic value of procalcitonin levels as an early indicator of sepsis. Am J Emerg Med 2002 20(3):202-6.
Rec#: 5350
Exclusion Codes: SMN, EXC

Guz, G., B. Colak, K. Hizel, K. A. Reis, Y. Erten, M. Bali, and S. Sindel. Procalcitonin and conventional markers of inflammation in peritoneal dialysis patients and peritonitis. Perit Dial Int 2006 26(2):240-8.
Rec#: 8810
Exclusion Codes: SMN, EXC

Haeuptle, J., R. Zaborsky, R. Fiumefreddo, A. Trampuz, I. Steffen, R. Frei, M. Christ-Crain, B. Muller, and P. Schuetz. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis 2009 28(1):55-60.
Rec#: 1460
Exclusion Codes: SMN, EXC

Hambach, L., M. Eder, E. Dammann, A. Schrauder, K. W. Sykora, C. Dieterich, P. Kirschner, J. Novotny, A. Ganser, and B. Hertenstein. Diagnostic value of procalcitonin serum levels in comparison with C-reactive protein in allogeneic stem cell transplantation. Haematologica 2002 87(6):643-51.
Rec#: 5310
Exclusion Codes: NDE, EXC

Hammer, C., P. Fraunberger, B. Meiser, and S. Hammer. Procalcitonin: a new marker for diagnosis of acute rejection and nonviral infection of heart and lung transplant patients. Transplant Proc 2001 33(3):2204-6.

Rec#: 5760
Exclusion Codes: NRO, EXC

Hammer, S., P. Fraunberger, B. Meiser, M. Stangl, D. Seidel, and C. Hammer. Procalcitonin, a new indicator for non-viral infections in heart, lung or liver transplant patients. Ann Transplant 1999 4(2):5-9.
Rec#: 6130
Exclusion Codes: NDE, EXC

Hammer, S., A. T. Fuchs, C. Rinker, S. Daebritz, R. Kozlik-Feldmann, and H. Netz. Interleukin-6 and procalcitonin in serum of children undergoing cardiac surgery with cardiopulmonary bypass. Acta Cardiol 2004 59(6):624-9.
Rec#: 9390
Exclusion Codes: NRO, EXC

Hammer, S., E. Meisner, P. Fraunberger, B. Meiser, M. Stangl, C. Hammer, and D. Seidel. Procalcitonin - Differential diagnosis of rejections and non viral infections in transplant patients: Procalcitonin - Differentialdiagnose von abstossungsreaktionen und nicht-viralen infektionen bei transplantationspatienten. Transplantationsmed. Organ Dtsch. Transplantationsges. 1999 11(1):54-58.
Rec#: 15080
Exclusion Codes: NDE, EXC

Hammer, S., F. Meisner, P. Dirschedl, P. Fraunberger, B. Meiser, B. Reichart, and C. Hammer. Procalcitonin for differential diagnosis of graft rejection and infection in patients with heart and/or lung grafts. Intensive Care Med 2000 26 Suppl 2:S182-6.
Rec#: 1710
Exclusion Codes: SMN, EXC

Hammer, S., F. Meisner, P. Dirschedl, G. Hobel, P. Fraunberger, B. Meiser, B. Reichardt, and C. Hammer. Procalcitonin: a new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation. Transpl Immunol 1998 6(4):235-41.
Rec#: 6500
Exclusion Codes: NDE, EXC

Han, Y. Y., L. A. Doughty, D. Kofos, H. Sasser, and J. A. Carcillo. Procalcitonin is persistently increased among children with poor outcome from bacterial sepsis. Pediatr Crit Care Med 2003 4(1):21-5.
Rec#: 4890
Exclusion Codes: NRO, EXC

Hanes, S.D., G.C. Wood, B. Ritter, and B.A. Boucher. Serum and alveolar procalcitonin concentrations during ventilator-associated pneumonia. J. Infect. Dis. Pharmacother. 2003 6(2):59-72.
Rec#: 14380
Exclusion Codes: NRO, EXC

Harbarth, S., W. C. Albrich, and B. Muller. When once is not enough--further evidence of procalcitonin-guided antibiotic stewardship. Crit Care 2009 13(4):165.
Rec#: 650
Exclusion Codes: NDE, EXC

Harbarth, S., K. Holeckova, C. Froidevaux, D. Pittet, B. Ricou, G. E. Grau, L. Vadas, and J. Pugin. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001 164(3):396-402.
Rec#: 5700
Exclusion Codes: SMN, EXC

Hatherill, M., G. Jones, E. Lim, S. M. Tibby, and I. A. Murdoch. Procalcitonin aids diagnosis of adrenocortical failure. Lancet 1997 350(9093):1749-50.
Rec#: 6820

Exclusion Codes: NRO, EXC

Hatherill, M., S. M. Tibby, K. Sykes, C. Turner, and I. A. Murdoch. Diagnostic markers of infection: comparison of procalcitonin with C reactive protein and leucocyte count. Arch Dis Child 1999 81(5):417-21.
Rec#: 6390
Exclusion Codes: NDE, EXC

Hatherill, M., S. M. Tibby, C. Turner, N. Ratnavel, and I. A. Murdoch. Procalcitonin and cytokine levels: relationship to organ failure and mortality in pediatric septic shock. Crit Care Med 2000 28(7):2591-4.
Rec#: 6080
Exclusion Codes: SMN, EXC

Hatzistilianou, M., S. Hitoglou, D. Gougoustamou, A. Rekliti, G. Tzouvelekis, Ch. Nanas, D. Catriu, and A. Kotsis. Serum procalcitonin, adenosine deaminase and its isoenzymes in the aetiological diagnosis of pneumonia in children. Int. J. Immunopathol. Pharmacol. 2002 15(2):119-127.
Rec#: 16910
Exclusion Codes: SMN, EXC

Hatzistilianou, M., A. Rekleity, F. Athanassiadou, M. A. DeLutiis, P. Conti, and D. Catriu. Serial procalcitonin responses in infection of children with secondary immunodeficiency. Clin Invest Med 2007 30(2):E75-85.
Rec#: 8280
Exclusion Codes: NDE, EXC

Hatzistilianou, M., A. Rekliti, F. Athanassiadou, and D. Catriu. Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia. Inflamm Res 2010 59(5):339-47.
Rec#: 420
Exclusion Codes: NDE, EXC

Hausfater, P. Procalcitonin measurement in adult clinical practice: Le dosage de la procalcitonine en pratique clinique chez l'adulte. Rev. Med. Interne 2007 28(5):296-305.
Rec#: 13360
Exclusion Codes: NDE, EXC

Hausfater, P., C. Brochet, Y. Freund, V. Charles, and M. Bernard. Procalcitonin measurement in routine emergency medicine practice: comparison between two immunoassays. Clin Chem Lab Med 2010 48(4):501-4.
Rec#: 6990
Exclusion Codes: NDE, EXC

Hausfater, P., S. Garric, S. B. Ayed, M. Rosenheim, M. Bernard, and B. Riou. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin Infect Dis 2002 34(7):895-901.
Rec#: 5480
Exclusion Codes: NDE, EXC

Hausfater, P., G. Juillien, B. Madonna-Py, J. Haroche, M. Bernard, and B. Riou. Serum procalcitonin measurement as diagnostic and prognostic marker in febrile adult patients presenting to the emergency department. Crit Care 2007 11(3):R60.
Rec#: 2750
Exclusion Codes: NDE, EXC

Hayashi, Y., L. Davis, and D.L. Paterson. Editorial: Why can't I prescribe that antibiotic? The role of antimicrobial stewardship programmes in modern medicine. Intern. Med. J. 2009 39(10):636-638.
Rec#: 15800
Exclusion Codes: NDE, EXC

Heath, V. Procalcitonin assay shows promise. Nat. Rev. Endocrionol. 2009 5(4):184.

Rec#: 15930
Exclusion Codes: NDE, EXC

Hedlund, J., and L. O. Hansson. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000 28(2):68-73.
Rec#: 10580
Exclusion Codes: SMN, EXC

Heffner, J.E. Empyema as an orphan disease: So many approaches and so few data. J. Infect. Public Health 2009 2(1):1-3.
Rec#: 15960
Exclusion Codes: NDE, EXC

Hellerstein, S. Acute urinary tract infection--evaluation and treatment. Curr Opin Pediatr 2006 18(2):134-8.
Rec#: 8840
Exclusion Codes: NDE, EXC

Hellwig, B. Respiratory tract infection: Procalcitonin as biomarker in practice guidelines: Atemwegsinfekte: Biomarker procalcitonin in leitlinien aufgenommen. Dtsch. Apoth. Ztg. 2009 149(45):50.
Rec#: 11970
Exclusion Codes: NDE, EXC

Hemmer, C. J., and E. C. Reisinger. Procalcitonin levels in severe Plasmodium falciparum malaria: predictor of outcome or reflection of pathomechanisms? J Infect Dis 2001 184(8):1091-2.
Rec#: 10260
Exclusion Codes: NDE, EXC

Hensler, T., S. Sauerland, R. Lefering, M. Nagelschmidt, B. Bouillon, J. Andermahr, and E. A. Neugebauer. The clinical value of procalcitonin and neopterin in predicting sepsis and organ failure after major trauma. Shock 2003 20(5):420-6.
Rec#: 4610
Exclusion Codes: NDE, EXC

Heper, Y., E. H. Akalin, R. Mistik, S. Akgoz, O. Tore, G. Goral, B. Oral, F. Budak, and S. Helvaci. Evaluation of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock. Eur J Clin Microbiol Infect Dis 2006 25(8):481-91.
Rec#: 3190
Exclusion Codes: SMN, EXC

Heppner, H.J., T. Bertsch, B. Alber, A.S. Esslinger, C. Dragonas, J.M. Bauer, and C.C. Sieber. Procalcitonin: Inflammatory biomarker for assessing the severity of community-acquired pneumonia - A clinical observation in geriatric patients. Gerontology 2010 56(4):385-389.
Rec#: 15340
Exclusion Codes: NRO, EXC

Herd, D. In children under age three does procalcitonin help exclude serious bacterial infection in fever without focus? Arch Dis Child 2007 92(4):362-4.
Rec#: 8500
Exclusion Codes: NDE, EXC

Hergert, M., H.-G. Lestin, M. Scherkus, K. Brinker, I. Klett, G. Stranz, and F. Lestin. Procalcitonin in patients with sepsis and polytrauma: Procalcitonin bei Sepsis und Polytrauma. Clin. Lab. 1998 44(9):659-670.
Rec#: 15150
Exclusion Codes: NRD, EXC

Herget-Rosenthal, S., G. Marggraf, F. Pietruck, J. Husing, M. Strupat, T. Philipp, and A. Kribben. Procalcitonin for accurate detection of infection in haemodialysis. Nephrol Dial Transplant 2001 16(5):975-9.
Rec#: 5800
Exclusion Codes: SMN, EXC

Herrlinger, K. R., R. Dittmann, G. Weitz, J. Wehkamp, D. Ludwig, M. Schwab, E. F. Stange, and K. Fellermann. Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis. Inflamm Bowel Dis 2004 10(3):229-33.
Rec#: 9550
Exclusion Codes: NDE, EXC

Herrmann, W., D. Ecker, S. Quast, M. Klieden, S. Rose, and I. Marzi. Comparison of procalcitonin, sCD14 and interleukin-6 values in septic patients. Clin Chem Lab Med 2000 38(1):41-6.
Rec#: 6220
Exclusion Codes: NRO, EXC

Hesselink, D. A., J. S. Burgerhart, H. Bosmans-Timmerarends, P. Petit, and P. J. van Genderen. Procalcitonin as a biomarker for severe Plasmodium falciparum disease: a critical appraisal of a semi-quantitative point-of-care test in a cohort of travellers with imported malaria. Malar J 2009 8:206.
Rec#: 7230
Exclusion Codes: NDE, EXC

Hesselink, D.A., J.-S. Burgerhart, H. Bosmans-Timmerarends, P. Petit, and P.J.J. Van Genderen. Procalcitonin as a biomarker for severe Plasmodium falciparum disease: A critical appraisal of a semi-quantitative point-of-care test in a cohort of travellers with imported malaria. Malaria J. 2009 8(1).
Rec#: 15780
Exclusion Codes: NDE, EXC

Hillas, G., T. Vassilakopoulos, P. Plantza, A. Rasidakis, and P. Bakakos. C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia. Eur Respir J 2010 35(4):805-11.
Rec#: 570
Exclusion Codes: SMN, EXC

Hirakata, Y., K. Yanagihara, S. Kurihara, K. Izumikawa, M. Seki, Y. Miyazaki, and S. Kohno. Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008 61(2):170-4.
Rec#: 2050
Exclusion Codes: SMN, EXC

Hitoglou-Hatzi, S., M. Hatzistilianou, D. Gougoustamou, A. Rekliti, C. h. Agguridaki, F. Athanassiadou, S. Frydas, A. Kotsis, and D. Catriu. Serum adenosine deaminase and procalcitonin concentrations in neutropenic febrile children with acute lymphoblastic leukaemia. Clin Exp Med 2005 5(2):60-5.
Rec#: 3680
Exclusion Codes: NDE, EXC

Hladik, M., A. Olosova, J. Neiser, and T. Zaoral. Procalcitonin--a marker and mediator of inflammation. Acta Chir Plast 2005 47(2):51-4.
Rec#: 3750
Exclusion Codes: NDE, EXC

Hoffken, G. Does procalcitonin (PCT) determination help for therapeutic decision in ambulant and nosocomial infections?: Ist die bestimmung von procalcitonin (PCT) hilfreich zum therapieentscheid bei ambulant und nosokomial erworbenen infektionen? Atemwegs- Lungenkr. 2007 33(10):433-434.
Rec#: 16250
Exclusion Codes: NRD, EXC

Hoffmann, G., and W. Schobersberger. Anti-inflammatory procalcitonin (PTC) in a human whole blood model septic shock. Cytokine 2001 14(2):127-8.
Rec#: 5780
Exclusion Codes: NDE, EXC

Hoffmann, G., and W. Schobersberger. Procalcitonin as a marker. Acta Anaesthesiol Scand 2003 47(2):237.
Rec#: 4920
Exclusion Codes: NDE, EXC

Hoffmann, O., U. Reuter, F. Masuhr, M. Holtkamp, N. Kassim, and J. R. Weber. Low sensitivity of serum procalcitonin in bacterial meningitis in adults. Scand J Infect Dis 2001 33(3):215-8.
Rec#: 10360
Exclusion Codes: SMN, EXC

Hoksch, B., R. Fahrner, and R. Alexander Schmid. Procalcitonin and brain natriuretic peptide as parameters in the postoperative course of patients with major pulmonary resection. Interact Cardiovasc Thorac Surg 2007 6(2):155-9.
Rec#: 2540
Exclusion Codes: SMN, EXC

Hoksch, B., and R.A. Schmid. Reply to Apostolakis et al. Eur. J. Cardio-thorac. Surg. 2009 35(1):194.
Rec#: 12450
Exclusion Codes: NDE, EXC

Hollenstein, U., S. Looareesuwan, A. Aichelburg, F. Thalhammer, B. Stoiser, S. Amradee, S. Chullawichit, I. El Menyawi, and H. Burgmann. Serum procalcitonin levels in severe Plasmodium falciparum malaria. Am J Trop Med Hyg 1998 59(6):860-3.
Rec#: 6610
Exclusion Codes: NRO, EXC

Holm, A., S. S. Pedersen, J. Nexoe, N. Obel, L. P. Nielsen, O. Koldkjaer, and C. Pedersen. Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. Br J Gen Pract 2007 57(540):555-60.
Rec#: 8270
Exclusion Codes: NDE, EXC

Huang, D. T., L. A. Weissfeld, J. A. Kellum, D. M. Yealy, L. Kong, M. Martino, and D. C. Angus. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008 52(1):48-58.e2.
Rec#: 8010
Exclusion Codes: NDE, EXC

Huber, W., J. Reichenberger, H. Salmhofer, B. Neu, R. Ermler, U. Schweigart, L. Rothmeier, P. Bottermann, and M. Classen. Procalcitonin - A routine parameter in intensive medicine?: Procalcitonin - Ein routineparameter in der intensivmedizin? Intensivmed. Notf.med. 1998 35(2):124-131.
Rec#: 15200
Exclusion Codes: NDE, EXC

Huber, W., U. Schweigart, and P. Bottermann. Failure of PCT to indicate severe fungal infection in two immunodeficient patients. Infection 1997 25(6):377-8.
Rec#: 10860
Exclusion Codes: NDE, EXC

Hubl, W., J. Krassler, C. Zingler, A. Pertschy, J. Hentschel, C. Gerhards-Reich, M. Mack, and T. Demant. Evaluation of a fully automated procalcitonin chemiluminescence immunoassay. Clin Lab 2003 49(7-8):319-27.
Rec#: 4690
Exclusion Codes: SMN, EXC

Hugle, T., P. Schuetz, B. Mueller, G. Laifer, A. Tyndall, S. Regenass, and T. Daikeler. Serum procalcitonin for discrimination between septic and non-septic arthritis. Clin Exp Rheumatol 2008 26(3):453-6.
Rec#: 1520
Exclusion Codes: SMN, EXC

Hunziker, S., T. Hugle, K. Schuchardt, I. Groeschl, P. Schuetz, B. Mueller, W. Dick, U. Eriksson, and A. Trampuz. The value of serum procalcitonin level for differentiation of infectious from noninfectious causes of fever after orthopaedic surgery. J Bone Joint Surg Am 2010 92(1):138-48.
Rec#: 260
Exclusion Codes: NDE, EXC

Indino, P., P. Lemarchand, P. Bady, A. de Torrente, L. Genne, and D. Genne. Prospective study on procalcitonin and other systemic infection markers in patients with leukocytosis. Int J Infect Dis 2008 12(3):319-24.
Rec#: 8170
Exclusion Codes: NDE, EXC

Ingram, P. R., T. Inglis, D. Moxon, and D. Speers. Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection. Intensive Care Med 2010 36(3):528-32.
Rec#: 240
Exclusion Codes: SMN, EXC

Ip, M., T. H. Rainer, N. Lee, C. Chan, S. S. Chau, W. Leung, M. F. Leung, T. K. Tam, G. E. Antonio, G. Lui, T. K. Lau, D. S. Hui, D. Fuchs, R. Renneberg, and P. K. Chan. Value of serum procalcitonin, neopterin, and C-reactive protein in differentiating bacterial from viral etiologies in patients presenting with lower respiratory tract infections. Diagn Microbiol Infect Dis 2007 59(2):131-6.
Rec#: 8340
Exclusion Codes: NDE, EXC

Isidor, B., G. Caillaux, V. Gilquin, V. Loubersac, J. Caillon, J. C. Roze, and C. Gras-le Guen. The use of procalcitonin in the diagnosis of late-onset infection in neonatal intensive care unit patients. Scand J Infect Dis 2007 39(11-12):1063-6.
Rec#: 2420
Exclusion Codes: NDE, EXC

Ito, S., N. Sato, M. Kojika, Y. Yaegashi, Y. Suzuki, K. Suzuki, and S. Endo. Serum procalcitonin levels are elevated in esophageal cancer patients with postoperative infectious complications. Eur Surg Res 2005 37(1):22-8.
Rec#: 3870
Exclusion Codes: SMN, EXC

Ittner, L., W. Born, B. Rau, G. Steinbach, and J. A. Fischer. Circulating procalcitonin and cleavage products in septicaemia compared with medullary thyroid carcinoma. Eur J Endocrinol 2002 147(6):727-31.
Rec#: 5050
Exclusion Codes: NRO, EXC

Ivancevic, N., D. Radenkovic, V. Bumbasirevic, A. Karamarkovic, V. Jeremic, N. Kalezic, T. Vodnik, B. Beleslin, N. Milic, P. Gregoric, and M. Zarkovic. Procalcitonin in preoperative diagnosis of abdominal sepsis. Langenbecks Arch Surg 2008 393(3):397-403.
Rec#: 2300
Exclusion Codes: SMN, EXC

Jacquot, A., J. M. Labaune, T. P. Baum, G. Putet, and J. C. Picaud. Rapid quantitative procalcitonin measurement to diagnose nosocomial infections in newborn infants. Arch Dis Child Fetal Neonatal Ed 2009 94(5):F345-8.
Rec#: 860
Exclusion Codes: NDE, EXC

Janota, J., Z. Stranak, S. Belohlavkova, K. Mudra, and J. Simak. Postnatal increase of procalcitonin in premature newborns is enhanced by chorioamnionitis and neonatal sepsis. Eur J Clin Invest 2001 31(11):978-83.
Rec#: 5600
Exclusion Codes: NDE, EXC

Jaoude, P. A., P. R. Knight, P. Ohtake, and A. A. El-Solh. Biomarkers in the diagnosis of aspiration syndromes. Expert Rev Mol Diagn 2010 10(3):309-19.
Rec#: 110
Exclusion Codes: NDE, EXC

Jaresova, M., I. Striz, J. Cermakova, J. Lacha, J. Sedlacek, K. Mudra, I. Hana, and S. Vitko. Serum procalcitonin concentrations in transplant patients with acute rejection and bacterial infections. Immunol Lett 1999 69(3):355-8.
Rec#: 6380
Exclusion Codes: NDE, EXC

Jeandrot, A., J. L. Richard, C. Combescure, N. Jourdan, S. Finge, M. Rodier, P. Corbeau, A. Sotto, and J. P. Lavigne. Serum procalcitonin and C-reactive protein concentrations to distinguish mildly infected from non-infected diabetic foot ulcers: a pilot study. Diabetologia 2008 51(2):347-52.
Rec#: 8230
Exclusion Codes: SMN, EXC

Jebali, M. A., P. Hausfater, Z. Abbes, Z. Aouni, B. Riou, and M. Ferjani. Assessment of the accuracy of procalcitonin to diagnose postoperative infection after cardiac surgery. Anesthesiology 2007 107(2):232-8.
Rec#: 2550
Exclusion Codes: NDE, EXC

Jensen, J. U., L. Heslet, T. H. Jensen, K. Espersen, P. Steffensen, and M. Tvede. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006 34(10):2596-602.
Rec#: 3160
Exclusion Codes: NDE, EXC

Jensen, J. U., B. Lundgren, L. Hein, T. Mohr, P. L. Petersen, L. H. Andersen, A. O. Lauritsen, S. Hougaard, T. Mantoni, B. Bomler, K. J. Thornberg, K. Thormar, J. Loken, M. Steensen, P. Carl, J. A. Petersen, H. Tousi, P. Soe-Jensen, M. Bestle, S. Hestad, M. H. Andersen, P. Fjeldborg, K. M. Larsen, C. Rossau, C. B. Thomsen, C. Ostergaard, J. Kjaer, J. Grarup, and J. D. Lundgren. The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. BMC Infect Dis 2008 8:91.
Rec#: 1490
Exclusion Codes: NRO, EXC

Jensen, J. U., B. Lundgren, and J. D. Lundgren. Meta-analysis of procalcitonin for sepsis detection. Lancet Infect Dis 2007 7(8):499-500; author reply 502-3.
Rec#: 2590
Exclusion Codes: NRD, EXC

Jensen, J. U., and J. Lundgren. Procalcitonin monitoring in trauma intensive care patients: how helpful is it? Crit Care Med 2009 37(6):2093-4.
Rec#: 840
Exclusion Codes: NDE, EXC

Jereb, M., and T. Kotar. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia. Wien Klin Wochenschr 2006 118(5-6):170-4.
Rec#: 8780
Exclusion Codes: SMN, EXC

Jereb, M., T. Kotar, T. Jurca, and T. Lejko Zupanc. Usefulness of procalcitonin for diagnosis of infective endocarditis. Intern Emerg Med 2009 4(3):221-6.
Rec#: 940
Exclusion Codes: SMN, EXC

Jereb, M., I. Muzlovic, S. Hojker, and F. Strle. Predictive value of serum and cerebrospinal fluid procalcitonin levels for the diagnosis of bacterial meningitis. Infection 2001 29(4):209-12.
Rec#: 10290
Exclusion Codes: SMN, EXC

Jimeno, A., A. Garcia-Velasco, O. del Val, E. Gonzalez-Billalabeitia, S. Hernando, R. Hernandez, A. Sanchez-Munoz, A. Lopez-Martin, I. Duran, L. Robles, H. Cortes-Funes, and L. Paz-Ares. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 2004 100(11):2462-9.
Rec#: 4320
Exclusion Codes: NDE, EXC

Jin, M., and A.I. Khan. Procalcitonin: Uses in the clinical laboratory for the diagnosis of sepsis. Lab. Med. 2010 41(3):173-177.
Rec#: 11740
Exclusion Codes: NDE, EXC

Johnston, I.G. Procalcitonin - An exciting prospect as a marker in sepsis. Care Crit. Ill 2001 17(3):81-82.
Rec#: 14750
Exclusion Codes: NDE, EXC

Jones, A. E., J. F. Fiechtl, M. D. Brown, J. J. Ballew, and J. A. Kline. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann Emerg Med 2007 50(1):34-41.
Rec#: 3030
Exclusion Codes: NDE, EXC

Jongwutiwes, U., K. Suitharak, S. Tiengrim, and V. Thamlikitkul. Serum procalcitonin in diagnosis of bacteremia. J Med Assoc Thai 2009 92 Suppl 2:S79-87.
Rec#: 760
Exclusion Codes: SMN, EXC

Joram, N., C. Boscher, S. Denizot, V. Loubersac, N. Winer, J. C. Roze, and C. Gras-Le Guen. Umbilical cord blood procalcitonin and C reactive protein concentrations as markers for early diagnosis of very early onset neonatal infection. Arch Dis Child Fetal Neonatal Ed 2006 91(1):F65-6.
Rec#: 3510
Exclusion Codes: NDE, EXC

Jung, B., N. Embriaco, F. Roux, J. M. Forel, D. Demory, J. Allardet-Servent, S. Jaber, B. La Scola, and L. Papazian. Microbiogical data, but not procalcitonin improve the accuracy of the clinical pulmonary infection score. Intensive Care Med 2010 36(5):790-8.
Rec#: 120
Exclusion Codes: SMN, EXC

Kabir, K., H. Keller, G. Grass, T. Minor, F. Stueber, S. Schroeder, C. Putensen, C. Paul, C. Burger, C. Rangger, L. F. Neville, and G. Mathiak. Cytokines and chemokines in serum and urine as early predictors to identify septic patients on intensive care unit. Int J Mol Med 2003 12(4):565-70.
Rec#: 4660
Exclusion Codes: NRO, EXC

Kafetzis, D. A., G. S. Tigani, and C. Costalos. Immunologic markers in the neonatal period: diagnostic value and accuracy in infection. Expert Rev Mol Diagn 2005 5(2):231-9.

Rec#: 9260
Exclusion Codes: NDE, EXC

Kahn, R. E. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: some research questions. Crit Care 2009 13(4):414; author reply 414.
Rec#: 640
Exclusion Codes: NDE, EXC

Kallio, R., H. M. Surcel, A. Bloigu, and H. Syrjala. C-reactive protein, procalcitonin and interleukin-8 in the primary diagnosis of infections in cancer patients. Eur J Cancer 2000 36(7):889-94.
Rec#: 6210
Exclusion Codes: SMN, EXC

Kandemir, O., B. Uluba, G. Polat, C. Sezer, H. Camdeviren, and A. Kaya. Elevation of procalcitonin level in patients with pulmonary tuberculosis and in medical staff with close patient contact. Arch Med Res 2003 34(4):311-4.
Rec#: 9840
Exclusion Codes: NRO, EXC

Kang, Y. A., S. Y. Kwon, H. I. Yoon, J. H. Lee, and C. T. Lee. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. Korean J Intern Med 2009 24(4):337-42.
Rec#: 7100
Exclusion Codes: SMN, EXC

Kapoor, S. Procalcitonin and its utility as a diagnostic and prognostic assay in patients with renal dysfunction and immunosuppressive conditions. J Infect Chemother 2009 15(1):58; author reply 59.
Rec#: 1020
Exclusion Codes: NDE, EXC

Kapoor, S. The rapidly expanding role of procalcitonin as a diagnostic and prognostic assay besides in UTIs. Int Urol Nephrol 2009 41(2):435-6.
Rec#: 7610
Exclusion Codes: NDE, EXC

Karavanaki, K., F. Angelos Haliotis, M. Sourani, C. Kariyiannis, E. Hantzi, L. Zachariadou, S. Avlonitis, I. Papassotiriou, and C.J. Stefanidis. DMSA scintigraphy in febrile urinary tract infections could be omitted in children with low procalcitonin levels. Infect. Dis. Clin. Pract. 2007 15(6):377-381.
Rec#: 16240
Exclusion Codes: SMN, EXC

Karzai, W., M. Oberhoffer, A. Meier-Hellmann, and K. Reinhart. Procalcitonin--a new indicator of the systemic response to severe infections. Infection 1997 25(6):329-34.
Rec#: 10870
Exclusion Codes: NDE, EXC

Karzai, W., and K. Reinhart. Sepsis: definitions and diagnosis. Int J Clin Pract Suppl 1998 95:44-8.
Rec#: 6650
Exclusion Codes: NDE, EXC

Keel, M., L. Harter, T. Reding, L. K. Sun, M. Hersberger, B. Seifert, D. Bimmler, and R. Graf. Pancreatic stone protein is highly increased during posttraumatic sepsis and activates neutrophil granulocytes. Crit Care Med 2009 37(5):1642-8.
Rec#: 970
Exclusion Codes: NRO, EXC

Keenan, J. The European Respiratory Society Congress Munich, Germany September 2-6, 2006. Ann. Long-Term Care 2007 15(1):28-32.
Rec#: 13570
Exclusion Codes: NRD, EXC

Khan, D. A., A. Rahman, and F. A. Khan. Is procalcitonin better than C-reactive protein for early diagnosis of bacterial pneumonia in children? J Clin Lab Anal 2010 24(1):1-5.
Rec#: 7020
Exclusion Codes: SMN, EXC

Kim, H.C., K.M. Kim, S.M. Lee, S.J. Lee, H.S. Ham, Y.J. Cho, Y.Y. Jeong, J.D. Lee, and Y.S. Hwang. Measuring serum procalcitonin in patients with fever in the ICU to differentiate infectious causes from non-infectious causes. Tuberc. Respir. Dis. 2006 61(1):20-25.
Rec#: 13790
Exclusion Codes: NRD, EXC

Kim, J.-Y., C.-H. Kim, S. Park, C.-Y. Lee, I.H. Yong, J.-H. Choi, T. Shin, Y.-B. Park, S.-H. Jang, Y.L. Jae, M.P. Sang, D.-G. Kim, M.-G. Lee, I.-G. Hyun, and K.-S. Jung. Semi-quantitative procalcitonin assay in critically ill patients with respiratory infections. Tuberc. Respir. Dis. 2009 67(3):205-211.
Rec#: 12120
Exclusion Codes: NRD, EXC

Kim, S.-H., Y.P. Joo, S.P. Hyun, S.S. Hee, T.K. Shin, W.K. Chong, G.L. Bu, J.L. Seok, N.L. Shun, K.N. Jin, S.L. Min, Y.L. Won, J.Y. Suk, and C.S. Kye. Diagnostic value of procalcitonin and C-reactive protein in differentiation of pleural effusions. Tuberc. Respir. Dis. 2007 63(4):353-361.
Rec#: 16270
Exclusion Codes: NRD, EXC

Kindberg Boysen, A., J. S. Madsen, and P. E. Jorgensen. Procalcitonin as a marker of postoperative complications. Scand J Clin Lab Invest 2005 65(5):387-94.
Rec#: 3700
Exclusion Codes: NDE, EXC

Kisacik, B., U. Kalyoncu, M. F. Erol, O. Karadag, M. Yildiz, A. Akdogan, B. Kaptanoglu, M. Hayran, K. Ureten, I. Ertenli, S. Kiraz, and M. Calguneri. Accurate diagnosis of acute abdomen in FMF and acute appendicitis patients: how can we use procalcitonin? Clin Rheumatol 2007 26(12):2059-62.
Rec#: 8490
Exclusion Codes: SMN, EXC

Kitanovski, L., J. Jazbec, S. Hojker, M. Gubina, and M. Derganc. Diagnostic accuracy of procalcitonin and interleukin-6 values for predicting bacteremia and clinical sepsis in febrile neutropenic children with cancer. Eur J Clin Microbiol Infect Dis 2006 25(6):413-5.
Rec#: 3290
Exclusion Codes: NDE, EXC

Knudsen, T. B., and T. B. Kristiansen. Issues pertaining to data extraction and classification and publication bias in meta-analysis of the diagnostic accuracy of markers for bacterial infection. Clin Infect Dis 2005 40(9):1372-3; author reply 1373-4.
Rec#: 9270
Exclusion Codes: NDE, EXC

Knudsen, T. B., K. Larsen, T. B. Kristiansen, H. J. Moller, M. Tvede, J. Eugen-Olsen, and G. Kronborg. Diagnostic value of soluble CD163 serum levels in patients suspected of meningitis: comparison with CRP and procalcitonin. Scand J Infect Dis 2007 39(6-7):542-53.
Rec#: 8390
Exclusion Codes: SMN, EXC

Kocabas, E., A. Sarikcioglu, N. Aksaray, G. Seydaoglu, Y. Seyhun, and A. Yaman. Role of procalcitonin, C-reactive protein, interleukin-6, interleukin-8 and tumor necrosis factor-alpha in the diagnosis of neonatal sepsis. Turk J Pediatr 2007 49(1):7-20.
Rec#: 2770
Exclusion Codes: NDE, EXC

Kocazeybek, B., S. Kucukoglu, and Y. A. Oner. Procalcitonin and C-reactive protein in infective endocarditis: correlation with etiology and prognosis. Chemotherapy 2003 49(1-2):76-84.
Rec#: 4830
Exclusion Codes: SMN, EXC

Kofoed, K., O. Andersen, G. Kronborg, M. Tvede, J. Petersen, J. Eugen-Olsen, and K. Larsen. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 2007 11(2):R38.
Rec#: 2880
Exclusion Codes: NDE, EXC

Kofteridis, D.P., G. Samonis, A.D. Karatzanis, G.M. Fragiadakis, C.A. Bourolias, S. Maraki, J.A. Papadakis, and G.A. Velegrakis. C-reactive protein and serum procalcitonin levels as markers of bacterial upper respiratory tract infections. Am. J. Infect. Dis. 2009 5(4):289-294.
Rec#: 15730
Exclusion Codes: NRO, EXC

Koksal, N., R. Harmanci, M. Cetinkaya, and M. Hacimustafaoglu. Role of procalcitonin and CRP in diagnosis and follow-up of neonatal sepsis. Turk J Pediatr 2007 49(1):21-9.
Rec#: 2760
Exclusion Codes: NDE, EXC

Korczowski, B. Serum concentration of procalcitonin in various childhood diseases. Med. Sci. Monit. 1999 5(5):996-1000.
Rec#: 15040
Exclusion Codes: NDE, EXC

Korczowski, B. Diagnostic usefulness of procalcitonin in acute pancreatitis: Diagnostyczna przydatnosc prokalcytoniny w ostrym zapaleniu trzustki. Gastroenterol. Pol. 2006 13(1):63-65.
Rec#: 13870
Exclusion Codes: NDE, EXC

Korczowski, B. Serum procalcitonin concentration in children with liver disease. Pediatr Infect Dis J 2006 25(3):268-9.
Rec#: 8920
Exclusion Codes: NRO, EXC

Korczowski, B., A. Mroczkowska-Juchkiewicz, and A. Papierkowski. High serum procalcitonin concentration in Kawasaki disease. Med. Sci. Monit. 1998 4(6):1072-1074.
Rec#: 17100
Exclusion Codes: NDE, EXC

Korczowski, B., and W. Szybist. Serum procalcitonin and C-reactive protein in children with diarrhoea of various aetiologies. Acta Paediatr 2004 93(2):169-73.
Rec#: 4430
Exclusion Codes: NDE, EXC

Korczowski, B., W. Szybist, W. Romanczuk, J. Sieklucki, and J. Rusin. Diagnostic usefulness of procalcitonin and C-reactive protein in the diarrhea of different etiology. Pediatr. Wspolczesna 2002 4(3):289-292.
Rec#: 14560
Exclusion Codes: NDE, EXC

Kordek, A., S. Giedrys-Kalemba, B. Pawlus, B. Loniewska, E. Bartkowiak, J. Rudnicki, Z. Szych, and R. Czajka. Comparison of quantitative (LUMItest) and semi-quantitative (Brahms PCT-Q) Tests for PCT concentration measurements in the newborn infants' blood: Porownanie ilosciowej (LUMItest) i pol ilosciowej (Brahms PCT-Q) medody oznaczania stezenia prokalcytoniny w surowicy krwi noworodkow. Adv. Clin. Exp. Med. 2004 13(6):945-948.
Rec#: 16690
Exclusion Codes: NRD, EXC

Kordek, A., S. Giedrys-Kalemba, B. Pawlus, W. Podraza, and R. Czajka. Umbilical cord blood serum procalcitonin concentration in the diagnosis of early neonatal infection. J Perinatol 2003 23(2):148-53.
Rec#: 9950
Exclusion Codes: NDE, EXC

Kordek, A., M. Halasa, and W. Podraza. Early detection of an early onset infection in the neonate based on measurements of procalcitonin and C-reactive protein concentrations in cord blood. Clin Chem Lab Med 2008 46(8):1143-8.
Rec#: 7850
Exclusion Codes: NDE, EXC

Kordek, A., W. Podraza, and R. Czajka. Reliability of semiquantitative determination of procalcitonin serum concentrations in neonates. Diagn Microbiol Infect Dis 2006 56(1):31-4.
Rec#: 8700
Exclusion Codes: NDE, EXC

Kordek, A., A. Torbe, and R. Czajka. Maternal venous procalcitonin levels do not correlate with umbilical cord blood and venous blood concentrations in the neonate. J Perinat Med 2006 34(6):462-5.
Rec#: 8610
Exclusion Codes: NRO, EXC

Korppi, M., M. Don, F. Valent, and M. Canciani. The value of clinical features in differentiating between viral, pneumococcal and atypical bacterial pneumonia in children. Acta Paediatr 2008 97(7):943-7.
Rec#: 7950
Exclusion Codes: NDE, EXC

Korppi, M., and S. Remes. Serum procalcitonin in pneumococcal pneumonia in children. Eur Respir J 2001 17(4):623-7.
Rec#: 10310
Exclusion Codes: NDE, EXC

Korppi, M., S. Remes, and T. Heiskanen-Kosma. Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings. Pediatr Pulmonol 2003 35(1):56-61.
Rec#: 10060
Exclusion Codes: NDE, EXC

Koskenvuo, M. M., K. Irjala, A. Kinnala, O. Ruuskanen, and P. Kero. Value of monitoring serum procalcitonin in neonates at risk of infection. Eur J Clin Microbiol Infect Dis 2003 22(6):377-8.
Rec#: 9910
Exclusion Codes: NDE, EXC

Kotoula, A., S. Gardikis, A. Tsalkidis, E. Mantadakis, A. Zissimopoulos, S. Deftereos, G. Tripsianis, K. Manolas, A. Chatzimichael, and G. Vaos. Comparative efficacies of procalcitonin and conventional inflammatory markers for prediction of renal parenchymal inflammation in pediatric first urinary tract infection. Urology 2009 73(4):782-6.
Rec#: 7590
Exclusion Codes: SMN, EXC

Kotoula, A., S. Gardikis, A. Tsalkidis, E. Mantadakis, A. Zissimopoulos, S. Deftereos, G. Tripsianis, K. Manolas, A. Chatzimichael, and G. Vaos. Comparative Efficacies of Procalcitonin and Conventional Inflammatory Markers for Prediction of Renal Parenchymal Inflammation in Pediatric First Urinary Tract Infection. Urology 2009 73(4):782-786.
Rec#: 15940
Exclusion Codes: NDE, EXC

Kotoula, A., S. Gardikis, A. Tsalkidis, E. Mantadakis, A. Zissimopoulos, K. Kambouri, S. Deftereos, G. Tripsianis, K. Manolas, A. Chatzimichael, and G. Vaos. Procalcitonin for the early prediction of renal parenchymal involvement in children with UTI: preliminary results. Int Urol Nephrol 2009 41(2):393-9.
Rec#: 7770
Exclusion Codes: SMN, EXC

Kruger, S., S. Ewig, J. Kunde, O. Hartmann, N. Suttorp, and T. Welte. Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax 2010 65(3):208-14.
Rec#: 6940
Exclusion Codes: NDE, EXC

Kruger, S., S. Ewig, R. Marre, J. Papassotiriou, K. Richter, H. von Baum, N. Suttorp, and T. Welte. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008 31(2):349-55.
Rec#: 8210
Exclusion Codes: NDE, EXC

Kruger, S., S. Ewig, J. Papassotiriou, J. Kunde, R. Marre, H. von Baum, N. Suttor, and T. Welte. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res 2009 10:65.
Rec#: 7310
Exclusion Codes: NDE, EXC

Kruseova, J., M. Prucha, M. Dostal, E. Pindurova, I. Liskova, O. Nyc, D. Sumerauer, J. Nemcova, and J. Stary. The role of plasma procalcitonin and other inflammatory markers as identifiers of bacterial infections in children with solid tumor: Diagnosticky vyznam prokalcitoninu a dalsich markeru zanetu u deti se solidnimi nadory. Cesko-Slov. Pediatr. 2005 60(4):206-212.
Rec#: 14110
Exclusion Codes: NRD, EXC

Krysan, D. Serum procalcitonin levels aid in distinguishing bacterial from aseptic meningitis in children. J. Pediatr. 2009 154(5):773.
Rec#: 12310
Exclusion Codes: NDE, EXC

Kunz, D., and K.P. Kohse. Diagnostic of inflammation in pediatric patients: Entzundungsdiagnostik in der padiatrie. LaboratoriumsMedizin 2002 26(5-6):335-340.
Rec#: 16900
Exclusion Codes: NDE, EXC

Kupeli, S., T. Turul, H. Cuzdanci, D. Uckan, M. Cetin, M. Tuncer, and I. Tezcan. Procalcitonin, C-reactive protein and erythrocyte sedimentation rate values in bone marrow transplanted children: Kemik iligi transplantasyonu

yapilan cocuklarda prokalsitonin, kantitatif C-reaktif protein ve eritrosit sedimentasyon hizi degerleri. Cocuk Sagligi Hast. Derg. 2007 50(1):1-5.
Rec#: 13500
Exclusion Codes: NRD, EXC

Kuse, E. R., and K. Jaeger. Procalcitonin increase after anti-CD3 monoclonal antibody therapy does not indicate infectious disease. Transpl Int 2001 14(1):55.
Rec#: 10380
Exclusion Codes: NDE, EXC

Kuse, E. R., I. Langefeld, K. Jaeger, and W. R. Kulpmann. Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection. Crit Care Med 2000 28(2):555-9.
Rec#: 6240
Exclusion Codes: NDE, EXC

Kuse, E. R., I. Langefeld, K. Jaeger, and W. R. Kulpmann. Procalcitonin-a new diagnostic tool in complications following liver transplantation. Intensive Care Med 2000 26 Suppl 2:S187-92.
Rec#: 1700
Exclusion Codes: NDE, EXC

Kushimoto, S., Y. Shibata, Y. Koido, M. Kawai, H. Yokota, and Y. Yamamoto. The clinical usefulness of procalcitonin measurement for assessing the severity of bacterial infection in patients requiring corticosteroid therapy. J. Nippon Med. Sch. 2006 73(6):354-356.
Rec#: 16380
Exclusion Codes: SMN, EXC

Kushimoto, S., Y. Shibata, Y. Koido, M. Kawai, H. Yokota, and Y. Yamamoto. The clinical usefulness of procalcitonin measurement for assessing the severity of bacterial infection in critically ill patients requiring corticosteroid therapy. J Nippon Med Sch 2007 74(3):236-40.
Rec#: 2630
Exclusion Codes: NDE, EXC

Kylanpaa-Back, M. L., A. Takala, E. Kemppainen, P. Puolakkainen, R. Haapiainen, and H. Repo. Procalcitonin strip test in the early detection of severe acute pancreatitis. Br J Surg 2001 88(2):222-7.
Rec#: 10430
Exclusion Codes: NDE, EXC

Lacoma, A., C. Prat, F. Andreo, and J. Dominguez. Biomarkers in the management of COPD. Eur. Respir. Rev. 2009 18(112):96-104.
Rec#: 12260
Exclusion Codes: NDE, EXC

Lacour, A. G., A. Gervaix, S. A. Zamora, L. Vadas, P. R. Lombard, J. M. Dayer, and S. Suter. Procalcitonin, IL-6, IL-8, IL-1 receptor antagonist and C-reactive protein as identificators of serious bacterial infections in children with fever without localising signs. Eur J Pediatr 2001 160(2):95-100.
Rec#: 5830
Exclusion Codes: NDE, EXC

Lacour, A. G., S. A. Zamora, and A. Gervaix. A score identifying serious bacterial infections in children with fever without source. Pediatr Infect Dis J 2008 27(7):654-6.
Rec#: 7890
Exclusion Codes: NDE, EXC

Lacroix, J. What tests can help diagnose and estimate the severity of sepsis? J Pediatr (Rio J) 2007 83(4):297-8.
Rec#: 2530
Exclusion Codes: NRD, EXC

Lagabrielle, J.-F., A. Tachet, and V. Boin. Evaluation of two automated immunoassays for procalcitonin measurement: Kryptor(registered trademark) (Brahms) and Vidas(registered trademark) (BioMerieux): Dosage de la procalcitonine : comparaison des resultats obtenus sur Kryptor(registered trademark) (Brahms) et Vidas(registered trademark) (BioMerieux). Immuno-Anal. Biol. Spec. 2008 23(4):245-250.
Rec#: 12790
Exclusion Codes: NDE, EXC

Lai, C. C., S. Y. Chen, C. Y. Wang, J. Y. Wang, C. P. Su, C. H. Liao, C. K. Tan, Y. T. Huang, H. I. Lin, and P. R. Hsueh. Diagnostic value of procalcitonin for bacterial infection in elderly patients in the emergency department. J Am Geriatr Soc 2010 58(3):518-22.
Rec#: 160
Exclusion Codes: NDE, EXC

Lam, H.S., and P.C. Ng. Diagnostic markers in neonatal sepsis. Fetal Matern. Med. Rev. 2007 18(1):53-65.
Rec#: 13550
Exclusion Codes: NDE, EXC

Lam, M. F., J. C. Leung, C. W. Lam, K. C. Tse, W. K. Lo, S. L. Lui, T. M. Chan, S. Tam, and K. N. Lai. Procalcitonin fails to differentiate inflammatory status or predict long-term outcomes in peritoneal dialysis-associated peritonitis. Perit Dial Int 2008 28(4):377-84.
Rec#: 7870
Exclusion Codes: SMN, EXC

Landman, G. W., and N. Kleefstra. Procalcitonin in intensive care units: the PRORATA trial. Lancet 2010 375(9726):1606; author reply 1606-7.
Rec#: 40
Exclusion Codes: NDE, EXC

Lanuti, M., Fahrner, Van Schil, A. End, T. Szoke, and A. Turna. Conference discussion. Interact. Cardiovasc. Thorac. Surg. 2007 6(2):158-159.
Rec#: 13420
Exclusion Codes: SMN, EXC

Lapillonne, A., E. Basson, G. Monneret, J. Bienvenu, and B. L. Salle. Lack of specificity of procalcitonin for sepsis diagnosis in premature infants. Lancet 1998 351(9110):1211-2.
Rec#: 6760
Exclusion Codes: NDE, EXC

Lavrentieva, A., T. Kontakiotis, L. Lazaridis, N. Tsotsolis, J. Koumis, G. Kyriazis, and M. Bitzani. Inflammatory markers in patients with severe burn injury. What is the best indicator of sepsis? Burns 2007 33(2):189-94.
Rec#: 3020
Exclusion Codes: SMN, EXC

Lawn, S. D., J. Obeng, J. W. Acheampong, and G. E. Griffin. Serum procalcitonin concentrations in patients with pulmonary tuberculosis. Trans R Soc Trop Med Hyg 1998 92(5):540-1.
Rec#: 10710
Exclusion Codes: NRO, EXC

Le Roux, P. Laboratory investigations in acute lower respiratory tract infections in children: Les examens a visee etiologique dans les pneumopathies communautaires de l'enfant (hors imagerie). Arch. Pediatr. 1998 5(SUPPL. 1):28s-32s.
Rec#: 17140
Exclusion Codes: NRD, EXC

Leaver, S. K., N. S. MacCallum, V. Pingle, M. B. Hacking, G. J. Quinlan, T. W. Evans, and A. Burke-Gaffney. Increased plasma thioredoxin levels in patients with sepsis: positive association with macrophage migration inhibitory factor. Intensive Care Med 2010 36(2):336-41.
Rec#: 510
Exclusion Codes: NDE, EXC

Leclerc, F., R. Cremer, and O. Noizet. Procalcitonin as a diagnostic and prognostic biomarker of sepsis in critically ill children. Pediatr Crit Care Med 2003 4(2):264-6.
Rec#: 4810
Exclusion Codes: SMN, EXC

Leclerc, F., S. Leteurtre, O. Noizet, A. Dorkenoo, A. Sadik, R. Cremer, and C. Fourier. Procalcitonin as a prognostic marker in children with meningococcal septic shock. Arch Dis Child 2002 87(5):450.
Rec#: 5100
Exclusion Codes: SMN, EXC

Lee, B. E., and H. D. Davies. Aseptic meningitis. Curr Opin Infect Dis 2007 20(3):272-7.
Rec#: 8470
Exclusion Codes: NDE, EXC

Lee, C. C., S. Y. Chen, C. L. Tsai, S. C. Wu, W. C. Chiang, J. L. Wang, H. Y. Sun, S. C. Chen, W. J. Chen, and P. R. Hsueh. Prognostic value of mortality in emergency department sepsis score, procalcitonin, and C-reactive protein in patients with sepsis at the emergency department. Shock 2008 29(3):322-7.
Rec#: 2460
Exclusion Codes: NDE, EXC

Lemiale, V., B. Renaud, S. Moutereau, A. N'Gako, M. Salloum, M. J. Calmettes, J. Herve, C. Boraud, A. Santin, J. C. Grego, F. Braconnier, and E. Roupie. A single procalcitonin level does not predict adverse outcomes of women with pyelonephritis. Eur Urol 2007 51(5):1394-401.
Rec#: 8570
Exclusion Codes: SMN, EXC

Leroy, S., C. Romanello, A. Galetto-Lacour, V. Smolkin, B. Korczowski, C. Rodrigo, D. Tuerlinckx, V. Gajdos, F. Moulin, M. Contardo, A. Gervaix, R. Halevy, B. Duhl, C. Prat, T. V. Borght, L. Foix-l'Helias, F. Dubos, D. Gendrel, G. Breart, and M. Chalumeau. Procalcitonin to reduce the number of unnecessary cystographies in children with a urinary tract infection: a European validation study. J Pediatr 2007 150(1):89-95.
Rec#: 8590
Exclusion Codes: NDE, EXC

Lestin, F., H.-G. Lestin, C. Burstein, O. Anders, and M. Freund. Provisional experience with procalcitonin, C-reactive protein, neopterin, selected cytokines, and hemostatic parameters in patients with malignant hematological diseases and febrile neutropenia induced by cytostatic treatment: Vorlaufige Erfahrungen mit Procalcitonin, C-reaktivem Protein, Neopterin, ausgewahlten Zytokinen und Hamostaseparametern an Patienten mit malignen hamatologischen Erkrankungen, bei Zytostatika-induzierter Neutropenie und Fieber. Clin. Lab. 1998 44(6):451-461.
Rec#: 17120
Exclusion Codes: NRD, EXC

Li, M.-X., B.-Y. Liu, M.-L. Jin, and Y. Song. Diagnostic value of procalcitonin in inflammation and sepsis. Chin. J. Infect. Chemother. 2008 8(3):216-218.
Rec#: 12910
Exclusion Codes: NDE, EXC

Liao, X.-L., X.-D. Jin, Y. Kang, Y.-Y. Deng, Z.-W. Zhang, Y. Zhou, Z.-W. Zhang, C. Liu, and W.-H. Yin. Role of procalcitonin in the diagnosis of ventilator-associated pneumonia. Chin. Crit. Care Med. 2010 22(3):142-145.
Rec#: 11690
Exclusion Codes: NRD, EXC

Liaudat, S., E. Dayer, G. Praz, J. Bille, and N. Troillet. Usefulness of procalcitonin serum level for the diagnosis of bacteremia. Eur J Clin Microbiol Infect Dis 2001 20(8):524-7.
Rec#: 5630
Exclusion Codes: NDE, EXC

Linssen, C. F., O. Bekers, M. Drent, and J. A. Jacobs. C-reactive protein and procalcitonin concentrations in bronchoalveolar lavage fluid as a predictor of ventilator-associated pneumonia. Ann Clin Biochem 2008 45(Pt 3):293-8.
Rec#: 1660
Exclusion Codes: NDE, EXC

Lisboa, T., and J. Rello. De-escalation in lower respiratory tract infections. Curr Opin Pulm Med 2006 12(5):364-8.
Rec#: 8660
Exclusion Codes: NDE, EXC

Liu, L., Y.-Q. Zhen, C.-M. Jing, W. Xie, and C.-L. Li. Dynamic monitoring the levels of endotoxin, IL-6, IL-10, TNF-(alpha) and procalcitonin (PCT) in serum of pediatric patients with systemic inflammatory response syndrome. Chin. J. Antibiot. 2008 33(5):297-299.
Rec#: 12730
Exclusion Codes: NRD, EXC

Livaditi, O., A. Kotanidou, A. Psarra, I. Dimopoulou, C. Sotiropoulou, K. Augustatou, C. Papasteriades, A. Armaganidis, C. Roussos, S. E. Orfanos, and E. E. Douzinas. Neutrophil CD64 expression and serum IL-8: sensitive early markers of severity and outcome in sepsis. Cytokine 2006 36(5-6):283-90.
Rec#: 2860
Exclusion Codes: SMN, EXC

Llorente, E., B. Prieto, L. Cardo, N. Avello, and F. V. Alvarez. Umbilical cord blood serum procalcitonin by Time-Resolved Amplified Cryptate Emission (TRACE) technology: reference values of a potential marker of vertically transmitted neonatal sepsis. Clin Chem Lab Med 2007 45(11):1531-5.
Rec#: 2380
Exclusion Codes: NDE, EXC

Lode, H. MRSA infections: Competent and safe treatment is the standard, but that is no reason for giving the all clear signal: An interview: MRSA-infektionen: Kompetente und sichere therapie ist standard, doch das ist kein grund zur entwarnung! Klinikartz 2007 36(6):350-351.
Rec#: 16310
Exclusion Codes: NDE, EXC

Loebe, M., S. Lodziewski, N. Qedra, F. Brunkhorst, F. Wagner, and R. Hetzer. Procalcitonin, a marker of infection in cardiac surgery: Der infektionsmarker procalcitonin in der herzchirurgie. Z. Herz- Thorax- Gefasschir. 1999 13(5):215-220.
Rec#: 15000
Exclusion Codes: NDE, EXC

Lommatzsch, M., A. Niewerth, J. Klotz, O. Schulte-Herbruggen, C. Zingler, P. Schuff-Werner, and J. C. Virchow. Platelet and plasma BDNF in lower respiratory tract infections of the adult. Respir Med 2007 101(7):1493-9.
Rec#: 8540
Exclusion Codes: NRO, EXC

Lopez Sastre, J. B., D. Perez Solis, V. Roques Serradilla, B. Fernandez Colomer, G. D. Coto Cotallo, X. Krauel Vidal, E. Narbona Lopez, M. Garcia del Rio, M. Sanchez Luna, A. Belaustegui Cueto, M. Moro Serrano, A. Urbon Artero, E. Alvaro Iglesias, A. Cotero Lavin, E. Martinez Vilalta, and B. Jimenez Cobos. Procalcitonin is not sufficiently reliable to be the sole marker of neonatal sepsis of nosocomial origin. BMC Pediatr 2006 6:16.
Rec#: 3330

Exclusion Codes: NDE, EXC

Lopez Sastre, J. B., D. P. Solis, V. R. Serradilla, B. F. Colomer, and G. D. Cotallo. Evaluation of procalcitonin for diagnosis of neonatal sepsis of vertical transmission. BMC Pediatr 2007 7:9.
Rec#: 2910
Exclusion Codes: NDE, EXC

Lorrot, M., F. Moulin, J. Coste, S. Ravilly, S. Guerin, P. Lebon, C. Lacombe, J. Raymond, C. Bohuon, and D. Gendrel. Procalcitonin in pediatric emergency situations: Comparison with C- reactive protein, interleukin-6, and alpha-interferon for differentiating bacterial and viral infections: Procalcitonine aux urgences pediatriques: Comparaison avec la proteine c-reactive, l'interleukine-6 et l'interferon-alpha pour la differenciation des infections bacteriennes et virales. Presse Med. 2000 29(3):128-134.
Rec#: 17040
Exclusion Codes: NDE, EXC

Lorton, F., F. Veinberg, D. Ielsch, G. Deschenes, A. Bensman, and T. Ulinski. Procalcitonin serum levels in children undergoing chronic haemodialysis. Pediatr Nephrol 2007 22(3):430-5.
Rec#: 8620
Exclusion Codes: NRO, EXC

Lotric-Furlan, S., T. Rojko, and F. Strle. Concentration of procalcitonin and C-reactive protein in patients with human granulocytic anaplasmosis and the initial phase of tick-borne encephalitis. Ann N Y Acad Sci 2005 1063:439-41.
Rec#: 8930
Exclusion Codes: SMN, EXC

Lukaszewski, M., G. Durek, and M. Mierzchala. Severe sepsis or clinical view of autoaggressive disease. Wegener's granulomatosis - Case report: Ciezka sepsa czy obraz kliniczny choroby z autoagresji. Ziarniniak wegenera - Opis przypadku. Pol. Merkuriusz Lek. 2006 21(124):351-353.
Rec#: 13640
Exclusion Codes: NDE, EXC

Luyt, C. E., A. Combes, C. Reynaud, G. Hekimian, A. Nieszkowska, M. Tonnellier, A. Aubry, J. L. Trouillet, M. Bernard, and J. Chastre. Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med 2008 34(8):1434-40.
Rec#: 1890
Exclusion Codes: NDE, EXC

Luyt, C. E., V. Guerin, A. Combes, J. L. Trouillet, S. B. Ayed, M. Bernard, C. Gibert, and J. Chastre. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005 171(1):48-53.
Rec#: 4120
Exclusion Codes: SMN, EXC

Luzzani, A., E. Polati, R. Dorizzi, A. Rungatscher, R. Pavan, and A. Merlini. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 2003 31(6):1737-41.
Rec#: 4780
Exclusion Codes: SMN, EXC

Macrina, F., L. Tritapepe, F. Pompei, A. Sciangula, E. Evangelista, F. Toscano, A. Criniti, G. Brancaccio, and P. E. Puddu. Procalcitonin is useful whereas C-reactive protein is not, to predict complications following coronary artery bypass surgery. Perfusion 2005 20(3):169-75.
Rec#: 3730
Exclusion Codes: SMN, EXC

Madhi, S. A., M. Kohler, L. Kuwanda, C. Cutland, and K. P. Klugman. Usefulness of C-reactive protein to define pneumococcal conjugate vaccine efficacy in the prevention of pneumonia. Pediatr Infect Dis J 2006 25(1):30-6.

Rec#: 8970
Exclusion Codes: NDE, EXC

Magadle, R., I. Mohammedi, O. Martin, L. Argaud, and D. Robert. Fever in a medical intensive care unit. Clin. Intensive Care 2003 14(1-2):31-35.
Rec#: 14490
Exclusion Codes: NRO, EXC

Maire, F., M.C. Heraud, Y. Loriette, B. Normand, R.J. Begue, and A. Labbe. Value of procalcitonin measurement in neonatal infections: Interet de la procalcitonine dans les infections neonatales. Arch. Pediatr. 1999 6(5):503-509.
Rec#: 15100
Exclusion Codes: NRD, EXC

Makhoul, I. R., A. Yacoub, T. Smolkin, P. Sujov, I. Kassis, and H. Sprecher. Values of C-reactive protein, procalcitonin, and Staphylococcus-specific PCR in neonatal late-onset sepsis. Acta Paediatr 2006 95(10):1218-23.
Rec#: 3130
Exclusion Codes: NDE, EXC

Malaska, J., M. Kratochvil, M. Kyr, P. Jabandziev, F. Otevrel, K. Muriova, M. Fedora, V. Sramek, J. Michalek, and P. Sevcik. Cytokine response in severe sepsis - Predicting and modelling the course of illness. Int. J. Infect. Dis. 2010 14:e367.
Rec#: 11720
Exclusion Codes: NRO, EXC

Malickova, K., H. Brodska, J. Lachmanova, S. Dusilova Sulkova, I. Janatkova, H. Mareckova, V. Tesar, and T. Zima. Plasma calprotectin in chronically dialyzed end-stage renal disease patients. Inflamm Res 2010 59(4):299-305.
Rec#: 7130
Exclusion Codes: SMN, EXC

Mandi, Y., G. Farkas, T. Takacs, K. Boda, and J. Lonovics. Diagnostic relevance of procalcitonin, IL-6, and sICAM-1 in the prediction of infected necrosis in acute pancreatitis. Int J Pancreatol 2000 28(1):41-9.
Rec#: 5890
Exclusion Codes: SMN, EXC

Manegold, C., S. Schmiedel, C.B. Chiwakata, and M. Dietrich. Procalcitonin serum levels in tertian malaria. Malaria J. 2003 2:1-3.
Rec#: 16790
Exclusion Codes: NDE, EXC

Manegold, C., S. Schmiedel, C. B. Chiwakata, and M. Dietrich. Procalcitonin serum levels in tertian malaria. Malar J 2003 2:34.
Rec#: 9790
Exclusion Codes: NRO, EXC

Manekeller, S., H. Lauschke, A. Hirner, C. Putensen, A. Hoeft, F. Stuber, and S. Schroeder. Severe falciparum malaria infection associated with sepsis and peritonitis - Case report of an intensive care patient: Schwere sepsis bei peritonitis im rahmen einer malaria-tropica-infektion: Ein fallbericht aus der operativen intensivmedizin. Anasthesiol. Intensivmed. 2002 43(12):765-769.
Rec#: 14530
Exclusion Codes: NRD, EXC

Maniaci, V., A. Dauber, S. Weiss, E. Nylen, K. L. Becker, and R. Bachur. Procalcitonin in young febrile infants for the detection of serious bacterial infections. Pediatrics 2008 122(4):701-10.
Rec#: 7780
Exclusion Codes: NDE, EXC

Mantadakis, E., E. Plessa, E. K. Vouloumanou, D. E. Karageorgopoulos, A. Chatzimichael, and M. E. Falagas. Serum procalcitonin for prediction of renal parenchymal involvement in children with urinary tract infections: a meta-analysis of prospective clinical studies. J Pediatr 2009 155(6):875-881.e1.
Rec#: 7140
Exclusion Codes: NDE, EXC

Marik, P.E. Monitoring therapeutic interventions in critically III septic patients. Nutr. Clin. Prac. 2004 19(5):423-432.
Rec#: 14190
Exclusion Codes: NDE, EXC

Mariscalco, M. M. Is plasma procalcitonin ready for prime time in the pediatric intensive care unit? Pediatr Crit Care Med 2003 4(1):118-9.
Rec#: 4880
Exclusion Codes: NDE, EXC

Marshall, J. C. Measurements in the intensive care unit: what do they mean? Crit Care 2003 7(6):415-6.
Rec#: 4570
Exclusion Codes: SMN, EXC

Martin-Denavit, T., G. Monneret, J. M. Labaune, C. Isaac, F. Bienvenu, G. Putet, and J. Bienvenu. Usefulness of procalcitonin in neonates at risk for infection. Clin Chem 1999 45(3):440-1.
Rec#: 10700
Exclusion Codes: NRO, EXC

Martinez, F. J., and J. L. Curtis. Procalcitonin-guided antibiotic therapy in COPD exacerbations: closer but not quite there. Chest 2007 131(1):1-2.
Rec#: 3000
Exclusion Codes: NDE, EXC

Martinez, R., C. Gaul, M. Buchfelder, F. Erbguth, and K. Tschaikowsky. Serum procalcitonin monitoring for differential diagnosis of ventriculitis in adult intensive care patients. Intensive Care Med 2002 28(2):208-10.
Rec#: 5450
Exclusion Codes: SMN, EXC

Martinez-Albarran, M., J. Perez-Molina Jde, S. Gallegos-Castorena, F. Sanchez-Zubieta, S. Del Toro-Arreola, R. Troyo-Sanroman, and O. Gonzalez-Ramella. Procalcitonin and C-reactive protein serum levels as markers of infection in a pediatric population with febrile neutropenia and cancer. Pediatr Hematol Oncol 2009 26(6):414-25.
Rec#: 670
Exclusion Codes: NDE, EXC

Martini, A., L. Gottin, N. Menestrina, V. Schweiger, D. Simion, and J.-L. Vincent. Procalcitonin levels in surgical patients at risk of candidemia. J. Infect. 2010 60(6):425-430.
Rec#: 11350
Exclusion Codes: SMN, EXC

Martinot, M., C. Sordet, M. Soubrier, X. Puechal, A. Saraux, F. Liote, P. Guggenbuhl, V. Legre, B. Jaulhac, J. F. Maillefert, M. Zeisel, G. Coumaros, and J. Sibilia. Diagnostic value of serum and synovial procalcitonin in acute arthritis: a prospective study of 42 patients. Clin Exp Rheumatol 2005 23(3):303-10.
Rec#: 3790
Exclusion Codes: SMN, EXC

Maruna, P., R. Frasko, and R. Gurlich. Plasma procalcitonin in patients with ileus. Relations to other inflammatory parameters. Physiol Res 2008 57(3):481-6.
Rec#: 2690

Exclusion Codes: SMN, EXC

Masia, M., F. Gutierrez, S. Padilla, B. Soldan, C. Mirete, C. Shum, I. Hernandez, G. Royo, and A. Martin-Hidalgo. Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. Clin Microbiol Infect 2007 13(2):153-61.
Rec#: 8530
Exclusion Codes: NDE, EXC

Masia, M., F. Gutierrez, C. Shum, S. Padilla, J. C. Navarro, E. Flores, and I. Hernandez. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 2005 128(4):2223-9.
Rec#: 9010
Exclusion Codes: NDE, EXC

Masia, M., J. Papassotiriou, N. G. Morgenthaler, I. Hernandez, C. Shum, and F. Gutierrez. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia. Clin Chem 2007 53(12):2193-201.
Rec#: 2320
Exclusion Codes: NDE, EXC

Massaro, K. S., S. F. Costa, C. Leone, and D. A. Chamone. Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis 2007 7:137.
Rec#: 2270
Exclusion Codes: SMN, EXC

Matesanz, J. L., E. Fernandez, J. M. Fernandez, and G. Viejo. Plasma procalcitonin and C-reactive protein concentrations in pediatric patients with Epstein-Barr virus infection. Clin Chem 2003 49(12):2103-4.
Rec#: 9750
Exclusion Codes: NDE, EXC

Matull, W. R., S. P. Pereira, and J. W. O'Donohue. Biochemical markers of acute pancreatitis. J Clin Pathol 2006 59(4):340-4.
Rec#: 8860
Exclusion Codes: NDE, EXC

Mayaud, C., M. Fartoukh, H. Prigent, A. Parrot, and J. Cadranel. Critical evaluation and predictive value of clinical presentation in out-patients with acute community-acquired pneumonia: 07 - Analyse critique et valeurs predictives des signes de pneumonies aigues communautaires en medecine ambulatoire. Med. Mal. Infect. 2006 36(11-12):625-635.
Rec#: 16400
Exclusion Codes: NDE, EXC

McLean, A. Procalcitonin: seeking a niche. Crit Care 2009 13(3):149.
Rec#: 810
Exclusion Codes: NDE, EXC

McMaster, P., D. Y. Park, F. Shann, A. Cochrane, K. Morris, J. Gray, S. Cottrell, and J. Belcher. Procalcitonin versus C-reactive protein and immature-to-total neutrophil ratio as markers of infection after cardiopulmonary bypass in children. Pediatr Crit Care Med 2009 10(2):217-21.
Rec#: 1190
Exclusion Codes: NDE, EXC

Meisner, M. Procalcitonin: Experience with a new diagnostic tool for bacterial infection and systemic inflammation: Procalcitonin: Erfahrungen mit einer neuen Messgrosse fur bakterielle Infektionen und systemische Inflammation. LaboratoriumsMedizin 1999 23(5):263-272.
Rec#: 15070

Exclusion Codes: NDE, EXC

Meisner, M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 2002 323(1-2):17-29.
Rec#: 5230
Exclusion Codes: NDE, EXC

Meisner, M. Biomarkers of sepsis: clinically useful? Curr Opin Crit Care 2005 11(5):473-80.
Rec#: 3660
Exclusion Codes: NDE, EXC

Meisner, M. Evidence-based diagnosis and treatment monitoring of septic patients: Evidenzbasierte diagnostik und therapiekontrolle septischer patienten. J. Anasth. Intensivbehandl. 2005 12(2):213-214.
Rec#: 13970
Exclusion Codes: NDE, EXC

Meisner, M. Diagnosis and treatment of shock types. Recommendations of the interdisciplinary working group shock of the DIVI - Part V: Septic shock [3]: Zur diagnostik und therapie der schockformen. Empfehlungen der interdisziplinaren arbeitsgruppe schock der DIVI - Teil V: Septischer schock. Anasthesiol. Intensivmed. 2006 47(3):173-175.
Rec#: 13910
Exclusion Codes: NRD, EXC

Meisner, M., H. Adina, and J. Schmidt. Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. Crit Care 2006 10(1):R1.
Rec#: 3540
Exclusion Codes: SMN, EXC

Meisner, M., E. Huttemann, T. Lohs, L. Kasakov, and K. Reinhart. Elimination of procalcitonin and plasma concentrations during continuous veno-venous haemodiafiltration in septic patients. Eur J Anaesthesiol 2000 17(11):665-71.
Rec#: 5990
Exclusion Codes: NRO, EXC

Meisner, M., T. Lohs, E. Huettemann, J. Schmidt, M. Hueller, and K. Reinhart. The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol 2001 18(2):79-87.
Rec#: 5850
Exclusion Codes: NRO, EXC

Meisner, M., C. Rauschmayer, J. Schmidt, R. Feyrer, R. Cesnjevar, D. Bredle, and K. Tschaikowsky. Early increase of procalcitonin after cardiovascular surgery in patients with postoperative complications. Intensive Care Med 2002 28(8):1094-102.
Rec#: 5210
Exclusion Codes: NDE, EXC

Meisner, M., and K. Reinhart. Is procalcitonin really a marker of sepsis? Int. J. Intensive Care 2001 8(1):15-25.
Rec#: 14770
Exclusion Codes: NDE, EXC

Meisner, M., K. Tschaikowsky, A. Hutzler, C. Schick, and J. Schuttler. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med 1998 24(7):680-4.
Rec#: 6690
Exclusion Codes: NDE, EXC

Meisner, M., K. Tschaikowsky, T. Palmaers, and J. Schmidt. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit. Care 1999 3(1):45-50.
Rec#: 15050
Exclusion Codes: SMN, EXC

Mejjad, O., O. Vittecoq, F. Tamion, C. Girault, S. Lecot, N. Cailleux, and X. Le Loet. A shock associated with adult-onset Still's disease. Joint Bone Spine 2001 68(1):76-8.
Rec#: 5870
Exclusion Codes: NDE, EXC

Mendes, A. V., R. Sapolnik, and N. Mendonca. New guidelines for the clinical management of febrile neutropenia and sepsis in pediatric oncology patients. J Pediatr (Rio J) 2007 83(2 Suppl):S54-63.
Rec#: 2720
Exclusion Codes: NDE, EXC

Mendonca Coelho, M.C., U. Tannuri, A.C. Aoun Tannuri, C. Reingenheim, and E.J. Troster. Is procalcitonin useful to differentiate rejection from bacterial infection in the early post-operative period of liver transplantation in children? Pediatr. Transplant. 2009 13(8):1004-1006.
Rec#: 11980
Exclusion Codes: NDE, EXC

Menendez, R., M. Cavalcanti, S. Reyes, J. Mensa, R. Martinez, M. A. Marcos, X. Filella, M. Niederman, and A. Torres. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008 63(5):447-52.
Rec#: 8090
Exclusion Codes: NDE, EXC

Menendez, R., R. Martinez, S. Reyes, J. Mensa, X. Filella, M. A. Marcos, A. Martinez, C. Esquinas, P. Ramirez, and A. Torres. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009 64(7):587-91.
Rec#: 7600
Exclusion Codes: NDE, EXC

Menendez, R., R. Martinez, S. Reyes, J. Mensa, E. Polverino, X. Filella, C. Esquinas, A. Martinez, P. Ramirez, and A. Torres. Stability in community-acquired pneumonia: one step forward with markers? Thorax 2009 64(11):987-92.
Rec#: 470
Exclusion Codes: NDE, EXC

Meng, F. S., L. Su, Y. Q. Tang, Q. Wen, Y. S. Liu, and Z. F. Liu. Serum procalcitonin at the time of admission to the ICU as a predictor of short-term mortality. Clin Biochem 2009 42(10-11):1025-31.
Rec#: 980
Exclusion Codes: SMN, EXC

Messer, J., and P. Kuhn. Biological markers of maternofetal infection: Marqueurs biologiques de l'infection materno-foetale. Med. Ther. Pediatr. 1999 2(1):41-45.
Rec#: 17090
Exclusion Codes: NRD, EXC

Micek, M., P. Feindt, T. Petzold, U. Boeken, N. Zimmermann, and E. Gams. A clinically reliable and fast differentiation between infection and rejection in heart transplantation: Results of procalcitonin (PCT) measurement. Z. Kardiovask. Med. 2000 4(4):143-148.
Rec#: 14790
Exclusion Codes: NDE, EXC

Michalik, D. E., B. W. Duncan, R. B. Mee, S. Worley, J. Goldfarb, L. A. Danziger-Isakov, S. J. Davis, A. M. Harrison, E. Appachi, and C. Sabella. Quantitative analysis of procalcitonin after pediatric cardiothoracic surgery. Cardiol Young 2006 16(1):48-53.
Rec#: 3460
Exclusion Codes: NRO, EXC

Michelow, I. C., K. Katz, G. H. McCracken, and R. D. Hardy. Systemic cytokine profile in children with community-acquired pneumonia. Pediatr Pulmonol 2007 42(7):640-5.
Rec#: 8440
Exclusion Codes: NRO, EXC

Mierzchala, M., M. Lipinska-Gediga, and G. Durek. The role of LBP in transduction of signal induced by LPS and in modulation of immune system response: Rola LBP w transdukcji sygnalu indukowanego LPS i w modulacji odpowiedzi ukladu immunologicznego. Adv. Clin. Exp. Med. 2006 15(1):127-134.
Rec#: 13880
Exclusion Codes: NRD, EXC

Mikic, D., S. Vasilijic, V. Maravic, and M. Colic. Relationship between plasma levels of procalcitonin, tumor necrosis factor-(alpha) and C-reactive protein and clinical characteristic of septic patients. Clin. Appl. Immunol. 2006 5(1):556-562.
Rec#: 13700
Exclusion Codes: SMN, EXC

Mills, G. D., H. M. Lala, M. R. Oehley, A. B. Craig, K. Barratt, D. Hood, C. N. Thornley, A. Nesdale, N. E. Manikkam, and P. Reeve. Elevated procalcitonin as a diagnostic marker in meningococcal disease. Eur J Clin Microbiol Infect Dis 2006 25(8):501-9.
Rec#: 3200
Exclusion Codes: NDE, EXC

Mimoz, O., J. F. Benoist, A. R. Edouard, M. Assicot, C. Bohuon, and K. Samii. Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome. Intensive Care Med 1998 24(2):185-8.
Rec#: 6780
Exclusion Codes: NDE, EXC

Mira, J. P., A. Max, and P. R. Burgel. The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy. Crit Care 2008 12 Suppl 6:S5.
Rec#: 1120
Exclusion Codes: NDE, EXC

Mitaka, C. Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome. Clin Chim Acta 2005 351(1-2):17-29.
Rec#: 4050
Exclusion Codes: NDE, EXC

Mittelkotter, U. Procalcitonin in the early treatment to prevent postoperative septic complications: Procalcitonin-gesteuerte fruhtherapie zur pravention postoperativer septischer komplikationen. J. Anasth. Intensivbehandl. 2003 10(1):186-187.
Rec#: 14350
Exclusion Codes: NDE, EXC

Modrau, I. S., A. K. Floyd, and O. Thorlacius-Ussing. The clinical value of procalcitonin in early assessment of acute pancreatitis. Am J Gastroenterol 2005 100(7):1593-7.
Rec#: 9200
Exclusion Codes: SMN, EXC

Mofidi, R., S. A. Suttie, P. V. Patil, S. Ogston, and R. W. Parks. The value of procalcitonin at predicting the severity of acute pancreatitis and development of infected pancreatic necrosis: systematic review. Surgery 2009 146(1):72-81.
Rec#: 7350
Exclusion Codes: NDE, EXC

Mokart, D., and M. Leone. Procalcitonin in intensive care units: the PRORATA trial. Lancet 2010 375(9726):1605; author reply 1606-7.
Rec#: 50
Exclusion Codes: NPD, EXC

Mokart, D., M. Merlin, A. Sannini, J. P. Brun, J. R. Delpero, G. Houvenaeghel, V. Moutardier, and J. L. Blache. Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major surgery. Br J Anaesth 2005 94(6):767-73.
Rec#: 3830
Exclusion Codes: SMN, EXC

Molnar, Z., T. Szakmany, and P. Heigl. Microalbuminuria does not reflect increased systemic capillary permeability in septic shock. Intensive Care Med 2003 29(3):391-5.
Rec#: 5000
Exclusion Codes: NRO, EXC

Mongardon, N., V. Lemiale, S. Perbet, F. Dumas, S. Legriel, S. Guerin, J. Charpentier, J. D. Chiche, J. P. Mira, and A. Cariou. Value of procalcitonin for diagnosis of early onset pneumonia in hypothermia-treated cardiac arrest patients. Intensive Care Med 2010 36(1):92-9.
Rec#: 390
Exclusion Codes: NDE, EXC

Monneret, G. Dear PCT, you are not a specific marker of bacterial infection. Intensive Care Med 2002 28(3):377-8.
Rec#: 10180
Exclusion Codes: NRD, EXC

Monneret, G., C. Doche, D. V. Durand, A. Lepape, and J. Bienvenu. Procalcitonin as a specific marker of bacterial infection in adults. Clin Chem Lab Med 1998 36(1):67-8.
Rec#: 10830
Exclusion Codes: NRD, EXC

Monneret, G., J. M. Labaune, C. Isaac, F. Bienvenu, G. Putet, and J. Bienvenu. Procalcitonin and C-reactive protein levels in neonatal infections. Acta Paediatr 1997 86(2):209-12.
Rec#: 6880
Exclusion Codes: NRO, EXC

Monneret, G., J. M. Labaune, C. Isaac, F. Bienvenu, G. Putet, and J. Bienvenu. Increased serum procalcitonin levels are not specific to sepsis in neonates. Clin Infect Dis 1998 27(6):1559-61.
Rec#: 6620
Exclusion Codes: NDE, EXC

Montagnana, M., A. M. Minicozzi, G. L. Salvagno, E. Danese, C. Cordiano, G. De Manzoni, G. C. Guidi, and G. Lippi. Postoperative variation of C-reactive protein and procalcitonin in patients with gastrointestinal cancer. Clin Lab 2009 55(5-6):187-92.
Rec#: 550
Exclusion Codes: NRO, EXC

Moosig, F., E. Csernok, E. Reinhold-Keller, W. Schmitt, and W. L. Gross. Elevated procalcitonin levels in active Wegener's granulomatosis. J Rheumatol 1998 25(8):1531-3.
Rec#: 10760

Exclusion Codes: NRO, EXC

Morath, C., J. Sis, G. M. Haensch, M. Zeier, K. Andrassy, and V. Schwenger. Procalcitonin as marker of infection in patients with Goodpasture's syndrome is misleading. Nephrol Dial Transplant 2007 22(9):2701-4.
Rec#: 8420
Exclusion Codes: NRO, EXC

Moreira, V. G., B. Prieto, J. S. Rodriguez, and F. V. Alvarez. Usefulness of cell-free plasma DNA, procalcitonin and C-reactive protein as markers of infection in febrile patients. Ann Clin Biochem 2010 47(Pt 3):253-8.
Rec#: 90
Exclusion Codes: NDE, EXC

Morgenthaler, N. G., J. Struck, C. Fischer-Schulz, and A. Bergmann. Sensitive immunoluminometric assay for the detection of procalcitonin. Clin Chem 2002 48(5):788-90.
Rec#: 10170
Exclusion Codes: NRD, EXC

Morgenthaler, N. G., J. Struck, C. Fischer-Schulz, E. Seidel-Mueller, W. Beier, and A. Bergmann. Detection of procalcitonin (PCT) in healthy controls and patients with local infection by a sensitive ILMA. Clin Lab 2002 48(5-6):263-70.
Rec#: 5290
Exclusion Codes: NDE, EXC

Moulin, F., J. Raymond, M. Lorrot, E. Marc, J. Coste, J. L. Iniguez, G. Kalifa, C. Bohuon, and D. Gendrel. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child 2001 84(4):332-6.
Rec#: 10390
Exclusion Codes: SMN, EXC

Mueller, C., M. Christ-Crain, and B. Muller. What cardiologists do need to know about procalcitonin. Clin Lab 2005 51(1-2):1-4.
Rec#: 9340
Exclusion Codes: NDE, EXC

Mueller, C., P. Huber, G. Laifer, B. Mueller, and A. P. Perruchoud. Procalcitonin and the early diagnosis of infective endocarditis. Circulation 2004 109(14):1707-10.
Rec#: 9660
Exclusion Codes: SMN, EXC

Muller, B. Endocrine aspects of critical illness. Ann Endocrinol (Paris) 2007 68(4):290-8.
Rec#: 2560
Exclusion Codes: NRD, EXC

Muller, B., K. L. Becker, H. Schachinger, P. R. Rickenbacher, P. R. Huber, W. Zimmerli, and R. Ritz. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000 28(4):977-83.
Rec#: 6170
Exclusion Codes: NDE, EXC

Muller, B., M. Christ-Crain, E. S. Nylen, R. Snider, and K. L. Becker. Limits to the use of the procalcitonin level as a diagnostic marker. Clin Infect Dis 2004 39(12):1867-8.
Rec#: 9420
Exclusion Codes: NDE, EXC

Muller, B., M. Christ-Crain, and P. Schuetz. Meta-analysis of procalcitonin for sepsis detection. Lancet Infect Dis 2007 7(8):498-9; author reply 502-3.
Rec#: 2600

Exclusion Codes: NRD, EXC

Muller, B., S. Harbarth, D. Stolz, R. Bingisser, C. Mueller, J. Leuppi, C. Nusbaumer, M. Tamm, and M. Christ-Crain. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007 7:10.
Rec#: 8520
Exclusion Codes: NDE, EXC

Muller, B., and C. Prat. Markers of acute inflammation in assessing and managing lower respiratory tract infections: Focus on procalcitonin. Clin. Microbiol. Infect. 2006 12(SUPPL. 9):8-16.
Rec#: 13590
Exclusion Codes: NDE, EXC

Muller, B., P. Schuetz, and A. Trampuz. Circulating biomarkers as surrogates for bloodstream infections. Int J Antimicrob Agents 2007 30 Suppl 1:S16-23.
Rec#: 2390
Exclusion Codes: NRD, EXC

Muller, B., E. Suess, P. Schuetz, C. Muller, R. Bingisser, A. Bergmann, D. Stolz, M. Tamm, N. G. Morgenthaler, and M. Christ-Crain. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J Intern Med 2006 260(6):568-76.
Rec#: 3070
Exclusion Codes: NDE, EXC

Muller, C. A., W. Uhl, G. Printzen, B. Gloor, H. Bischofberger, O. Tcholakov, and M. W. Buchler. Role of procalcitonin and granulocyte colony stimulating factor in the early prediction of infected necrosis in severe acute pancreatitis. Gut 2000 46(2):233-8.
Rec#: 10630
Exclusion Codes: SMN, EXC

Muller, F., M. Christ-Crain, T. Bregenzer, M. Krause, W. Zimmerli, B. Mueller, and P. Schuetz. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: A prospective cohort trial. Chest 2010 138(1):121-129.
Rec#: 11310
Exclusion Codes: NDE, EXC

Muller-Werdan, U., K. Werdan, and H.-P. Schuster. Monitoring of critically ill patients with sepsis, multiple organ dysfunction syndrome and cardiovascular disease: Monitoring von kritisch kranken mit sepsis, multiorgandysfunktionssyndrom und herz-kreislauf-erkrankungen. Intensiv- Notfallbehandl. 1999 24(1):10-24.
Rec#: 15090
Exclusion Codes: NDE, EXC

Munoz, P., N. Simarro, M. Rivera, R. Alonso, L. Alcala, and E. Bouza. Evaluation of procalcitonin as a marker of infection in a nonselected sample of febrile hospitalized patients. Diagn Microbiol Infect Dis 2004 49(4):237-41.
Rec#: 4160
Exclusion Codes: NDE, EXC

Mussap, M., R. Degrandi, L. Cataldi, V. Fanos, and M. Plebani. Biochemical markers for the early assessment of neonatal sepsis: the role of procalcitonin. J Chemother 2007 19 Suppl 2:35-8.
Rec#: 1920
Exclusion Codes: NRD, EXC

Muthiah, K. A., K. S. Rachakonda, M. J. Davis, E. G. Simmons, G. Schier, and F. S. Gil. Prospective evaluation of procalcitonin in sepsis in the Illawarra area of Australia: PEPSIA study. Crit Care Resusc 2007 9(2):137-42.
Rec#: 2700
Exclusion Codes: NDE, EXC

Naderi, M., M. Hashemi, H. Kouhpayeh, and R. Ahmadi. The status of serum procalcitonin in pulmonary tuberculosis and nontuberculosis pulmonary disease. J Pak Med Assoc 2009 59(9):647-8.
Rec#: 7190
Exclusion Codes: NDE, EXC

Naeini, A. E., and S. Montazerolghaem. Procalcitonin marker for sepsis diagnosis. Evaluating a rapid immuno-chromatografic test. Saudi Med J 2006 27(3):422-4.
Rec#: 3420
Exclusion Codes: NRD, EXC

Nakamura, A., H. Wada, M. Ikejiri, T. Hatada, H. Sakurai, Y. Matsushima, J. Nishioka, K. Maruyama, S. Isaji, T. Takeda, and T. Nobori. Efficacy of procalcitonin in the early diagnosis of bacterial infections in a critical care unit. Shock 2009 31(6):586-91.
Rec#: 1180
Exclusion Codes: NDE, EXC

Nathan, B. R., and W. M. Scheld. The potential roles of C-reactive protein and procalcitonin concentrations in the serum and cerebrospinal fluid in the diagnosis of bacterial meningitis. Curr Clin Top Infect Dis 2002 22:155-65.
Rec#: 10040
Exclusion Codes: NDE, EXC

Neely, A. N., L. A. Fowler, R. J. Kagan, and G. D. Warden. Procalcitonin in pediatric burn patients: an early indicator of sepsis? J Burn Care Rehabil 2004 25(1):76-80.
Rec#: 4490
Exclusion Codes: SMN, EXC

Nicolau-Raducu, R.E., L. Eleborg, M. Kristiansson, and L.-O. Hansson. Systemic concentrations of procalcitonin, amyloid-A, C-reactive protein and cytokines during and after liver transplantation. Rom. J. Gastroenterol. 2001 10(4):305-310.
Rec#: 14700
Exclusion Codes: NDE, EXC

Niederman, M. S. Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin. Clin Infect Dis 2008 47 Suppl 3:S127-32.
Rec#: 7680
Exclusion Codes: NDE, EXC

Nikfar, R., G. Khotaee, N. Ataee, and S. Shams. Usefulness of procalcitonin rapid test for the diagnosis of acute pyelonephritis in children in the emergency department. Pediatr. Int. 2010 52(2):196-198.
Rec#: 15460
Exclusion Codes: NDE, EXC

Nonnenmacher, L. Informations about reagents: Brain natriuretic peptide (BNP), procalcitonin (PCT) and protein S-100 (beta): Informations reactifs: Brain Natriuretic Peptide (BNP), procalcitonine (PCT) et proteine S-100 (beta). Immuno-Anal. Biol. Spec. 2003 18(6):365-368.
Rec#: 16770
Exclusion Codes: NDE, EXC

Novotny, A., K. Emmanuel, E. Matevossian, M. Kriner, K. Ulm, H. Bartels, B. Holzmann, H. Weighardt, and J. R. Siewert. Use of procalcitonin for early prediction of lethal outcome of postoperative sepsis. Am J Surg 2007 194(1):35-9.
Rec#: 2670
Exclusion Codes: NDE, EXC

Novotny, A. R., K. Emmanuel, N. Hueser, C. Knebel, M. Kriner, K. Ulm, H. Bartels, J. R. Siewert, and B. Holzmann. Procalcitonin ratio indicates successful surgical treatment of abdominal sepsis. Surgery 2009 145(1):20-6.
Rec#: 1150
Exclusion Codes: NDE, EXC

Novotny, A. R., P. Luppa, R. Rosenberg, H. Schneider, M. Maak, H. Bartels, B. Holzmann, and H. Friess. Procalcitonin can be used for monitoring sepsis in patients with medullary thyroid carcinoma. Thyroid 2009 19(11):1287-9.
Rec#: 440
Exclusion Codes: NDE, EXC

Nseir, S., B. Cavestri, C. Di Pompeo, M. Diarra, H. Brisson, M. Lemyze, M. Roussel-Delvallez, and A. Durocher. Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease. Respiration 2008 76(3):253-60.
Rec#: 1560
Exclusion Codes: SMN, EXC

Nunez, A.A. To convert the low risk in zero risk in patients with febrile neutropenia: Neutropenia febril: Convertir el bajo riesgo en cero riesgo. Rev. Cuba. Hematol. Imunol. Hemoterapia 2009 25(2):29-33.
Rec#: 12300
Exclusion Codes: NRD, EXC

Nyamande, K., and U. G. Lalloo. Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lung Dis 2006 10(5):510-5.
Rec#: 3340
Exclusion Codes: NDE, EXC

Nylen, E., B. Muller, K. L. Becker, and R. Snider. The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin Infect Dis 2003 36(6):823-4; author reply 826-7.
Rec#: 4950
Exclusion Codes: NDE, EXC

Nylen, E. S., R. H. Jr Snider, K. A. Thompson, P. Rohatgi, and K. L. Becker. Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci 1996 312(1):12-8.
Rec#: 6900
Exclusion Codes: NRO, EXC

Oberhoffer, M., W. Karzai, A. Meier-Hellmann, D. Bogel, J. Fassbinder, and K. Reinhart. Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-alpha and interleukin-6 in patients with sepsis. Crit Care Med 1999 27(9):1814-8.
Rec#: 6400
Exclusion Codes: NDE, EXC

Oberhoffer, M., W. Karzai, A. Meier-Hellmann, and K. Reinhart. Procalcitonin. A new diagnostic parameter for severe infection and sepsis: Procalcitonin. Ein neur diagnostischer parameter bei schweren infektionen und sepsis. Anaesthesist 1998 47(7):581-587.
Rec#: 15160
Exclusion Codes: NRD, EXC

Oberhoffer, M., S. Russwurm, D. Bredle, K. Chatzinicolaou, and K. Reinhart. Discriminative power of inflammatory markers for prediction of tumor necrosis factor-alpha and interleukin-6 in ICU patients with systemic inflammatory response syndrome (SIRS) or sepsis at arbitrary time points. Intensive Care Med 2000 26 Suppl 2:S170-4.
Rec#: 1730
Exclusion Codes: NDE, EXC

Oberhoffer, M., H. Vogelsang, S. Russwurm, T. Hartung, and K. Reinhart. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med 1999 37(3):363-8.
Rec#: 6480
Exclusion Codes: NDE, EXC

Oberholzer, A., S. M. Souza, S. K. Tschoeke, C. Oberholzer, A. Abouhamze, J. P. Pribble, and L. L. Moldawer. Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis. Shock 2005 23(6):488-93.
Rec#: 3810
Exclusion Codes: NRO, EXC

Obladen, M. Infection parameters: What helps me further? Interleukins, TNF-alpha, CRP, PCT in the evaluation of neonates: Infektionsparameter: Was hilft mir weiter? Interleukine, TNF-(alpha), CRP, PCT in evaluation bei neonaten. J. Anasth. Intensivbehandl. 2002 9(2):114-115.
Rec#: 16870
Exclusion Codes: NDE, EXC

Oconnor, E., B. Venkatesh, C. Mashongonyika, J. Lipman, J. Hall, and P. Thomas. Serum procalcitonin and C-reactive protein as markers of sepsis and outcome in patients with neurotrauma and subarachnoid haemorrhage. Anaesth Intensive Care 2004 32(4):465-70.
Rec#: 3980
Exclusion Codes: SMN, EXC

Oczenski, W., R. D. Fitzgerald, and S. Schwarz. Procalcitonin: a new parameter for the diagnosis of bacterial infection in the peri-operative period. Eur J Anaesthesiol 1998 15(2):202-9.
Rec#: 6770
Exclusion Codes: NDE, EXC

Oezcueruemez-Porsch, M., D. Kunz, P. D. Hardt, T. Fadgyas, O. Kress, H. U. Schulz, H. Schnell-Kretschmer, H. Temme, S. Westphal, C. Luley, and H. U. Kloer. Diagnostic relevance of interleukin pattern, acute-phase proteins, and procalcitonin in early phase of post-ERCP pancreatitis. Dig Dis Sci 1998 43(8):1763-9.
Rec#: 10740
Exclusion Codes: SMN, EXC

Oh, J. S., S. U. Kim, Y. M. Oh, S. M. Choe, G. H. Choe, S. P. Choe, Y. M. Kim, T. Y. Hong, and K. N. Park. The usefulness of the semiquantitative procalcitonin test kit as a guideline for starting antibiotic administration. Am J Emerg Med 2009 27(7):859-63.
Rec#: 620
Exclusion Codes: SMN, EXC

Okada, Y., H. Minakami, T. Tomomasa, M. Kato, Y. Inoue, K. Kozawa, H. Kimura, and A. Morikawa. Serum procalcitonin concentration in patients with Kawasaki disease. J Infect 2004 48(2):199-205.
Rec#: 9720
Exclusion Codes: SMN, EXC

Okimoto, N., Y. Hayashi, M. Ishiga, F. Nanba, M. Kishimoto, S. Yagi, T. Kurihara, N. Asaoka, and S. Tamada. Procalcitonin and severity of community-acquired pneumonia. J Infect Chemother 2009 15(6):426-7.
Rec#: 7080
Exclusion Codes: NRO, EXC

Olaciregui, I., U. Hernandez, J. A. Munoz, J. I. Emparanza, and J. J. Landa. Markers that predict serious bacterial infection in infants under 3 months of age presenting with fever of unknown origin. Arch Dis Child 2009 94(7):501-5.
Rec#: 1060
Exclusion Codes: NDE, EXC

Olah, A., T. Belagyi, A. Issekutz, R. Makay, and A. Zaborszky. Value of procalcitonin quick test in the differentiation between sterile and infected forms of acute pancreatitis. Hepatogastroenterology 2005 52(61):243-5.
Rec#: 3890
Exclusion Codes: SMN, EXC

Oppert, M., A. Reinicke, C. Muller, D. Barckow, U. Frei, and K. U. Eckardt. Elevations in procalcitonin but not C-reactive protein are associated with pneumonia after cardiopulmonary resuscitation. Resuscitation 2002 53(2):167-70.
Rec#: 10150
Exclusion Codes: SMN, EXC

Orlowska, H., and M. Roszkowska-Blaim. Procalcitonin - A new inflammatory marker in children with urinary tract infection - A preliminary study: Prokalcytonina - Nowy marker stanu zapalnego u dzieci z zakazeniem ukladu moczowego - Doniesienie wstepne. Pediatr. Pol. 2004 79(2):111-114.
Rec#: 16750
Exclusion Codes: NDE, EXC

Ortega, M., M. Rovira, X. Filella, M. Almela, J. Puig de la Bellacasa, E. Carreras, and J. Mensa. Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation. Br J Haematol 2004 126(3):372-6.
Rec#: 4230
Exclusion Codes: NDE, EXC

Ortega, M., M. Rovira, X. Filella, J. A. Martinez, M. Almela, J. Puig, E. Carreras, and J. Mensa. Prospective evaluation of procalcitonin in adults with non-neutropenic fever after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006 37(5):499-502.
Rec#: 8950
Exclusion Codes: NDE, EXC

Oshita, H., J. Sakurai, and M. Kamitsuna. Semi-quantitative Procalcitonin Test for the Diagnosis of Bacterial Infection: Clinical Use and Experience in Japan. J. Microbiol. Immunol. Infect. 2010 43(3):222-227.
Rec#: 11420
Exclusion Codes: NDE, EXC

Ozdemir, O., B. Baytan, M. Demirkaya, and S. Celebi. The value of C-reactive protein and procalcitonin in febrile neutropenia: Febril notropenide C-reaktif protein ve prokalsitoninin yeri. Guncel Pediatr. 2009 7(1):7-12.
Rec#: 11990
Exclusion Codes: NRD, EXC

Ozturk, R., G.R. Yilmaz, C. Bulut, H. Parpucu, S. Kinikli, M. Duranay, and A.P. Demiroz. Assessment of procalcitonin and other inflammatory markers in peritoneal dialysis-related peritonitis: Peritoneal diyalizle iliskili peritonitte prokalsitonin ve diger inflamatuar parametrelerin degerlendirilmesi. Turk. J. Med. Sci. 2010 40(2):199-206.
Rec#: 15290
Exclusion Codes: NDE, EXC

Park, H.-P., J.-S. Lee, Y.-S. Jang, and M.-S. Kim. Usefulness of procalcitonin in the assessing the severity of community-acquired pneumonia patient. Tuberc. Respir. Dis. 2009 67(5):430-435.
Rec#: 15760
Exclusion Codes: NRD, EXC

Paugam-Burtz, C., J. Mantz, H. Dupont, and M. Dehoux. Procalcitonin levels and sequential organ failure assessment scores in secondary peritonitis. Arch Surg 2007 142(8):803; author reply 803-4.
Rec#: 8300
Exclusion Codes: NDE, EXC

Pavcnik-Arnol, M., S. Hojker, and M. Derganc. Lipopolysaccharide-binding protein in critically ill neonates and children with suspected infection: comparison with procalcitonin, interleukin-6, and C-reactive protein. Intensive Care Med 2004 30(7):1454-60.
Rec#: 4340
Exclusion Codes: NDE, EXC

Pavcnik-Arnol, M., S. Hojker, and M. Derganc. Lipopolysaccharide-binding protein, lipopolysaccharide, and soluble CD14 in sepsis of critically ill neonates and children. Intensive Care Med 2007 33(6):1025-32.
Rec#: 2820
Exclusion Codes: NDE, EXC

Pavic, M., A. Bronic, and L.M. Kopcinovic. Procalcitonin in systemic and localized bacterial infection. Biochem Med. 2010 20(2):236-241.
Rec#: 11380
Exclusion Codes: SMN, EXC

Pecile, P., E. Miorin, C. Romanello, E. Falleti, F. Valent, F. Giacomuzzi, and A. Tenore. Procalcitonin: a marker of severity of acute pyelonephritis among children. Pediatrics 2004 114(2):e249-54.
Rec#: 9560
Exclusion Codes: NDE, EXC

Pecile, P., and C. Romanello. Procalcitonin and pyelonephritis in children. Curr Opin Infect Dis 2007 20(1):83-7.
Rec#: 8580
Exclusion Codes: NDE, EXC

Pelinka, L.E., H. Petto, A. Kroepfl, R. Schmidhammer, and H. Redl. Serum Procalcitonin and S100B Are Associated with Mortality after Traumatic Brain Injury. Eur. J. Trauma 2003 29(5):316-323.
Rec#: 14360
Exclusion Codes: SMN, EXC

Pelinka, L.E., K. Sendova, W. Mauritz, and H. Redl. Quantitative versus semiquantitative procalcitonin measurement: Experience in a trauma intensive care unit. Eur. J. Trauma 2003 29(2):81-84.
Rec#: 14480
Exclusion Codes: SMN, EXC

Pelosi, P., A. Barassi, P. Severgnini, B. Gomiero, S. Finazzi, G. Merlini, G. M. d'Eril, M. Chiaranda, and M. S. Niederman. Prognostic role of clinical and laboratory criteria to identify early ventilator-associated pneumonia in brain injury. Chest 2008 134(1):101-8.
Rec#: 1930
Exclusion Codes: SMN, EXC

Penel, N., C. Fournier, S. Clisant, and M. N'Guyen. Causes of fever and value of C-reactive protein and procalcitonin in differentiating infections from paraneoplastic fever. Support Care Cancer 2004 12(8):593-8.
Rec#: 9690
Exclusion Codes: NRO, EXC

Perren, A., B. Cerutti, M. Lepori, V. Senn, B. Capelli, F. Duchini, and G. Domenighetti. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. Infection 2008 36(2):163-6.
Rec#: 2040
Exclusion Codes: NRO, EXC

Persson, L., P. Engervall, A. Magnuson, T. Vikerfors, B. Soderquist, L. O. Hansson, and U. Tidefelt. Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis 2004 36(5):365-71.

Rec#: 4190
Exclusion Codes: NDE, EXC

Persson, L., B. Soderquist, P. Engervall, T. Vikerfors, L. O. Hansson, and U. Tidefelt. Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol 2005 74(4):297-303.
Rec#: 3900
Exclusion Codes: NDE, EXC

Peters, R. P., J. W. Twisk, M. A. van Agtmael, and A. B. Groeneveld. The role of procalcitonin in a decision tree for prediction of bloodstream infection in febrile patients. Clin Microbiol Infect 2006 12(12):1207-13.
Rec#: 3060
Exclusion Codes: NDE, EXC

Petrikkos, G. L., S. A. Christofilopoulou, N. K. Tentolouris, E. A. Charvalos, C. J. Kosmidis, and G. L. Daikos. Value of measuring serum procalcitonin, C-reactive protein, and mannan antigens to distinguish fungal from bacterial infections. Eur J Clin Microbiol Infect Dis 2005 24(4):272-5.
Rec#: 9210
Exclusion Codes: SMN, EXC

Pettila, V., M. Hynninen, O. Takkunen, P. Kuusela, and M. Valtonen. Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med 2002 28(9):1220-5.
Rec#: 5180
Exclusion Codes: SMN, EXC

Pezzilli, R., A. M. Morselli-Labate, E. Romboli, F. Dibenedetti, M. Massa, M. Migliori, B. Barakat, G. Merlini, R. Corinaldesi, and G. V. Melzi d'Eril. Pancreatic involvement during the early phase of shock. JOP 2002 3(5):139-43.
Rec#: 10120
Exclusion Codes: NDE, EXC

Pfafflin, A., and E. Schleicher. Inflammation markers in point-of-care testing (POCT). Anal Bioanal Chem 2009 393(5):1473-80.
Rec#: 1130
Exclusion Codes: NDE, EXC

Phua, J., E. S. Koay, and K. H. Lee. Lactate, procalcitonin, and amino-terminal pro-B-type natriuretic peptide versus cytokine measurements and clinical severity scores for prognostication in septic shock. Shock 2008 29(3):328-33.
Rec#: 2110
Exclusion Codes: SMN, EXC

Phua, J., E. S. Koay, D. Zhang, and K. H. Lee. How well do serum sTREM-1 measurements prognosticate in septic shock? Anaesth Intensive Care 2008 36(5):654-8.
Rec#: 1330
Exclusion Codes: SMN, EXC

Piechota, M., M. Banach, R. Irzmanski, M. Barylski, M. Piechota-Urbanska, J. Kowalski, and L. Pawlicki. Plasma endothelin-1 levels in septic patients. J Intensive Care Med 2007 22(4):232-9.
Rec#: 2470
Exclusion Codes: NRO, EXC

Piechota, M., M. Banach, R. Irzmanski, M. Misztal, J. Rysz, M. Barylski, M. Piechota-Urbanska, J. Kowalski, and L. Pawlicki. N-terminal brain natriuretic propeptide levels correlate with procalcitonin and C-reactive protein levels in septic patients. Cell Mol Biol Lett 2007 12(2):162-75.
Rec#: 3040
Exclusion Codes: NRO, EXC

Pihusch, M., R. Pihusch, P. Fraunberger, V. Pihusch, R. Andreesen, H. J. Kolb, and E. Holler. Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol 2006 76(2):93-101.
Rec#: 8960
Exclusion Codes: NDE, EXC

Pindak, D., V. Parrak, J. Pechan, A. Vavrecka, L. Kuzela, D. Fuchs, and J. Irsakova. The clinical value of the procalcitonin in prediction of severity and outcome in acute pancreatitis. Hepatogastroenterology 2003 50 Suppl 2:ccviii-ccix.
Rec#: 4240
Exclusion Codes: NDE, EXC

Ploder, M., L. Pelinka, C. Schmuckenschlager, B. Wessner, H. J. Ankersmit, W. Fuerst, H. Redl, E. Roth, and A. Spittler. Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock 2006 25(2):129-34.
Rec#: 3430
Exclusion Codes: NRO, EXC

Polzin, A., M. Pletz, R. Erbes, M. Raffenberg, H. Mauch, S. Wagner, G. Arndt, and H. Lode. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003 21(6):939-43.
Rec#: 4750
Exclusion Codes: NDE, EXC

Pontier, S. Nosocomial pneumonia: Les pneumonies nosocomiales. Rev. Mal. Respir. 2007 24(ATS):166-172.
Rec#: 16280
Exclusion Codes: NDE, EXC

Porcel, J.M. Pleural fluid tests to identify complicated parapneumonic effusions. Curr. Opin. Pulm. Med. 2010 16(4):357-361.
Rec#: 15270
Exclusion Codes: NDE, EXC

Porcel, J. M., M. Vives, G. Cao, S. Bielsa, A. Ruiz-Gonzalez, A. Martinez-Iribarren, and A. Esquerda. Biomarkers of infection for the differential diagnosis of pleural effusions. Eur Respir J 2009 34(6):1383-9.
Rec#: 7340
Exclusion Codes: NDE, EXC

Povoa, P. Serum markers in community-acquired pneumonia and ventilator-associated pneumonia. Curr Opin Infect Dis 2008 21(2):157-62.
Rec#: 2060
Exclusion Codes: NDE, EXC

Poyrazoglu, M.H., H. Per, M. Ozturk, N. Bingol, and K. Uzums. Serum procalcitonin concentrations in pneumonia in children: Cocukluk cagi pnomonilerinde serum prokalsitonin duzeyleri. Cocuk Sagligi Hast. Derg. 2003 46(3):169-176.
Rec#: 16780
Exclusion Codes: NDE, EXC

Prat, C., J. Dominguez, F. Andreo, S. Blanco, A. Pallares, F. Cuchillo, C. Ramil, J. Ruiz-Manzano, and V. Ausina. Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. J Infect 2006 52(3):169-77.
Rec#: 9130
Exclusion Codes: NRO, EXC

Prat, C., J. Dominguez, C. Rodrigo, M. Gimenez, M. Azuara, S. Blanco, and V. Ausina. Use of quantitative and semiquantitative procalcitonin measurements to identify children with sepsis and meningitis. Eur J Clin Microbiol Infect Dis 2004 23(2):136-8.

Rec#: 4510
Exclusion Codes: SMN, EXC

Prat, C., J. Dominguez, C. Rodrigo, M. Gimenez, M. Azuara, O. Jimenez, N. Gali, and V. Ausina. Elevated serum procalcitonin values correlate with renal scarring in children with urinary tract infection. Pediatr Infect Dis J 2003 22(5):438-42.
Rec#: 9890
Exclusion Codes: SMN, EXC

Prat, C., J. Dominguez, C. Rodrigo, M. Gimenez, M. Azuara, O. Jimenez, N. Gali, and V. Ausina. Procalcitonin, C-reactive protein and leukocyte count in children with lower respiratory tract infection. Pediatr Infect Dis J 2003 22(11):963-8.
Rec#: 9780
Exclusion Codes: NDE, EXC

Prat, C., P. Ricart, X. Ruyra, J. Dominguez, J. Morillas, S. Blanco, T. Tomasa, T. Torres, L. Camara, S. Molinos, and V. Ausina. Serum concentrations of procalcitonin after cardiac surgery. J Card Surg 2008 23(6):627-32.
Rec#: 1270
Exclusion Codes: NDE, EXC

Prat, C., J. M. Sancho, J. Dominguez, B. Xicoy, M. Gimenez, C. Ferra, S. Blanco, A. Lacoma, J. M. Ribera, and V. Ausina. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma 2008 49(9):1752-61.
Rec#: 1470
Exclusion Codes: NDE, EXC

Price, S., and T. Evans. Bacterial translocation in cardiopenic shock: the gastrointestinal tract as the motor of sepsis? Int J Cardiol 1999 72(1):11-2.
Rec#: 6310
Exclusion Codes: NDE, EXC

Prieto, B., and F. V. Alvarez. Lack of transferability of results between procalcitonin assays. Clin Chem 2009 55(12):2226-7; author reply 2227-8.
Rec#: 7150
Exclusion Codes: NDE, EXC

Prieto, B., E. Llorente, I. Gonzalez-Pinto, and F. V. Alvarez. Plasma procalcitonin measured by time-resolved amplified cryptate emission (TRACE) in liver transplant patients. A prognosis marker of early infectious and non-infectious postoperative complications. Clin Chem Lab Med 2008 46(5):660-6.
Rec#: 1350
Exclusion Codes: NDE, EXC

Prucha, M., R. Zazula, and J. Hyanek. Procalcitonin - The sensitive and specific marker of severe bacterial inflammation: Prokalcitonin - Senzitivni a specificky parametr tezkeho bakterialniho zanetu. Anesteziol. Neodkladna Pece 2002 13(2):83-85.
Rec#: 14650
Exclusion Codes: NRD, EXC

Pugin, J. Biomarkers of sepsis: is procalcitonin ready for prime time? Intensive Care Med 2002 28(9):1203-4.
Rec#: 5090
Exclusion Codes: NDE, EXC

Puhan, M. Procalcitonin guidance of antibiotic therapy in pneumonia in the future? Comment: In zukunft procalcitonin-geleitete antibiotikatherapie bei pneumonie? Kommentar. Schweiz. Rundsch. Med. Prax. 2007 96(12):479-480.
Rec#: 16370

Exclusion Codes: FLA, EXC

Purkayastha, S., A. Chow, T. Athanasiou, A. Cambaroudis, S. Panesar, J. Kinross, P. Tekkis, and A. Darzi. Does serum procalcitonin have a role in evaluating the severity of acute pancreatitis? A question revisited. World J Surg 2006 30(9):1713-21.
Rec#: 8650
Exclusion Codes: NDE, EXC

Qu, J.-M., and H. Summah. Biomarkers: A definite plus in pneumonia. Mediators Inflamm. 2009 2009.
Rec#: 15640
Exclusion Codes: NDE, EXC

Quintana, G., Y. F. Medina, C. Rojas, A. Fernandez, J. F. Restrepo, F. Rondon, and A. Iglesias. The use of procalcitonin determinations in evaluation of systemic lupus erythematosus. J Clin Rheumatol 2008 14(3):138-42.
Rec#: 1570
Exclusion Codes: SMN, EXC

Quintilla, J.M., and C. Luaces. Update in emergency care: Novetats a urgencies. Pediatr. Catalana 2003 63(6):339-346.
Rec#: 14340
Exclusion Codes: NDE, EXC

Ramirez, P., M. A. Garcia, M. Ferrer, J. Aznar, M. Valencia, J. M. Sahuquillo, R. Menendez, M. A. Asenjo, and A. Torres. Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia. Eur Respir J 2008 31(2):356-62.
Rec#: 2310
Exclusion Codes: SMN, EXC

Ramirez, P., R. Menendez, and A. Torres. New biological markers of ventilator-associated pneumonia. Clin. Pulm. Med. 2007 14(2):93-98.
Rec#: 13510
Exclusion Codes: NDE, EXC

Rammaert, B., N. Verdier, B. Cavestri, and S. Nseir. Procalcitonin as a prognostic factor in severe acute exacerbation of chronic obstructive pulmonary disease. Respirology 2009 14(7):969-74.
Rec#: 660
Exclusion Codes: NDE, EXC

Ramos Amador, J.T., J.M. Sanchez Granados, M.I. Gonzalez Tome, and M.P. Carreno Guerra. Infection markers in pediatrics: Marcadores de infeccion en pediatria. Acta Pediatr. Esp. 2003 61(2):58-64.
Rec#: 16830
Exclusion Codes: NRD, EXC

Ramsthaler, F., M. Kettner, G. Mall, and H. Bratzke. The use of rapid diagnostic test of procalcitonin serum levels for the postmortem diagnosis of sepsis. Forensic Sci Int 2008 178(2-3):139-45.
Rec#: 1810
Exclusion Codes: NDE, EXC

Rau, B., M. K. Schilling, and H. G. Beger. Laboratory markers of severe acute pancreatitis. Dig Dis 2004 22(3):247-57.
Rec#: 9290
Exclusion Codes: NDE, EXC

Rau, B., G. Steinbach, K. Baumgart, F. Gansauge, A. Grunert, and H. G. Beger. The clinical value of procalcitonin in the prediction of infected necrosis in acute pancreatitis. Intensive Care Med 2000 26 Suppl 2:S159-64.
Rec#: 1750

Exclusion Codes: NDE, EXC

Rau, B., G. Steinbach, F. Gansauge, J. M. Mayer, A. Grunert, and H. G. Beger. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut 1997 41(6):832-40.
Rec#: 6800
Exclusion Codes: SMN, EXC

Rau, B. M., I. Frigerio, M. W. Buchler, K. Wegscheider, C. Bassi, P. A. Puolakkainen, H. G. Beger, and M. K. Schilling. Evaluation of procalcitonin for predicting septic multiorgan failure and overall prognosis in secondary peritonitis: a prospective, international multicenter study. Arch Surg 2007 142(2):134-42.
Rec#: 2930
Exclusion Codes: SMN, EXC

Rau, B. M., E. A. Kemppainen, A. A. Gumbs, M. W. Buchler, K. Wegscheider, C. Bassi, P. A. Puolakkainen, and H. G. Beger. Early assessment of pancreatic infections and overall prognosis in severe acute pancreatitis by procalcitonin (PCT): a prospective international multicenter study. Ann Surg 2007 245(5):745-54.
Rec#: 2790
Exclusion Codes: NDE, EXC

Ravishankar, K. Laboratory diagnosis of neonatal sepsis. J. Neonatal. 2009 23(1):48-52.
Rec#: 12480
Exclusion Codes: NDE, EXC

Ray, P., G. Badarou-Acossi, A. Viallon, D. Boutoille, M. Arthaud, D. Trystram, and B. Riou. Accuracy of the cerebrospinal fluid results to differentiate bacterial from non bacterial meningitis, in case of negative gram-stained smear. Am J Emerg Med 2007 25(2):179-84.
Rec#: 8550
Exclusion Codes: NDE, EXC

Rea-Neto, A., N. C. Youssef, F. Tuche, F. Brunkhorst, V. M. Ranieri, K. Reinhart, and Y. Sakr. Diagnosis of ventilator-associated pneumonia: a systematic review of the literature. Crit Care 2008 12(2):R56.
Rec#: 1880
Exclusion Codes: NRD, EXC

Reina, P.M., I.R. Alcantara, S.V. Mico, J.L.L.-P. Lucea, and V.M.I. Alapont. Accuracy of the procalcitonin test in the diagnosis of occult bacteremia in paediatrics: A systematic review and meta-analysis: Exactitud del test de procalcitonina en el diagnostico de bacteriemia oculta en pediatria: revision sistematica y metanalisis. An. Pediatr. 2010 72(6):403-412.
Rec#: 11390
Exclusion Codes: NDE, EXC

Reinhart, K., O. Bayer, F. Brunkhorst, and M. Meisner. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002 30(5 Suppl):S302-12.
Rec#: 5340
Exclusion Codes: NDE, EXC

Reinhart, K., and F. M. Brunkhorst. Meta-analysis of procalcitonin for sepsis detection. Lancet Infect Dis 2007 7(8):500-2; author reply 502-3.
Rec#: 2580
Exclusion Codes: NRD, EXC

Reinhart, K., and W. Karzai. Re: Procalcitonin: a new parameter for the diagnosis of bacterial infection in the perioperative period. Oczenski et al., Eur J Anaesthesiol 1998; 15: 129-132. Eur J Anaesthesiol 1998 15(5):618-9.
Rec#: 6660
Exclusion Codes: NDE, EXC

Reinhart, K., M. Meisner, and F. M. Brunkhorst. Markers for sepsis diagnosis: what is useful? Crit Care Clin 2006 22(3):503-19, ix-x.
Rec#: 3210
Exclusion Codes: NDE, EXC

Reith, H.B. Patients with abdominal sepsis - Options for using adjuvant intravenous immunoglobulins: Przydatnosc dozylnych preparatow immunoglobulin w leczeniu chorych z objawami posocznicy w przebiegu zakazen wewnatrzbrzusznych. Pol. Prz. Chir. 2007 79(2):234-247.
Rec#: 13440
Exclusion Codes: NRO, EXC

Reith, H.B., P. Lehmkuhl, W. Beier, and B. Hogy. Procalcitonin - A prognostic parameter of infection in peritonitis: PROCALCITONIN-EIN PROGNOSTISCHER INFEKTIONS-PARAMETER BEI DER PERITONITIS. CHIR. GASTROENTEROL. INTERDISZIP. GESPR. 1995 11(SUPPL. 2):47-50.
Rec#: 15230
Exclusion Codes: NRD, EXC

Reith, H. B., U. Mittelkotter, E. S. Debus, C. Kussner, and A. Thiede. Procalcitonin in early detection of postoperative complications. Dig Surg 1998 15(3):260-5.
Rec#: 6630
Exclusion Codes: SMN, EXC

Reith, H.B., U. Mittelkotter, T. Maseizik, S. Hager, U. Beutner, K. Ulrichs, and A. Thiede. Peritonitis monitoring with procalcitonin and diagnostic of immune function disorder with HLA-DR expression on monocytes: Peritonitis-monitoring mit procalcitonin und diagnostik von immunfunktionsstorungen durch HLA-DR-expression auf monozyten. Chir. Gastroenterol. Interdiszip. 1999 15(SUPPL. 1):8-14.
Rec#: 15030
Exclusion Codes: NRD, EXC

Reith, H. B., U. Mittelkotter, R. Wagner, and A. Thiede. Procalcitonin (PCT) in patients with abdominal sepsis. Intensive Care Med 2000 26 Suppl 2:S165-9.
Rec#: 1740
Exclusion Codes: NDE, EXC

Reith, H.B., and S.K. Rauchschwalbe. Pro-atrial natriuretic peptide (proANP) a new prognostic marker in clinical outcome of critically ill patients: Prekursor przedsionkowego peptydu natriuretycznego - Nowy marker o znaczeniu rokowniczym odnosnie do wyniku klinicznego leczenia chorych w stanie ciezkim. Pol. Prz. Chir. 2007 79(3):293-302.
Rec#: 13430
Exclusion Codes: NRO, EXC

Reith, H. B., S. K. Rauchschwalbe, and U. Mittelkotter. Nosocomial pneumonia: third-group chinolone versus clindamycin/ceftriaxone in modulation of the acute phase reaction and outcome and cost efficacy. Int Surg 2006 91(5):272-5.
Rec#: 3080
Exclusion Codes: NRO, EXC

Repetto, H. A., P. A. Alarcon, and M. Pellegrini. Procalcitonin as a marker of acute pyelonephritis. Pediatr Nephrol 2003 18(7):726.
Rec#: 9940
Exclusion Codes: NDE, EXC

Resch, B., W. Gusenleitner, and W. Muller. Procalcitonin, interleukin-6, C-reactive protein and leukocyte counts in infants with bronchiolitis. Pediatr Infect Dis J 2003 22(5):475-6.
Rec#: 9880
Exclusion Codes: NDE, EXC

Resch, B., W. Gusenleitner, and W. D. Muller. Procalcitonin and interleukin-6 in the diagnosis of early-onset sepsis of the neonate. Acta Paediatr 2003 92(2):243-5.
Rec#: 4850
Exclusion Codes: NDE, EXC

Rey, C., M. Los Arcos, A. Concha, A. Medina, S. Prieto, P. Martinez, and B. Prieto. Procalcitonin and C-reactive protein as markers of systemic inflammatory response syndrome severity in critically ill children. Intensive Care Med 2007 33(3):477-84.
Rec#: 2960
Exclusion Codes: SMN, EXC

Rhodes, A., S. J. Wort, H. Thomas, P. Collinson, and E. D. Bennett. Plasma DNA concentration as a predictor of mortality and sepsis in critically ill patients. Crit Care 2006 10(2):R60.
Rec#: 3370
Exclusion Codes: NRO, EXC

Richard-Lenoble, D., T. H. Duong, A. Ferrer, C. Lacombe, M. Assicot, D. Gendrel, C. Bohuon, and M. Kombila. Changes in procalcitonin and interleukin 6 levels among treated African patients with different clinical forms of malaria. Trans R Soc Trop Med Hyg 1997 91(3):305-6.
Rec#: 10930
Exclusion Codes: NRO, EXC

Richards, G.A., and G.K. Schleicher. Targeted interventions to decrease sepsis in the ICU. South. Afr. J. Crit. Care 2003 19(2):49-52.
Rec#: 14280
Exclusion Codes: NDE, EXC

Riche, F. C., B. P. Cholley, M. J. Laisne, E. Vicaut, Y. H. Panis, E. J. Lajeunie, M. Boudiaf, and P. D. Valleur. Inflammatory cytokines, C reactive protein, and procalcitonin as early predictors of necrosis infection in acute necrotizing pancreatitis. Surgery 2003 133(3):257-62.
Rec#: 4870
Exclusion Codes: SMN, EXC

Rinaldi, S., C. Adembri, S. Grechi, and A. R. De Gaudio. Low-dose hydrocortisone during severe sepsis: effects on microalbuminuria. Crit Care Med 2006 34(9):2334-9.
Rec#: 3250
Exclusion Codes: NRO, EXC

Rintala, E. M., J. Aittoniemi, S. Laine, T. J. Nevalainen, and J. Nikoskelainen. Early identification of bacteremia by biochemical markers of systemic inflammation. Scand J Clin Lab Invest 2001 61(7):523-30.
Rec#: 5570
Exclusion Codes: SMN, EXC

Rizza, A., R. Rodak, and L. Zimmerli. Increased inflammatory signs: Role of BSR, CRP, PCT in practice: Erhohte entzundungszeichen: Rolle von BSR, CRP, PCT in der praxis. Schweiz. Rundsch. Med. Prax. 2009 98(12):625-633.
Rec#: 15830
Exclusion Codes: FLA, EXC

Rosmarakis, E. S., S. N. Prapas, K. Rellos, A. Michalopoulos, G. Samonis, and M. E. Falagas. Nosocomial infections after off-pump coronary artery bypass surgery: frequency, characteristics, and risk factors. Interact Cardiovasc Thorac Surg 2007 6(6):759-67.
Rec#: 2370
Exclusion Codes: NDE, EXC

Rothenburger, M., A. Markewitz, T. Lenz, H. G. Kaulbach, K. Marohl, W. D. Kuhlmann, and C. Weinhold. Detection of acute phase response and infection. The role of procalcitonin and C-reactive protein. Clin Chem Lab Med 1999 37(3):275-9.
Rec#: 6490
Exclusion Codes: NDE, EXC

Rowther, F. B., C. S. Rodrigues, M. S. Deshmukh, F. N. Kapadia, A. Hegde, A. P. Mehta, and V. R. Joshi. Prospective comparison of eubacterial PCR and measurement of procalcitonin levels with blood culture for diagnosing septicemia in intensive care unit patients. J Clin Microbiol 2009 47(9):2964-9.
Rec#: 690
Exclusion Codes: SMN, EXC

Ruiz-Alvarez, M. J., S. Garcia-Valdecasas, R. De Pablo, M. Sanchez Garcia, C. Coca, T. W. Groeneveld, A. Roos, M. R. Daha, and I. Arribas. Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis. J Intensive Care Med 2009 24(1):63-71.
Rec#: 1210
Exclusion Codes: NDE, EXC

Ruokonen, E., L. Ilkka, M. Niskanen, and J. Takala. Procalcitonin and neopterin as indicators of infection in critically ill patients. Acta Anaesthesiol Scand 2002 46(4):398-404.
Rec#: 5410
Exclusion Codes: NDE, EXC

Ruokonen, E., T. Nousiainen, K. Pulkki, and J. Takala. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis 1999 18(4):283-5.
Rec#: 6450
Exclusion Codes: NDE, EXC

Russwurm, S., M. Oberhoffer, P. F. Zipfel, and K. Reinhart. Procalcitonin--a novel biochemical marker for the mediator-directed therapy of sepsis. Mol Med Today 1999 5(7):286-7.
Rec#: 6460
Exclusion Codes: NDE, EXC

Sabat, R., C. Hoflich, W. D. Docke, M. Oppert, F. Kern, B. Windrich, C. Rosenberger, J. Kaden, H. D. Volk, and P. Reinke. Massive elevation of procalcitonin plasma levels in the absence of infection in kidney transplant patients treated with pan-T-cell antibodies. Intensive Care Med 2001 27(6):987-91.
Rec#: 5710
Exclusion Codes: NRO, EXC

Sablotzki, A., J. Borgermann, W. Baulig, I. Friedrich, J. Spillner, R. E. Silber, and E. Czeslick. Lipopolysaccharide-binding protein (LBP) and markers of acute-phase response in patients with multiple organ dysfunction syndrome (MODS) following open heart surgery. Thorac Cardiovasc Surg 2001 49(5):273-8.
Rec#: 5640
Exclusion Codes: NRO, EXC

Sablotzki, A., M. G. Dehne, I. Friedrich, S. Grond, B. Zickmann, J. Muhling, R. E. Silber, and E. G. Czeslick. Different expression of cytokines in survivors and non-survivors from MODS following cardiovascular surgery. Eur J Med Res 2003 8(2):71-6.
Rec#: 4960
Exclusion Codes: NRO, EXC

Sachse, C., F. Dressler, and E. Henkel. Increased serum procalcitonin in newborn infants without infection. Clin Chem 1998 44(6 Pt 1):1343-4.
Rec#: 10810
Exclusion Codes: NRO, EXC

Sachse, C., H. G. Machens, G. Felmerer, A. Berger, and E. Henkel. Procalcitonin as a marker for the early diagnosis of severe infection after thermal injury. J Burn Care Rehabil 1999 20(5):354-60.
Rec#: 6410
Exclusion Codes: NDE, EXC

Sakha, K., M. B. Husseini, and N. Seyyedsadri. The role of the procalcitonin in diagnosis of neonatal sepsis and correlation between procalcitonin and C-reactive protein in these patients. Pak J Biol Sci 2008 11(14):1785-90.
Rec#: 1380
Exclusion Codes: NDE, EXC

Sakr, Y., U. Burgett, F. E. Nacul, K. Reinhart, and F. Brunkhorst. Lipopolysaccharide binding protein in a surgical intensive care unit: a marker of sepsis? Crit Care Med 2008 36(7):2014-22.
Rec#: 1550
Exclusion Codes: NDE, EXC

Sakr, Y., C. Sponholz, F. Tuche, F. Brunkhorst, and K. Reinhart. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 2008 36(5):396-407.
Rec#: 1420
Exclusion Codes: NDE, EXC

Sanchez, R., C. Gutierrez, M. Angeles Cesar, R. Pastor, and A. Vilanova. Procalcitonin and C-reactive protein in the diagnosis of bacterial pneumonias in patients in the Emergency Department: Procalcitonina y proteina C reactiva en el diagnostico de neumonias bacterianas en pacientes de urgencias. Rev. Lab. Clin. 2008 1(2):59-63.
Rec#: 16150
Exclusion Codes: NDE, EXC

Sand, M., X. V. Trullen, F. G. Bechara, X. F. Pala, D. Sand, G. Landgrafe, and B. Mann. A prospective bicenter study investigating the diagnostic value of procalcitonin in patients with acute appendicitis. Eur Surg Res 2009 43(3):291-7.
Rec#: 630
Exclusion Codes: NDE, EXC

Sandek, A., J. Springer, D. Habedank, F. Brunkhorst, and S. D. Anker. Procalcitonin-guided antibiotic treatment in heart failure. Lancet 2004 363(9420):1555; author reply 1555-6.
Rec#: 9610
Exclusion Codes: NDE, EXC

Sandner, F. The ProHOSP Study shows benefits of procalcitonin determination in deep respiratory tract infections: ProHOSP-Studie zeigt Nutzen der Procalcitonin-Bestimmung bei tiefen Atemwegsinfekten. J. Pharmakol. Ther. 2009 18(4):124-125.
Rec#: 15810
Exclusion Codes: NDE, EXC

Sandri, M. T., R. Passerini, M. E. Leon, F. A. Peccatori, L. Zorzino, M. Salvatici, D. Riggio, C. Cassatella, S. Cinieri, and G. Martinelli. Procalcitonin as a useful marker of infection in hemato-oncological patients with fever. Anticancer Res 2008 28(5B):3061-5.
Rec#: 1260
Exclusion Codes: NDE, EXC

Santolaya, M. E., A. M. Alvarez, C. L. Aviles, A. Becker, A. King, C. Mosso, M. O'Ryan, E. Paya, C. Salgado, P. Silva, S. Topelberg, J. Tordecilla, M. Varas, M. Villarroel, T. Viviani, and M. Zubieta. Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer, neutropenia, and fever: a prospective, multicenter trial. Pediatr Infect Dis J 2008 27(6):538-43.
Rec#: 1800
Exclusion Codes: NDE, EXC

Santuz, P., M. Soffiati, R. M. Dorizzi, M. Benedetti, F. Zaglia, and P. Biban. Procalcitonin for the diagnosis of early-onset neonatal sepsis: a multilevel probabilistic approach. Clin Biochem 2008 41(14-15):1150-5.
Rec#: 1500
Exclusion Codes: NDE, EXC

Saribas, S., B. Kocazeybek, M. Aslan, S. Altun, Y. Seyhun, Y. A. Oner, and N. Memisoglu. Do procalcitonin and C-reactive protein levels have a place in the diagnosis and follow-up of Helicobacter pylori infections? J Med Microbiol 2004 53(Pt 7):639-44.
Rec#: 9590
Exclusion Codes: SMN, EXC

Sarmati, L., A. Beltrame, L. Dori, G. Maffongelli, L. Cudillo, G. De Angelis, A. Picardi, L. Ottaviani, M. G. Cefalo, A. Venditti, S. Amadori, W. Arcese, and M. Andreoni. Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis. Am J Hematol 2010 85(5):380-3.
Rec#: 80
Exclusion Codes: NRD, EXC

Sauer, M., K. Tiede, D. Fuchs, B. Gruhn, D. Berger, and F. Zintl. Procalcitonin, C-reactive protein, and endotoxin after bone marrow transplantation: identification of children at high risk of morbidity and mortality from sepsis. Bone Marrow Transplant 2003 31(12):1137-42.
Rec#: 4770
Exclusion Codes: NDE, EXC

Savagner, C., A. Hoppe, Y. Montcho, B. Leboucher, S. Le Bouedec, C. Lemarie, F. Boux de Casson, and C. Bouderlique. Interest of Procalcitonin in neonatal intensive care unit for patients suspected of nosocomial sepsis: Retrospective study on 40 children: Interet de la procalcitonine pour le diagnostic d'infections nosocomiales bacteriennes en neonatalogie : etude retrospective sur 40 enfants. J. Pediatr. Pueric. 2008 21(7):292-298.
Rec#: 12700
Exclusion Codes: NDE, EXC

Schalinski, S., C. Braun, and M. Tsokos. High-grade decubitus ulcers and sepsis in the end-of-life phase. A prospective autopsy study: Hohergradige dekubitalulzera und sepsis im umfeld der sterbephase. Prospektive obduktionsstudie. Rechtsmedizin 2007 17(6):376-379.
Rec#: 13170
Exclusion Codes: NDE, EXC

Schinella, M., G. Lippi, V. Curci, P. Gualdi, L. Collini, and M. Mattarei. Procalcitonin concentrations in bacteremia. Riv. Ital. Med. Labor. 2009 5(1):38-43.
Rec#: 12220
Exclusion Codes: NRO, EXC

Schneider, H. G., and Q. T. Lam. Procalcitonin for the clinical laboratory: a review. Pathology 2007 39(4):383-90.
Rec#: 2520
Exclusion Codes: NRD, EXC

Schroder, J., K. H. Staubach, P. Zabel, F. Stuber, and B. Kremer. Procalcitonin as a marker of severity in septic shock. Langenbecks Arch Surg 1999 384(1):33-8.
Rec#: 6470
Exclusion Codes: NRO, EXC

Schuetz, P., W. Albrich, M. Christ-Crain, J. Chastre, and B. Mueller. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 2010 8(5):575-87.
Rec#: 30
Exclusion Codes: NDE, EXC

Schuetz, P., M. Batschwaroff, F. Dusemund, W. Albrich, U. Burgi, M. Maurer, M. Brutsche, A. R. Huber, and B. Muller. Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey. Eur J Clin Microbiol Infect Dis 2010 29(3):269-77.
Rec#: 7050
Exclusion Codes: NDE, EXC

Schuetz, P., M. Briel, M. Christ-Crain, M. Wolbers, D. Stolz, M. Tamm, H. Bucher, and B. Muller. Procalcitonin to initiate or withhold antibiotics in acute respiratory tract infections. Cochrane Database Syst. Rev. 2008 (4).
Rec#: 12570
Exclusion Codes: NDE, EXC

Schuetz, P., M. Christ-Crain, W. Albrich, W. Zimmerli, and B. Mueller. Guidance of antibiotic therapy with procalcitonin in lower respiratory tract infections: Insights into the ProHOSP study. Virulence 2010 1(2):88-92.
Rec#: 11730
Exclusion Codes: NDE, EXC

Schuetz, P., M. Christ-Crain, N. G. Morgenthaler, J. Struck, A. Bergmann, and B. Muller. Circulating precursor levels of endothelin-1 and adrenomedullin, two endothelium-derived, counteracting substances, in sepsis. Endothelium 2007 14(6):345-51.
Rec#: 2240
Exclusion Codes: NDE, EXC

Schuetz, P., M. Christ-Crain, and B. Muller. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care 2007 13(5):578-85.
Rec#: 2450
Exclusion Codes: NRD, EXC

Schuetz, P., M. Christ-Crain, and B. Muller. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections--hope for hype? Swiss Med Wkly 2009 139(23-24):318-26.
Rec#: 800
Exclusion Codes: NDE, EXC

Schuetz, P., M. Christ-Crain, M. Wolbers, U. Schild, R. Thomann, C. Falconnier, I. Widmer, S. Neidert, C. A. Blum, R. Schonenberger, C. Henzen, T. Bregenzer, C. Hoess, M. Krause, H. C. Bucher, W. Zimmerli, and B. Muller. Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res 2007 7:102.
Rec#: 8370
Exclusion Codes: NDE, EXC

Schuetz, P., B. Mueller, and A. Trampuz. Serum procalcitonin for discrimination of blood contamination from bloodstream infection due to coagulase-negative staphylococci. Infection 2007 35(5):352-5.
Rec#: 2400
Exclusion Codes: SMN, EXC

Schuetz, P., D. Stolz, B. Mueller, N. G. Morgenthaler, J. Struck, C. Mueller, R. Bingisser, M. Tamm, and M. Christ-Crain. Endothelin-1 precursor peptides correlate with severity of disease and outcome in patients with community acquired pneumonia. BMC Infect Dis 2008 8:22.
Rec#: 2090
Exclusion Codes: NDE, EXC

Schuttrumpf, S., L. Binder, T. Hagemann, D. Berkovic, L. Trumper, and C. Binder. Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients? Ann Hematol 2003 82(2):98-103.
Rec#: 9990
Exclusion Codes: SMN, EXC

Schuttrumpf, S., L. Binder, T. Hagemann, D. Berkovic, L. Trumper, and C. Binder. Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis 2006 43(4):468-73.
Rec#: 8720
Exclusion Codes: NDE, EXC

Schutzle, H., J. Forster, A. Superti-Furga, and R. Berner. Is serum procalcitonin a reliable diagnostic marker in children with acute respiratory tract infections? A retrospective analysis. Eur J Pediatr 2009 168(9):1117-24.
Rec#: 7620
Exclusion Codes: NDE, EXC

Schwarz, S., M. Bertram, S. Schwab, K. Andrassy, and W. Hacke. Serum procalcitonin levels in bacterial and abacterial meningitis. Crit Care Med 2000 28(6):1828-32.
Rec#: 6090
Exclusion Codes: SMN, EXC

Schwenger, V., J. Sis, A. Breitbart, and K. Andrassy. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection 1998 26(5):274-6.
Rec#: 10730
Exclusion Codes: NRO, EXC

Scire, C. A., L. Cavagna, C. Perotti, E. Bruschi, R. Caporali, and C. Montecucco. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol 2006 24(2):123-8.
Rec#: 8790
Exclusion Codes: NDE, EXC

Scott, L. K., L. R. Grier, T. C. Arnold, and S. A. Conrad. Serum procalcitonin concentration as a negative predictor of serious bacterial infection in acute sickle cell pain crisis. Med Sci Monit 2003 9(10):CR426-31.
Rec#: 9830
Exclusion Codes: NDE, EXC

Secmeer, G., I. Devrim, A. Kara, M. Ceyhan, B. Cengiz, T. Kutluk, M. Buyukpamukcu, S. Yetgin, M. Tuncer, A. K. Uludag, H. Tezer, and I. Yildirim. Role of procalcitonin and CRP in differentiating a stable from a deteriorating clinical course in pediatric febrile neutropenia. J Pediatr Hematol Oncol 2007 29(2):107-11.
Rec#: 2950
Exclusion Codes: NDE, EXC

Selberg, O., H. Hecker, M. Martin, A. Klos, W. Bautsch, and J. Kohl. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6. Crit Care Med 2000 28(8):2793-8.
Rec#: 6050
Exclusion Codes: SMN, EXC

Seligman, R., M. Meisner, T. C. Lisboa, F. T. Hertz, T. B. Filippin, J. M. Fachel, and P. J. Teixeira. Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care 2006 10(5):R125.
Rec#: 3140
Exclusion Codes: SMN, EXC

Setvak, D., R. Zahorec, and J. Misianik. The use of procalcitonin as a marker of sepsis in postoperative and intensive care: Vyuzitie procalcitoninu ako zapaloveho markeru v pooperacnej a intenzivnej starostlivosti. Anesteziol. Neodkladna Pece 2000 11(4):165-169.
Rec#: 14820
Exclusion Codes: NRD, EXC

Sfia, M., P. Boeckler, and D. Lipsker. High procalcitonin levels in patients with severe drug reactions. Arch Dermatol 2007 143(12):1591.
Rec#: 8150
Exclusion Codes: NDE, EXC

Shafiq, N., S. Malhotra, D. K. Bhasin, S. Rana, S. Siddhu, and P. Pandhi. Estimating the diagnostic accuracy of procalcitonin as a marker of the severity of acute pancreatitis: a meta-analytic approach. JOP 2005 6(3):231-7.
Rec#: 9230
Exclusion Codes: NDE, EXC

Sherlock, R. Neonatal sepsis and septic shock: Current trends in epidemiology and management. J. Pediatr. Infect. Dis. 2009 4(2):153-159.
Rec#: 12350
Exclusion Codes: NDE, EXC

Sherwin, C., R. Broadbent, S. Young, J. Worth, F. McCaffrey, N. J. Medlicott, and D. Reith. Utility of interleukin-12 and interleukin-10 in comparison with other cytokines and acute-phase reactants in the diagnosis of neonatal sepsis. Am J Perinatol 2008 25(10):629-36.
Rec#: 1340
Exclusion Codes: NDE, EXC

Shimetani, N., K. Shimetani, and M. Mori. Levels of three inflammation markers, C-reactive protein, serum amyloid A protein and procalcitonin, in the serum and cerebrospinal fluid of patients with meningitis. Scand J Clin Lab Invest 2001 61(7):567-74.
Rec#: 5560
Exclusion Codes: NRO, EXC

Shimizu, T., K. Hanasawa, K. Sato, M. Umeki, N. Koga, T. Naganuma, S. Sato, T. Shimonishi, T. Ikeda, N. Matsuno, S. Ono, H. Saitoh, K. Satoh, Y. Otani, Y. Endo, Y. Eguchi, and T. Tani. The clinical significance of serum procalcitonin levels following direct hemoperfusion with polymyxin B-immobilized fiber column in septic patients with colorectal perforation. Eur Surg Res 2009 42(2):109-17.
Rec#: 1110
Exclusion Codes: NDE, EXC

Shin, K. C., Y. J. Lee, S. W. Kang, H. J. Baek, E. B. Lee, H. A. Kim, and Y. W. Song. Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE. Ann Rheum Dis 2001 60(10):988-9.
Rec#: 10230
Exclusion Codes: NRO, EXC

Siassi, M., J. Riese, R. Steffensen, M. Meisner, S. Thiel, W. Hohenberger, and J. Schmidt. Mannan-binding lectin and procalcitonin measurement for prediction of postoperative infection. Crit Care 2005 9(5):R483-9.
Rec#: 3600
Exclusion Codes: NRO, EXC

Siempos, I. I., A. Michalopoulos, and M. E. Falagas. Treatment of acute bacterial exacerbations of chronic bronchitis. Expert Opin Pharmacother 2009 10(7):1173-82.
Rec#: 7400
Exclusion Codes: NDE, EXC

Sierra, R. C-reactive protein and procalcitonin as markers of infection, inflammatory response, and sepsis. Clin. Pulm. Med. 2007 14(3):127-139.
Rec#: 13390
Exclusion Codes: NDE, EXC

Simon, L., F. Gauvin, D. K. Amre, P. Saint-Louis, and J. Lacroix. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004 39(2):206-17.

Rec#: 9540
Exclusion Codes: NDE, EXC

Simon, L., P. Saint-Louis, D. K. Amre, J. Lacroix, and F. Gauvin. Procalcitonin and C-reactive protein as markers of bacterial infection in critically ill children at onset of systemic inflammatory response syndrome. Pediatr Crit Care Med 2008 9(4):407-13.
Rec#: 1620
Exclusion Codes: SMN, EXC

Sitter, T., M. Schmidt, S. Schneider, and H. Schiffl. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. J Nephrol 2002 15(3):297-301.
Rec#: 10130
Exclusion Codes: NDE, EXC

Sleglova, O., H. Dejmkova, and J. Uhrova. Can the determination of serum procalcitonin be helpful in the differential diagnosis of an infection and an acute exacerbation in patients with a systemic autoimmune disease?: Muze stanoveni seroveho prokalcitoninu pomoci v diferencialni diagnoze mezi infekci a akutnim zhorsenim u pacientu se syste movym autoimunitnim onemocnenim? Ceska Revmatol. 2010 18(1):4-11.
Rec#: 15390
Exclusion Codes: NRD, EXC

Smith, L. Management of bacterial meningitis: New guidelines from the IDSA. Am. Fam. Phys. 2005 71(10):2003-2008.
Rec#: 16640
Exclusion Codes: NRD, EXC

Smith, M. D., Y. Suputtamongkol, W. Chaowagul, M. Assicot, C. Bohuon, S. Petitjean, and N. J. White. Elevated serum procalcitonin levels in patients with melioidosis. Clin Infect Dis 1995 20(3):641-5.
Rec#: 10970
Exclusion Codes: SMN, EXC

Smolkin, V., A. Koren, R. Raz, R. Colodner, W. Sakran, and R. Halevy. Procalcitonin as a marker of acute pyelonephritis in infants and children. Pediatr Nephrol 2002 17(6):409-12.
Rec#: 10140
Exclusion Codes: SMN, EXC

Snider, R. H. Jr, E. S. Nylen, and K. L. Becker. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med 1997 45(9):552-60.
Rec#: 6810
Exclusion Codes: NRO, EXC

Soderquist, B., I. Jones, H. Fredlund, and T. Vikerfors. Bacterial or crystal-associated arthritis? Discriminating ability of serum inflammatory markers. Scand J Infect Dis 1998 30(6):591-6.
Rec#: 6520
Exclusion Codes: NDE, EXC

Sorbera, L. A. Procalcitonin as an effective biomarker for the diagnosis and prognosis of severe sepsis. Highlights from the 25th International Symposium on Intensive Care and Emergency Medicine. March 21-25, 2005, Brussels, Belgium. Drugs Today (Barc) 2005 41(4):253-6.
Rec#: 3740
Exclusion Codes: NDE, EXC

Soto, G. J. Diagnostic strategies for nosocomial pneumonia. Curr Opin Pulm Med 2007 13(3):186-91.
Rec#: 2810
Exclusion Codes: NDE, EXC

Spada, S., A. Cuccu, M. Mussap, M. Testa, M. Puddu, C. Pisu, P. Burrai, and V. Fanos. Reliability of procalcitonin in neonatology. Experience in 59 preterm newborns. J Matern Fetal Neonatal Med 2009 22 Suppl 3:96-101.
Rec#: 330
Exclusion Codes: NDE, EXC

Spahr, L., I. Morard, A. Hadengue, L. Vadas, and J. Pugin. Procalcitonin is not an accurate marker of spontaneous bacterial peritonitis in patients with cirrhosis. Hepatogastroenterology 2001 48(38):502-5.
Rec#: 10320
Exclusion Codes: NRO, EXC

Spapen, H. D., S. Hachimi-Idrissi, L. Corne, and L. P. Huyghens. Diagnostic markers of sepsis in the emergency department. Acta Clin Belg 2006 61(3):138-42.
Rec#: 3230
Exclusion Codes: NDE, EXC

Spiegler, P. Using procalcitonin to refine treatment of chronic obstructive pulmonary disease exacerbations. Clin. Pulm. Med. 2007 14(3):184-185.
Rec#: 13380
Exclusion Codes: NRD, EXC

Spiegler, P. Do antibiotics for copd exacerbations improve outcomes? Clin. Pulm. Med. 2009 16(4):226-227.
Rec#: 12210
Exclusion Codes: NRD, EXC

Sponholz, C., Y. Sakr, K. Reinhart, and F. Brunkhorst. Diagnostic value and prognostic implications of serum procalcitonin after cardiac surgery: a systematic review of the literature. Crit Care 2006 10(5):R145.
Rec#: 3100
Exclusion Codes: NDE, EXC

Staehler, M., C. Hammer, B. Meiser, and B. Reichart. Procalcitonin: a new marker for differential diagnosis of acute rejection and bacterial infection in heart transplantation. Transplant Proc 1997 29(1-2):584-5.
Rec#: 6870
Exclusion Codes: NDE, EXC

Steichen, O., E. Bouvard, G. Grateau, S. Bailleul, J. Capeau, and G. Lefevre. Diagnostic value of procalcitonin in acutely hospitalized elderly patients. Eur J Clin Microbiol Infect Dis 2009 28(12):1471-6.
Rec#: 7220
Exclusion Codes: NDE, EXC

Steinbach, G., E. Bolke, A. Grunert, M. Storck, and K. Orth. Procalcitonin in patients with acute and chronic renal insufficiency. Wien Klin Wochenschr 2004 116(24):849-53.
Rec#: 3960
Exclusion Codes: NDE, EXC

Steinbach, G., and A. Grunert. Procalcitonin--a new indicator for bacterial infections. Exp Clin Endocrinol Diabetes 1998 106(3):164-7.
Rec#: 10770
Exclusion Codes: NDE, EXC

Steinbach, G., B. Rau, A. L. Debard, J. F. Javourez, J. Bienvenu, A. Ponzio, A. Bonfa, W. Hubl, T. Demant, W. R. Kulpmann, J. Buchholz, and G. Schumann. Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor System. Clin Chem Lab Med 2004 42(4):440-9.
Rec#: 9600
Exclusion Codes: NDE, EXC

Steurer, J. Procalcitonin determination as decision support for antibiotic therapy in acute respiratory tract infections: Procalcitonin-bestimmungen als entscheidungshilfe fur antibiotikatherapie bei akuten infekten des respirationstraktes. Schweiz. Rundsch. Med. Prax. 2009 98(23):1383-1384.
Rec#: 15690
Exclusion Codes: FLA, EXC

Stijnis, C., C. van Nieuwkoop, and J. T. van Dissel. Procalcitonin-based guidelines and lower respiratory tract infections. JAMA 2010 303(5):418-9; author reply 419-20.
Rec#: 7010
Exclusion Codes: NDE, EXC

Stolz, D., M. Christ-Crain, M. M. Gencay, R. Bingisser, P. R. Huber, B. Muller, and M. Tamm. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infection. Swiss Med Wkly 2006 136(27-28):434-40.
Rec#: 8690
Exclusion Codes: NDE, EXC

Stolz, D., M. Christ-Crain, N. G. Morgenthaler, J. Leuppi, D. Miedinger, R. Bingisser, C. Muller, J. Struck, B. Muller, and M. Tamm. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007 131(4):1058-67.
Rec#: 2800
Exclusion Codes: NDE, EXC

Stolz, D., A. Stulz, B. Muller, A. Gratwohl, and M. Tamm. BAL neutrophils, serum procalcitonin, and C-reactive protein to predict bacterial infection in the immunocompromised host. Chest 2007 132(2):504-14.
Rec#: 8400
Exclusion Codes: NDE, EXC

Stolz, D., and M. Tamm. Discriminate use of antibiotics for exacerbation of COPD. Curr Opin Pulm Med 2009 15(2):126-32.
Rec#: 790
Exclusion Codes: NDE, EXC

Streit, G., D. Alber, M. M. Toubin, E. Toussirot, and D. Wendling. Procalcitonin, C-reactive protein, and complement-3a assays in synovial fluid for diagnosing septic arthritis: preliminary results. Joint Bone Spine 2008 75(2):238-9.
Rec#: 2200
Exclusion Codes: NRO, EXC

Striz, I., M. Jaresova, J. Lacha, J. Sedlacek, and S. Vitko. MRP 8/14 and procalcitonin serum levels in organ transplantations. Ann Transplant 2001 6(2):6-9.
Rec#: 10200
Exclusion Codes: NRO, EXC

Struck, J. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 2003 328(1-2):199; author reply 201.
Rec#: 10030
Exclusion Codes: NRD, EXC

Stryjewski, G. R., E. S. Nylen, M. J. Bell, R. H. Snider, K. L. Becker, A. Wu, C. Lawlor, and H. Dalton. Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediatr Crit Care Med 2005 6(2):129-35.
Rec#: 3930
Exclusion Codes: NDE, EXC

Stucker, F., F. Herrmann, J. D. Graf, J. P. Michel, K. H. Krause, and G. Gavazzi. Procalcitonin and infection in elderly patients. J Am Geriatr Soc 2005 53(8):1392-5.

Rec#: 3710
Exclusion Codes: NDE, EXC

Suberviola Canas, B., A. Gonzalez Castro, B. Fernandez Miret, I. Rubio Lopez, and L.A. Garcia Astudillo. Procalcitonin: An ally in the management of patient subjected to abdominal surgery: Procalcitonina: Un aliado en el manejo del paciente sometido a cirugia abdominal. Rev. Esp. Enferm. Dig. 2009 101(7):513-514.
Rec#: 12180
Exclusion Codes: NRO, EXC

Summah, H., and J. M. Qu. Biomarkers: a definite plus in pneumonia. Mediators Inflamm 2009 2009:675753.
Rec#: 7090
Exclusion Codes: NDE, EXC

Summerton, N. Diagnostic testing: the importance of context. Br J Gen Pract 2007 57(541):678-9.
Rec#: 8320
Exclusion Codes: NDE, EXC

Sun, B., F. Xu, and W. Yu. Sepsis and septic shock study in pediatric critical care: An overview of recent Chinese literature. J. Pediatr. Infect. Dis. 2009 4(2):147-152.
Rec#: 12340
Exclusion Codes: NDE, EXC

Suprin, E., C. Camus, A. Gacouin, Y. Le Tulzo, S. Lavoue, A. Feuillu, and R. Thomas. Procalcitonin: a valuable indicator of infection in a medical ICU? Intensive Care Med 2000 26(9):1232-8.
Rec#: 5950
Exclusion Codes: NDE, EXC

Suzuki, N., H. Mizuno, M. Nezu, Y. Takai, T. Misu, H. Kuroda, M. Aoki, I. Nakashima, and Y. Itoyama. Procalcitonin might help in discrimination between meningeal neuro-Behcet disease and bacterial meningitis. Neurology 2009 72(8):762-3.
Rec#: 7540
Exclusion Codes: NRO, EXC

Svaldi, M., J. Hirber, A. I. Lanthaler, O. Mayr, S. Faes, E. Peer, and M. Mitterer. Procalcitonin-reduced sensitivity and specificity in heavily leucopenic and immunosuppressed patients. Br J Haematol 2001 115(1):53-7.
Rec#: 5610
Exclusion Codes: NDE, EXC

Szakmany, T., and Z. Molnar. Procalcitonin levels do not predict mortality following major abdominal surgery. Can J Anaesth 2003 50(10):1082-3.
Rec#: 4540
Exclusion Codes: NDE, EXC

Takubo, T., T. Kumura, K. Ohta, T. Yamane, M. Hino, T. Kamitani, and N. Tatsumi. Elevation of serum procalcitonin level in a patient with chronic myelocytic leukemia. Haematologia (Budap) 2001 31(2):177-9.
Rec#: 10240
Exclusion Codes: NDE, EXC

Tamaki, K., Y. Kogata, D. Sugiyama, T. Nakazawa, S. Hatachi, G. Kageyama, K. Nishimura, A. Morinobu, and S. Kumagai. Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol 2008 35(1):114-9.
Rec#: 8190
Exclusion Codes: SMN, EXC

Tang, B. M., and G. D. Eslick. Procalcitonin for sepsis: methodological issues in meta-analysis lead to further uncertainty. Crit Care Med 2007 35(2):679; author reply 679-80.

Rec#: 2980
Exclusion Codes: NDE, EXC

Tang, B. M., G. D. Eslick, J. C. Craig, and A. S. McLean. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007 7(3):210-7.
Rec#: 2920
Exclusion Codes: NDE, EXC

Tang, H., T. Huang, J. Jing, H. Shen, and W. Cui. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009 37(6):497-507.
Rec#: 400
Exclusion Codes: NDE, EXC

Tasabehji, W. R., F. A. Al-Quobaili, and N. A. Al-Daher. Usefulness of procalcitonin and some inflammatory parameters in septic patients. Saudi Med J 2008 29(4):520-5.
Rec#: 1940
Exclusion Codes: NRD, EXC

Tasci, C., A. Balkan, N. Karadurmus, S. Inal, S. Kilic, M. Ozkan, H. Bigic, and K. Ekiz. The importance of serum procalcitonin levels in patients with chronic obstructive pulmonary disease exacerbations. Turk. J. Med. Sci. 2008 38(2):139-144.
Rec#: 12980
Exclusion Codes: SMN, EXC

Tasdelen Fisgin, N., Y. Aliyazicioglu, E. Tanyel, A. Y. Coban, F. Ulger, M. Zivalioglu, S. Esen, and H. Leblebicioglu. The value of neopterin and procalcitonin in patients with sepsis. South Med J 2010 103(3):216-9.
Rec#: 180
Exclusion Codes: SMN, EXC

Taskin, E., M. Turgut, M. Kilic, H. Akbulut, and A. D. Aygun. Serum procalcitonin and cerebrospinal fluid cytokines level in children with meningitis. Mediators Inflamm 2004 13(4):269-73.
Rec#: 9430
Exclusion Codes: SMN, EXC

ten Boekel, E., K. Vroonhof, A. Huisman, C. van Kampen, and W. de Kieviet. Clinical laboratory findings associated with in-hospital mortality. Clin Chim Acta 2006 372(1-2):1-13.
Rec#: 3350
Exclusion Codes: NDE, EXC

Tessmer, M. Community-acquired lower respiratory tract infections/community-acquired pneumonias in adult patients - Diagnosis, antimicrobial therapy and management: Recommendations of the current S3 guideline: Ambulant erworbene untere atemwegs-infektionen/ambulant erworbene pneumonien bei erwachsenen patienten - Diagnostik, antimikrobielle therapie und management: Empfehlungen der aktuellen S3-leitlinie. Arzneimitteltherapie 2010 28(2):60-67.
Rec#: 11810
Exclusion Codes: NRD, EXC

Thayyil, S., M. Shenoy, M. Hamaluba, A. Gupta, J. Frater, and I. G. Verber. Is procalcitonin useful in early diagnosis of serious bacterial infections in children? Acta Paediatr 2005 94(2):155-8.
Rec#: 3780
Exclusion Codes: SMN, EXC

Thia, K. T., E. S. Chan, K. L. Ling, W. Y. Ng, E. Jacob, and C. J. Ooi. Role of procalcitonin in infectious gastroenteritis and inflammatory bowel disease. Dig Dis Sci 2008 53(11):2960-8.
Rec#: 7960
Exclusion Codes: SMN, EXC

Thiemermann, C. What's new in SHOCK, October 2007? Shock 2007 28(4):371-374.
Rec#: 13220
Exclusion Codes: NRD, EXC

Toikka, P., K. Irjala, T. Juven, R. Virkki, J. Mertsola, M. Leinonen, and O. Ruuskanen. Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. Pediatr Infect Dis J 2000 19(7):598-602.
Rec#: 10550
Exclusion Codes: NDE, EXC

Tollens, M., S. Westerholt, M. Oberhoffer, B. Klare, P. Emmrich, and R. Oberhoffer. Procalcitonin in children with hemolytic uremic syndrome (HUS) - First clinical experiences: Procalcitonin bei kindern mit hamolytisch-uramischem syndrom (HUS): Erste klinische erfahrungen. Monatsschr. Kinderheilkd. 1999 147(4):373-376.
Rec#: 17070
Exclusion Codes: NDE, EXC

Topolcan, O., L. Bartunek, L. Holubec Jr., V. Polivkova, M. Casova, T. Hajek, and O.J. Wolfe. Importance of procalcitonin in post-cardiosurgical patients. J. Clin. Ligand Assay 2008 31(1-4):57-60.
Rec#: 12590
Exclusion Codes: NDE, EXC

Torbe, A. Maternal plasma procalcitonin concentrations in pregnancy complicated by preterm premature rupture of membranes. Mediators Inflamm 2007 2007:35782.
Rec#: 8290
Exclusion Codes: NDE, EXC

Torbe, A., and R. Czajka. Maternal plasma procalcitonin concentrations in patients with preterm labor and intact membranes--prediction of preterm delivery and admission-to-delivery interval. J Perinat Med 2004 32(4):332-6.
Rec#: 9520
Exclusion Codes: SMN, EXC

Trallero-Araguas, E., A. Selva-O'Callaghan, and M. Vilardell-Tarres. Serum procalcitonin levels in febrile patients with systemic autoimmune diseases. Curr. Rheumatol. Rev. 2007 3(2):103-111.
Rec#: 13370
Exclusion Codes: NDE, EXC

Trelinska, J., M. Stolarska, B. Zalewska-Szewczyk, K. Wyka, A. Pastorczak, and W. Mlynarski. Hypophosphatemia correlates with high procalcitonin level in bacterial infections in children with cancer: Hipofosfatemia koreluje z wysokimi stezeniami prokalcytoniny w przebiegu zakazen bakteryjnych u dzieci leczonych z powodu choroby nowotoworowej. Acta Haematol. Pol. 2008 39(3):469-475.
Rec#: 12580
Exclusion Codes: NRD, EXC

Tsangaris, I., D. Plachouras, D. Kavatha, G. M. Gourgoulis, A. Tsantes, P. Kopterides, G. Tsaknis, I. Dimopoulou, S. Orfanos, E. Giamarellos-Bourboulis, H. Giamarellou, and A. Armaganidis. Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. BMC Infect Dis 2009 9:213.
Rec#: 290
Exclusion Codes: SMN, EXC

Tschaikowsky, K., M. Hedwig-Geissing, A. Schiele, F. Bremer, M. Schywalsky, and J. Schuttler. Coincidence of pro- and anti-inflammatory responses in the early phase of severe sepsis: Longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med 2002 30(5):1015-23.
Rec#: 5330
Exclusion Codes: NRO, EXC

Tseng, J. S., M. C. Chan, J. Y. Hsu, B. I. Kuo, and C. L. Wu. Procalcitonin is a valuable prognostic marker in ARDS caused by community-acquired pneumonia. Respirology 2008 13(4):505-9.
Rec#: 7940
Exclusion Codes: SMN, EXC

Tsokos, M. Postmortem measurement of serum procalcitonin concentration in Waterhouse-Friderichsen syndrome. Virchows Arch 2002 441(6):629-31.
Rec#: 10010
Exclusion Codes: NDE, EXC

Tsokos, M. Fatal Waterhouse-Friderichsen syndrome due to Ewingella americana infection. Am J Forensic Med Pathol 2003 24(1):41-4.
Rec#: 4980
Exclusion Codes: NRO, EXC

Tsokos, M., U. Reichelt, A. Nierhaus, and K. Puschel. Serum procalcitonin (PCT): a valuable biochemical parameter for the post-mortem diagnosis of sepsis. Int J Legal Med 2001 114(4-5):237-43.
Rec#: 5790
Exclusion Codes: NRO, EXC

Tugrul, S., F. Esen, S. Celebi, P. E. Ozcan, O. Akinci, N. Cakar, and L. Telci. Reliability of procalcitonin as a severity marker in critically ill patients with inflammatory response. Anaesth Intensive Care 2002 30(6):747-54.
Rec#: 5040
Exclusion Codes: SMN, EXC

Tugrul, S., P. E. Ozcan, O. Akinci, Y. Seyhun, A. Cagatay, N. Cakar, and F. Esen. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis. Crit Care 2002 6(4):357-62.
Rec#: 5140
Exclusion Codes: SMN, EXC

Turner, D., C. Hammerman, B. Rudensky, Y. Schlesinger, C. Goia, and M. S. Schimmel. Procalcitonin in preterm infants during the first few days of life: introducing an age related nomogram. Arch Dis Child Fetal Neonatal Ed 2006 91(4):F283-6.
Rec#: 3400
Exclusion Codes: NRO, EXC

Turner, D., C. Hammerman, B. Rudensky, Y. Schlesinger, and M. S. Schimmel. The role of procalcitonin as a predictor of nosocomial sepsis in preterm infants. Acta Paediatr 2006 95(12):1571-6.
Rec#: 3050
Exclusion Codes: NDE, EXC

Turner, D., C. Hammerman, B. Rudensky, Y. Schlesinger, E. Wine, A. Muise, and M. S. Schimmel. Low levels of procalcitonin during episodes of necrotizing enterocolitis. Dig Dis Sci 2007 52(11):2972-6.
Rec#: 2830
Exclusion Codes: NDE, EXC

Turton, P. Ventilator-associated pneumonia in paediatric intensive care: a literature review. Nurs Crit Care 2008 13(5):241-8.
Rec#: 1390
Exclusion Codes: NDE, EXC

Ucar, B., B. Yildiz, M. A. Aksit, C. Yarar, O. Colak, Y. Akbay, and E. Colak. Serum amyloid A, procalcitonin, tumor necrosis factor-alpha, and interleukin-1beta levels in neonatal late-onset sepsis. Mediators Inflamm 2008 2008:737141.
Rec#: 1230

Exclusion Codes: NDE, EXC

Uettwiller-Geiger, D.L. Clinical applications of procalcitonin (PCT). J. Clin. Ligand Assay 2007 30(1-2):20-28.
Rec#: 13490
Exclusion Codes: NDE, EXC

Ugarte, H., E. Silva, D. Mercan, A. De Mendonca, and J. L. Vincent. Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 1999 27(3):498-504.
Rec#: 6540
Exclusion Codes: NDE, EXC

Uys, A., B. L. Rapoport, H. Fickl, P. W. Meyer, and R. Anderson. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care (Engl) 2007 16(6):475-83.
Rec#: 2330
Exclusion Codes: NDE, EXC

Uzun, G., E. Solmazgul, H. Curuksulu, V. Turhan, N. Ardic, C. Top, S. Yildiz, and M. Cimsit. Procalcitonin as a diagnostic aid in diabetic foot infections. Tohoku J Exp Med 2007 213(4):305-12.
Rec#: 2260
Exclusion Codes: SMN, EXC

Uzzan, B., R. Cohen, P. Nicolas, M. Cucherat, and G. Y. Perret. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006 34(7):1996-2003.
Rec#: 3320
Exclusion Codes: NDE, EXC

Uzzan, B., A. Izri, R. Durand, M. Deniau, O. Bouchaud, and G. Y. Perret. Serum procalcitonin in uncomplicated falciparum malaria: a preliminary study. Travel Med Infect Dis 2006 4(2):77-80.
Rec#: 3220
Exclusion Codes: SMN, EXC

Valencia, M., and A. Torres. Ventilator-associated pneumonia. Curr. Opin. Crit. Care 2009 15(1):30-35.
Rec#: 15980
Exclusion Codes: NDE, EXC

Valenta, J., A. Jabor, H. Brodska, Z. Stach, A. Kazda, and M. Stritesky. Analysis of the specificity and sensitivity of procalcitonin in relation to other markers of inflammation in critically ill patients: Analyza specificity a senzitivity prokalcitoninu ve srovnani s dalsimi markery zanetu u kriticky nemocnych. Anesteziol. Intenzivni Med. 2006 17(3):164-170.
Rec#: 13600
Exclusion Codes: NRD, EXC

Vallianou, N., and P. Koutalas. Procalcitonin and infections. Arch. Hell. Med. 2008 25(5):602-604.
Rec#: 12760
Exclusion Codes: NDE, EXC

van den Broek, M. A., S. W. Olde Damink, B. Winkens, C. E. Broelsch, M. Malago, A. Paul, and F. H. Saner. Procalcitonin as a prognostic marker for infectious complications in liver transplant recipients in an intensive care unit. Liver Transpl 2010 16(3):402-10.
Rec#: 140
Exclusion Codes: NDE, EXC

Van der Kaay, D. C., E. D. De Kleijn, Y. B. De Rijke, W. C. Hop, R. De Groot, and J. A. Hazelzet. Procalcitonin as a prognostic marker in meningococcal disease. Intensive Care Med 2002 28(11):1606-12.
Rec#: 5060
Exclusion Codes: SMN, EXC

Van Der Kaay, D.C.M., E.D. De Kleijn, R. De Groot, J.A. Hazelzet, and Y.B. De Rijke. BRAHMS PCT(registered trademark)-Q semi-quantitative test method to determine procalcitonin in children with meningococcal disease: BRAHMS PCT(registered trademark)-Q semi-kwantitatieve test voor procalcitoninebepaling bij kinderen met meningokokkenziekte. Ned. Tijdschr. Klin. Chem. Lab. Geneeskd. 2004 29(6):308-313.
Rec#: 14160
Exclusion Codes: NRD, EXC

van Dissel, J. T. Procalcitonin and other markers of infection. What should be their role in clinical practice? Clin Microbiol Infect 2002 8(2):70-3.
Rec#: 5400
Exclusion Codes: NDE, EXC

van Dissel, J. T. Procalcitonin: what should be its role in the clinical management of febrile patients admitted to the hospital? Clin Infect Dis 2003 36(6):824-5; author reply 826-7.
Rec#: 4940
Exclusion Codes: NDE, EXC

van Langevelde, P., K. Joop, J. van Loon, M. Frolich, P. H. Groeneveld, R. G. Westendorp, and J. T. van Dissel. Endotoxin, cytokines, and procalcitonin in febrile patients admitted to the hospital: identification of subjects at high risk of mortality. Clin Infect Dis 2000 31(6):1343-8.
Rec#: 5930
Exclusion Codes: NDE, EXC

van Oers, J. A., J. E. Tulleken, and J. G. Zijlstra. Does serum procalcitonin have a diagnostic value in febrile adult patients presenting to the emergency department? Crit Care 2007 11(6):422; author reply 422.
Rec#: 8160
Exclusion Codes: NDE, EXC

van Rossum, A. M., R. W. Wulkan, and A. M. Oudesluys-Murphy. Procalcitonin as an early marker of infection in neonates and children. Lancet Infect Dis 2004 4(10):620-30.
Rec#: 4110
Exclusion Codes: NDE, EXC

Vandewoude, M.F.J. Infections in older people. Aging Health 2007 3(6):711-714.
Rec#: 13150
Exclusion Codes: NRD, EXC

Vandijck, D. M., N. Brusselaers, and S. I. Blot. Inflammatory markers in patients with severe burn injury: what is the best indicator of sepsis? Burns 2007 33(7):939-40; author reply 941-2.
Rec#: 2610
Exclusion Codes: NRD, EXC

Vassilopoulou, S., A. Antonopoulou, E.J. Giamarellos-Bourboulis, D. Plachouras, M. Raftogiannis, T. Tsaganos, F. Baziaka, V. Syriopoulou, and H. Giamarellou. Is there any role for innate immunity in the pathogenesis of bacterial and abacterial meningitis? Infect. Dis. Clin. Pract. 2006 14(1):17-22.
Rec#: 16540
Exclusion Codes: NRO, EXC

Vazzalwar, R., E. Pina-Rodrigues, B. L. Puppala, D. B. Angst, and L. Schweig. Procalcitonin as a screening test for late-onset sepsis in preterm very low birth weight infants. J Perinatol 2005 25(6):397-402.
Rec#: 3850

Exclusion Codes: NDE, EXC

Vega, V.L. A marker for posttraumatic-sepsis: Searching for the Holy Grail around intensive care units. Crit. Care Med. 2009 37(5):1806-1807.
Rec#: 12270
Exclusion Codes: NDE, EXC

Venkatesh, B., P. Kennedy, P. S. Kruger, D. Looke, M. Jones, J. Hall, and G. R. Barruel. Changes in serum procalcitonin and C-reactive protein following antimicrobial therapy as a guide to antibiotic duration in the critically ill: a prospective evaluation. Anaesth Intensive Care 2009 37(1):20-6.
Rec#: 1070
Exclusion Codes: SMN, EXC

Verboon-Maciolek, M. A., S. F. Thijsen, M. A. Hemels, M. Menses, A. M. van Loon, T. G. Krediet, L. J. Gerards, A. Fleer, H. A. Voorbij, and G. T. Rijkers. Inflammatory mediators for the diagnosis and treatment of sepsis in early infancy. Pediatr Res 2006 59(3):457-61.
Rec#: 3440
Exclusion Codes: NDE, EXC

Verheij, T. Excessive use of antibiotics still a relevant problem in the Netherlands as well: Overmatig gebruik van antibiotica ook in Nederland nog een relevant probleem. Huisarts Wet. 2009 52(12):570-571.
Rec#: 15770
Exclusion Codes: NDE, EXC

Verner, L., E. Czaja, M. Szabo, and V. Maravic-Stojkovic. Relation between pro-calcitonin levels with apache II-score in intensive care unit patients: Korelacija prokalcitonina sa apache-II klasifikacionim sistemom kod pacijenata na jedinici za intenzivnu negu. Jugosl. Med. Biokem. 1999 18(1):23-28.
Rec#: 15110
Exclusion Codes: NDE, EXC

Viallon, A., P. Guyomarc'h, S. Guyomarc'h, B. Tardy, F. Robert, O. Marjollet, A. Caricajo, C. Lambert, F. Zeni, and J. C. Bertrand. Decrease in serum procalcitonin levels over time during treatment of acute bacterial meningitis. Crit Care 2005 9(4):R344-50.
Rec#: 9050
Exclusion Codes: NRO, EXC

Viallon, A., S. Guyomarc'h, O. Marjollet, C. Berger, A. Carricajo, F. Robert, S. Laporte, C. Lambert, Y. Page, F. Zeni, and J. C. Bertrand. Can emergency physicians identify a high mortality subgroup of patients with sepsis: role of procalcitonin. Eur J Emerg Med 2008 15(1):26-33.
Rec#: 2190
Exclusion Codes: NDE, EXC

Viallon, A., S. Guyomarc'h, F. Zeni, I. Piteaud, F. Lucht, M. Levy, L. Cotte, G. Aubert, and J.-C. Bertrand. Serum procalcitonin and cerebrospinal fluid lactate levels in emergency room differential diagnosis of acute meningitis with a negative Gram stain: Meningites aigues de l'adulte a examen direct negatif: Interet de la procalcitonine serique et de l'acide lactique cephalo-rachidien dans la prise en charge diagnostique en urgence. JEUR 2003 16(1):4-12.
Rec#: 16820
Exclusion Codes: NDE, EXC

Viallon, A., F. Zeni, C. Lambert, B. Pozzetto, B. Tardy, C. Venet, and J. C. Bertrand. High sensitivity and specificity of serum procalcitonin levels in adults with bacterial meningitis. Clin Infect Dis 1999 28(6):1313-6.
Rec#: 10690
Exclusion Codes: NDE, EXC

Viallon, A., F. Zeni, V. Pouzet, C. Lambert, S. Quenet, G. Aubert, S. Guyomarch, B. Tardy, and J. C. Bertrand. Serum and ascitic procalcitonin levels in cirrhotic patients with spontaneous bacterial peritonitis: diagnostic value and relationship to pro-inflammatory cytokines. Intensive Care Med 2000 26(8):1082-8.
Rec#: 10500
Exclusion Codes: SMN, EXC

Villanueva, J. L., and R. J. Cervin. Serum procalcitonin levels and empirical antibiotic treatment of patients with community-acquired febrile syndromes. Clin Infect Dis 2003 36(6):822; author reply 826-7.
Rec#: 9980
Exclusion Codes: NDE, EXC

Vincent, J.-L., M. Vannuffelen, and A. Zakariah. Sepsis: Current state of play. Crit. Care Shock 2004 7(1):1-4.
Rec#: 14270
Exclusion Codes: NDE, EXC

Volante, E., S. Moretti, F. Pisani, and G. Bevilacqua. Early diagnosis of bacterial infection in the neonate. J Matern Fetal Neonatal Med 2004 16 Suppl 2:13-6.
Rec#: 4040
Exclusion Codes: NDE, EXC

Volk, H. D., P. Reinke, and W. D. Docke. Immunological monitoring of the inflammatory process: Which variables? When to assess? Eur J Surg Suppl 1999 (584):70-2.
Rec#: 6100
Exclusion Codes: NDE, EXC

von Heimburg, D., W. Stieghorst, R. Khorram-Sefat, and N. Pallua. Procalcitonin--a sepsis parameter in severe burn injuries. Burns 1998 24(8):745-50.
Rec#: 6600
Exclusion Codes: NRO, EXC

von Lilienfeld-Toal, M., M. P. Dietrich, A. Glasmacher, L. Lehmann, P. Breig, C. Hahn, I. G. Schmidt-Wolf, G. Marklein, S. Schroeder, and F. Stuber. Markers of bacteremia in febrile neutropenic patients with hematological malignancies: procalcitonin and IL-6 are more reliable than C-reactive protein. Eur J Clin Microbiol Infect Dis 2004 23(7):539-44.
Rec#: 4280
Exclusion Codes: NDE, EXC

von Lilienfeld-Toal, M., A. Schneider, K. Orlopp, C. Hahn-Ast, A. Glasmacher, and F. Stuber. Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignancies. Support Care Cancer 2006 14(12):1241-5.
Rec#: 3300
Exclusion Codes: SMN, EXC

Wagner, F. Immunomonitoring in sepsis: Immunmonitoring bei sepsis. Z. Herz- Thorax- Gefasschir. 2003 17(4):185-190.
Rec#: 14400
Exclusion Codes: NDE, EXC

Wanner, G. A., M. Keel, U. Steckholzer, W. Beier, R. Stocker, and W. Ertel. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit Care Med 2000 28(4):950-7.
Rec#: 6180
Exclusion Codes: NDE, EXC

Watkin, R. W., L. V. Harper, A. B. Vernallis, S. Lang, P. A. Lambert, A. M. Ranasinghe, and T. S. Elliott. Pro-inflammatory cytokines IL6, TNF-alpha, IL1beta, procalcitonin, lipopolysaccharide binding protein and C-reactive protein in infective endocarditis. J Infect 2007 55(3):220-5.
Rec#: 8380
Exclusion Codes: NRO, EXC

Weinberg, G.A., and C.T. D'Angio. The search for new diagnostic tests for neonatal sepsis. J. Pediatr. 2009 155(5):763-764.
Rec#: 12020
Exclusion Codes: NRD, EXC

Werner, J., W. Hartwig, W. Uhl, C. Muller, and M. W. Buchler. Useful markers for predicting severity and monitoring progression of acute pancreatitis. Pancreatology 2003 3(2):115-27.
Rec#: 9920
Exclusion Codes: NDE, EXC

Werner, M., U. Otto, D. Schreiter, P. Lamesch, K. Kohlhaw, H. Witzigmann, J. Hauss, M. Fiedler, and J. Thiery. The Immunological Patient at Risk in Sepsis and Transplantation: Der Immunologische Risikopatient bei Sepsis und Transplantation. Transplantationsmed. Organ Dtsch. Transplantationsges. 2003 15(2):70-90.
Rec#: 14300
Exclusion Codes: NDE, EXC

Whang, K. T., P. M. Steinwald, J. C. White, E. S. Nylen, R. H. Snider, G. L. Simon, R. L. Goldberg, and K. L. Becker. Serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocrinol Metab 1998 83(9):3296-301.
Rec#: 6680
Exclusion Codes: SMN, EXC

Wolk, D.M., and A.B. Fiorello. Code Sepsis: Rapid Methods To Diagnose Sepsis and Detect Hematopathogens. Part II: Challenges to the Laboratory Diagnosis of Sepsis. Clin. Microbiol. Newsl. 2010 32(6):41-49.
Rec#: 11680
Exclusion Codes: NDE, EXC

Worthington, T., D. Dunlop, A. Casey, P. Lambert, J. Luscombe, and T. Elliott. Serum procalcitonin, interleukin-6, soluble intercellular adhesin molecule-1 and IgG to short-chain exocellular lipoteichoic acid as predictors of infection in total joint prosthesis revision. Br. J. Biomed. Sci. 2010 67(2):71-76.
Rec#: 11290
Exclusion Codes: NDE, EXC

Wroblewski, T., and C. Marcisz. Procalcitonin as a biomarker of acute lower respiratory tract infections. Expert Opin. Med. Diagn. 2009 3(1):67-79.
Rec#: 12460
Exclusion Codes: NDE, EXC

Wunder, C., O. Eichelbronner, and N. Roewer. Are IL-6, IL-10 and PCT plasma concentrations reliable for outcome prediction in severe sepsis? A comparison with APACHE III and SAPS II. Inflamm Res 2004 53(4):158-63.
Rec#: 4410
Exclusion Codes: SMN, EXC

Yaegashi, Y., K. Shirakawa, N. Sato, Y. Suzuki, M. Kojika, S. Imai, G. Takahashi, M. Miyata, S. Furusako, and S. Endo. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother 2005 11(5):234-8.
Rec#: 3610
Exclusion Codes: NDE, EXC

Yamada, H., S. Matsuda, Y. Ushio, K. Nakamura, S. Kobatake, S. Satomura, and S. Matsuura. Determination of procalcitonin concentration using the SphereLight 180 clinical auto-analyzer. Clin Chim Acta 2008 388(1-2):38-40.
Rec#: 2280
Exclusion Codes: NRD, EXC

Yan, S.-Y. Premonitor indexes for early diagnosis of sepsis. Chin. Crit. Care Med. 2009 21(3):185-188.
Rec#: 12410
Exclusion Codes: NDE, EXC

Yealy, D. M., and M. J. Fine. Measurement of serum procalcitonin: a step closer to tailored care for respiratory infections? JAMA 2009 302(10):1115-6.
Rec#: 7210
Exclusion Codes: NDE, EXC

Yildiz, C., H. Yildiz, S. Kavuncuoglu, and R. Siraneci. Procalcitonin levels in the diagnosis of early neonatal sepsis: Yenidogan sepsisin erken tanisinda prokalsitonin. Cocuk Sagligi Hast. Derg. 2003 46(2):90-97.
Rec#: 14420
Exclusion Codes: NDE, EXC

Yildiz, O., and B. Aygen. The role of procalcitonin in diagnosis and following of infectious diseases: Infeksiyon hastaliklarinin tani ve takibinde prokalsitoninin yeri. Erciyes Tip Derg. 2000 22(2):105-109.
Rec#: 14800
Exclusion Codes: NDE, EXC

Yilmaz, F. M., G. Yilmaz, H. Akay, M. Duranay, and D. Yucel. Evaluation of a card test for procalcitonin in continuous ambulatory peritoneal dialysis peritonitis. Ann Clin Biochem 2007 44(Pt 5):482-4.
Rec#: 8260
Exclusion Codes: SMN, EXC

Yoshihara, T., T. Imamura, K. Yokoi, M. Shibata, G. Kano, S. Osone, K. Yagi, S. Todo, Y. Murakami, Y. Yamada, H. Yamada, S. Satomura, and H. Ishida. Potential use of procalcitonin concentrations as a diagnostic marker of the PFAPA syndrome. Eur J Pediatr 2007 166(6):621-2.
Rec#: 3110
Exclusion Codes: NRO, EXC

Yukioka, H., G. Yoshida, S. Kurita, and N. Kato. Plasma procalcitonin in sepsis and organ failure. Ann Acad Med Singapore 2001 30(5):528-31.
Rec#: 5650
Exclusion Codes: NRO, EXC

Zahedpasha, Y., M. Ahmadpour-Kacho, M. Hajiahmadi, and M. Haghshenas. Procalcitonin as a marker of neonatal sepsis. Iran. J. Pediatr. 2009 19(2):117-122.
Rec#: 12170
Exclusion Codes: NDE, EXC

Zahorec, R., D. Setvak, D. Cintula, C. Belovicova, and A. Blaskova. Renal rescue therapy in early stage of severe sepsis: a case study approach. Bratisl Lek Listy 2004 105(10-11):345-52.
Rec#: 3990
Exclusion Codes: NDE, EXC

Zakariah, A. N., S. M. Cozzi, M. Van Nuffelen, C. M. Clausi, O. Pradier, and J. L. Vincent. Combination of biphasic transmittance waveform with blood procalcitonin levels for diagnosis of sepsis in acutely ill patients. Crit Care Med 2008 36(5):1507-12.
Rec#: 1840
Exclusion Codes: NDE, EXC

Zazula, R., M. Prucha, A. Spaleny, M. Jaresova, and S. Vitko. Procalcitonin not only in the differential diagnosis of the inflammatory response: Prokalcitonin nejen v diferencialni diagnostice zanetlive odpovedi organismu. Anesteziol. Neodkladna Pece 2002 13(2):86-91.
Rec#: 14640
Exclusion Codes: NRD, EXC

Zeglen, S., J. Wojarski, E. Wozniak-Grygiel, M. Siola, M. Szewczyk, E. Kucewicz-Czech, J. Nozynski, and M. Zembala. Procalcitonin serum concentration during Pneumocystis jiroveci colonization or Pseudomonas aeruginosa infection/colonization in lung transplant recipients. Transplant Proc 2009 41(8):3225-7.
Rec#: 380
Exclusion Codes: NRO, EXC

Zeitoun, A. A., S. S. Gad, F. M. Attia, A. S. Abu Maziad, and E. F. Bell. Evaluation of neutrophilic CD64, interleukin 10 and procalcitonin as diagnostic markers of early- and late-onset neonatal sepsis. Scand J Infect Dis 2010 42(4):299-305.
Rec#: 220
Exclusion Codes: NDE, EXC

Zhang, D., T. Lavaux, A. C. Voegeli, T. Lavigne, V. Castelain, N. Meyer, R. Sapin, D. Aunis, M. H. Metz-Boutigue, and F. Schneider. Prognostic value of chromogranin A at admission in critically ill patients: a cohort study in a medical intensive care unit. Clin Chem 2008 54(9):1497-503.
Rec#: 1480
Exclusion Codes: NDE, EXC

Zycinska, K., K. A. Wardyn, T. M. Zielonka, P. Tyszko, and M. Straburzynski. Procalcitonin as an indicator of systemic response to infection in active pulmonary Wegener's granulomacytosis. J Physiol Pharmacol 2008 59 Suppl 6:839-44.
Rec#: 7530
Exclusion Codes: NRO, EXC

Appendix C. Abstraction Tables

Evidence Table 1A. Study Description Table for Bouadma et al., 2010.[1]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Bouadma et al., 2010. PRORATA (procalcitonin to reduce antibiotic treatments in acutely ill patients) **Country, institution type:** France, 5 university-affiliated hospitals **Enrollment period:** 06/07 – 05/08 **Funding:** Assistance Publique-Hôpitaux de Paris, France, and Brahms, Germany **Author industry relationship disclosures:** 4 authors disclosed conflicts	**Design:** RCT; 1:1, masked until randomization, stratified by center Superior for antibiotics free days Non-inferior with respect to mortality **Interventions:** **G1:** PCT-guided antibiotic therapy **G2:** Standard antibiotic therapy **Presenting condition:** Critically ill patients, , suspected bacterial infection on admission to ICU or during stay **Setting:** ICU (5 MICU, 2 SICU) N screened, reasons for exclusion **N at enrollment:** **G1:** 311 **G2:** 319 **N at follow-up:** **G1:** 307	**Primary outcome:** Mortality at days 28 and 60 (non-inferiority analysis), and number of days without antibiotics by day 28 (superiority analysis) 90 % power to detect a 3 day increase in days without antibiotics, 133 subjects per study group. To have 80 % chance of non-inferiority with respect to mortality (10 % alpha risk), 300 patients needed per study arm Secondary outcomes: ABT exposure, morbidity **Assay type:** Kryptor PCT, Brahms **Decision-making:** 2 interventions For antibiotic initiation **G1:** PCT < 0.25 antibiotics strongly discouraged; PCT ≥ 0.25, < 0.5 antibiotics discouraged; PCT ≥ 0.5 and < 1,	**Inclusion criteria:** • Critically ill patients • ICU • Suspected bacterial infection **Exclusion criteria:** • Age < 18 years • Antibiotics > 24 hours before enrollment • Pregnancy • Expected ICU stay < 3 days • Stem cell transplantation • ANC < 500 • Chronic infections • SAPS II > 65 (unlikely to survive) • Do not resuscitate	**Age, years:** [mean (SD), median (range/IQR)] **G1:** 61.0 (15.2) **G2:** 62.1 (15.0) [test, result (p-value, 95% CI)] **G1/G2:** **Women, n (%):** **G1:** 100 (33 %) **G2:** 110 (35 %) [test, result (p-value, 95% CI)] **G1/G2:** **PCT:** [mean (SD), median (range/IQR)] **G1:** 12.0 (30.9) **G2:** 12.0 (32.6) [test, result (p-value, 95% CI)] **G1/G2:** **Infection site, n (%):** **G1:** Pulmonary (183) 71 % UTI (24) 9 % SSI (5) 2 % Intra-abdominal (14) 5 % CNS (7) 2 % CVC (5) 3 % Bacteremia (9) 4 % Other (11) 4 %	**CHF (NYHA III/IV), n (%):** [test, result (p-value, 95% CI)] **G1:** 16 (5 %) **G2:** 13 (4 %) **G1/G2:** **Insulin-dependent diabetes, n (%):** **G1:** 27 (9 %) **G2:** 22 (7 %) [test, result (p-value, 95% CI)] **G1/G2:** **Cirrhosis, n (%):** **G1:** 20 (7 %) **G2:** 13 (4 %) [test, result (p-value, 95% CI)] **G1/G2:** **Home oxygen, n (%):** **G1:** 23 (7 %) **G2:** 18 (6 %) [test, result (p-value, 95% CI)] **G1/G2:** **CRF on hemodialysis, n (%):** **G1:** 17 (6 %) **G2:** 11 (4 %) [test, result (p-value, 95%

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
	G2: 314 **Average follow-up, days:** [mean (SD), median (range/IQR)] **G1:** NR **G2:** NR Follow-up to 60 days	antibiotics encouraged; PCT $\geq$ 1.0, antibiotics strongly encouraged **G2:** Standard therapy For antibiotic discontinuation **G1:** PCT < 0.25, stopping antibiotics strongly encouraged; PCT $\geq$ 80 % decrease from peak or < 0.5 ng/mL, stopping antibiotics encouraged; PCT < 80 % decrease from peak or $\geq$ 0.5, continuing antibiotics encouraged; PCT > baseline and $\geq$ 0.5, continuing antibiotics strongly encouraged **G2:** Standard therapy **Condition = definition:** Suspected bacterial infections **Condition = definition:** Sepsis		**G2:** Pulmonary (211)71 % UTI (18) 9 % SSI (6) 2 % Intra -abdominal (20) 5 % CNS (6) 2 % CVC (3) 3 % Bacteremia (11) 4 % Other (9) 4 %	CI)] **G1/G2:** **Metastatic cancer, n (%):** **G1:** 8 (3 %) **G2:** 5 (2 %) [test, result (p-value, 95% CI)] **G1/G2:** **Immunocompromised, n (%):** **G1:** 47 (15 %) **G2:** 51 (16 %) [test, result (p-value, 95% CI)] **G1/G2:** **SAPS II, mean (std dev):** **G1:** 47.1 (17.9) **G2:** 46.9 (17.2) **SOFA, mean (std dev):** **G1:** 8.0 (4.7) **G2:** 7.7 (4.6) **Septic shock, n (%):** **G1:** 53 (17 %) **G2:** 55 (18 %)

Evidence Table 2A. Intermediate Outcomes for Bouadma et al., 2010.[1]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
Days without antibiotics at 28 days (superiority): [mean (SD), median (range/IQR)] **G1:** 14.3 (9.1) **G2:** 11.6 (8.2) [test, result (p-value, 95% CI)] p < 0.0001 **G1/G2:** **Duration of first episode antibiotic treatment, mean (std dev):** **G1:** 6.1 (6.0) **G2:** 9.9 (7.1) [test, result (p-value, 95% CI)] p < 0.0001 **G1/G2:** **Days antibiotic exposure/1,000:** (rate days exposed per #patient-days) **G1:** 653 **G2:** 812 [test, result (p-value, 95% CI)] **G1/G2:** -159(-185 to -131)	NR	NR	**Days:** [mean (SD), median (range/IQR)] **G1:** 26.1 (19.3) **G2:** 26.4 (18.3) [test, result (p-value, 95% CI)] **G1/G2:** NSS	**Days:** [mean (SD), median (range/IQR)] **G1:** 15.9 (16.1) **G2:** 14.4 (14.1) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 3A. Morbidity Outcomes for Bouadma et al., 2010.[1]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
SOFA day 28, mean (std dev): **G1:** 1.5 (3.0) **G2:** 0.9 (2.4) [test, result (p-value, 95% CI)] **G1/G2:**	**Mechanical ventilation-free days:** [mean (SD), median (range/IQR)] **G1:** 16.2 (11.1) **G2:** 16.9 (10.9) [test, result (p-value, 95% CI)] **G1/G2:** **Nosocomial superinfection, n, (%):** **G1:** 106 (34.5 %) **G2:** 97 (30.9 %) [test, result (p-value, 95% CI)] **G1/G2:** **Multi drug resistant, n (%):** **G1:** 55 (17.9 %) **G2:** 52 (16.6 %) [test, result (p-value, 95% CI)] **G1/G2:**	**Relapse, n, (%):** **G1:** 20 (6.5 %) **G2:** 16 (5.1 %) [test, result (p-value, 95% CI)] **G1/G2:**	NR	NR

Evidence Table 4A. Mortality Outcomes for Bouadma et al., 2010.[1]

In-hospital mortality	28-day mortality	60-day mortality	Pneumonia-related death	Proportion surviving hospitalization
NR	**Proportion (%):** **G1:** 21.2 % **G2:** 20.4 % [test, result (p-value, 95% CI)] **G1/G2:** Non-inferiority, 10 % margin	**Proportion (%):** **G1:** 30.0 % **G2:** 26.1 % [test, result (p-value, 95% CI)] **G1/G2:** Non-inferiority, 10 % margin	NR	NR

Evidence Table 5A. Function and Quality of Life Outcomes for Bouadma et al., 2010.[1]

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	NR	NR

Evidence Table 6A. Adverse Effects, Adherence for Bouadma et al., 2010.[1]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence
NR	NR	NR	NR

Evidence Table 7A. Randomized Trial Study Quality Ratings for Bouadma et al., 2010.[1]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y	Y	Y	Y	Y	Y	Y

Evidence Table 1B. Study Description Table for Briel et al., 2008.[2]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Briel et al., 2008. **Country, institution type:** Switzerland **Enrollment period:** December 13, 2004-April 30, 2006 **Funding:** Swiss National Science Foundation; Assoc. for the Promotion of Science and Postgraduate Training of the University Hospital of Basel; Brahms **Author industry relationship disclosures:** 1 author consultant and recipient of funds from Brahms for travel, speaking	**Design:** RCT, open, multicenter, non-inferiority **Interventions:** **G1:** Procalcitonin-guided therapy **G2:** Standard therapy **Presenting condition:** Adults with acute respiratory tract infection in need of antibiotics **Setting:** 53 primary care physicians, multi-center, non-inferiority trial, monitored by independent monitoring board 8162 patients consulted for RTI 1480 assessed because of perceived need for antibiotics 1022 excluded 67 with symptoms> 28 days 21 given antibiotics within 28 days 180 not fluent 41 psych issues 35 needed immediate hospitalization 63 with severe immunosuppression 152 not available for	**Primary outcome:** Intent to treat and per protocol Primary outcomes Number of days in first 14 days after baseline with restricted activities due to RTI Intent to treat and per protocol **Secondary outcomes:** Only per protocol analysis Antibiotic prescription rate Duration of antibiotic Discomfort scale Days of work missed Days with adverse medication effects Ongoing or relapsed RTI SAEs within 28 days 275 needed to show hat at worst PCT-guided therapy increased antibiotic duration by 1 day, alpha error 5 % **Response criteria, independent outcome assessor:** **Assay type:** Kryptor, Brahms Results available within	**Inclusion criteria:** • Cold • Sinusitis • Pharyngitis • Tonsillitis, • Tracheobronchitis • AECOPD, • CAP • Intention to prescribe antibiotics **Exclusion criteria:** • Antibiotics in previous 28 days • Psych disorders • Severe immunosuppression • Cystic fibrosis • TB • Need for immediate hospitalization • Not available for follow-up • Not fluent in German	**Age, years:** [mean (SD), **G1:** 48 (18) **G2:** 48 (18) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Men, n (%):** **G1:** 98 (42 %) **G2:** 87 (38 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Days with restricted activities, mean (SD):** **G1:** 5.8 (4.7) **G2:** 6.5 (4.7) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Discomfort score, mean (SD):** **G1:** 6.1 (2.6) **G2:** 6.2 (2.4) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Diagnosis Common cold, n, (%):**] **G1:** 13 (5.6 %) **G2:** 18 (8.0 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Acute sinusitis, n, (%):**] **G1:** 52 (22 %)	**Any co-morbidities, n (%):** [test, result (p-value, 95% CI)] **G1:** 33 (14 %) **G2:** 37 (16 %) **G1/G2:** NSS **Chronic lung disease, n (%):** [test, result (p-value, 95% CI)] **G1:** 12 (5.2 %) **G2:** 14 (6.2 %) **G1/G2:** NSS **Diabetes mellitus, n (%):** **G1:** 6 (2.6 %) **G2:** 7 (3.1 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Congestive heart failure, n (%):** **G1:** 8 (3.4 %) **G2:** 6 (2.6 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Other, n (%):** **G1:** 7 (3.0 %) **G2:** 10 (4.4 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **PCT, mean (SD):** **G1:** 0.39 (2.7)

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
	follow-up 217 physician not able to follow 246 refused consent 458 randomized **N at enrollment:** **G1:** 232 **G2:** 226 **N at follow-up:** **G1:** 230 (2 LTFU) **G2:** 223 (2 LTFU) **Average follow-up, days:** [mean (SD), median (range/IQR)] **G1:** 28 days **G2:** 28 days	2-4 hours **Decision-making:** **G1:** For PCT 0.01, antibiotics discouraged For PCT between 0.1-0.25, antibiotics not recommended For PCT > 0.25, antibiotics recommended Also if second PCT in 6-24 hours was increased by 50 % **G2:** Physicians encouraged to use evidence-based guidelines **Decision-making:** **G1:** If PCT < 0.25 at day 3, discontinuation recommended **Condition = definition:** Physician diagnosis		**G2:** 52 (23 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Pharyngitis/tonsillitis, n, (%):**] **G1:** 42 (18 %) **G2:** 33 (15 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Laryngitis/tracheitis, n, (%):**] **G1:** 8 (3.5 %) **G2:** 4 (1.8 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Acute otitis media, n, (%):**] **G1:** 0 **G2:** 5 (2.2 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Acute bronchitis, n, (%):**] **G1:** 58 (25 %) **G2:** 70 (31 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Influenza, n, (%):**] **G1:** 3 (1.3 %) **G2:** 1 (0.4 %) [test, result (p-value, 95%	**G2:** 0.25 (1.3) [test, result (p-value, 95% CI)] **G1/G2:** NSS **CRP, mean (SD):** **G1:** 51 (65) **G2:** 51 (55) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
				CI)] **G1/G2:** NSS **AECOPD, n, (%):**] **G1:** 12 (5.2 %) **G2:** 9 (4.0 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Acute asthma attack, n, (%):**] **G1:** 6 (2.6 %) **G2:** 2 (1.3 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **CAP, n, (%):**] **G1:** 38 (16 %) **G2:** 31 (14 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	

Evidence Table 2B. Intermediate Outcomes for Briel et al., 2008.[2]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
Days with antibiotics: mean (SD) **G1:** 6.2 (2.5) **G2:** 7.1 (2.2) [test, result (p-value, 95% CI)] **G1/G2:** Adjusted difference in days (95 % CI) -1.0 (-1.7 to -0.4)	**Any antibiotic use, antibiotic prescription rate (%):** **G1:** 58 (25 %) **G2:** 219 (97 %) [test, result (p-value, 95% CI)] **G1/G2:** Difference -72 % (-78 to -66) Adjusted odds ratio (95 % CI) 0.01 (0.002 to 0.02)	NR	NR	NR

Evidence Table 3B. Morbidity Outcomes for Briel et al., 2008.[2]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
NR	**Intent to treat** **Restricted activities, days:** [mean (SD), median (range/IQR)] **G1:** 8.7 (3.9) **G2:** 8.6 (3.0) [test, result (p-value, 95% CI)] **G1/G2:** Adjusted difference (95 % CI) 0.2 (-0.4 to 0.9) **Days of work missed within 14 days:** [mean (SD), median (range/IQR)] **G1:** 4.9 (4.6) **G2:** 4.8 (4.2) [test, result (p-value, 95% CI)] **G1/G2:** Adjusted difference (95 % CI) 0.3 (-0.6 to 1.2)	NR	NR	**RTI symptoms at 28 days (%):** **G1:** 69 (30 %) **G2:** 67 (30 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Degree of discomfort score at 14 days:** [mean (SD) **G1:** 1.9 (2.7) **G2:** 1.1 (1.9) [test, result (p-value, 95% CI)] **G1/G2:** Adjusted difference (95 % CI) 0.8 (0.4 to 1.2)

Evidence Table 4B. Mortality Outcomes for Briel et al., 2008.[2]

In-hospital mortality	28-day mortality	Death	Pneumonia-related death	Proportion surviving hospitalization
NR	NR	NR	NR	NR

Evidence Table 5B. Function and Quality of Life Outcomes for Briel et al., 2008.[2]

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	NR	NR

Evidence Table 6B. Adverse Effects and Adherence for Briel et al., 2008.[2]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence
Proportion (%): **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:**	**Days of AEs within 14 days:** [mean (SD), median (range/IQR)] **G1:** 2.3 (4.6) **G2:** 3.6 (6.1) [test, result (p-value, 95% CI)] **G1/G2:** Adjusted difference (95 % CI) -1.1 (-2.1 to -0.1) Mainly due to number with diarrhea (47/231 vs 76/224)	NR	NR

Evidence Table 7B. Randomized Trial Study Quality Ratings for Briel et al., 2008.[2]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y- balanced Y-concealment	Y	Y	Y	Y	Y	Y

Evidence Table 1C. Study Description Table for Burkhardt et al., 2010.[3]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Burkhardt et al., 2010. **Country, institution type:** Germany, Medical Hospital Hannover **Enrollment period:** Not given **Funding:** Not given **Author industry relationship disclosures:** Conflicts for 7 authors available at www.erj.ersjournals.com/misc/statements.dtl, 3 authors from Brahms Research Dept.	**Design:** RCT, intent to treat analysis **Interventions:** **G1:** PCT-guided antibiotic therapy **G2:** Standard care **Presenting condition:** Acute respiratory tract infection **Setting:** Primary care offices **N at enrollment:** **G1:** 275 **G2:** 275 **N at follow-up:** **G1:** NR **G2:** NR **Average follow-up, days:** [mean (SD), median (range/IQR)] **G1:** 14 day **G2:** 28 day	**Primary outcome:** Number of days with significant health impairment due to RTI at day 14 Non-inferior of the 95 % CI for the difference between groups in number of days with impairment was < 1 day 90 % chance to show that PCT-guided therapy does not lead to > 1 additional day of impairment with 275 patients per group **Secondary outcomes:** Prescription rate, duration of antibiotic, days with antibiotic-associated SEs, symptoms on day 14 and 28, revisit within 28 days, change of antibiotics within 28 days, hospitalization within 28 days, 28 day mortality Kruskal-Willis and Pearson's Chi-squared test **Assay type:** Brahms Kryptor PCT **Decision-making:** G1: PCT < 0.25, no antibiotics; PCT > 0.25, antibiotics recommended G2: Standard care	**Inclusion criteria:** • > 18 years of age • Symptoms of acute RTI, URTI or LRTI-no standardized clinical diagnosis **Exclusion criteria:** • Antibiotics in previous 2 weeks • Major surgery in past 4 weeks • Chronic liver disease • Autoimmune or systemic disorders • HD • Medullary thyroid cancer • Inflammatory diseases	**Age, years:** [mean (SD), median (range/IQR)] **G1:** 41.4 ±15.3 **G2:** 43.4 ±15.5 [test, result (p-value, 95% CI)] **G1/G2:** NSS **Male, n (%):** **G1:** 164 (59.6) **G2:** 161 (58.5) [test, result (p-value, 95% CI)] **G1/G2:** NSS **PCT :** [mean (SD), median (range/IQR)] **G1:** 0.054 ng/mL **G2:** 0.057 ng/mL [test, result (p-value, 95% CI)] **G1/G2:** NSS	**Insulin-dependent diabetes, n (%):** **G1:** 15/275 (5.5 %) **G2:** 9/275 (3.3 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Congestive heart failure, n (%):** **G1:** 5/275 (1.8 %) **G2:** 5/275 (1.8 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **COPD, n (%):** **G1:** 4/275 (1.5 %) **G2:** 9/275 (3.3 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 2C. Intermediate Outcomes for Burkhardt et al., 2010.[3]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
Days: [mean (SD), median (range/IQR)] **G1:** 7.8 ± 2.8 **G2:** 7.7 ± 3.3 [test, result (p-value, 95% CI)] **G1/G2:** p = 0.68	**Any antibiotic use, antibiotic prescription rate (%):** **G1:** 59/275 (21.5 %) **G2:** 101/275 (36.8 %) [test, result (p-value, 95% CI)] **G1/G2:** p = 0.0005	NR	**Hospitalization, n (%):** [mean (SD), median (range/IQR)] **G1:** 0 (0.0 %) **G2:** 1/275 (0.4 %) [test, result (p-value, 95% CI)] **G1/G2:**	NR

Evidence Table 3C. Morbidity Outcomes for Burkhardt et al., 2010.[3]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
NR	NR	NR	NR	NR

Evidence Table 4C. Mortality Outcomes for Burkhardt et al., 2010.[3]

In-hospital mortality	28-day mortality	Death	Pneumonia-related death	Proportion surviving hospitalization
NR	NR	NR	NR	NR

Evidence Table 5C. Function and Quality of Life Outcomes for Burkhardt et al., 2010.[3]

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
Modified intention to treat analysis **Days:** [mean (SD), median (range/IQR)] **G1:** 9.04 **G2:** 9.00 [test, result (p-value, 95% CI)] **G1/G2:** difference between G1 and G2 0.04 days, 95% CI -0.53 to 0.95) Worst case sensitivity analysis **Days:** [mean (SD), median (range/IQR)] **G1:** 9.06 **G2:** 8.80 [test, result (p-value, 95% CI)] **G1/G2:** difference between G1 and G2 0.25 days, 95% CI -0.52 to 1.03)	NR	NR	NR

Evidence Table 6C. Adverse Effects and Adherence for Burkhardt et al., 2010.[3]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence
NR	**Antibiotic adverse effects (%):** **G1:** 11 **G2:** 16 [test, result (p-value, 95% CI)] **G1/G2:** p = 0.331	NR	NR

Evidence Table 7C. Randomized Trial Study Quality Ratings for Burkhardt et al., 2010.[3]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y balanced Y-concealment	Y	Y	Y	Y	Y	Y

Evidence Table 1D. Study Description Table for Christ-Crain et al., 2004.[4]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Christ-Crain et al., 2004. **Country, institution type:** Switzerland, University Hospital **Enrollment period:** December 16, 2002, April 13, 2003 **Funding:** Brahms, Dept of Medicine, Freiwillige Akadmische Gesellschaft Basel **Author industry relationship disclosures:** 1 author consultant, recipient of payments from Brahms	**Design:** Prospective, cluster-randomized, single-blinded study **Interventions:** **G1:** Procalcitonin-based therapeutic strategy **G2:** Standard care **Presenting condition:** LRTI **Setting:** ED 4119 patients in ED 597 (14 %) with cough, dyspnea Screened Excluded **N at enrollment:** **G1:** 124 **G2:** 119 **N at follow-up:** **G1:** 112 (4 died, 8 LTFU) **G2:** 110 (4 died, 5 LTFU) **Average follow-up, days:** [mean (SD), median (range/IQR)] **G1:** NR **G2:** NR	**Primary outcome:** Use of antibiotics % prescription Patient-days RR antibiotic exposure for LRTI and AECOPD 95 % chance of detecting a 30 % reduction in antibiotic exposure **Secondary outcomes:** Clinical and laboratory outcome QOL Temp WBC count CRP PCT Admission rates LOS ICU Death for LRTIs Re-exacerbation, readmission for AECOPD **Response criteria, independent outcome assessor:** **Assay type:** Kryptor PCT, Brahms **Decision-making:** **G1:** For antibiotic initiation PCT < 0.1, antibiotics strongly discouraged PCT 0.1-0.25. antibiotics discouraged	**Inclusion criteria:** • Cough • Dyspnea • Both • Lower RTI **Exclusion criteria:** • Severely immuno-compromised • Neutropenic • SCT • Cystic fibrosis • TB • Nosocomial pneumonia • HIV with CD4 < 200/mm^3	**Age, years:** mean (SD): **G1:** 62.8 (19.8) **G2:** 65.3 (17.3) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Men, n (%):** **G1:** 67 (54 %) **G2:** 61 (51 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Current smoker, n, (%):** **G1:** 27 (22 %) **G2:** 35 (29 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Pack- years:** mean (SD): **G1:** 41.4 (25.0) **G2:** 40.0 (26.0) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Abnormal CXR, n, (%):** **G1:** 48 (39 %) **G2:** 46 (39 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **CAP, n, (%):** **G1:** 42 (34 %) **G2:** 45 (38 %) [test, result (p-value, 95% CI)]	**Coronary artery disease, n (%):** [test, result (p-value, 95% CI)] **G1:** 27 (22 %) **G2:** 32 (27 %) **G1/G2:** NSS **Congestive heart failure, n (%):** **G1:** 11 (9%) **G2:** 7 (6 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Peripheral vascular disease, n (%):** **G1:** 10 (8 %) **G2:** 9 (8 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Cerebrovascular disease, n (%):** **G1:** 4 (3 %) **G2:** 5 (4 5) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Renal dysfunction, n (%):** 22 (18 %) **G1:** 18 (15 %) **G2:** [test, result (p-value, 95% CI)] **G1/G2:** NSS

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
		PCT 0.25-0.5, antibiotics encouraged PCT 0.5 or greater, antibiotics strongly encouraged **G2:** Standard therapy **Decision-making:** **G1:** For antibiotic discontinuation PCT < 0.25, d/c antibiotics **G2:** Standard therapy **Condition = definition:**		**G1/G2:** NSS **AECOPD, n, (%):** **G1:** 29 (23 %) **G2:** 31 (26 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Acute bronchitis, n, (%):** **G1:** 28 (23 %) **G2:** 31 (26 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Asthma attack, n, (%):** **G1:** 10 (8 %) **G2:** 3 (3 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Other, n, (%):** **G1:** 15 (12 %) **G2:** 9 (8 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **PCT:** mean (SD): **G1:** 1.6 (7.7) **G2:** 1.6 (4.2) [test, result (p-value, 95% CI)] **G1/G2:** NSS	**Liver dysfunction, n (%):** 6 (5 %) **G1:** 6 (5 %) **G2:** [test, result (p-value, 95% CI)] **G1/G2:** NSS **Diabetes mellitus, n (%):** **G1:** 15 (12 %) **G2:** 17 (14 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Initial VAS:** [mean (SD), median (range/IQR)] **G1:** 42.5 (20.4) **G2:** 43.1 (21.0) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Initial Quality of life:** [mean (SD), median (range/IQR)] **G1:** 41.3 (14.3) **G2:** 39.3 (13.2) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 2D. Intermediate Outcomes for Christ-Crain et al., 2004.[4]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
Days: [mean (SD), median (range/IQR)] **G1:** 10.9 +/- 3.6 **G2:** 12.8 +/- 5.5 [test, result (p-value, 95% CI)] **G1/G2:** p =0.03 **Incidence density antibiotic exposure:** (rate days exposed per 1,000 patient-days) **G1:** 332 +/- 433 **G2:** 661 +/- 398 [test, result (p-value, 95% CI)] **G1/G2:** p < 0.0001 **Antibiotic cost per patient, US $, mean(SD):** **G1:** 96.3 (172.8) **G2:** 202.5 (250.6) [test, result (p-value, 95% CI)] **G1/G2:** p < 0.0001	**Any antibiotic use, antibiotic prescription rate (%):** **G1:** 55/124 (44 %) **G2:** 99/119 (83 %) [test, result (p-value, 95% CI)] **G1/G2:** p < 0.001 **G1-CAP:** 38/42 **G1-AECOPD:** 11/29 **G1-Bronchitis:** 4/28 **G1-Asthma:** 0/10 **G1-Others:** 2/15 **G2-CAP:** 45/45, p = 0.003 **G2-AECOPD:** 27/31, p < 0.001 **G2-Bronchitis:** 16/31, p = 0.003 **G2-Asthma:** 2/3, p = 0.003 **G2-Others:** 9/9, p < 0.001 [test, result (p-value, 95% CI)] **G1/G2:**	NR	**Admission rate (%):** **G1:** 101 (81 %) **G2:** 88 (74 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Days:** [mean (SD), median (range/IQR)] **G1:** 10.7 (8.9) **G2:** 11.2 (10.6) [test, result (p-value, 95% CI)] **G1/G2:** NSS	**ICU admission (%):** **G1:** 5 (4 %) **G2:** 6 (5 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 3D. Morbidity Outcomes for Christ-Crain et al., 2004.[4]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
NR	NR	NR	NR	NR

Evidence Table 4D. Mortality Outcomes for Christ-Crain et al., 2004.[4]

In-hospital mortality	28-day mortality	Death	Pneumonia-related death	Proportion surviving hospitalization
NR	NR	**Proportion (%):** **G1:** 4 (3 %) **G2:** 4 (3 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR	NR

Evidence Table 5D. Function and Quality of Life Outcomes for Christ-Crain et al., 2004.[4]

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	**Final VAS:** [mean (SD), median (range/IQR)] **G1:** 65.1 (21.8) **G2:** 64.1 (21.5) [test, result (p-value, 95% CI)] **G1/G2:** NSS	**Final Quality of life:** [mean (SD), median (range/IQR)] **G1:** 21.9 (14.7) **G2:** 22.9 (15.1) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 6D. Adverse Effects and Adherence for Christ-Crain et al., 2004.[4]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence
NR	NR	NR	NR

Evidence Table 7D. Randomized Trial Study Quality Ratings for Christ-Crain et al., 2004.[4]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y-balanced N/A-concealment	Y	Y	Y	Y	Y	N

Evidence Table 1E. Study Description Table for Christ-Crain et al., 2006.[5]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Christ-Crain et al., 2006. **Country, institution type:** Switzerland, University Hospital of Basel **Enrollment period:** November 2003-February 2005 **Funding:** Brahms, Pfizer, Mepha, University Hospital of Basel **Author industry relationship disclosures:** 1 author received grants and lecture fees from Brahms, 1 author was on the Brahms advisory board for lecture fees	**Design:** RCT, 1:1, intent-to-treat **Interventions:** **G1:** Procalcitonin guidance **G2:** Usual practice **Presenting condition:** CAP admitted to ED, single center **Setting:** ED 404 with CAP 102 excluded 37 immuno-compromised 3 TB 1 cystic fibrosis 17 HAP 17 no infiltrate 2 death before inclusion 25 no consent **N at enrollment:** **G1:** 151 **G2:** 151 **N at follow-up:** **G1:** 131 (20 died) **G2:** 131 (18 died, 2 LTFU) **Average follow-up, days:** [mean (SD), median (range/IQR)] **G1:** NR **G2:** NR 6 weeks	**Primary outcome:** Total antibiotic use (prescription) and duration Study powered to detect a 30 % reduction in antibiotic exposure (95 %). This also gave the study a 74 % chance to detect a 10 % increase in failure or complications **Secondary outcomes:** Laboratory, clinical outcomes Also cost assessment, direct (PCT, antibiotics) Indirect (adverse events, multidrug resistance, etc.) not considered **Response criteria, independent outcome assessor:** **Assay type:** Kryptor PCT, Brahms **Decision-making:** **G1:** 2 interventions For antibiotic initiation and discontinuation PCT < 0.1 antibiotics strongly discouraged PCT $\geq$ 0.1, < 0.25, antibiotics discouraged	**Inclusion criteria:** • > 18 years of age • CAP principle diagnosis defined by new infiltrate on CXR and one of the following: cough, sputum production, dyspnea, fever > 38^{o} C, abnormal breath sounds, white blood count > 10,000 or < 4,000 **Exclusion criteria:** • Cystic fibrosis • TB • HAP • severely immuno-compromised hosts	**Age, years:** mean (SD) **G1:** 70 (17) **G2:** 70 (17) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Men, n (%):** **G1:** 94 (62 %) **G2:** 93 (62%) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Current smoker, n (%):** **G1:** 34 (23 %) **G2:** 39 (26 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Pack- years:** mean (SD) **G1:** 42 (27) **G2:** 38 (20) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Fever:** [mean (SD) **G1:** 38.4 (1.1) **G2:** 38.4 (1.1) [test, result (p-value, 95% CI)] **G1/G2:** NSS **PCT:** median (range) **G1:** 0.57 (0.2-2.5) **G2:** 0.44 (0.2-1.9) [test, result (p-value, 95% CI)]	**Coronary artery diseases, n (%):**] **G1:** 49 (33 %) **G2:** 48 (32 %) **G1/G2:** NSS **Hypertensive heart failure, n (%):** **G1:** 42 (28 %) **G2:** 36 (24 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Congestive heart failure, n (%):** **G1:** 7 (5 %) **G2:** 9 (6 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Peripheral vascular disease, n (%):** **G1:** 11 (7 %) **G2:** 9 (6 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Cerebrovascular disease, n (%):** **G1:** 8 (5 %) **G2:** 8 (5 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Renal dysfunction, n (%):**

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
		PCT $\geq$ 0.25, $\leq$ 0.5, antibiotics encouraged PCT > 0.5, antibiotics strongly encouraged I f baseline > 10, antibiotics discontinued if less than 10 % of initial value **G2:** Standard therapy		**G1/G2:** NSS **CRP:** median (range) **G1:** 111 (57-204) **G2:** 152 (72-212) [test, result (p-value, 95% CI)] **G1/G2:** NSS **WBC count:** [mean (SD) **G1:** 13.7 (6.7) **G2:** 13.4 (6.6) [test, result (p-value, 95% CI)] **G1/G2:** NSS **QOL score:** mean (SD) **G1:** 40 (13) **G2:** 39 (13) [test, result (p-value, 95% CI)] **G1/G2:** NSS **VAS, %:** mean (SD) **G1:** 43 (20) **G2:** 39 (21) [test, result (p-value, 95% CI)] **G1/G2:** NSS **PSI points:** mean (SD) **G1:** 99.7 (36.1) **G2:** 99.2 (34.5) [test, result (p-value, 95% CI)] **G1/G2:** NSS	**G1:** 36 (24 %) **G2:** 45 (30 %) [test, result (p-value, 95% CI)] **G1/G2:** **Liver disease, n (%):** **G1:** 12 (8 %) **G2:** 19 (13 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Diabetes mellitus, n (%):** **G1:** 32 (21 %) **G2:** 29 (19 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **COPD, n (%):** **G1:** 44 (29 %) **G2:** 32 (21 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Cancer, n (%):** **G1:** 25 (17 %) **G2:** 23 (15 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
				PSI class I, II, III, n (%): **G1:** 54 (36 %) **G2:** 66 (44 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **PSI class IV, n (%):** **G1:** 68 (45 %) **G2:** 62 (41 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **PSI class V, n (%):** **G1:** 29 (19 %) **G2:** 23 (15 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	

Evidence Table 2E. Intermediate Outcomes for Christ-Crain et al., 2006.[5]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
Days: [mean (SD), median (range/IQR)] **G1:** 5.8 (5.3) **G2:** 12.9 (6.5) [test, result (p-value, 95% CI)] **G1/G2:** p < 0.001 **Days, if prescribed:** [mean (SD), median (range/IQR)] **G1:** 6.8 (5.1) **G2:** 13.1 (6.4) [test, result (p-value, 95% CI)] **G1/G2:** p < 0.001 **Days if bacteremic:** [mean (SD), median (range/IQR)] **G1:** 13.0 (8.9) **G2:** 13.9 (4.9) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Incidence density antibiotic exposure:** (rate days exposed per 1,000 patient-days) **G1:** 136 (95% CI 126 to 146) **G2:** 323 (95% CI 309 to 338) [test, result (p-value, 95% CI)] **G1/G2:** p < 0.001 **Antibiotic cost, US $:** **G1:** 29,248 **G2:** 59,535 [test, result (p-value, 95% CI)] **G1/G2:** p < 0.001 **Antibiotic cost per patient, US $:** **G1:** 100 (33-186) **G2:** 190 (133-337) [test, result (p-value, 95% CI)] **G1/G2:** p < 0.001	**Any antibiotic use, antibiotic prescription rate (%):** **G1:** 128 (85 %) **G2:** 149 (99 %) [test, result (p-value, 95% CI)] **G1/G2:** p < 0.001	NR	**Hospitalization (%):** **G1:** 146 (97 %) **G2:** 146 (97 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Days:** [mean (SD), median (range/IQR)] **G1:** 12.0 (9.1) **G2:** 13.0 (9.0) [test, result (p-value, 95% CI)] **G1/G2:** NSS	**ICU admission (%):** **G1:** 20 (13 %) **G2:** 21 (14 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 3E. Morbidity Outcomes for Christ-Crain et al., 2006.[5]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
NR	NR	**Microbiological recurrence of infection (%):** **G1:** 1 (1 %) **G2:** 0 [test, result (p-value, 95% CI)] **G1/G2:** NSS **Clinical/radiological recurrence (%):** **G1:** 4 (3 %) **G2:** 4 (3 %) [test, result (p-value, 95% CI)] **G1/G2:** **Persistent of pneumonia:** **G1:** 1 (1 %) **G2:** 3 (2 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Empyema, n (%):** **G1:** 4 (3 %) **G2:** 7 (5 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **ARDS, n (%):** **G1:** 1 (1 %) **G2:** 1 (1 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR	**Success at follow-up, n, (%):** **G1:** 127/151 (84 %) **G2:** 124/151 (82 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Clinical cure, n, (%):** **G1:** 108/127 (85 %) **G2:** 105/124 (85 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Improved, n, (%):** **G1:** 19/127 (15 %) **G2:** 19/124 (15 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 4E. Mortality Outcomes for Christ-Crain et al., 2006.[5]

In-hospital mortality	28-day mortality	Death	Pneumonia-related death	Proportion surviving hospitalization
NR	NR	**Proportion (%):** **G1:** 18 (12 %) **G2:** 20 (13 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	**Proportion (%):** **G1:** 10 (56 %) **G2:** 10 (50 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR

Evidence Table 5E. Function and Quality of Life Outcomes for Christ-Crain et al., 2006.[5]

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	**Function:** [mean (SD), median (range/IQR)] **G1:** 79 (18) **G2:** 74 (20) [test, result (p-value, 95% CI)] **G1/G2:** NSS	**Quality of life:** [mean (SD) **G1:** 10 (10) **G2:** 11 (10) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 6E. Adverse Effects and Adherence for Christ-Crain et al., 2006.[5]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence
NR	NR	NR	NR

Evidence Table 7E. Randomized Trial Study Quality Ratings for Christ-Crain et al., 2006.[5]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y- balanced Y-concealment	Y	Y	Y	Y	Y	Y

Evidence Table 1F. Study Description Table for Chromik et al., 2005.[6]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Chromik et al., 2005. **Country, institution type:** Germany, University Hospital of Wurzburg **Enrollment period:** Not given **Funding:** Not given **Author industry relationship disclosures:** Not given	**Design:** RCT, 1:1, single arm with respect to PCT **Interventions:** **G1:** Preemptive treatment **G2:** Standard treatment **Presenting condition:** 250 consecutive colorectal surgery patients **Setting:** Inpatient hospital, surgical service **N at enrollment:** **G1:** 10 **G2:** 10 **N at follow-up:** **G1:** 10 **G2:** 10	**Primary outcome:** Post-op complications; local wound or systemic infection Secondary outcomes: Mortality for post-op infections, complications, fever, WBC, duration of antibiotics, LOS No power calculation **Response criteria, independent outcome assessor:** **Assay type:** Kryptor, Brahms **Decision-making:** **G1:** PCT-guided pre-emptive antibiotics If PCT > 1.5 post-op, randomized 1 :1 to receive Ceftriaxone or placebo **G2:** No pre-emptive antibiotics, patients followed for signs of post-op infections **Condition = definition:** Colorectal surgery	**Inclusion criteria:** • Elective colonic surgery • Written consent • Peri-operative antibiotic prophylaxis for < 24 hours • PCT < 1.0 pre-op • PCT > 1.5 post-op • Age > 18 years **Exclusion criteria:** • > 24 hours of peri-operative antibiotic prophylaxis • SZ • pregnancy or lactation • cephalosporin allergy • renal failure • HIV • immune deficiency • investigational treatment within last 30 days • current cytostatic immunosuppressive medications	**Age, years:** [mean (SD), median (range/IQR)] **G1:** 62 (38-82) **G2:** 70 (62-89) [test, result (p-value, 95% CI)] **G1/G2:**	NR

Evidence Table 2F. Intermediate Outcomes for Chromik et al., 2005.[6]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
Days: median (range): **G1:** 5.5 (4-20) **G2:** 9 (3-16) [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR	NR	**Days:** median (range): **G1:** 18 (10-49) **G2:** 30 (9-82) [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR

Evidence Table 3F. Morbidity Outcomes for Chromik et al., 2005.[6]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
NR	**Wound infection (%):** **G1:** 1/10 **G2:** 2/10 [test, result (p-value, 95% CI)] **G1/G2:** **G1 + G2:** 3/20 (15 %) **G3:** 16/230 (7.0 %) No antibiotics or further surgery **Systemic infection (%):** **G1:** 3/10 **G2:** 8/10 [test, result (p-value, 95% CI)] **G1/G2:** p = 0.001 **G1 + G2:** 11/20 (55 %) **G3:** 4/230 (1.7 %) No antibiotics or further surgery NPV for wound 93 % 98.3 % for systemic infection **Multiple systemic infections (%):** **G1:** 0/3 **G2:** 1/7 [test, result (p-value, 95% CI)] **G1/G2:**	NR	**SIRS (C1), sepsis (C2), severe sepsis (C3), septic shock (C4), (%)** **G1-C1 1** **G1-C2 0** **G1-C3 1** **G1-C4 0** **G2-C1 1** **G2-C2 4** **G2-C3 2** **G2-C4 1** **Total G1:** 2 **Total G2:** 8 [test, result (p-value, 95% CI)] **G1/G2:** p = 0.007 for total **Requiring pressors (%):** **G1:** 1 **G2:** 6 [test, result (p-value, 95% CI)] **G1/G2:** p = 0.019	NR

Evidence Table 4F. Mortality Outcomes for Chromik et al., 2005.[6]

In-hospital mortality	28-day mortality	Death	Pneumonia-related death	Proportion surviving hospitalization
Proportion (%): **G1:** 1/10 (10 %) **G2:** 3/10 (30 %) [test, result (p-value, 95% CI)] **G1/G2:**	NR	NR	NR	NR

Evidence Table 5F. Function and Quality of Life Outcomes for Chromik et al., 2005.[6]

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	NR	NR

Evidence Table 6F. Adverse Effects and Adherence for Chromik et al., 2005.[6]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence
NR	NR	NR	NR

Evidence Table 7F. Randomized Trial Study Quality Ratings for Chromik et al., 2005.[6]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y	Y	Y	Y	Y	Y	Y

Evidence Table 1G. Study Description Table for Hochreiter et al., 2009.[7]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Hochreiter et al., 2009. **Country, institution type:** Germany, University affiliate **Enrollment period:** January 2006-March 2007 **Funding:** Not listed **Author industry relationship disclosures:** 1 author speaker's bureau, no other conflicts	**Design:** RCT, 1:1 randomization **Interventions:** **G1:** PCT-guided antibiotics therapy **G2:** Standard therapy **Presenting condition:** Proven or suspected post-op bacterial infection **Setting:** ICU **N at enrollment:** **G1: 57** **G2:** 53 **N at follow-up:** **G1:** 57 **G2:** 53 **Average follow-up, days:** [mean (SD), median (range/IQR)] **G1:** NR **G2:** NR	**Primary outcome:** **Response criteria, independent outcome assessor:** No outcomes specified, no power calculation **Assay type:** Kryptor, Brahms Also CRP, IL-6, WBC **Decision-making:** **G1:** PCT Algorithm PCT < 1.0 and clinical signs resolved, stop antibiotics; PCT > 1.0 but dropped to 25-35 % of initial value over 3 days; stop antibiotics **G2:** Antibiotics standard regimen for 8 days **Condition = definition:**	**Inclusion criteria:** • Proven or suspected bacterial infections needing antibiotics + 2 SIRS criteria **Exclusion criteria:** • Refused consent • Antibiotics initiated before ICU admission	**Age, years:** Mean (SD) **G1:** 67.3 (14.4) **G2:** 66.6 (15.5) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Disease, n, (%):** **Pneumonia** **G1:** 24/57 **G2:** 19/53 [test, result (p-value, 95% CI)] **G1/G2:** NSS **Pneumonia** **G1:** 24/57 **G2:** 19/53 [test, result (p-value, 95% CI)] **G1/G2:** NSS **Peritonitis** **G1:** 29/57 **G2:** 30/53 [test, result (p-value, 95% CI)] **G1/G2:** NSS **Skin, soft tissue infection** **G1:** 2/57 **G2:** 1/53 [test, result (p-value, 95% CI)] **G1/G2:** NSS **UTI** **G1:** 2/57	**SAPS II, Mean (SD):** [test, result (p-value, 95% CI)] **G1:** 40.1 ± 17.1 **G2:** 40.5 ± 15.1 **G1/G2:** NSS

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
				G2: 3/53 [test, result (p-value, 95% CI)] **G1/G2:** NSS	

Evidence Table 2G. Intermediate Outcomes for Hochreiter et al., 2009.[7]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
Days: [mean (SD), median (range/IQR)] **G1:** 5.9 (1.7) **G2:** 7.9 (0.5) [test, result (p-value, 95% CI)] **G1/G2:** $p < 0.001$	NR	No differences in antibiotics used	NR	**ICU LOS, days, Mean (SD):** **G1:** 15.5 (12.5) **G2:** 17.7 (10.1) [test, result (p-value, 95% CI)] **G1/G2:** $p = 0.046$

Evidence Table 3G. Morbidity Outcomes for Hochreiter et al., 2009.[7]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
NR	NR	NR	NR	NR

Evidence Table 4G. Mortality Outcomes for Hochreiter et al., 2009.[7]

In-hospital mortality	28-day mortality	Death	Pneumonia-related death	Proportion surviving hospitalization
NR	NR	**Proportion, (%):** **G1:** 15/57 **G2:** 14/53 [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR	NR

Evidence Table 5G. Function and Quality of Life Outcomes for Hochreiter et al., 2009.[7]

Days $\leq$ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	NR	NR

Evidence Table 6G. Adverse Effects and Adherence for Hochreiter et al., 2009.

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence
NR	NR	NR	NR

Evidence Table 7G. Randomized Trial Study Quality Ratings for Hochreiter et al., 2009.[7]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y*	Y	Y	Y	Y	Y	Y

*No details on allocation concealment but groups were comparable

Evidence Table 1H. Study Description Table for Jensen et al., 2011.[8]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Jensen et al., 2011. **Country, institution type:** Denmark, Tertiary Care Public University Hospital **Enrollment period:** 2006-2009 **Funding:** Danish State, Lundbeck Foundation, Toyota Foundation, H.P. Moller Foundation, Hurbec Foundation, and Capitol Region of Denmark **Author industry relationship disclosures:** One author disclosed speaking and travel reimbursement from Brahms	**Design:** RCT; Open label **Interventions:** **G1:** expanded diagnostic radiology and expanded spectrum of antibiotic therapy for "alert procalcitonin"; de-escalation only after PCT < 1.0 for 3 days **G2:** Standard microbiologic sampling, radiology, and antibiotic therapy **Presenting condition:** Critically ill in ICU **Setting:** ICUs **N at enrollment:** **G1:** 604 **G2:** 596 **N at follow-up:** **G1:** 604 **G2:** 596 **Average follow-up, days:** [mean (SD), median (range/IQR)] **G1:** 28 days **G2:** 28 days	**Primary outcome:** 28 day mortality **Secondary outcomes:** Shorter ICU LOS; shorter duration of organ failure **Response criteria, independent outcome assessor:** Investigators, treating physicians, and coordinator were unaware of outcomes as well as procalcitonin measurements in the control group **Assay type:** Brahms Kryptor-PCT **Decision-making:** **G1:** Intervention algorithm based on "alert procalcitonin" (≥ 1.0 ng/mL that was not decreasing by at least 10 % from the previous day). At baseline a single measurement of > 1.0 ng/ml was also considered alert procalcitonin; **G2:** Standard of care algorithm	**Inclusion criteria:** • ≥ 18 years of age • Enrolled within 24 hours of admission to ICU • Expected ICU stay ≥ 24 hours **Exclusion criteria:** • High bilirubin (> 40 mg/dL) or • High triglycerides (> 1,000 mg/dL) • Patients judged to be at an increased risk from blood sampling	**Age, years:** median (range/IQR)] **G1:** 67 (58-76) **G2:** 67 (58-75) [test, result (p-value, 95% CI)] **G1/G2:** **Women, n (%):** **G1:** 274 (45.4 %) **G2:** 263 (44.1 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **APACHE Score:** median (range/IQR)] **G1:** 18 (13-25) **G2:** 18 (13-24) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Infection, Clinical Assessment** **No infection, n, (%):** **G1:** 86 (14.2 %) **G2:** 118 (19.8 %) **G1/G2:** NSS **Infection, n, (%):** **G1:** 271 (44.9 %) **G2:** 266 (44.6 %) **G1/G2:** NSS **Severe sepsis, septic shock, n, (%):** **G1:** 247 (40.9 %) **G2:** 212 (35.6 %) **G1/G2:** NSS	**Surgical patient, n (%):** [test, result (p-value, 95% CI)] **G1:** 227 (37.6 %) **G2:** 260 (43.6 %) **G1/G2:** NSS **1 chronic co-morbidity, n (%):** **G1:** 257 (42.6 %) **G2:** 279 (46.8 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **2 chronic co-morbidities, n (%):** **G1:** 171 (28.3 %) **G2:** 173 (29.0 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **3 chronic co-morbidities, n (%) Congestive heart failure, n (%):** **G1:** 53 (8.8 %) **G2:** 42 (7.1 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 2H. Intermediate Outcomes for Jensen et al., 2011.[8]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
Days: median (range/IQR)] **G1:** 6 (3-11) **G2:** 4 (3-10) [test, result (p-value, 95% CI)] **G1/G2:** **Days spent in ICU with ≥ 3** antibiotics**, n (%):** **G1:** 3570 (65.5 %) **G2:** 2721 (57.7 %) **G1/G2:** 7.8, p = 0.002	NR	NR	NR	**Days:** median (range/IQR)] **G1:** 6 (3-12) **G2:** 5 (3-11) [test, result (p-value, 95% CI)] **G1/G2:** p = 0.004

Evidence Table 3H. Morbidity Outcomes Jensen et al., 2011.[8]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
NR	**ICU days on mechanical ventilation:** [mean (SD), median (range/IQR)] **G1:** 3569 (65.5 %) **G2:** 2861 (60.7 %) [test, result (p-value, 95% CI)] **G1/G2:** 4.9 (3.0 to 6.7) **ICU days with GFR < 60 mL/1.73 ml) on mechanical ventilation:** [mean (SD), median (range/IQR)] **G1:** 2796 (51.3 %) **G2:** 2187 (46.4 %) [test, result (p-value, 95% CI)] **G1/G2:** 5.0 (3.0 to 6.9)	NR	**NR**	NR

Evidence Table 4H. Mortality Outcomes for Jensen et al., 2011.[8]

In-hospital mortality	28-day mortality	Death	Pneumonia-related death	Proportion surviving hospitalization
NR	**Proportion (%):** **G1:** 190/604 (31.5 %) **G2:** 191 /596 (32.0 %) [test, result (p-value, 95% CI)] **G1/G2:** -0.6 % (-4.7 to 5.9 %)	NR	NR	NR

Evidence Table 5A Function and Quality of Life Outcomes for Jensen et al., 2011.[8]

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	NR	NR

Evidence Table 6H. Adverse Effects and Adherence for Jensen et al., 2011.[8]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence	
NR	NR	NR	**Proportion of patients with baseline PCT alert who received antibiotics (G1) (%):** G1: 256/312 (82.1 %) **Proportion of patients at baseline who were judged to have severe sepsis or septic shock and who received antibiotics (G2)** G2: 172/209 (82.4 %) [test, result (p-value, 95% CI)] **G1/G2:**	NR

Evidence Table 7H. Randomized Trial Study Quality Ratings for Jensen et al., 2011.[8]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y	Y	Y	Y	Y	Y	Y

Evidence Table 1I. Study Description Table for Kristoffersen et al., 2009.[9]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Kristoffersen et al., 2009. **Country, institution type:** Denmark **Enrollment period:** June 1, 2006 to April 30, 2007 **Funding:** Danish Medical Research Council, Danish Lung Association **Author industry relationship disclosures:** No conflicts	**Design:** RCT, multi-center **Interventions:** **G1:** Procalcitonin-guided treatment **G2:** Standard treatment **Presenting condition:** Hospitalized patients with LRTI, suspicion of pneumonia based on history (cough, sputum, dyspnea, and fever > 38o C) and physical (no CXR requirement) **Setting:** 223 enrolled 210 analyzed **N at enrollment:** **G1:** 103 **G2:** 107 **N at follow-up:** **G1:** 103 **G2:** 107 **Average follow-up, days:** [mean (SD), median (range/IQR)] **G1:** NR **G2:** NR	**Primary outcome:** Primary-intent to treat analysis Antibiotics use (days of antibiotics during hospitalization) LOS hospital **Secondary outcome:** Proportion of patients for whom physicians disregarded treatment guidelines 90 % power to detect a 20 % decrease in antibiotic exposure **Response criteria, independent outcome assessor:** **Assay type:** Kryptor, Brahms **Decision-making:** **G1:** PCT guided continuation or cessation of antibiotics If PCT < 0.25 ng/mL, antibiotics should be discouraged PCT 0.25-5.0, antibiotic encouraged PCT > 0.5, antibiotic strongly encouraged **G2:**	**Inclusion criteria:** • ≥ 18 years of age • Suspected pneumonia • One or more symptoms of cough, expectoration, dsypnea, fever > 38^{o} C **Exclusion criteria:** •	**Age, years:** [mean (SD), median (range/IQR)] **G1:** 67.2 (17.6) **G2:** 67 (15.6) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Men, n (%):** **G1:** 54 (52 %) **G2:** 58 (54 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Current/former smoker, n (%):** **G1:** 68 (66 %) **G2:** 82 (77 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Antibiotics pre-treatment, n (%):** **G1:** 48 (47 %) **G2:** 46 (43 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **PSI, mean (SD):** **G1:** 79.2 (27.8) **G2:** 75.8 (24.3) [test, result (p-value, 95% CI)] **G1/G2:** NSS **PSI, I-III, n (%):** **G1:** 65 (63 %)	**Diabetes mellitus, n (%):** **G1:** 13 (13 %) **G2:** 11 (10 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Cancer, n (%):** **G1:** 7 (7 %) **G2:** 0 [test, result (p-value, 95% CI)] **G1/G2:** **Congestive heart failure, n (%):** **G1:** 15 (15 %) **G2:** 14 (13 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Cerebrovascular disease, n (%):** **G1:** 4 (4 %) **G2:** 4 (4 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **COPD, n (%):** **G1:** 38 (37 %) **G2:** 51 (48 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Final Diagnosis CAP, n (%):**

				G2: 78 (73%) [test, result (p-value, 95% CI)] **G1/G2:** NSS **PSI, IV, n (%):** **G1:** 35 (34 %) **G2:** 27 (25 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **PSI, V, n (%):** **G1:** 3 (3 %) **G2:** 2 (2 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Abnormal CXR, n (%):** **G1:** 40 (39 %) **G2:** 43 (40 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **WBC, mean (SD):** **G1:** 13.2 (7.5) **G2:** 12.1 (5.9) [test, result (p-value, 95% CI)] **G1/G2:** NSS **CRP, mean (SD):** **G1:** 1091 (1080) **G2:** 971 (1000) [test, result (p-value, 95% CI)] **G1/G2:** NSS **PCT, median (range):** **G1:** 0.14 (0.05-42.13) **G2:** 0.13 (0.02-30.12) [test, result (p-value, 95% CI)] **G1/G2:** NSS	**G1:** 47 (46 %) **G2:** 50 (47 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **AECOPD, n (%):** **G1:** 28 (37 %) **G2:** 32 (30 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Acute bronchitis, n (%):** **G1:** 3 (3 %) **G2:** 5 (5 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Acute asthma, n (%):** **G1:** 2 (2 %) **G2:** 3 (3 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Viral infection, n (%):** **G1:** 2 (2 %) **G2:** 2 (2 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Other, n (%):** **G1:** 21 (20 %) **G2:** 15 (14 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 2I. Intermediate Outcomes for Kristoffersen et al., 2009.[9]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
Days: [mean (SD), median (range/IQR)] **G1:** 5.1 (95 % CI 4.4-6.0) **G2:** 6.8 (95 % CI 5.9-7.7) [test, result (p-value, 95% CI)] **G1/G2:** p = 0.007 In 42/103 patients (41 %), treatment guidelines were ignored 47 % due to clinical presentation, 41 % due to late report 1.6 days to get report	**Any antibiotic use, antibiotic prescription rate (%):** **G1:** 88 (85 %) **G2:** 85 (79 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR	**Days:** [mean (SD), median (range/IQR)] **G1:** 5.9 (95 % CI 5.1-6.9) **G2:** 6.7 (95 % CI 5.9-7.7) [test, result (p-value, 95% CI)] **G1/G2:** NSS	**ICU admission (%):** **G1:** 7 (7 %) **G2:** 5 (5 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 3I. Morbidity Outcomes for Kristoffersen et al., 2009.[9]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
NR	NR	NR	NR	NR

Evidence Table 4I. Mortality Outcomes for Kristoffersen et al., 2009.[9]

In-hospital mortality	28-day mortality	Death	Pneumonia-related death	Proportion surviving hospitalization
Proportion (%): **G1:** 2 (2 %) **G2:** 1 (1 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR	NR	NR	NR

Evidence Table 5I. Function and Quality of Life Outcomes for Kristoffersen et al., 2009.[9]

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	NR	NR

Evidence Table 6I. Adverse Effects and Adherence for Kristoffersen et al., 2009.[9]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence
NR	NR	NR	NR

Evidence Table 7I. Randomized Trial Study Quality Ratings for Kristoffersen et al., 2009.[9]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y- balanced Y-concealment	Y	Y	Y	Y	Y	N

Evidence Table 1J. Study Description Table for Long et al., 2011.[10]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Long et al., 2011. **Country, institution type:** Shanghai China, University hospital **Enrollment period:** February 2005 – December 2008 **Funding:** Grant Shanghai Fifth People's Hospital Science Foundation **Author industry relationship disclosures:** Not stated	**Design:** RCT, intention to treat **Interventions:** **G1:** PCT-guided antibiotic therapy **G2:** standard antimicrobial therapy **Presenting condition:** Suspected CAP outpatient **Setting:** ER 287 screened 172 enrolled **N at enrollment:** **G1:** 86 **G2:** 86 **N at follow-up:** **G1:** 77 4 lost to follow-up 4 withdrew 1 lung CA **G2:** 79 2 lost to follow-up 3 withdrew	**Primary outcome:** Total antibiotic use and duration of antibiotic treatment, antibiotic prescription rate **Secondary outcomes:** Treatment failure, treatment success, death, recurrence, relapse, patients lost to follow-up **Response criteria, independent outcome assessor:** **Assay type:** Kryptor-Brahms **Decision-making:** **G1:** PCT< 0.1 µg/L strongly discourage antibiotic use PCT 0.1-0.25 µg/L antibiotics discouraged PCT >0.25 antibiotics encouraged **G2:** Standard PCT levels tested at 6-12 hours then 3,6 and 8 days antibiotics were discontinued based on	**Inclusion criteria:** • > 18 years of age • PSI class I-III **Exclusion criteria:** • Age 65 or older • pregnancy • Antibiotic 48-hour before enrollment • systemic immune deficiency • Withholding life-support • Active TB	**Age, years:** [mean (SD), median (range/IQR)] **G1:** 44 +/- 16 **G2:** 47 +/- 19 [test, result (p-value, 95% CI)] **G1/G2:** **Males, n (%):** **G1:** 46 (59.7) **G2:** 49 (62.0) [test, result (p-value, 95% CI)] **G1/G2:**	**Current Smokers, n (%):** [test, result (p-value, 95% CI)] **G1:** 34 (44.2) **G2:** 33 (41.8) **G1/G2:** **PSI class I-III n (%):** **I G1:** 22 (28.6) **I G2:** 24 (30.4) **II G1:** 38 (49.3) **II G2:** 39 (49.4) **III G1:** 17 (22.1) **III G2:** 16 (20.2) [test, result (p-value, 95% CI)] **G1/G2:** **Former Smokers, n (%):** **G1:** 41 (53.2) **G2:** 45 (56.9) [test, result (p-value, 95% CI)] **G1/G2:** **Body temperature n :** [mean (SD), median (range/IQR)]**:** **G1:** 38.6 +/- 1.3 **G2:** 38.4 +/- 1.2 [test, result (p-value, 95% CI)] **G1/G2:**

	2 TB **Average follow-up, days:** 28 day follow-up	previous defined values			**PCT n :** [mean (SD), median (range/IQR)]**:** **G1:** 0.39 (0.26-1.12) **G2:** 0.42 (0.28-1.19) [test, result (p-value, 95% CI)]

Evidence Table 2J. Intermediate Outcomes for Long et al., 2011.[10]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
Per protocol analysis median duration of therapy: Days: [mean (SD), median (range/IQR)] **G1:** 5 (3-6) **G2:** 7 (5-9) [test, result (p-value, 95% CI)] **G1/G2:** p<0.001	**Antibiotic use on initial assessment, antibiotic prescription rate (%):** **G1:** 84.4% **G2:** 97.5% [test, result (p-value, 95% CI)] **G1/G2:** p=0.0004 Total rate antibiotics exposure decreased in G1 RR 0.55 95% CI: 0.51-0.60 p=0.003	NR	NR	NR

Evidence Table 3J. Morbidity Outcomes for Long et al., 2011.[10]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
All patient survived	NR	NR	NR	**Clinical success (%):** ITT analysis **G1:** 69 (85.2) **G2:** 72 (88.9) [test, result (p-value, 95% CI)] **G1/G2:** absolute difference -3.7 (14.1-6.7)

Evidence Table 4J. Mortality Outcomes for Long et al., 2011.[10]

In-hospital mortality	28-day mortality	Death	Pneumonia-related death	Proportion surviving hospitalization
NR	NR	NR	NR	NR

Evidence Table 5J. Function and Quality of Life Outcomes for Long et al., 2011.[10]

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	NR	NR

Evidence Table 6J. Adverse Effects and Adherence for Long et al., 2011.[10]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence
NR	NR	NR	NR

Evidence Table 7J. Randomized Trial Study Quality Ratings for Long et al., 2011.[10]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y- balanced U-concealment	Y	Y	Y	Y	Y	N

Evidence Table 1K. Study Description Table for Manzano et al., 2010.[11]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Manzano et al., 2010. **Country, institution type:** Canada, CHU Ste-Justine, Montreal, Tertiary care center **Enrollment period:** Not given **Funding:** PCT-Q supplied by Brahms **Author industry relationship disclosures:** None disclosed	**Design:** RCT, 1:1 block randomization **Interventions:** **G1:** PCT result available, no recommendations PCT < 0.5, low risk of bacterial infection; PCT >/= 0.5 moderate risk; PCT >/= 2.0 high risk **G2:** Blinded to PCT result **Presenting condition:** Fever **Setting:** Pediatric ED **N at enrollment:** **G1:** 220 **G2:** 220	**Primary outcome:** Antibiotic prescription rate 80 % power to detect a difference in rate of Antibiotic prescriptions Needed 335-419 Secondary outcomes Hospitalization rate Additional studies, i.e., CXR, lumbar puncture; prescription rates without excluding patients treated for a bacterial infection **Response criteria, independent outcome assessor:** **Assay type:** PCT-Q, Brahms **Decision-making:**	**Inclusion criteria:** • Age 1-36 months • T > 38^{o} • No identified source of infection **Exclusion criteria:** • Congenital immune deficiencies • Known bacterial infection • ANC < 500 • Children already treated with antibiotics	**Age, years:** [mean (SD), median (range/IQR)] **G1:** 12 +/- 8 mos **G2:** 12 +/- 8 mos [test, result (p-value, 95% CI)] **G1/G2:** NSS **Triage level (5), n (%):** **G1-1:** 0 (0) **G1-2:** 26 (14) **G1-3:** 77 (40) **G1-4:** 88 (46) **G1-5:** 1 (1) **G2-1:** 0 (0) **G2-2:** 34 (18) **G2-3:** 74 (39) **G2-4:** 83 (43) **G2-5:** 1 (1) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Tmax:** [mean (SD), median (range/IQR)]	NR

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
	N at follow-up: **G1:** 192 **G2:** 192 Insufficient blood for 28 in each group	**G1:** PCT result revealed to treating physician **G2:** PCT result not revealed to treating physician		**G1:** 39.6 +/- 0.7 **G2:** 39.6 +/- 0.6 [test, result (p-value, 95% CI)] **G1/G2:** NSS **Fever duration, hours:** [mean (SD), median (range/IQR)] **G1:** 62 +/-48 **G2:** 64 +/- 50 [test, result (p-value, 95% CI)] **G1/G2:** NSS **VAS for serious bacterial infection, %:** median (range/IQR)] **G1:** 19 (12-29) **G2:** 19 (11-31) [test, result (p-value, 95% CI)] **G1/G2:** NSS	

Evidence Table 2K. Intermediate Outcomes for Manzano et al., 2010.[11]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
NR	**All children** **Any antibiotic use, antibiotic prescription rate (%):** **G1:** 48/192 (25) **G2:** 54/192 (28) [test, result (p-value, 95% CI)] **G1/G2:** -3 (-12 to 6) **Children without SBI or neutropenia** **Any antibiotic use, antibiotic prescription rate (%):** **G1:** 14/158 (9) **G2:** 16/154 (10) [test, result (p-value, 95% CI)] **G1/G2:** -2 (-8 to 5)	NR	**All children** **Hospitalization rate, n (%):** **G1:** 50/192 (26) **G2:** 48/192 (25) [test, result (p-value, 95% CI)] **G1/G2:** 1 (-8 to 10) **Children without SBI or neutropenia** **Hospitalization rate, n (%):** **G1:** 16/158 (10) **G2:** 11/154 (7) [test, result (p-value, 95% CI)] **G1/G2:** 3 (-3 to 10)	NR

Evidence Table 3K. Morbidity Outcomes for Manzano et al., 2010.[11]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
NR	NR	NR	NR	NR

Evidence Table 4K. Mortality Outcomes for Manzano et al., 2010.[11]

In-hospital mortality	28-day mortality	Death	Pneumonia-related death	Proportion surviving hospitalization
NR	NR	NR	NR	NR

Evidence Table 5K. Function and Quality of Life Outcomes for Manzano et al., 2010.[11]

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	NR	NR

Evidence Table 6K. Adverse Effects and Adherence for Manzano et al., 2010.[11]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence
NR	NR	NR	NR

Evidence Table 7K. Randomized Trial Study Quality Ratings for Manzano et al., 2010.[11]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y	Y	Y	Y	Y	Y	N

Evidence Table 1L: Study Description Table for Nobre et al., 2008.[12]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Nobre et al., 2008. **Country, institution type:** Switzerland, University Hospital, ICU **Enrollment period:** February 2006-April 2007 **Funding:** Not listed **Author industry relationship disclosures:** 2 authors with research funding from Brahms, and 1 author Brahms speaker's bureau	**Design:** RCT, 1:1 randomization Intent to treat **Interventions:** **G1:** PCT-guided antibiotics **G2:** Standard antibiotic therapy **Presenting condition:** Severe sepsis, septic shock **Setting:** ICU 282 assessed 203 excluded 42 > 48 hours antibiotics 35 severe immuno-suppression 37 long-term antibiotics anticipated 20 DNR 32 with consent issues 8 PSAR 7 endocarditis 6 early ICU discharge 16 other **N at enrollment:** **G1:** 39 **G2:** 40 **N at follow-up:** **G1:** 31 **G2:** 37 G1 4 decreased or	**Primary outcome:** Systemic antibiotic exposure 90 % power to detect a 33 % (4 day) difference in antibiotic duration **Secondary outcomes:** 28 day mortality, IH mortality, ICU LOS. cure, recurrence, superinfection **Response criteria, independent outcome assessor:** **Assay type:** Kryptor, Brahms **Decision-making:** **G1:** PCT-guided antibiotic discontinuation Baseline PCT > 1.0, PCT decreased by 90 % from peak or < 0.25, stop antibiotic Baseline PCT < 1.0, PCT < 0.1, discontinue antibiotics **G2:** Standard antibiotic therapy **Condition = definition:** Sepsis, ATS, RCCM, 1992	**Inclusion criteria:** • **Exclusion criteria:** • Pseudomonas aeruginosa, Acinetobacter, Listeria, Legionella, PCP, TB, other chronic infections • Solid organ transplantation • AIDS • ANC < 500 • Antibiotics > 48 hours before enrollment	**Age, years:** [mean (SD), median (range/IQR)] **G1:** 64.0 (12.3) **G2:** 66.9 (13.8) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Male, n (%):** **G1:** 21 (67.7 %) **G2:** 25 (67.6 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Disease** **Pneumonia, n, (%):** **G1:** 22 (71.0 %) **G2:** 25 (67.6 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Abdominal sepsis, n, (%):** **G1:** 2 (6.5 %) **G2:** 6 (16.2 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Urosepsis, n, (%):** **G1:** 5 (16.1 %) **G2:** 5 (13.5 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Other sepsis, n, (%):** **G1:** 2 (6.5 %)	**Cancer, n (%):** [test, result (p-value, 95% CI)] **G1:** 4 (12.9 %) **G2:** 5 (13.9 %) **G1/G2:** NSS **Immunosuppression, n (%):** **G1:** 1 (3.2 %) **G2:** 1 (2.7 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Cardiomyopathy, n (%):** **G1:** 11 (35.5 %) **G2:** 17 (45.5 %) [test, result (p-value, 95% CI)] **G1/G2:** **COPD, n (%):** **G1:** 12 (38.7 %) **G2:** 7 (18.9 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Insulin-dependent diabetes, n (%):** **G1:** 0 **G2:** 2 (5.4 %) [test, result (p-value, 95% CI)] **G1/G2:** **Non-insulin-dependent diabetes, n (%):**

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
	transferred early, 4 complicated infection G2 2 deceased of transferred, 1 complicated **Average follow-up, days:** [mean (SD), median (range/IQR)] **G1:** NR **G2:** NR Follow-up 28 days	**Condition = definition:** Septic shock, ATS, RCCM, 1992		**G2:** 1 (2.7 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Septic shock, n, (%):** **G1:** 15 (48.4 %) **G2:** 16 (43.2 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **SAPS III, mean (SD):** **G1:** 68.5 (12.1) **G2:** 70.1 (13.1) [test, result (p-value, 95% CI)] **G1/G2:** NSS **SOFA, Mean (SD):** **G1:** 6.4 (3.3) **G2:** 6.6 (3.0) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Baseline PCT, Median (range):** **G1:** 7.3 (0.1-93) **G2:** 5.4 (0.1-354) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Baseline PCT < 1.0, n, (%):** **G1:** 7 (22.5 %) **G2:** 6 (16.2) [test, result (p-value, 95% CI)] **G1/G2:** NSS	**G1:** 4 (12.9 %) **G2:** 6 (16.2 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Chronic renal failure, n (%):** **G1:** 2 (6.5 %) **G2:** 6 (16.2 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Peripheral vascular disease, n (%):** **G1:** 1 (3.2 %) **G2:** 1 (2.72 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Chronic liver disease, n (%):** **G1:** 5 (16.1 %) **G2:** 5 (13.5 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 2L. Intermediate Outcomes for Nobre et al., 2008.[12]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
Intent to treat **Duration antibiotics, Days:** Median (range) **G1:** 6 (3-24) **G2:** 9.5 (2-33) [test, result (p-value, 95% CI)] **G1/G2:** Mean difference 2.6 (-0.3 to 5.5), p = 0.15 **Incidence density antibiotic exposure:** (rate days exposed per 1,000 patient-days) **G1:** 541 **G2:** 644 [test, result (p-value, 95% CI)] **G1/G2:** Mean difference 1.1 (0.9 to 1.3), p = 0.07 **Days alive without antibiotics, mean (SD):** **G1:** 15.3 (8.9) **G2:** 13 (8.2) [test, result (p-value, 95% CI)] **G1/G2:** Mean difference 2.3 (-5.9 to 1.8), p = 0.28 **Per protocol** **Duration antibiotics, Days:** Median (range) **G1:** 6 (4-16) **G2:** 10 (3-33) [test, result (p-value, 95% CI)] **G1/G2:** Mean difference 3.2 (1.1 to 5.4), p = 0.003 **Incidence density antibiotic exposure:** (rate days exposed per 1,000 patient-days) **G1:** 504 **G2:** 655 [test, result (p-value, 95% CI)]	NR	NR	**Intent to treat** **Days:** [mean (SD), median (range) **G1:** 17 (3-96) **G2:** 23.5 (5-44) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Per protocol** **Days:** [mean (SD), median (range) **G1:** 14 (5-64) **G2:** 21 (5-89) [test, result (p-value, 95% CI)] **G1/G2:** NSS	**Intent to treat** **ICU LOS, Days:** [mean (SD), median (range) **G1:** 4 (1-21) **G2:** 7 (1-91) [test, result (p-value, 95% CI)] **G1/G2:** p = 0.02 Mean difference 4.6 (1.0 to 8.2) **Per protocol** **ICU LOS, Days:** [mean (SD), median (range) **G1:** 3 (1-8) **G2:** 5 (1-30) [test, result (p-value, 95% CI)] **G1/G2:** p = 0.03 Mean difference 4.3 (0.4 to 8.3)

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
G1/G2: Mean difference 1.3 (1.1 to 1.5), p = 0.0002 **Days alive without antibiotics, mean (SD):** **G1:** 17.4 (7.6) **G2:** 13.6 (7.6) [test, result (p-value, 95% CI)] **G1/G2:** Mean difference 3.8 (0.1 to 7.5), p = 0.04				

Evidence Table 3L: Morbidity Outcomes for Nobre et al., 2008.[12]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
NR	NR	**Intent to treat** **Relapse infection rate, n (%):** **G1:** 1 (2.6 %) **G2:** 1 (2.5 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Per protocol** **Relapse infection rate, n (%):** **G1:** 1 (3.2 %) **G2:** 1 (2.7 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR	**Intent to treat** **Clinical cure (%):** **G1:** 31 (79.4 %) **G2:** 32 (80 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Per protocol** **Clinical cure (%):** **G1:** 28 (90.3 %) **G2:** 31 (83.8 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 4L. Mortality Outcomes for Nobre et al., 2008.[12]

In-hospital mortality	28-day mortality	Death	Sepsis--related death	Proportion surviving hospitalization
Intent to treat **Proportion (%):** **G1:** 9 (23.1 %) **G2:** 9 (22.5 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Per protocol** **Proportion (%):** **G1:** 6 (19.4 %) **G2:** 7 (18.9 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	**Intent to treat** **Proportion (%):** **G1:** 8 (20.5 %) **G2:** 8 (20 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Per protocol** **Proportion (%):** **G1:** 5 (16.1 %) **G2:** 6 (16.2 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR	**Intent to treat** **Proportion (%):** **G1:** 3 (37.5 %) **G2:** 2 (25 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Per protocol** **Proportion (%):** **G1:** 3/5 (60 %) **G2:** 1/6 (16.6 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR

Evidence Table 5L. Function and Quality of Life Outcomes for Nobre et al., 2008.[12]

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	NR	NR

Evidence Table 6L: Adverse Effects and Adherence for Nobre et al., 2008.[12]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence
NR	NR	NR	NR

Evidence Table 7L. Randomized Trial Study Quality Ratings for Nobre et al., 2008.[12]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y	Y	Y	Y	Y	Y	Y

Evidence Table 1M. Study Description Table for Schuetz et al., 2009.[13]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Schuetz et al., 2009. (ProHOSP) **Country, institution type:** Switzerland, multi-center, tertiary care hospitals (6 hospitals) **Enrollment period:** October 2006-March 2008 **Funding:** Swiss Nat'l Science Foundation; Gottried and Julia Bangerter-Rhyner Foundation, the University Hospital of Basel; the Medical University Clinic Liestal; the Medical Clinic Buergerspital Solothurn; the Cantonal Hospitals Muensterlingen; the Swiss Society for Internal Medicine; Brahms supplied the diagnostic kits **Author industry relationship disclosures:** 3 authors with support from Brahms; 1 author consultant for Brahms	**Design:** RCT, 1:1, non-inferiority **Interventions:** **G1:** PCT-guided initiation of antibiotics; PCT-guided discontinuation of antibiotics **G2:** Standard therapy **Presenting condition:** LRTI; CAP, AECOPD, acute bronchitis, other **Setting:** EDs 1825 with LRTI in Eds 1359 randomized **N at enrollment:** **G1:** 687 **G2:** 694 **N at follow-up:** **G1:** 671 **G2:** 688 G1: 34 died, 16 withdrew, 1 LTFU G2: 33 died, 6 withdrew, 0 LTFU **Average follow-up, days:** [mean (SD), median (range/IQR)] **G1:** NR **G2:** NR	**Primary outcome:** Overall adverse event rate within 30 days (death, ICU, disease-specific complications, recurrence), non-inferiority Both intent to treat and per protocol analysis performed for primary outcomes Study powered to detect a 7.5 % increase in combined endpoint; 90 % chance of detection, needed 1002 patients **Secondary outcome:** Antibiotic exposure Duration of antibiotics Adverse antibiotic effects LOS Superiority **Response criteria, independent outcome assessor:** Outcomes assessed by blinded investigators **Assay type:** Rapid Kryptor, Brahms **Decision-making:** **G1:** **G2:** Algorithm for PCT guided therapy	**Inclusion criteria:** • ED patients with LRTIs • Age > 18 years • Duration of illness < 28 days • 1 respiratory symptom, 1 physical finding OR fever OR leukocytosis **Exclusion criteria:** • Intravenous drug use • Severe immuno-suppression (except corticosteroids) • HAP • Chronic infection • Imminent death	**Age, years:** [mean (SD), median (range/IQR)] **G1:** 73 (59-82) **G2:** 72 (59-82) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Male, n (%):** **G1:** 402 (59.9 %) **G2:** 380 (55.2 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Disease** **CAP, n, (%):** [mean (SD), median (range/IQR)] **G1:** 460 (68.6 %) **G2:** 465 (67.6 %) [test, result (p-value, 95% CI)] **G1/G2:** **PSI for CAP, n, (%):** [mean (SD), median (range/IQR)] **G1:** 91 (67-117) **G2:** 91 (66-114) [test, result (p-value, 95% CI)] **G1/G2:** NSS Over 50 % of patients with CAP were high-risk by PSI **AECOPD, n, (%):** [mean (SD), median (range/IQR)]	**Coronary artery disease, n (%):** [test, result (p-value, 95% CI)] **G1:** 146 (21.8 %) **G2:** 136 (19.8 %) **G1/G2:** **Cerebrovascular disease, n (%):** [test, result (p-value, 95% CI)] **G1:** 54 (8.1 %) **G2:** 56 (8.1 %) **G1/G2:** **Renal dysfunction, n (%):** [test, result (p-value, 95% CI)] **G1:** 156 (23.3 %) **G2:** 146 (21.2 %) **G1/G2:** **COPD, n, (%):** [test, result (p-value, 95% CI)] **G1:** 265 (39.5 %) **G2:** 268 (39.0 %) **G1/G2:** **Cancer, n (%):** **G1:** 69 (10.3 %) **G2:** 98 (14.2 %) [test, result (p-value, 95% CI)] **G1/G2:** **Diabetes mellitus, n (%):**

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
	Duration of follow-up 30 days (phone interview)	For antibiotic initiation PCT < 0.1, antibiotics strongly discouraged; PCT ≤ 0.25, antibiotics discouraged; PCT > 0.25, antibiotics encouraged; PCT > 0.5, antibiotics strongly encouraged For antibiotic discontinuation PCT < 10 % of baseline, stopping antibiotics strongly encouraged; PCT < 20 % of baseline, stopping antibiotics discouraged Protocol could be overruled if ICU, hemodynamic instability, + Legionella Other interventions adequate antibiotic therapy **Condition = definition:** CAP = new infiltrate **Condition = definition:** COPD = GOLD criteria		**G1:** 115 (17.1 %) **G2:** 113 (16.4 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Acute bronchitis, n, (%):** [mean (SD), median (range/IQR)] **G1:** 69 (10.3 %) **G2:** 82 (11.9 %) [test, result (p-value, 95% CI)] **G1/G2:**NSS **Other, n, (%):** [mean (SD), median (range/IQR)] **G1:** 27 (4.0 %) **G2:** 28 (4.0 %) [test, result (p-value, 95% CI)] **G1/G2:**NSS **Hospitalized, n, (%):** [mean (SD), median (range/IQR)] **G1:** 628 (93.7 %) **G2:** 629 (91.4 %) [test, result (p-value, 95% CI)] **G1/G2:**NSS	**G1:** 118 (17.0 %) **G2:** 113 (16.4 %) [test, result (p-value, 95% CI)] **G1/G2:**

Evidence Table 2M. Intermediate Outcomes for Schuetz et al., 2009.[13]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
Days: Mean,(median/ IQR)] **G1:** 5.7 (5/1-8) **G2:** 8.7 (9/6-11) [test, result (p-value, 95% CI)] **G1/G2:** % difference 95 % CI, -34.8 (-40.3 to -28.7)	**Any antibiotic use, antibiotic prescription rate, n, (%):** **G1:** 506/671 (75.4 %) **G2:** 603/688 (87.7 %) [test, result (p-value, 95% CI)] **G1/G2:** CI -12.2 (-16.3 to -8.1)	NR	**Days:** Mean, (median/IQR) **G1:** 9.4 (8/4-12) **G2:** 9.2 (8/4-12) [test, result (p-value, 95% CI)] **G1/G2:** Relative mean change 1.8 (-6.9 to 11.0)	NR

Evidence Table 3M. Morbidity Outcomes for Schuetz et al., 2009.[13]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
Intent to Treat **Overall adverse outcome, n, (%):** **G1:** 103/671 (15.4 %) **G2:** 130/688 (18.9 %) [test, result (p-value, 95% CI)] **G1/G2:** CI for difference by Mantel-Haenszel weights stratified by site of infection. -3.5 (-7.6 to 0.4) Kaplan-Meier curves for time to first adverse event were calculated **ICU, n, (%):** **G1:** 43/671 (6.4 %) **G2:** 60/688 (8.7 %) [test, result (p-value, 95% CI)] **G1/G2:** CI -2.3 (-5.2 to 0.4) **Disease-specific complications (%):** **G1:** 17/671 (2.5 %) **G2:** 14/688 (2.0 %) [test, result (p-value, 95% CI)] **G1/G2:** **Per protocol** **Overall adverse outcome, n, (%):** **G1:** 95/633 (15.0 %) **G2:** 123/650 (18.9 %) [test, result (p-value, 95% CI)] **G1/G2:** -3.9 (-8.2 to 0.03)	**Antibiotic adverse effects, n, (%):** [mean (SD), median (range/IQR)] **G1:** 133/671 (19.8 %) **G2:** 193/688 (28.1 %) [test, result (p-value, 95% CI)] **G1/G2:** CI -8.2 (-12.7 to -3.7)	**Intent to Treat** **Recurrence of infection (%):** **G1:** 25/671 (3.7 %) **G2:** 45/688 (6.5 %) [test, result (p-value, 95% CI)] **G1/G2:** CI -2.8 (-5.1 to -0.4)	NR	NR

Evidence Table 4M. Mortality Outcomes for Schuetz et al., 2009.[13]

In-hospital mortality	30-day mortality	Death	Pneumonia-related death	Proportion surviving hospitalization
NR	**Intent to treat** **Proportion, n, (%):** **G1**: 34/671 (5.1 %) **G2:** 33/688 (4.8 %) [test, result (p-value, 95% CI)] **G1/G2:** CI 0.3 (-2.1 to 2.5) **Per protocol** **Proportion, n, (%):** **G1**: 29/633 (4.6 %) **G2:** 31/650 (4.8 %) [test, result (p-value, 95% CI)] **G1/G2:**	NR	NR	NR

Evidence Table 5M. Function and Quality of Life Outcomes for Schuetz et al., 2009.[13]

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	NR	NR

Evidence Table 6M. Adverse Effects and Adherence for Schuetz et al., 2009.[13]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence
NR	NR	NR	NR

Evidence Table 7M. Randomized Trial Study Quality Ratings for Schuetz et al., 2009.[13]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y-balanced Y-concealment	Y	Y	Y	Y	Y	Y

Evidence Table 1N. Study Description Table for Schroeder et al., 2009.[14]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Schroeder et al., 2009. **Country, institution type:** Germany, University hospital SICU **Enrollment period:** October 2006-April 2007 **Funding:** None listed **Author industry relationship disclosures:** 1 author Brahms speaker's bureau, no other conflicts	**Design:** RCT, 1:1 **Interventions:** **G1:** PCT-guided antibiotic therapy **G2:** Standard therapy **Presenting condition:** Status-post abdominal surgery **Setting:** SICU 125 screened 27 met inclusion criteria **N at enrollment:** **G1:** 14 **G2:** 13 **N at follow-up:** **G1:** 14 **G2:** 13 **Average follow-up, days:** [mean (SD), median (range/IQR)] **G1:** NR **G2:** NR	**Primary outcome:** **Response criteria, independent outcome assessor:** No power calculation **Assay type:** Kryptor, Brahms Also CRP, IL-6, WBC **Decision-making:** **G1:** PCT decreased to 1 or 25-35 % of baseline over 3 days **G2:** Standard **Condition = definition:** Severe sepsis, 1992 ATS, RCCM	**Inclusion criteria:** • Status-post abdominal surgery • Severe sepsis **Inclusion criteria:** • None listed	**Age, years:** [mean (SD), median (range/IQR)] **G1:** 69.3 (10.6) **G2:** 68.4 (13.7) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Male, n (%):** **G1:** 8/14 **G2:** 7/13 [test, result (p-value, 95% CI)] **G1/G2:** NSS **Disease Pneumonia, n, (%):** [mean (SD), median (range/IQR)] **G1:** 4/14 **G2:** 4/13 [test, result (p-value, 95% CI)] **G1/G2:** NSS **Disease Peritonitis, n, (%):** [mean (SD), median (range/IQR)] **G1:** 10/14 **G2:** 9/13 [test, result (p-value, 95% CI)] **G1/G2:** NSS	**SAPS II, Mean (SD):** [test, result (p-value, 95% CI)] **G1:** 45.6± 18.5 **G2:** 53.7 ±14.7 **G1/G2:** NSS **SOFA max, Mean (SD):** **G1:** 7.3 (3.5) **G2:** 8.3 (4.2) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 2N. Intermediate Outcomes for Schroeder et al., 2009.[14]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
Days: [mean (SD), median (range/IQR)] **G1:** 6.6 (1.1) **G2:** 8.3 (0.7) [test, result (p-value, 95% CI)] **G1/G2:** p < 0.001	NR	NR	NR	**ICU admission, days:** [mean (SD), median (range/IQR)] **G1:** 16.4 (8.3) **G2:** 16.7 (5.6) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 3N. Morbidity Outcomes for Schroeder et al., 2009.[14]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
NR	NR	NR	NR	NR

Evidence Table 4N. Mortality Outcomes for Schroeder et al., 2009.[14]

In-hospital mortality	28-day mortality	Death	Pneumonia-related death	Proportion surviving hospitalization
NR	NR	**Proportion (%):** **G1:** 3/14 **G2:** 3/13 [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR	NR

Evidence Table 5N. Function and Quality of Life Outcomes for Schroeder et al., 2009.[14]

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	NR	NR

Evidence Table 6N. Adverse Effects and Adherence[14]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence
NR	NR	NR	NR

Evidence Table 7N. Randomized Trial Study Quality Ratings for Schroeder et al., 2009.[14]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y*	Y	Y	Y	Y	Y	Y

*No details on allocation concealment but groups were comparable

Evidence Table 1O. Study Description Table for Stocker et al., 2010.[15]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Stocker et al., 2010. **Country, institution type:** Switzerland, single tertiary care institution **Enrollment period:** June 1, 2005-December 31, 2006 **Funding:** Brahms supplied test kits **Author industry relationship disclosures:** Not given	**Design:** RCT; 1:1, masked until randomization **Interventions:** **G1:** Procalcitonin-guided decision-making **G2:** Standard treatment **Presenting condition:** Suspected early-onset neonatal sepsis **Setting:** Neonatal and Pediatric ICU 126 screened, 5 excluded (2 no consent, 2 protocol errors, and 1 surgery in first 3 days) **N at enrollment:** **G1:** 60 **G2:** 61 **N at follow-up:** **G1:** 60 **G2:** 61 **Average follow-up, days:** [mean (SD), median (range/IQR)] **G1:** 3 days to 1 month **G2:** 3 days to 1 month	**Primary outcome:** Proportion of infants treated with antibiotics $\geq$ 72 hours Absolute reduction in duration of antibiotic therapy Trial 90 % powered to detect a 30 % difference in duration of antibiotic therapy **Secondary outcome:** Survival Recurrence of infection in first month (antibiotics given > 120 hours **Assay type:** Kryptor, Brahms **Decision-making:** **G1:** PCT age-adjusted for 0-120 hours of age, peak at 18-30 hours of 10 ng/mL **G2:** Standard therapy **Condition = definition:** Sepsis Diagnosis by risk factors, group B streptococcus, premature rupture of membranes, clinical status, including respiratory distress, tachycardia, bradycardia, hypotension, seizures, irritability, vomiting, feeding intolerance, ileus, WBC count, immature to total granulocytes, CRP	**Inclusion criteria:** • Gestational age $\geq$ 34 weeks • Early-onset sepsis (3 days) **Exclusion criteria:** • Severe congenital malformations, , • Chromosomal abnormalities • Surgery in first 3 days of life	**Gestational age (weeks), mean (std dev):** [test, result (p-value, 95% CI)] **G1:** 39.4 (34.4-42.0) **G2:** 39.7 (34.0-41.7) **G1/G2:** NSS Mann-Whitney U test, $p < 0.05$ significant **Birth weight (grams), mean (std dev):** **G1:** 3,200 (2,000-4.640) **G2:** 3,330 (1,800-4,900) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Male sex, n, (%):** **G1:** 35 (58 %) **G2:** 40 (65 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Normal spontaneous vaginal delivery, n (%):** **G1:** 36 (60 %) **G2:** 31 (51 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **APGAR 1, median:** **G1:** 8 **G2:** 8 [test, result (p-value, 95% CI)] **G1/G2:** NSS	**APGAR 5, mean (std dev):** **G1:** 9 **G2:** 9 [test, result (p-value, 95% CI)] **G1/G2:** NSS **APGAR 10, mean (std dev):** **G1:** 9 **G2:** 10 [test, result (p-value, 95% CI)] **G1/G2:** NSS **Infection proven/probable, n, (%):** **G1:** 9/0 (15 %) **G2:** 11/1 (20 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Infection possible, n, (%):** **G1:** 21 (35 %) **G2:** 19/1(31 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Infection unlikely, n, (%):** **G1:** 30 (50 %) **G2:** 30.1 (49 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 2O. Intermediate Outcomes for Stocker et al., 2010.[15]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
Reduction in duration of antibiotics (hours), mean (std dev): **All newborns** **G1:** 79.1 **G2:** 101.5 [test, result (p-value, 95% CI)] **G1/G2:** Abs reduction 22.4, Mann-Whitney U test, p = 0.012 **Infection proven/probably** **G1:** 177.8 **G2:** 170.8 [test, result (p-value, 95% CI)] **G1/G2:** Abs reduction 7, NSS **Infection possible** **G1:** 83.4 **G2:** 111.5 [test, result (p-value, 95% CI)] **G1/G2:** Abs reduction 28.1, p < 0.001 **Infection unlikely** **G1:** 46.5 **G2:** 67.4 [test, result (p-value, 95% CI)] **G1/G2:** Abs reduction 20.9, p = 0.001	**Proportion treated with antibiotics ≥ 72 hours, n, %:** [mean (SD), median (range/IQR)] **All newborns** **G1:** 33/60 (55 %) **G2:** 50/61 (82 %) [test, result (p-value, 95% CI)] **G1/G2:** RR 27 %, Fisher's exact test, p = 0.002 **Infection proven/probably** **G1:** 9/9 (100 %) **G2:** 12/12 (100 %) [test, result (p-value, 95% CI)] **G1/G2:** RR 0 %, NSS **Infection possible** **G1:** 13/21 (61.9 %) **G2:** 19/19 (100 %) [test, result (p-value, 95% CI)] **G1/G2:** RR 38.1 %, p < 0.001 **Infection unlikely** **G1:** 11/30 (36.7 %) **G2:** 19/30 (63.3 %) [test, result (p-value, 95% CI)] **G1/G2:** RR, 26.6 %, p = 0.038	NR	NR	NR

Evidence Table 3O. Morbidity Outcomes for Stocker et al., 2010.[15]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
NR	NR	**Recurrence (%):** **G1:** 32 % **G2:** 39 % [test, result (p-value, 95% CI)] **G1/G2:** OR 0.71, 95 % CI 0.34/1.51, Fisher's exact test, non-inferiority, NSS	NR	NR

Evidence Table 4O. Mortality Outcomes for Stocker et al., 2010.[15]

In-hospital mortality	28-day mortality	Death	Pneumonia-related death	Proportion surviving hospitalization
Proportion (%): **G1:** 0 % **G2:** 0 % [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR	NR	NR	NR

Evidence Table 5O. Function and Quality of Life Outcomes for Stocker et al., 2010.[15]

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	NR	NR

Evidence Table 6O. Adverse Effects and Adherence for Stocker et al., 2010.[15]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence
NR	NR	NR	NR

Evidence Table 7O. Randomized Trial Study Quality Ratings for Stocker et al., 2010.[15]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y	Y	Y	Y	Y	Y	Y

Evidence Table 1P. Study Description Table for Stolz et al., 2007.[16]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Stolz et al., 2007. **Country, institution type:** Switzerland, University Hospital of Basel **Enrollment period:** November 2003-March 2005 **Funding:** Clinic of Pulmonary Medicine; Clinic of Endo, Diabetes, and Clinical Nutrition; ED of University Hospital of Basel; Brahms supplied the kits **Author industry relationship disclosures:** I author a consultant and recipient of payments for meetings, travel, speaking, and research; no other conflicts reported	**Design:** RCT; 1:1, masked until randomization, single center **Interventions:** **G1:** Procalcitonin guidance **G2:** Standard therapy **Presenting condition:** AECOPD **Setting:** ED **N at enrollment:** **G1:** 102 **G2:** 106 **N at 14 days follow-up:** blinded **G1**: 99 (3 deaths) **G2:** 104 (2 deaths) **N at 6 months follow-up:** blinded **G1:** 97 (2 deaths) **G2:** 97 (7 deaths)	**Primary outcome:** Antibiotic use at index ECOPD Antibiotic use up to 6 months **Secondary outcomes:** Success, LOS, ICU need, CRP, PCT, PFTs on admission, short- and long-term follow-up, exacerbation rate, time to next exacerbation Time to clinic events by Kaplan-Meier and log-rank test 85 % chance of detecting a 30 % reduction in antibiotic use, alpha error of 0.05; needed 223 patients enrolled assuming a 20 % dropout rate **Response criteria, independent outcome assessor:** **Assay type:** Kryptor PCT, Brahms **Decision-making:** **G1:** For antibiotic initiation PCT < 0.1 antibiotics strongly discouraged; PCT ≥ 1.0 ≤ 0.25,	**Inclusion criteria:** • ≥ 40 years of age • Met post-bronchodilator therapy criteria for E-COPD within 48 hours of ED admission **Exclusion criteria:** • Other explanation for illness • Psychiatric co-morbidities • Immunosuppression • Asthma • Cystic fibrosis • Infiltrate on CXR	**Age, years:** median (range/IQR)] **G1:** 69.5 (65-77) **G2:** 69.5 (64.8-79) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Men, n (%):** **G1:** 50 (49 %) **G2:** 44 (41.5 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Current smoker, n (%):** **G1:** 40 (39.2 %) **G2:** 54 (50.9 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Pack-years:** median (range/IQR)]: **G1:** 43 (30-58.5) **G2:** 50 (30-60) [test, result (p-value, 95% CI)] **G1/G2:** NSS **COPD duration, months:** [mean (SD): **G1:** 128 (82) **G2:** 123 (85) [test, result (p-value, 95% CI)] **G1/G2:** NSS **AECOPD previous year:** [mean (SD):	**Diabetes mellitus, n (%):** **G1:** 12 (11.8) **G2:** 11 (10.4) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Renal insufficiency, n (%):** **G1:** 5 (4.9 %) **G2:** 12 (11.3 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Cardiomyopathy, n (%):** **G1:** 42 (41.2) **G2:** 49 (46.2) [test, result (p-value, 95% CI)] **G1/G2:** NSS **HTN, n (%):** **G1:** 23 (22.5 %) **G2:** 27 (25.5 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Osteoporosis, n (%):** **G1:** 17 (16.7 %) **G2:** 9 (8.5 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Cancer, n (%):** **G1:** 12 (11.8 %) **G2:** 14 (13.2 %)

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
		antibiotics based on clinical condition; PCT > 0.25, antibiotics encouraged **G2:** Standard management		**G1:** 2.4 (2.1) **G2:** 1.9 (1.8) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Severity of COPD (GOLD staging), n, (%):** **G1- I:** 6 (5.9 %) **G1- II:** 15 (14.7 %) **G1- III:** 47 (46.1 %) **G1- IV:** 34 (33.3 %) **G2- I:** 5 (4.7 %) **G2- II:** 25 (23.6 %) **G2- III:** 51 (48.1 %) **G2- IV:** 25 (23.6 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Home oxygen, n, (%):** **G1:** 21 (20.6 %) **G2:** 13 (12.3 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Severity of AECOPD, n, (%):** **G1- 1:** 51 (50 %) **G1- 2:** 24 (23.5 %) **G1- 3:** 27 (26.5 % **G2- 1:** 49 (46.2 %) **G2- 2:** 28 (26.4 %) **G2- 3:** 29 (27.4 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **FEV1:** [mean (SD): **G1:** 0.88 (0.41)	[test, result (p-value, 95% CI)] **G1/G2:** NSS

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
				G2: 0.98 (0.41) [test, result (p-value, 95% CI)] **G1/G2:** p = 0.02 **Positive sputum culture, n, (%):** **G1:** 37 (36 %) **G2:** 40 (38 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS Mostly gram negative rods and Pneumococcus **PCT:** mean,(SD): **G1:** 0.274 (1.049) **G2:** 0.244 (0.516) [test, result (p-value, 95% CI)] **G1/G2:** NSS **CRP,** mean,(SD): **G1:** 32 (42) **G2:** 44 (55) [test, result (p-value, 95% CI)] **G1/G2:** NSS **WBC count:** mean,(SD): **G1:** 11.7 (8.4) **G2:** 11.5 (4.6) [test, result (p-value, 95% CI)] **G1/G2:** NSS	

Evidence Table 2P. Intermediate Outcomes for Stolz et al., 2007.[16]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
Antibiotic exposure: (rate days exposed per #patient-days) **G1:** NR **G2:** NR [test, result (p-value, 95% CI)] **G1/G2:** Absolute risk reduction 31.5 (18.7 to 44.3), p < 0.0001 RR 0.56 (0.43 to 0.73), p<0.0001 RRR 44% (27 to 57%), p < 0.0001 At 6 months RR 0.76, (0.64 to 0.92), p = 0.004 **Subsequent antibiotic use within 6 months (%):** **G1:** 46 **G2:** 43 [test, result (p-value, 95% CI)] **G1/G2:** NSS **Steroid use, n, (%):** **G1:** 89 (87.3 %) **G2:** 93 (87.7 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Steroid dose, median, range:** **G1:** 250 (119-400) **G2:** 280 (183-421) [test, result (p-value, 95% CI)] **G1/G2:** NSS	**Any antibiotic use, antibiotic prescription rate (%):** **G1:** 40 % **G2:** 72 % [test, result (p-value, 95% CI)] **G1/G2:** p < 0.0001 **Number of courses of antibiotics:** [mean (SD), median (range/IQR)] **G1:** NR **G2:** NR [test, result (p-value, 95% CI)] **G1/G2:**	**Antibiotic classes, n (%):** **G1-1 antibiotic: 80 %** **G1-2 antibiotic: 15 %** **G1-3 antibiotic: 2 %** **G2-1 antibiotic:** 68 % **G2-2 antibiotic:** 29 % **G2-3 antibiotic:** 3 % [test, result (p-value, 95% CI)] **G1/G2:** NSS Antibiotics prescribed were amino penicillin's (62 %), fluoroquinolones (16 %), cephalosporin's (11 %), macrolides (8 %), anti-Pseudomonas aeruginosa penicillin's (2 %), and other (1 %)	**Days:** [mean (SD), median (range/IQR)] **G1:** 9 (1-15) **G2:** 10 (1-15) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Hospital LOS < 24 hours, n, (%):** **G1:** 22 (21.6 %) **G2:** 24 (22.6 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	**ICU admission (%):** **G1:** 8 (7.8 %) **G2:** 11 (10.4 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **ICU LOS, days:** mean (SD) **G1:** 3.3 (2.7) **G2:** 3.7 (2.1) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 3P. Morbidity Outcomes for Stolz et al., 2007.[16]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
NR	FEV1 at 14 days, mean (SD): G1: 1.04 (0.48) G2: 1.01 (0.57) G1/G2: NSS FEV1 at 6 months, mean (SD): G1: 1.07 (0.55) G2: 1.11 (0.57) G1/G2: NSS	**Recurrence of AECOPD 6 months, n, (%):** **G1:** 44 (43.1 %) **G2:** 43 (40.1 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Hospitalization for recurrence of AECOPD 6 months, n, (%):** **G1:** 18 (17.7 %) **G2:** 22 (20.8 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR	**Clinical cure (%):** **G1:** 84 (82.4 %) **G2:** 89 (83.9 %) [test, result (p-value, 95% CI)] **G1/G2:**

Evidence Table 4P. Mortality Outcomes for Stolz et al., 2007.[16]

In-hospital mortality	28-day mortality	Death within 6 months	Pneumonia-related death	Proportion surviving hospitalization
NR	NR	**Death of any cause, n (%):** **G1:** 5 (4.9 %) **G2:** 9 (8.5 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR	NR

Evidence Table 5P. Function and Quality of Life Outcomes for Stolz et al., 2007.[16]

Days < 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	NR	NR

Evidence Table 6P. Adverse Effects and Adherence for Stolz et al., 2007.[16]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence
NR	NR	NR	NR

Evidence Table 7P. Randomized Trial Study Quality Ratings for Stolz et al., 2007.[16]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y- balanced U-concealment	Y	Y	Y	Y	Y	N

Evidence Table 1Q. Study Description Table for Stolz et al., 2009.[17]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Stolz et al., 2009. (ProVAP) **Country, institution type:** Switzerland, USA **Enrollment period:** Not given **Funding:** Swiss Nat'l Foundation; Margarete and Walter Liechtenstein Foundation; Friewillige Akademische Gesellschaft Basel; Will Rogers Foundation; Clinic of Pulmonary Medicine-University Hospital Basel; Brahms, Germany **Author industry relationship disclosures:** Statement at website	**Design:** Multi-national, RCT, 1:1, open interventional, 7 ICUs **Interventions:** **G1:** Procalcitonin guidance **G2:** Treatment according to guidelines **Presenting condition:** VAP **Setting:** ICU **N at enrollment:** **G1:** 51 **G2:** 50 **N at follow-up:** **G1:** 51 **G2:** 50 **Average follow-up, days:** [mean (SD), median (range/IQR)] **G1:** NR **G2:** NR Patients re-evaluated daily up to 10 days after inclusion 164 patients screened 23 unable to consent 1 mental retardation 6 refused consent	**Primary outcome:** Antibiotic-free days alive assessed at 28 days After enrollment Secondary outcomes Vent-free days, ICU-free days, clinical evidence of progression, and mortality Superiority trial for antibiotic free days. 84 patients needed to have a 90 % chance of detecting a 5 day difference 100 enrolled assuming 8 % lost to follow-up **Response criteria, independent outcome assessor:** **Assay type:** Kryptor, Brahms **Decision-making:** Measured at baseline, at 72 hours, and daily up to 10 days After 72 hours of empiric antibiotics, daily PCT reported to physician **G1:** PCT < 0.25, d/c antibiotics strongly	**Inclusion criteria:** • In ICU on vent > 48 hours • Age > 18 years • VAP by ATS criteria **Exclusion criteria:** • Pregnant • Enrolled in another trial • On immuno-suppressants or long-term corticosteroids (> 1 month) • Severely immunosuppressed (AIDS, etc.) • Extra-pulmonary infections	**Age, years:** [mean (SD), median (range/IQR)] **G1:** 53 (21-88) **G2:** 59 (18-83) [test, result (p-value, 95% CI)] **G1/G2:** **Male, n (%):** **G1:** 38 (75 %) **G2:** 37 (74 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS Admission **Medical, n (%):** **G1:** 27 (53 %) **G2:** 26 (52 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Emergency surgery, n (%):** **G1:** 23 (45 %) **G2:** 20 (40 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Elective surgery, n (%):** **G1:** 1 (2 %) **G2:** 3 (6 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Duration of MV before VAP, days, mean**	**Coronary artery disease, n (%):** **G1:** 9 (18 %) **G2:** 4 (8 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Hypertensive heart failure, n (%):** **G1:** 8 (16 %) **G2:** 8 (16 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Congestive heart failure, n (%):** **G1:** 21 (41 %) **G2:** 27 (54 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Renal dysfunction, n (%):** [test, result (p-value, 95% CI)] **G1:** 9 (18 %) **G2:** 7 (14 %) **G1/G2:** **Liver disease, n (%):** [test, result (p-value, 95% CI)] **G1:** 4 (8 %) **G2:** 3 (6 %) **G1/G2:** NSS **Diabetes mellitus, n**

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
	3 physician refused 17 immunocompromised 5 CAP 4death before inclusion 4 other study	encouraged, PCT 0.25-0.5 or decrease by 80 % from day 0, d/c antibiotics encouraged, PCT 0.5 or greater or decrease of less than 80 % from baseline, antibiotics encouraged, PCT > 1, antibiotics strongly encouraged **G2:** Standard antibiotic therapy based on respiratory secretions **Condition = definition:** VAP by ATS definition		**(range):** **G1:** 6 (3-7) **G2:** 6 (4-10) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Antibiotics before VAP, n (%):** **G1:** 35 (69 %) **G2:** 41 (82 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Shock, n (%):** **G1:** 11 (22 %) **G2:** 12 (24 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Bacteremia, n (%):** **G1:** 14 (28 %) **G2:** 18 (36 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **SAPS II, mean (SD):** **G1:** 42 (13) **G2:** 45 (14) [test, result (p-value, 95% CI)] **G1/G2:** NSS PCT correlated with severity of disease, SAPSII (r2=0.358, p < 0.001)	**(%):** **G1:** 10 (20 %) **G2:** 13 (26 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **COPD, n (%):** **G1:** 8 (16 %) **G2:** 11 (22 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Cancer, n (%):** [test, result (p-value, 95% CI)] **G1:** 3 (6 %) **G2:** 5 (10 %) **G1/G2:** NSS **Substance abuse, n (%):** [test, result (p-value, 95% CI)] **G1:** 5 (10 %) **G2:** 8 (16 %) **G1/G2:** NSS

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
				ODIN, mean (SD): **G1:** 1.9 (0.9) **G2:** 2.3 (1.0) [test, result (p-value, 95% CI)] **G1/G2:** NSS **SOFA, mean (SD):** **G1:** 7.3 (3.4) **G2:** 8.2 (3.4) [test, result (p-value, 95% CI)] **G1/G2:** NSS **WBC, mean (SD):** **G1:** 12.0 (6.6) **G2:** 13.3 (5.9) [test, result (p-value, 95% CI)] **G1/G2:** NSS **PCT, mean (SD):** **G1:** 0.66 (0.22-2.69) **G2:** 0.73 (0.21-2.36) [test, result (p-value, 95% CI)] **G1/G2:** NSS	

Evidence Table 2Q. Intermediate Outcomes for Stolz et al., 2009.[17]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
Superiority **Antibiotic-free days at day 28:** [mean (SD), median (range/IQR)] **G1:** 13 (2-21) **G2:** 9.5 (1.5-17) [test, result (p-value, 95% CI)] **G1/G2:** p = 0.049 **Incidence density antibiotic exposure:** (rate days exposed per #patient-days) **G1:** 1,077 **G2:** 1,341 [test, result (p-value, 95% CI)] **G1/G2:** **Antibiotic duration:** **G1**: 10 (6-16) **G2:** 15 (10-23) **Antibiotics > 7 days, n, %:** **G1:** 65 % **G2:** 82 %, p = 0.044 **Antibiotic discontinuation at day 10, HR:** 2.235 (CI 1.077-4.64, p = 0.031) Duration of antibiotic longer for PSAR, Acinetobacter, Stenotrophomonas, and Klebsiella	**Any antibiotic use,**	NR	**Days:** [mean (SD), median (range/IQR)] **G1:** 26 (7-21) **G2:** 26 (17-22.3) [test, result (p-value, 95% CI)] **G1/G2:** NSS Did not depend on Micro	**ICU free days alive:** **G1:** 10 (0-18) **G2:** 8.5 (0-18) [test, result (p-value, 95% CI)] **G1/G2:** NSS Did not depend on Micro

Evidence Table 3Q. Morbidity Outcomes for Stolz et al., 2009.[17]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
Vent-free days, mean (std dev): **G1:** 21 (2-24) **G2:** 19(8.5-22.5) [test, result (p-value, 95% CI)] **G1/G2:** NSS **ICU-free days, mean (std dev):** **G1:** 10 (0-18) **G2:** 8.5 (0-18) [test, result (p-value, 95% CI)] **G1/G2:** **VAP-related deterioration days 1-28, n, %:** **G1:** 5 (10 %) **G2:** 7 (14 %) [test, result (p-value, 95% CI)] **G1/G2:** **Discharge home days 1-28, n, (%):** **G1:** 5 (10 %) **G2:** 3 (6 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Discharge elsewhere, n, (%):** **G1:** 35 (69 %) **G2:** 32 (64 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR	NR	NR	NR

Evidence Table 4Q. Mortality Outcomes for Stolz et al., 2009.[17]

In-hospital mortality	28-day mortality	Death	Pneumonia-related death	Proportion surviving hospitalization
Proportion (%): **G1:** 20 % **G2:** 28 % [test, result (p-value, 95% CI)] **G1/G2:**	NR	**All causes days 1-28 (%):** **G1:** 8 (16 %) **G2:** 12 (24 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR	NR

Evidence Table 5Q. Function and Quality of Life Outcomes for Stolz et al., 2009.[17]

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	NR	NR

Evidence Table 6Q. Adverse Effects and Adherence for Stolz et al., 2009.[17]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence	Acquisition or persistence of pathogens up to day 28
NR	NR	NR	NR	NR

Evidence Table 7Q. Randomized Trial Study Quality Ratings for Stolz et al., 2009.[17]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y	Y	Y	Y	Y	Y	Y

Evidence Table 1R. Study Description Table for Svoboda et al., 2007.[18]

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: Svoboda et al., 2007. **Country, institution type:** Czech, Academic medical center **Enrollment period:** May, 2003-September, 2005 **Funding:** Grant from IGA MZ CR ND 7676-3 **Author industry relationship disclosures:** Not given	**Design:** Single center, RCT **Interventions:** **G1:** Procalcitonin guidance **G2:** Standard treatment **Presenting condition:** Multiple trauma (289 ISS≥ 25)settings, 164 major abdominal surgeries (time > 120 minutes) admitted to ICU with severe sepsis **Setting:** ICU 453 screened 72 enrolled **N at enrollment:** **G1:** 38 **G2:** 34 **N at follow-up:** **G1:** NR **G2:** NR **Average follow-up, days:** [mean (SD), median (range/IQR)] **G1:** **G2:**	**Primary outcome:** No defined prospectively **Response criteria, independent outcome assessor:** No power calculation **Assay type:** PCT-Q, Brahms; good correlation with PCT LUMI Also WBC, CRP, IL-6, TNF, and AT III **Decision-making:** **G1:** PCT-guided treatment, PCT > 2, change antibiotics and IV catheters; PCT < 2 get US and/or CT with repeat surgical treatment **G2:** Standard treatment **Condition = definition:** Severe sepsis. ATS/RCCM definition, 1992.	**Inclusion criteria:** • Age > 18 years **Inclusion criteria:** • Chemical trauma • Burn trauma • Moribund patients • DNR	**Age, years:** median (range) **G1:** 43 (19-88) **G2:** 49 (20-86) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Male, n (%):** **G1:** 23 (61 %) **G2:** 23 (68 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS **Septic shock, n, (SD):** **G1:** 27 (71 %) **G2:** 23 (68 %) [test, result (p-value, 95% CI)] **G1/G2**: NSS **APACHE II, mean (SD):** **G1:** 15.7 (7.9) **G2:** 17.3 (9.3) [test, result (p-value, 95% CI)] **G1/G2:** NSS **PCT > 2, n, (%):** **G1:** 21 (55 %) **G2:** 16 (47 %) **G1/G2**: NSS	**Multiple trauma, n (%):** **G1:** 27 (71 %) **G2:** 22 (65 %) **G1/G2:** NSS **Abdominal surgery, n (%):** **G1:** 11 (29 %) **G2:** 12 (35 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS

Evidence Table 2R. Intermediate Outcomes for Svoboda et al., 2007.[18]

Antibiotic treatment duration	Antibiotic prescription rate, number of courses of antibiotics	Antibiotic classes	Hospital length of stay	ICU admission, length of stay
NR	NR	NR	NR	**ICU LOS, days, mean (SD):** **G1:** 16.1 (6.9) **G2:** 19.4 (8.9) [test, result (p-value, 95% CI)] **G1/G2:** p = 0.09

Evidence Table 3R. Morbidity Outcomes for Svoboda et al., 2007.[18]

Morbidity	Morbidity	Recurrence	Sepsis/SIRS frequency	RTI symptoms, overall health, cure, success
SOFA, mean (DS): **G1:** 7.9 (2.8 **G2:** 9.3 (3.3) [test, result (p-value, 95% CI)] **G1/G2:** p = 0.06	**Days on ventilation, mean, (SD):** **G1:** 10.3 (7.8) **G2:** 13.9 (9.4) [test, result (p-value, 95% CI)] **G1/G2**: p = 0.08	NR	NR	NR

Evidence Table 4R. Mortality Outcomes for Svoboda et al., 2007.[18]

In-hospital mortality	28-day mortality	Death	Pneumonia-related death	Proportion surviving hospitalization
NR	**Proportion (%):** **G1:** 10 (26 %) **G2:** 13 (38 %) [test, result (p-value, 95% CI)] **G1/G2:** NSS	NR	NR	NR

Evidence Table 5R. Function and Quality of Life Outcomes for Svoboda et al., 2007.[18]

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score
NR	NR	NR	NR

Evidence Table 6R. Adverse Effects and Adherence for Svoboda et al., 2007.[18]

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence
NR	NR	NR	NR

Evidence Table 7R. Randomized Trial Study Quality Ratings[18]

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results
Y	Y	Y	Y	N	Y	Y

References

1. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010 Feb 6;375(9713):463-74. PMID: 20097417
2. Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008 Oct 13;168(18):2000-7; discussion 7-8. PMID: 18852401
3. Burkhardt O, Ewig S, Haagen U, et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J 2010 Sep;36(3):601-7. PMID: 20185423
4. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004 Feb 21;363(9409):600-7. PMID: 14987884
5. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006 Jul 1;174(1):84-93. PMID: 16603606
6. Chromik AM, Endter F, Uhl W, et al. Pre-emptive antibiotic treatment vs 'standard' treatment in patients with elevated serum procalcitonin levels after elective colorectal surgery: a prospective randomised pilot study. Langenbecks Arch Surg 2006 Jun;391(3):187-94. PMID: 16369855
7. Hochreiter M, Kohler T, Schweiger AM, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009;13(3):R83. PMID: 19493352
8. Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial. Crit Care Med 2011 May 12. PMID: 21572328
9. Kristoffersen KB, Sogaard OS, Wejse C, et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission--a randomized trial. Clin Microbiol Infect 2009 May;15(5):481-7. PMID: 19416298
10. Long W, Deng X, Zhang Y, et al. Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 2011 Jul;16(5):819-24. PMID: 21507143
11. Manzano S, Bailey B, Girodias JB, et al. Impact of procalcitonin on the management of children aged 1 to 36 months presenting with fever without source: a randomized controlled trial. Am J Emerg Med 2010 Jul;28(6):647-53. PMID: 20637377
12. Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008 Mar 1;177(5):498-505. PMID: 18096708
13. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009 Sep 9;302(10):1059-66. PMID: 19738090
14. Schroeder S, Hochreiter M, Koehler T, et al. Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 2009 Mar;394(2):221-6. PMID: 19034493
15. Stocker M, Fontana M, El Helou S, et al. Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology 2010;97(2):165-74. PMID: 19776651

16. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007 Jan;131(1):9-19. PMID: 17218551
17. Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009 Dec;34(6):1364-75. PMID: 19797133
18. Svoboda P, Kantorova I, Scheer P, et al. Can procalcitonin help us in timing of re-intervention in septic patients after multiple trauma or major surgery? Hepatogastroenterology 2007 Mar;54(74):359-63. PMID: 17523274

Appendix D. Ongoing Procalcitonin Studies in ClinicalTrials.gov

	NCT ID	Title	Presenting condition(s)	n	Primary outcome	Secondary outcome	Date[†]
1	NCT00914550 [1]	Use Of Procalcitonin Level For Guidance of The Treatment of Suspected Community Acquired Pneumonia[*]	• Pneumonia • Radiographic Lung Infiltrates	100	• Differences in antibiotic discontinuation as an effect of the caregivers learning Procalcitonin levels for the therapy of new radiographic lung infiltrates	-	1-Jun-10
2	NCT01139489 [2]	Safety and Efficacy of Procalcitonin Guided Antibiotic Therapy in Adult Intensive Care Units (ICU's)[*]	• Sepsis • Severe Sepsis • Septic Shock	2246	• 28-day mortality • Consumption of antibiotics (defined daily dosage and duration of antibiotic therapy)	• Length of ICU stay • Acquisition costs of antibiotics • Acquisition costs of procalcitonin	1-Jul-11
3	NCT01379547 [3]	Procalcitonin to Shorten Antibiotics Duration in ICU Patients[*]	• Sepsis	1700	• Average antibiotics duration • 28-day mortality	• % of antibiotics use • Length of ICU stay • Recurrence of fever • Re-infection • APACHE-II score or SOFA score • 90-day mortality • 90-day infection related readmission rate	1-Jun-13
4	NCT00854932 [4]	Neonatal Procalcitonin Intervention Study[*]	• Sepsis	1600	• The absolute reduction of the duration of antibiotic therapy with unchanged outcome	• Duration of hospitalization	1-Jul-12

	NCT ID	Title	Presenting condition(s)	n	Primary outcome	Secondary outcome	Date[†]
5	NCT00832039 [5]	Placebo Controlled Trial of Sodium Selenite and Procalcitonin Guided Antimicrobial Therapy in Severe Sepsis[*]	• Severe Sepsis • Septic Shock	1180	• All cause mortality	• SOFA and SOFA subscores • Frequency and duration of mechanical ventilation • Frequency and duration of vasopressor support • Frequency of adverse events and severe adverse events • Clinical cure and microbiological cure • Duration of antimicrobial therapy • Costs of antimicrobial therapy • Time to change of antibiotic therapy • Days alive without antimicrobial therapy • Frequency of resistance against antibiotics • ICU length of stay • Hospital length of stay • Rate of surgical procedures for focus control • Rate of procedures to diagnose infections • Frequency of new infections	1-Apr-14
6	NCT01018199 [6]	Procalcitonin Versus C-reactive Protein to Guide Therapy in Community Acquired Pneumonia[**]	• Community-Acquired Pneumonia	66	• Duration of antibiotic therapy • Total antibiotic exposure days per 1,000 days • Days alive without antibiotics	• All cause 28-day mortality • clinical cure rate • Infection relapse • Length of hospitalization stay • In-hospital mortality • Nosocomial infection rate • Nosocomial superinfection • Isolation of resistant bacteria • All cause 90-day mortality • Costs of hospitalization	1-Dec-10
7	NCT00987818 [7]	Procalcitonin Guided Versus Conventional Antibiotic Therapy in Patients With Sepsis in the ICU[**]	• Sepsis • Intensive Care	50	• Duration of antibiotic therapy	• 28 day mortality	1-Apr-10

	NCT ID	Title	Presenting condition(s)	n	Primary outcome	Secondary outcome	Date†
8	NCT01250574 [8]	Neutrophil CD64 and Procalcitonin as Novel Biomarkers for Postoperative Infections*	• Bacterial Infection • Postoperative Infection • Abdominal Infection	150	-	-	-
9	NCT00870623 [9]	Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections*	• Infection of Bloodstream	136	• Length of treatment by observing the normalization of procalcitonin (PCT) and Endotoxin levels, compared with the length of treatment by standard of care.	• Treatment failure • Complications • Survival, cost • Length of stay • Progression to severe sepsis or superinfections	-
10	NCT00934011 [10]	Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections*	• Severe Sepsis • Septic Shock	124	• Duration of antibiotic therapy • Total antibiotic exposure days per 1,000 days • Days alive without antibiotics	• 28-day mortality • Clinical cure rate • Infection relapse • Length of ICU stay • Nosocomial infection rate • In-hospital mortality • Sepsis-associated death • Nosocomial superinfection • Isolation of resistant bacteria Length of hospital stay	1-Aug-11
11	NCT01264549 [11]	Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI) *	• Ischemic Stroke	200	• Modified Rankin scale	• % of patients receiving any antibiotic therapy • % of patients receiving any antibiotic therapy for any duration within 90 days • Barthel Index score • Days alive and out of hospital • Time to first event of death, re-hospitalization or recurrent stroke • Proportion of events of post stroke infections • Median number of days with fever (≥ 37,5°C) per patient Stroke volume analysis	1-Dec-12

	NCT ID	Title	Presenting condition(s)	n	Primary outcome	Secondary outcome	Date[†]
12	NCT01125098 [12]	Comparison of a Serum PRO-CT Guided Treatment and the Recommended Antibiotic Treatment for COPD[*]	• COPD	200	• Rate of severe ECOPD	• Costs • Duration of antibiotic therapy Hospital re-admissions • Any cause deaths • FEV1 • Duration of hospitalization for severe ECOPD	1-Dec-11
13	NCT01091493 [13]	Utility of Antibiotic Treatment in Non-purulent Exacerbations of Chronic Obstructive Pulmonary Disease: a Double Blinded, Randomized, Placebo-controlled Trial of Security and Efficacy[*]	• COPD	224	• Efficacy of treatment WITHOUT antibiotics in non-purulent exacerbations of COPD	• Re-hospitalizations at six months. • In-hospital stay (days) • All cause mortality • Procalcitonin levels • Quality of Life (QoL) (Saint George Respiratory Questionnaire) • CRP levels • Cytokines levels (IL-1, IL-6, IL-8, IL-10) • TNF- alpha levels	1-Mar-13

	NCT ID	Title	Presenting condition(s)	n	Primary outcome	Secondary outcome	Date†
14	NCT01311765 [14]	Duration of Antibiotic Therapy in the Treatment of Severe Postoperative Peritonitis Admitted in ICU*	• Postoperative Peritonitis	620	• Number of antibiotic-free days at D28 after inclusion • Mortality at D45 after inclusion	• Duration of ICU and hospital stay • Changes in SOFA score • Number of days alive without organ failure • Failure rate for clinically evaluable patients • Failure rate for microbiologically evaluable patients • Rate of relapse within 45 days • Emergence of multidrug resistant microorganisms in clinical isolates and hygiene samples • Total cost of antibiotic agents • Evolution of procalcitonin plasma concentration • Rate of death within 45 days • Total cost of hospital stay and evaluation of costs and resources impact for the hospital administration	1-Nov-14
15	NCT01232140 [15]	CRP-guided Antibiotic Treatment in COPD Exacerbations Admitted to the Hospital**	• COPD • ECOPD • Bronchitis	220	• Number of patients treated with antibiotics during hospital stay	• Time to treatment failure within 30-days • Length of stay • Time to next exacerbation • Symptom scores (VAS-LRTI, George's Respiratory Questionnaire) • Adverse events	1-Jul-13

†Expected date of completion of the study, *Study listed as recruiting,** Study listed as not yet recruiting

1. Use Of Procalcitonin Level For Guidance of The Treatment of Suspected Community Acquired Pneumonia. Available from: http://clinicaltrials.gov/ct2/show/NCT00914550. Last accessed 2011 August 18.
2. Safety and Efficacy of Procalcitonin Guided Antibiotic Therapy in Adult Intensive Care Units (ICU's) (SAPS). Available from: http://clinicaltrials.gov/ct2/show/NCT01139489. Last accessed 2011 August 18.
3. Procalcitonin to Shorten Antibiotics Duration in ICU Patients (ProShort). Available from: http://clinicaltrials.gov/ct2/show/NCT01379547. Last accessed 2011 August 18.
4. Neonatal Procalcitonin Intervention Study (NeoPInS). Available from: http://clinicaltrials.gov/ct2/show/NCT00854932. Last accessed 2011 August 18.
5. Placebo Controlled Trial of Sodium Selenite and Procalcitonin Guided Antimicrobial Therapy in Severe Sepsis (SISPCT). Available from: http://clinicaltrials.gov/ct2/show/NCT00832039. Last accessed 2011 August 18.
6. Procalcitonin Versus C-reactive Protein to Guide Therapy in Community Acquired Pneumonia (CAP-Marker). Available from: http://clinicaltrials.gov/ct2/show/NCT01018199. Last accessed 2011 August 18.
7. Procalcitonin Guided Versus Conventional Antibiotic Therapy in Patients With Sepsis in the ICU. Available from: http://clinicaltrials.gov/ct2/show/NCT00987818. Last accessed 2011 August 18.
8. Neutrophil CD64 and Procalcitonin as Novel Biomarkers for Postoperative Infections. Available from: http://clinicaltrials.gov/ct2/show/NCT01250574. Last accessed 2011 August 18.
9. Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections. Available from: http://clinicaltrials.gov/ct2/show/NCT00870623. Last accessed 2011 August 18.
10. Use of Inflammatory Biomarkers to Guide Antibiotic Therapy in Patients With Severe Infections. Available from: http://clinicaltrials.gov/ct2/show/NCT00934011. Last accessed 2011 August 18.
11. Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI). Available from: http://clinicaltrials.gov/ct2/show/NCT01264549. Last accessed 2011 August 18.
12. Comparison of a Serum PRO-CT Guided Treatment and the Recommended Antibiotic Treatment for COPD. Available from: http://clinicaltrials.gov/ct2/show/NCT01125098. Last accessed 2011 August 18.
13. Utility of Antibiotic Treatment in Non-purulent Exacerbations of Chronic Obstructive Pulmonary Disease: a Double Blinded, Randomized, Placebo-controlled Trial of Security and Efficacy (AEPOC-ATB). Available from: http://clinicaltrials.gov/ct2/show/NCT01091493. Last accessed 2011 August 18.
14. Duration of Antibiotic Therapy in the Treatment of Severe Postoperative Peritonitis Admitted in ICU (DURAPOP). Available from: http://clinicaltrials.gov/ct2/show/NCT01311765. Last accessed 2011 August 18.
15. CRP-guided Antibiotic Treatment in COPD Exacerbations Admitted to the Hospital (CATCH). Available from: http://clinicaltrials.gov/ct2/show/NCT01232140. Last accessed 2011 August 18.

Appendix E. Screening Guide for Title and Abstract

Key Questions	Not relevant question Key question1
Study Design	administrative database animal study cost/cost-effectiveness analysis case-control study cohort study commentary case report (n<5) case series design unclear/possibly relevant diagnostic accuracy study editorial guideline in vitro letter meta-analysis no abstract not relevant design no primary data narrative review article phase I trial phase II trial physics study phantom study patient positioning study prognostic study prospective single-arm study quasi-experimental study (nonrandomized comparative) radiology/imaging study randomized controlled trial registry retrospective study systematic review disease staging study cross-sectional study
Study Setting	emergency department hospital wards medical intensive care unit primary care clinic surgical intensive care unit teaching hospital
Age	adult geriatrics neonate pediatrics
Disease	acute bronchitis autoimmune diseases acute lymphoblastic leukemia acute pyelonephritis aspiration syndromes bacteremia bacterial infection community-acquired pneumonia culture-negative sepsis chronic obstructive pulmonary disease chronic bronchitis diabetic foot infection

	empyema fever fungal infection fever of unknown origin hematological tumor H1N1 influenza intra-abdominal infection immunocompromised post-liver transplantation malnutrition meningitis not relevant disease neutropenia neonatal sepsis osteomyelitis peritonitis post-orthopedic surgery post-resuscitation disease parasitic infection sepsis (culture positive) systemic inflammatory response syndrome solid organ tumor septic shock skin/soft tissue infection severe sepsis urinary tract infection ventilator-associated pneumonia viral infection
Biomarker	atrial natriuretic peptide CD14 complement 3 complement 4 C-reactive protein C-terminal pro-atrial vasopressin cell-free plasma DNA interleukin-1b interleukin-4 interleukin-6 interleukin-8 interleukin-10 interleukin-12 lipopolysaccharide binding protein Mid-regional pro-atrial natriuretic peptide macrophage migration inhibitory factor neutrophilic CD64 neopterin procalcitonin (alveolar) procalcitonin (serum) procalcitonin (pleural fluid) soluble triggering receptor expressed on myeloid cells-1 thioredoxin tumor necrosis factor-α TNF receptor II TREM-1
Labs	bronchoalveolar lavage bone biopsy blood cultures erythrocyte sedimentation rate endotracheal aspirate ferritin Gram staining magnetic resonance imaging

	nuclear medicine scan real-time polymerase chain reaction pleural fluid culture swab culture serum sodium urine culture plain radiographs white blood cell count
Outcomes	antibiotic resistance antibiotic-free days antibiotic side effects prediction of bacterial infection detection of complications of infection diagnosis of bacterial infection diagnosis of sepsis duration of intravenous antibiotic total duration of antibiotic therapy initiation of antibiotic therapy length of stay in ICU length of stay in hospital mortality not relevant outcome (or no follow-up) persistent or recurrent fever response to antibiotic therapy septic shock development termination of antibiotic therapy
Assay type	Brahms PCT Kryptor rapid PCT test (semi-quantitative) Vidas Brahms PCT
Sample	n < 10 10 < n < 25 25 < n < 50 50 < n < 100 n > 100 n unclear
Scoring	APACHE II CRB Clinical Pulmonary Infection CURB-65 Sequential Organ Failure Assessment
Retrieval	do not retrieve full copy retrieve full copy uncertain; needs check by second reviewer

Appendix F. Screening Guide for Full-Text Articles

Population	Does the study include adults or children with suspected local or systemic infection?
Design	Was study designed to compare procalcitonin-guided treatment and comparator-guided treatment (RCT or QEX)?
Outcome	Does the study mention at least one of these outcomes: •changes in patient management •duration of antibiotic therapy •length of stay •antibiotic exposure •morbidity •mortality •function •quality of life •adverse events (associated with testing, persistent/recurrent infection, antibiotic resistance)

Appendix G. Data Abstraction Form

Table 1. Study Description

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
Author, year: **Country, institution type:** **Enrollment period:** **Funding:** **Author industry relationship disclosures:**	**Design:** **Interventions:** **G1:** **G2:** **Presenting condition:** **Setting:** **N at enrollment:** **G1:** **G2:** **N at follow-up:** **G1:** **G2:** **Average follow-up, days:** [mean (SD), median (range/IQR)] **G1:** **G2:**	**Primary outcome:** **Assay type:** **Decision-making:** **G1:** **G2:** **Condition = definition:**	**Inclusion criteria:** **Exclusion criteria:**	**Age, years:** [mean (SD), median (range/IQR)] **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:** **Women, n (%):** **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:** **PCT:** [mean (SD), median (range/IQR)] **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:** **Infection site, n (%):** **G1:** **G2:**	**CHF (NYHA III/IV), n (%):** [test, result (p-value, 95% CI)] **G1:** **G2:** **G1/G2:** **Insulin-dependent diabetes, n (%):** **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:** **Cirrhosis, n (%):** **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:** **Home oxygen, n (%):** **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:** **CRF on hemodialysis, n (%):** **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:**

Study Description	Study design, interventions, presenting condition, setting, enrollment and follow-up numbers	Primary outcome, procalcitonin assay, decision-making processes, definitions of sepsis and related conditions	Inclusion/exclusion criteria	Participant characteristics	Participant characteristics
					Metastatic cancer, n (%): **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:** **Immunocompromised, n (%):** **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:** **SAPS II, mean (std dev):** **G1:** **G2:** **SOFA, mean (std dev):** **G1:** **G2:** **Septic shock, n (%):** **G1:** **G2:**

Table 2. Intermediate Outcomes

Antibiotic treatment duration	**Antibiotic prescription rate, number of courses of antibiotics**	**Antibiotic classes**	**Hospital length of stay**	**ICU admission, length of stay**
Days without antibiotics at 28 days (superiority): [mean (SD), median (range/IQR)] **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:** **Duration of first episode antibiotic treatment, mean (std dev):** **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:** **Days antibiotic exposure/1,000:** (rate days exposed per #patient-days) **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:**			**Days:** [mean (SD), median (range/IQR)] **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:**	**Days:** [mean (SD), median (range/IQR)] **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:**

Table 3. Morbidity Outcomes

Morbidity	**Morbidity**	**Recurrence**	**Sepsis/SIRS frequency**	**RTI symptoms, overall health, cure, success**
SOFA day 28, mean (std dev): **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:**	**Mechanical ventilation-free days:** [mean (SD), median (range/IQR)] **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:** **Nosocomial superinfection, n, (%):** **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:** **Multi drug resistant, n (%):** **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:**	**Relapse, n, (%):** **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:**		

Table 4. Mortality Outcomes

In-hospital mortality	28-day mortality	60-day mortality	Pneumonia-related death	Proportion surviving hospitalization
	Proportion (%): **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:**	**Proportion (%):** **G1:** **G2:** [test, result (p-value, 95% CI)] **G1/G2:**		

Table 5. Function and Quality of Life Outcomes

Days ≤ 14 days of baseline with daily activities restricted by RTI	Days work missed	Visual analog functional scale	Quality of life score

Table 6. Adverse Effects and Adherence

Combined adverse outcome < 30 days	Antibiotic adverse effects, days with adverse effects from medication, antibiotic resistance	Pain, bleeding, local infection	Adherence

Table 7. Study Quality Ratings

Assembled comparable groups	Maintained comparable groups	Minimal follow-up loss	Measurements equal, valid, and reliable	Interventions clearly defined	Important outcomes considered	Appropriate analysis of results